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Abstract 
 
An effective vaccine against mucosal pathogens such as the Human 
Immunodeficiency Virus 1 (HIV-1) must provide immunity at the mucosal level. 
Understanding the ability of mucosal dendritic cells (DCs) to induce gut homing 
lymphocytes plays a crucial parameter in the development of vaccines that mount 
a specific immune response in the intestine. Gut-tropic T cells are characterised by 
the expression of the integrin heterodimer α4β7 and the chemokine receptors 
CCR9 and CCR10, with CCR9 being specific for the small intestine. While CCR10 
has been suggested to play a role in lymphocyte homing to the large intestine, 
together with CCR4, it has been implicated in lymphocyte trafficking to the skin. In 
addition, it is thought that induction of gut homing T cells is associated with the 
ability of intestinal DCs to metabolise vitamin A to retinoic acid (RA).  
Mucosal vaccination is known to induce mucosal and systemic immune 
responses, while systemic vaccination has been thought to only induce systemic 
immune responses. However, recent publications have shown systemic 
vaccination to induce mucosal immune responses. 
This project investigates the ability of different types of human systemic DCs to 
modulate expression of receptors specific to mucosal and skin homing T cells in 
the presence of retinoids and vitamin D. Co-culture of DCs with various T cell 
populations in the presence of RA revealed the ability of systemic DCs to increase 
α4β7 expression and decrease surface expression of cutaneous lymphocyte-
associated antigen (CLA), a marker for skin homing T cells. We also showed that 
vitamin D plays a role in modulating CCR4 and CCR10 expression. Having 
investigated the ability of RA to modulate homing receptor expression on T cells, 
we confirmed the potential of systemic DCs to metabolize retinol and retinal in vitro 
by molecular means and flow cytometric analysis. Finally, we examined the role of 
retinoic acid receptors (RARs) in regulating α4β7 and CLA expressing T cells. 
This is the first study that investigates the potential of different subsets of human 
systemic DCs to differentially induce and modulate homing properties of T cells in 
vitro. The findings presented in this thesis could have major implications in the 
development of systemic vaccines aimed at inducing mucosal immune responses.     
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%   percent 
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SEM   Standard Error of the Mean 
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TBE   Tris-Borate EDTA 
TCI   Transcutaneous Immunization 
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VCAM  Vascular Cell Adhesion Molecule 
VDR   Vitamin D Receptor 
VDRE  Vitamin D Response Element 
VLA   Very Late Antigen 
vs   versus 
VSV   Vesicular Stomatitis Virus 
 
  Publications 
    
19 
Publications 
 
 
Manuscript 
Hornig, J.; S. Duraisingham, F. Gotch and S. Patterson. Induction of α4β7 expression on 
T cells by systemic DCs. 
 
 
Articles 
Wahren, B.; P. Biswas, M. Borggren, A. Coleman, K. Da Costa, W. De Haes, T. Dieltjens, 
S. Dispinseri, K. Grupping, D. Hallengärd, J. Hornig, K. Klein, L. Mainetti, P. Palma, M. 
Reudelsterz, J. Seifried, P. Selhorst, A. Sköld, M. J. van Gils, C. Weber, R. Shattock, and 
G. Scarlatti. (2010). Rational design of HIV vaccine and microbicides: report of the 
EUROPRISE annual conference. J. Transl. Med., 8(72): 1-11. 
 
Duraisingham, S. S; J. Hornig, F. Gotch, and S. Patterson. (2010). CD34-derived human 
Langerhans cells stimulate a T helper type 2 response independently of extracellular-
signal-regulated kinase phosphorylation. Immunol., 131(2): 210-219. 
 
Duraisingham, S., J. Hornig , F. Gotch, and S. Patterson. (2009). TLR-stimulated CD34 
stem cell-derived human skin-like and monocyte-derived dendritic cells fail to induce Th17 
polarization of naive T cells but do stimulate Th1 and Th17 memory responses. J. 
Immunol., 183(4): 2242-51. 
 
Benlahrech, A., J. Harris, A. Meiser, T. Papagatsias, J. Hornig, P. Hayes, A. Lieber, T. 
Athanasopoulos, V. Bachy, E. C., R. Daniels, K. Fisher, F. Gotch, L. Seymour, K. Logan, 
R. Barbagallo, L. Klavinskis, G. Dickson and S. Patterson. (2009). Adenovirus vector 
vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype 
that are readily susceptible to HIV-1. PNAS, 106: 19940-19945. 
 
 
Poster Presentations 
Europrise Conference 2009, Budapest, Hungary 
Initiation of Mucosal Immune Response by Systemic and Mucosal Dendritic  
Hornig, J., R. Stebbings, F. Gotch, S. Patterson 
 
Europrise Conference 2008, London, UK 
Initiation of Mucosal Immune Response by Systemic and Mucosal Dendritic Cells (DCs) 
as determined by the Generation of Gut-Homing T cells 
Hornig, J., R. Stebbings, F. Gotch, S. Patterson 
 
Europrise Conference 2007, Siena, Italy 
Initiation of Mucosal Immune Response by Systemic and Mucosal Dendritic Cells (DCs) 
as determined by the Generation of Gut-Homing T cells 
Hornig, J., R. Stebbings, F. Gotch, S. Patterson 
 
  Chapter 1 
    
20 
 
 
 
Chapter 1 
 
 
 
 
 
Introduction 
 
 
 
1.1 Human Immunodeficiency Virus -1: A Global Challenge 
Worldwide, the estimated number of people living with HIV-1 has reached nearly 
30 million and each year an estimated 2-3 million people are newly infected with 
the virus (UNAIDS, 2009).. However, over the past 10 years, a reduction in the 
annual infection rate has been observed. In sub-Saharan Africa alone, the 
epidemic has orphaned nearly 12 million children (UNAIDS, 2009), while in Asia, 
HIV-1 is the major disease-causing agent responsible for socio-economic 
problems such as poverty and economic unproductiveness. Over the past years, 
the annual number of acquired immunodeficiency syndrome (AIDS) deaths has 
decreased from 2.2 million in 2005 to 2.0 million in 2007 (UNAIDS, 2009). This 
decline is most likely due to improved access to HIV-1 treatment, as well as 
changes in sexual behavior, especially in third world countries. However, a 
reduction in newly acquired HIV-1 infections is not ubiquitously observed. 
Surprisingly, developed countries such as Germany and the United Kingdom have 
been recording increased numbers of new HIV-1 infections (UNAIDS, 2009). 
When HIV-1 was first discovered by Luc Montagnier and Françoise Barré-Sinoussi 
in 1983, it was predominantly found among the homosexual community. However, 
in developed and underdeveloped countries, HIV-1 has quickly shifted from being 
a primarily homosexual disease to a heterosexual epidemic. Data published by 
Ellerbrock et al. (1992) and Cleghorn et al. (2000) showed that HIV-1 is 
increasingly spread through heterosexual contact.  
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Although HIV-1 directly and indirectly affects millions of people, there are a few 
groups that seem to be resistant to HIV-1 infection. HIV-1 resistance has been 
observed among some African Sex Workers (Kaul et al., 1999) and people 
carrying the Δ32 mutation in the chemokine (C-C motif) receptor (CCR) 5 gene 
resulting in a truncated version of the protein (Michael et al., 1997, Liu et al., 
1996). In addition there are so-called “elite controllers” who become infected but 
are able to control the virus and remain resistant to disease for 15 to 20 years 
(Saksena et al., 2007).  
Some of the major challenges with HIV-1 and the endeavor to cure the disease 
are the rate at which the HIV epidemic is spreading as well as the choice of 
treatment currently available. As recorded by UNAIDS (2009) the speed at which 
new HIV-1 infections arise outpaces the speed at which drugs can be delivered.  
Therefore, the fight against the global HIV/AIDS epidemic relies on the 
discovery and development of an efficient antiretroviral agent that prevents new 
HIV-1 infections and decreases, if not eliminates, the rate of viral dissemination. 
Overall, this advocates for the development of an efficient HIV-1 vaccine.  
 
 
1.1.1 Antiviral Agents and Vaccine Development in HIV-1 Infection 
1.1.1.1 Therapeutic Measures 
Today, the most effective way to suppress HIV-1 replication in infected individuals 
is by antiretroviral therapy (ART) of which highly active antiretroviral therapy 
(HAART) is coined the standard of care. With the discovery that Zidovudine (AZT), 
a drug initially developed against oncoviruses, could decrease mortality in 
individuals with AIDS or AIDS-related infections (Fischl et al., 1987), there was 
great hope that a cure against the disease would soon be found. However, it 
quickly became apparent that HIV has the ability to mutate and escape the 
neutralizing specificity of individual drugs. To avoid the escape of HIV variants, 
HAART was introduced. The types of drugs used can be classified into three 
groups, namely: nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTI/NtRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and 
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protease inhibitors (PI). Most current HAART regimens consist of three drugs, 
including a backbone of two NRTIs combined with a PI or NNRTI. Today, in 
industrialised countries most regimes include drugs such as Atripla®, Truvada®, 
Combivir® or Kivexa®, which have substantially minimized the pill burden and 
regimen intake per day. 
Although HAART is currently considered to be the most efficient treatment against 
HIV-1, antiretroviral therapy is unable to cure HIV-1 infection. Once an individual 
has been infected with the virus, there will always be a low level of replicating virus 
even in the absence of apparent disease symptoms. Furthermore, it has been 
shown that even early administration of HAART fails to reverse HIV-1-induced 
pathologies in gut-associated lymphoid tissue (GALT) (Tincati et al., 2009), 
emphasizing the requirement for an HIV-1 vaccine. 
 
 
1.1.1.2 Microbicides as potential Treatment against HIV-1 
Ever since the discovery of HIV-1, HIV/AIDS research has placed much emphasis 
on the development of effective antiviral agents such as microbicides and vaccines 
to prevent de novo HIV-1 infections and reduce viral transmission frequency, 
potentially eliminating the virus from the pool of human disease causing agents.  
Microbicides are chemical compounds that can be administered via mucosal 
surfaces to protect against sexually transmitted infections (STIs) such as HIV-1. 
Microbicides against HIV-1 include a vast variety of agents that function by either 
directly targeting specific components of the viral particle or acting on the host or 
by providing a more general enhancement of intrinsic mucosal defences. 
However, the fundamental requirements of those substances not only include 
them to be efficient against the virus, but also to be safe, easily applicable, and 
affordable to those living in economically disadvantaged countries.  
Current research focuses on the development of new microbicides and 
mechanisms by which they can be delivered. Commonly, microbicides are 
delivered vaginally or rectally as formulated gels, creams, films, or rings. 
The earliest anti-retroviral microbicides, so called first-generation microbicides, 
were based on surfactants and had detergent activity to directly target the viral 
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particle. Microbicides such as nonoxynol-9 (N-9) were developed as a vaginal 
microbicide that function by destroying the lipid bilayer of the viral envelope 
(Weber et al., 2005). N-9 was first reported by Hicks et al. (1985) to prevent HIV-1 
infection in vitro. This compound was later shown to also reduce the frequency of 
SIV transmission (Miller et al., 1992). However, N-9 phase III clinical trials have 
been unsuccessful (Van Damme et al., 2002) and in addition, N-9 was also shown 
to trigger severe side effects including the development of genital ulcers (Kreiss et 
al., 1992). Other first-generation microbicides include chemicals such as SAVVY. 
However, studies (Feldblum et al., 2008) have shown that SAVVY did not 
significantly reduce the incidence of HIV infection. 
Later developed second-generation microbicides aimed to kill virions or 
inhibit virus binding to its target cells, and include sulphated polymers such as 
PRO2000, Carrageenan, and Cellulose Sulphate (Weber et al., 2005). The viral 
envelope is comprised of sugars, which are important in evading the host immune 
response. Monoclonal antibodies, such as 2G12 and 2F5, have been developed to 
neutralize a broad range of HIV-1 strains by binding to glycans on the viral 
surface. Other antiviral agents include PRO140, Maraviroc, or Aplaviroc, which 
engage CCR5 and thereby prevent the virus from binding to its target cell 
(Lederman et al., 2006). However, due to high selective pressure viral escape 
mutants arise that are able to bind CCR5 using alternative amino acid sequences. 
Recognizing that HIV-1 infection is not dependent on one definite cellular receptor, 
a combination of treatments is often considered in order to reduce infection.  
 Finally, a new group of topical antiretrovirals (third-generation microbicides) 
have been developed that work within infected cells to stop HIV-1 from replicating. 
Some of these include nucleotide analogue reverse transcriptase inhibitors such 
as tenofovir gels or non-nucleoside reverse transcriptase inhibitors such as UC-
781 and TMC120. However, protection by these microbicides is not absolute and 
they are known to exert selective pressure on the viral genome. This emphasizes 
the requirement for an HIV-1 vaccine that eradicates the virus and confers 
protection.  
New potential ways in which HIV-1 may be targeted involves the use of RNA 
interference (RNAi) and adapted antibodies. Kumar et al. (2008) was able to show 
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that a modified single chain antibody targeting CD7 (scFvCD7) that had been 
conjugated to a nona-d-arginine (9R) peptide efficiently delivered CD4-short 
interference RNA (siRNA) into T cells (Kumar et al., 2008). They showed that the 
combined targeting of cellular as well as viral genes can protect against viral HIV-1 
challenge in mice, establishing a new nonviral method for the systemic delivery of 
antiviral siRNAs to T cells in the context of HIV infection. 
 
 
1.1.1.3 Potential Vaccine Candidates against HIV-1 
The persisting requirement for the development of an HIV-1 vaccine is highlighted 
by the fact that currently no proven vaccine against HIV-1 is available, no HIV-
infected human has been able to eliminate the virus, and most non-infected “high-
risk” individuals have no apparent protective HIV-1 immunity. HIV poses several 
challenges with respect to vaccine development in that the virus not only 
comprises antigenically different clades and shows an extraordinarily high 
mutation rate but also integrates into the human genome upon host cell entry 
thereby establishing a lifelong reservoir (Finzi et al., 1999).  
One of the most critical questions is whether focus should be put on the 
development of a prophylactic or therapeutic vaccine. Although harder to develop, 
it is generally noted that a prophylactic vaccine would be most efficient in the fight 
against the HIV-1 epidemic as it prevents the pathogen from infecting host cells. 
However, so far, HIV-1-specific prophylactic vaccines have shown low efficacy in 
humans, and subunit vaccines have failed to elicit HIV-1 envelope-specific 
cytotoxic T lymphocytes (CTLs) or neutralizing antibody responses due to low 
immunogenicity. In contrast, therapeutic vaccines are designed to boost the 
immune response to HIV in order to better control the infection and will mostly be 
used in combination with HAART. 
Historically, immunization with live attenuated pathogens has been proven to 
mount antigen-specific protective immune responses. This type of vaccination 
strategy has been used against viruses such as measles, mumps, rubella, polio, 
and influenza. However, the use of live attenuated HIV-1 in vaccination is 
restrained by the ability of HIV-1 to revert back to a pathogenic strain that 
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integrates in to the hosts’ genome, causing a lifelong reservoir. This was 
previously shown in rhesus macaques (Whatmore et al., 1995; Sawai et al., 2000), 
where Simian Immunodeficiency Virus (SIV) reverted back from a non-pathogenic 
to a pathogenic strain.  
Studies involving the Sydney Blood Bank Cohort (SBBC) of long-term survivors 
infected with nef-deleted HIV-1 have shown the development of HIV-1 specific 
CTL activity, suggesting the virus to form the basis of live attenuated 
immunotherapy and immunoprophylaxis against HIV-1 (Dyer et al., 1997). 
However, to date, only one gp120-depleted whole HIV-1 vaccine (Remune) has 
been used in human trials; yet, it has failed to show significant benefits (Glidden et 
al., 2001). 
 
The development of an inactivated HIV-1 vaccine to induce sterilizing immunity 
has also been considered as inactivated virus vaccines against a number of 
viruses, including hepatitis A, rabies, and polio have been proven efficient. The 
ability of inactivated HIV to induce neutralizing antibodies and CTLs has previously 
been shown in mice (Addawe et al., 1996). Similarly, it has been shown that 
formalin-inactivated whole SIV vaccine confers protection in macaques (Murphey-
Corb et al., 1989). However, the overall response was weak and subsequent 
challenge with genetically different HIV-1 strains failed to protect from infection. 
The use of inactivated virus for human vaccination does not exhibit strong 
immunogenicity and protective efficacy due to the disruption of virion structure 
during thermal or chemical inactivation. Hence, new approaches involving the use 
of gases have been employed to inactivate the virus (Ilyinskii et al., 2001).  
 
Subunit vaccines have been known to confer protection in cases such as hepatitis 
B. In the case of HIV-1, sublingual immunization with HIV-1 gp41 has been 
successful in inducing antigen-specific IgA production (Hervouet et al., 2010). 
However, subunit antigens generally trigger only low mucosal and CTL responses. 
AIDSVAX and ALVAC are two HIV-1 subunit vaccines that have been developed 
based on gp120. However, both vaccines only induced low levels of 
immunogenicity (Pitisuttithum et al., 2006; Cao et al., 2003). In 2009, results of a 
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more recent RV144 trial were published (Rerks-Ngarm et al. 2009). Here, the 
ALVAC-HIV canarypox vector (env E, gag B, pro B) and the AIDSVAX B/E 
(gp120) subunit vaccine were used in a prime-boost vaccine strategy. Results 
showed a moderate efficacy of 31% in reducing the risk of HIV infection.  
 
One of the advantages of DNA vaccination is that it can induce both, antibody and 
cell-mediated immune responses. In HIV-1 vaccination, viral replicons have been 
shown to successfully express gp120 and gp160 (Pang et al., 2001). However, so 
far, no DNA vaccines have been licenced for use in humans due to low vaccine 
efficiency (Ulmer et al., 2006). Other approaches have focused on the 
development of VLPs (Karacostas et al., 1989) or anti-idiotypic antibodies (Boudet 
et al., 1994). 
 
 
  Table 1.1: Potential HIV-1 vaccine candidates. Kutzler and Weiner (2008); Letvin et al., (1998) 
Approach Characteristics 
Live attenuated virus  Potentially pathogenic in recipients (infants) 
 Not for immunecompromised individuals 
 Temperature sensitive 
 Response may be impacted by B cell response 
Inactivated virus with adjuvant  Protection based on anti-cell rather than antiviral 
antibodies 
 Restricted specificity of neutralizing antibodies 
 Poor CTL response 
Live vector-based vaccines  High Immunogenicity 
 Induction of CD4 and CD8 T cells 
 Level of in vivo replication and vector pathogenicity 
closely related 
Subunit Vaccines (Peptides)  Absence of HIV-1 neutralizing antibodies 
 Good CD4 T cell response, Poor CTL response 
DNA vaccine  First-generation DNA plasmids elicit low levels of T cell 
and B cell memory 
 Risk of affecting genes controlling cell growth 
 Possibility of inducing antibody production against 
DNA 
Virus like particles (VLPs)  Induction of CD4 and CD8 T cell response 
Anti-idiotypic antibodies  Vaccination with anti-idiotypic antibodies may not 
confer a complete protection and may require 
subsequent exposure to an antigen 
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Based on the mucosal route of entry, the combined induction of neutralizing 
antibodies and cellular immunity at the mucosal level may be the decisive solution 
to efficiently combat HIV/AIDS, by preventing systemic infection and CD4+ T cell 
depletion. Hence, mucosal immunity plays an important role in the prevention of 
HIV-1 infection and transmission. As the mucosal immune system is one of the 
first sites where entry of HIV-1 can be blocked by preventing viral interaction with 
CD4+ T cells of the mucosa, one should aim to develop a vaccine that induces 
HIV-1-specific mucosal homing CD8+ T cells that specifically target infected gut 
CD4+ T cells. Such a targeted approach would lessen the extent of potentially 
infected CD4+ T cells able to home to lymphoid tissues and establish a persistent 
infection. Yet, this notion assumes sufficient and timely surface presentation of 
processed antigen peptides by infected CD4+ T cells prior to their migration and 
antigen recognition by cognate CD8+ T cells. Consequently, this concept would 
result in a reduction in the viral titer and disease progression or prevention. 
 
 
1.1.2 HIV-1 Infection occurs at the Mucosal Surface 
HIV-1 transmission generally occurs through sexual contacts as semen and 
cervico-vaginal secretions may contain the virus. This allows the virus to access 
sites such as the gastrointestinal, anorectal, genitourinary and male genital tracts, 
which are lined by a mucosal surface. It is estimated that T cells associated with 
the small intestinal epithelium account for more than 60 % of the total body 
lymphocytes (Guy-Grand and Vassalli, 1993), making it the ideal site for HIV-1 
replication. However, more recent data suggest that only 5-20 % of all 
lymphocytes reside in the gastrointestinal tract and that a sole 1-9 % of all 
lymphocytes reside in the gut lamina propria (LP) (Ganusov and De Boer, 2007). 
 
The HIV-1 infection process can be subdivided into two main events including 
“viral translocation” across mucosal surface that facilitates virus penetration and 
spreading into the body, and “infection” that leads to viral entry into target cells. 
Several mechanisms have been proposed for transmission of HIV-1 across the 
mucosal barrier (Figure 1.1). Regardless of the type of the mucosa, under normal 
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physiological conditions, this barrier is relatively effective in blocking viral entry. 
However, in cases where mucosal disruption has taken place by either physical 
damage or chemical composition, the likelihood of acquiring HIV-1 increases.  
HIV-1 infection primarily occurs through the vaginal, cervical, male genital or rectal 
route. Within the cervix, HIV-1 is thought to enter the subepithelial tissue by either 
directly infecting cells (Figure 1.1a), transcytosis (b) or transmigration (c), where it 
is subsequently recognized and bound by DCs. On the other hand, vaginal 
infection requires the virus to cross a layer of stratified epithelium. Here, it is 
thought that HIV-1 may be taken up and transported by Langerhans cells (LCs) (d) 
or physical ruptures in the epithelial lining (e).  
 
 
 
Figure 1.1: Mechanisms for HIV-1 transmission at the mucosal epithelium.  
HIV-1 is thought to employ different modes of crossing the epithelial barrier. Depending on the 
differences in epithelial structure, HIV-1 uses different modes of crossing. a) infection of epithelial 
cells; b) transcytosis; c) transmigration; d) uptake by intra-epithelial Langerhans cells; e) viral entry 
through physical breaches. Figure taken from Shattock and Moore (2003). 
 
 
Studies involving the rhesus macaque SIV model have shown that shortly after 
infection the mucosa of the gastrointestinal tract becomes a major site of virus 
replication resulting in the loss of 80% of the memory CD4+CCR5+ T cells within a 
few days (Veazey, 1998). Similarly, HIV-1-infected humans have been shown to 
experience severe depletion of memory CD4+CCR5+ T cells in the gut (Brenchley, 
2004). Consequently, the massive loss of CD4+ T cells during the first two weeks 
of HIV-1 infection leaves affected individuals susceptible to opportunistic 
infections.  
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As reviewed by Brenchley and Douek (2008), HIV-1 is thought to cause epithelial 
damage by inducing apoptosis of enterocytes. This enteropathy allows the virus to 
pass across the epithelial barrier into the lymphoid tissue. The mechanisms by 
which the virus directly results in the death or dysfunctions of enterocytes remain 
unclear and only a few of these studies suggest that enterocytes actually become 
infected with the virus (Schneider et al., 1996). 
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1.2 Mucosal and Systemic Immunology 
1.2.1 Systemic Immune Response 
Pathogens can enter the body by various routes, resulting in the establishment of 
local or systemic infections. The local site of infection or immunization often 
orchestrates the nature of the immune response, determining whether a systemic 
or mucosal immune response will be generated. Most often, effector cells that 
home to the skin are preferentially generated in the skin-draining lymph nodes 
(LNs), whereas mesenteric lymph nodes (MLNs) or Peyer's patches (PPs) 
produce mucosa-homing subsets specific to the intestine.  
 
Within this thesis the term “systemic DCs” refers to all non-mucosal DCs, including 
those generated in vitro, isolated from the dermis, epidermis and blood. In terms of 
vaccine delivery “systemic vaccination” refers to intramuscular (IM), intravenous 
(IV) as well as subcutaneous or transcutaneous vaccination. 
 
 
1.2.1.1 Antigen Sampling in the Skin 
The human skin consists of three major components that are relevant to its 
immunoregulatory function. The epidermis, which is composed of epithelial and 
immune cells, functions as the immediate physical barrier between the outside 
environment and underlying tissue. Within the epidermis, epidermal LCs function 
as specialized antigen presenting cells (APCs). In addition, intraepithelial 
lymphocytes (IEL) can be found in the epidermis.  
Within the dermis, dermal DCs, mast cells, macrophages, and cutaneous CLA 
positive memory T cells are present. In addition, dermal post-capillary venules 
constitutively function for imprinted cells to home to the skin.  
Antigens that enter through the skin will be detected and processed by antigen 
presenting cells within the layers of the skin. However, the mechanism by which 
LCs are able to recognize antigens through the stratum corneum and tight 
junctions has only been recently clarified. As shown by Kubo et al. (2009) LCs are 
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able to elongate their dendrites and penetrate keratinocyte tight junctions just 
beneath the stratum corneum, allowing them to survey the environment for 
antigens.  
Upon infection, LCs and dermal DCs take up antigens and become activated 
through the recognition of pathogen specific structures such as pathogen 
associated molecular patterns (PAMPs). This activation process leads them to 
migrate from the tissue to the skin draining lymph nodes via the afferent 
lymphatics, where they present processed antigen to naive and memory T cells. 
Naive T cells activated by this process become CLA+ effector cells that can 
migrate into the skin via the efferent lymphatics. The process of T cell migration 
from the circulation back into its effector tissue is controlled by numerous 
molecules, including selectins, chemokines, and integrins. 
 
 
 
Figure 1.2: Immune response in the skin. 
Upon infection, antigens are recognized and process by APCs such as LCs and dermal DCs 
located in the epidermis and dermis respectively. DCs then become activated and migrate to the 
lymph node where they present antigen to circulating naive and memory T cells. Antigen-specific T 
cell activation leads to the migration of effector T cells via the efferent lymphatics into the blood 
stream and homing into the skin. Figure based on Kupper and Fuhlbrigge, (2004). 
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1.2.1.2 DC Activation and Regulation of Peripheral Tolerance 
Dendritic cells play a major role in mounting an innate immune response against 
invading pathogens and transferring the information regarding the nature of the 
pathogen to the adaptive immune system. Dendritic cells constantly take up and 
process antigen that may be obtained from an exogenous source or self. For the 
recognition of sugar residues, DCs express receptors such as DC-SIGN, MMR or 
Langerin. However, to distinguish between non-self and self antigen and the 
decision to trigger an immune response, DCs express pattern recognition 
receptors including the toll-like receptors (TLRs). These different TLRs are used to 
simultaneously detect several features of the pathogens (Figure 1.3). Signals 
generated from various TLRs coordinately regulate the production of distinct 
inflammatory cytokines. Antigen presentation in the present of such cytokines and 
increased levels of co-stimulatory molecules subsequently leads to the activation 
of the adaptive immune response. 
 
 
 
Figure 1.3: Activation of TLRs by microbial molecules.  
In the event of a microbial or viral invasion, DCs use various TLRs to detect different features of the 
pathogen in form of pathogen associated molecular patterns (PAMPs). TLR activation 
subsequently leads to the production and secretion of particular cytokines to modulate immune 
responses. In addition, TLR signaling induces DCs to up-regulate co-stimulatory molecules. Figure 
taken from Immunologie et Chimie Therapeutiques, accessed February 2011. 
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The activation status of DCs not only plays a major role in the induction of immune 
responses but also in the regulation of peripheral tolerance. In the absence of 
forein antigens and inflammatory cytokines, DCs express an immature phenotype. 
Self antigen presentation in the context of MHC thus leads to the generation of 
anergic T cells.  
There are some populations of DCs that are able to migrate from the periphery to 
the LNs. These cells are phenotypically mature and yet, present self antigen. As 
there are no inflammatory cytokines present, these DCs – referred to as veiled 
cells – induce peripheral tolerance (Steinman, 2000). 
 
 
1.2.1.3 Systemic Vaccination 
The concept of transdermal immunization by antigen delivery through the skin has 
long been recognized and the earliest records of variolation date back to the 18th 
century. It was in 1717, when Lady Mary Wortley Montague first introduced the 
method of variolation in Europe. Today, much credit is given to Edward Jenner, 
who showed in 1796 that after inoculation with cowpox, deliberate inoculation with 
smallpox failed to induce disease. Today, the most common route of parenteral 
vaccination in humans includes intramuscular vaccine administration, which has 
been used as a common vaccine delivery method for vaccines against diphtheria, 
tetanus, pertussis, and inactivated influenza. In contrast, vaccines against 
measles, mumps, and rubella are given subcutaneously.  
The skin has become a more attractive site for vaccine delivery not only because it 
is a less invasive method, but also because it is able to induce mucosal 
responses. The notion of transcutaneous immunization using cholera toxin (CT) 
for antigen delivery was first described by Glenn et al. (1998), who subsequently 
demonstrated its protective mechanism against mucosal toxin challenge in mice. 
Using a needle-free epidermal powder deliver system, Chen et al. (2000) were 
able to induce mucosal and systemic immune responses against influenza in mice. 
Epidermal powder immunization (EPI) has also been shown to elicit strong serum 
IgG and CTL responses against the recombinant HIV-1 gp120 envelop protein 
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(Chen et al., 2002). However, induction of mucosal immune response remains to 
be determined. 
Intriguingly, several mouse and human studies suggest that systemic vaccination 
can, in addition to systemic immune responses, also induce mucosal responses.  
It has been noted that the function of epidermal and dermal DCs plays a significant 
role in skin vaccination and induction of immune responses. Enioutina et al. (2002) 
suggested that the interplay between DCs and vitamin D production plays a role in 
the regulation of systemic and mucosal immune responses. However, the 
mechanism underlying the induction of mucosal immune responses by systemic 
vaccination is currently not known. 
 
 
1.2.1.4 Vaccine Delivery via the Systemic Route Triggers Mucosal Responses 
Upon infection, the gut mucosa rapidly becomes the major site of HIV replication, 
which strongly underscores the requirement for a vaccine that establishes 
protection at the mucosal level. Early studies of the mucosal immune system 
proposed (McDermott and Bienenstock, 1979) mucosal infection or vaccination to 
induce mucosal protection as well as systemic immunity. Oral administration of 
DNA plasmids encoding the hepatitis B surface antigen (HBsAg) were shown to 
induce a long-lasting and stable antigen-specific antibody response in serum and 
intestinal mucosa in mice (He et al., 2005). Similarly, mucosal immunization 
studies have shown (Wang et al., 1997) that mucosal administration of a DNA 
vaccine against HIV-1 induces an antigen-specific mucosal immune response, as 
well as systemic CTLs (Belyakov et al., 1998; Sasaki et al., 1998). In contrast, 
systemic infection or vaccination has so far only been considered to induce 
systemic but not mucosal immunity. The general failure of systemic immunisation 
to establish a mucosal immune response in the gut has, in part, been shown by a 
lack of IgA secretion, a lack of CCR10 and α4β7 expression, and other mucosal 
homing receptors (Kunkel and Butcher, 2003).  
However, recent studies have suggested that systemic vaccination can induce 
mucosal responses. The ability of skin immunization to generate mucosal 
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responses in the female reproductive tract has been shown in the case of 
Chlamydia muridarum (Berry et al., 2004). Similarly, studies involving repeated 
transcutaneous vaccination of an SIV DNA vaccine in macaques elicited 
significant levels of antigen-specific CTLs and SIV-specific antibodies in gut-
associated lymphoid tissue (Fuller et al., 2002).  
 
More recently, Belyakov et al. (2004) were able to confirm the potential of 
transcutaneous immunization (TCI) to induce mucosal CTLs and protective 
immunity. Using an HIV-1 peptide vaccine, they were able to trigger robust, HIV-1-
specific CTL responses in the splenic and intestinal mucosa of mice, establishing 
protection against recombinant vaccinia virus expressing the HIV gp160. Similarly, 
Berry et al. (2004) showed TCI to enhance clearance of Chlamydia trachomatis 
from mucosal tissue in mice. They were able to show that transcutaneous 
administration of a DNA vaccine in combination with an adjuvant could induce 
strong mucosal T helper (Th) 1 responses, as well as the production of antigen-
specific IgG and IgA. Most recently, Trumpfheller et al. demonstrated (2006) that 
transcutaneous administration of an engineered HIV-1 antibody vaccine targeting 
DEC205 elicited an antigen-specific CD4+ T cell immune response in the 
respiratory mucosa in mice. 
 
Recent studies of intramuscular vaccination (IMV) similarly suggest that it can 
induce mucosal immune responses. As shown by Kaufman et al. (AIDS vaccine 
conference, Seattle 2007), IMV led to the development of Ag-specific mucosal 
responses. Other studies (Tatsis et al. 2007) have shown the IMV in combination 
with the prime boost strategy has led to the development of high frequencies of 
transgene-specific CD8+ T cells. Using triple immunization strategies in mice, they 
were able to record increased levels of HIV-1-gag-specific T cells at mucosal sites, 
including mesenteric lymph nodes, intestinal epithelium, and Peyer’s patches. 
More recently (Schoenly et al. 2007), intramuscular vaccination in combination 
with chemokines has been used to immunize mice. Intramuscular vaccination of 
mice with HIV gag protein together with chemokines CCL27 and CCL28 led to the 
activation of mucosal immunity. This was mediated by T cells expressing the 
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chemokine receptor CCR9/10 and α4β7 integrin that subsequently localised to the 
site of injection to initiate mucosal responses. 
Other modes of vaccine administration have focused on intravenous vaccination 
(IVV), which has been shown to induce T cell proliferation, followed by migration to 
the lungs, liver, gut and salivary glands. Intravenous vaccination of the antigen in 
conjunction with lipopolysaccharide (LPS) led to enhanced T cell proliferation and 
migration, followed by expression of memory cells (Reinhardt et al., 2001). 
Similarly, time course experiments by Masopust et al. (2001), in which mice were 
intravenously infected with vesicular stomatitis virus (VSV), showed the 
development of VSV-specific T cells in the LP of the small intestine.  
 
 
1.2.2 Mucosal Immune Response  
Early studies of the mucosal immune system suggested (McDermott and 
Bienenstock, 1979) that mucosal infection or vaccination at mucosal surfaces not 
only provides mucosal protection at all surfaces but also systemic immunity. 
However, the idea of a 'common mucosal immune system' is more restricted than 
previously thought. With regard to the induction of a mucosal immune response in 
humans, it has been shown that immunization by different mucosal routes results 
in differences in intensity and location of mucosal responses (reviewed by 
Holmgren and Czerkinsky, 2005). The strongest mucosal immune response takes 
place at the site of direct vaccine-exposure and the second-best responses at 
adjacent mucosae. The mucous-associated lymphoid tissue (MALT) represents a 
highly structured immunological system which comprises small concentrations of 
lymphoid tissue at various sites, including the gastrointestinal, respiratory, and 
reproductive tract and is thought to function independent from the systemic 
immune compartment.  
Mucosal epithelial defences against viruses such as HIV-1, are considered the first 
line of defence against pathogenic invasion. The mucosal immune system is 
characterized by the production of secretory IgA, Th1 and Th2-type CD4+ and 
CD8+ CTL responses. With respect to the development of an HIV vaccine, vaginal 
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and nasal immunizations have been found to induce IgA and IgG antibody 
responses in the human cervicovaginal mucosa (Kozlowski et al., 1997; 
Johansson et al., 1998). In addition, mucosal CTL responses have been described 
after mucosal immunization (Staats et al., 2001). 
 
 
1.2.2.1 Gut Associated Lymphoid Tissue 
The 400 m2 surface area of the gastrointestinal (GI) tract is about 200 times larger 
than the surface area of the skin (Mowat and Viney, 1997) and it is thought that 
the intestinal epithelium may contain the majority of all lymphocytes (Guy-Grand 
and Vassalli, 1993), making it the most important inductive site for mucosal 
immune responses.  
The GALT consists of two major sites, that can be divided into immune inductive 
sites such as MLNs, PPs, and lymphoid aggregates, as well as effector sites, 
consisting of lymphocytes scattered throughout the mucosal epithelium (villus) and 
lamina propria (Mehandru, 2007; Holmgren and Czerkinsky, 2005; Mowat et al., 
2003) (Figure 1.4).  
The MLNs are the largest lymph nodes in the body and are thought to constitute 
the “crossroads” of systemic and mucosal immunity, in that they are the sites 
where lymphoid cells from systemic and mucosal immunity interact (Mowat et al., 
2003). The PPs consist of lymphoid aggregates located just underneath the 
mucosal lining of the intestine. The epithelium covering the PPs not only differs 
from the villus mucosa in that it has a less pronounced brush border, large 
numbers of DCs, macrophages, and B and T cells, but also specialized microfold/ 
multi-fenestrated or ‘M’ cells (Mowat et al., 2003), which have been shown to 
differentiate from enterocytes in the presence of lymphotoxin (LTα1β2) (Debard et 
al., 2001). 
The immune effector sites contain lamina propria lymphocytes (LPLs) and IELs, 
which have been proposed to play a role in cytotoxicity (Guy-Grand and Vassalli, 
1993). 
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1.2.2.2 Antigen Sampling in the Intestine  
The general consensus states that antigen uptake within the gut is primarily 
mediated by enterocytes and ‘M’ cells located in the follicle-associated epithelium 
of the PPs (Kraehenbuhl and Neuter, 2000). However, antigens can also be 
sampled via the Fc receptor for IgG (Yoshida et al., 2004), or by DCs through tight 
junctions within the intestinal epithelium (Rescigno et al., 2001). Upon antigen 
recognition and transport across the epithelium, antigens are delivered to immune 
inductive sites or taken up by antigen presenting cells such as DCs, B cells and 
macrophages. Depending on the nature of the immune response, APCs present 
processed antigens to naïve and memory CD4+ and CD8+ T cells present in 
inductive and effector sites. As shown by Kunkel et al. (2003), naïve T cell 
activation and division predominantly occur in the MLNs. After activation, naïve 
lymphocytes are thought to move through the lymph into systemic circulation, after 
which they return to the inductive (PPs and MLNs) and effector sites (LP and IEL) 
of the mucosa, waiting to mount an immune response. 
 
Interestingly, there has been debate on the role of PPs in the induction of immune 
responses and oral tolerance. Using genetic knockout mice, it had been shown 
that PPs are not required for the induction of oral tolerance (Spahn et al., 2002). 
Furthermore, it has been shown that B-cell deficient mice, which also lack M cells 
and normal PPs, are able to generate oral tolerance (Alpan et al., 2001). It is 
believed that this is associated with the presence of DCs in the MLNs that are able 
to produce interleukin (IL) -4 and IL-10, two cytokines required for the induction of 
oral tolerance Rizzo et al. (1999).  
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Figure 1.4: Organization of the gastrointestinal immune system. 
M cells mediate the transport of antigens across the intestinal epithelium for delivery into the PPs 
and MLNs where they are presented to DCs. The lymphocytes form a follicle consisting of a large 
central dome of B cells surrounded by smaller numbers of T cells. Activation of T cells leads to their 
tissue-specific imprinting of homing receptors. α4β7, CCR9, and CCR10 expression enables T 
cells to home to the intestinal mucosa. Figure adapted from data by Cheroutre and Madakamutil, 
(2004), Mowat (2003), and Bilsborough and Viney (2004). 
 
 
1.2.2.3 Mucosal Vaccination 
Mucosal vaccination allows induction of local immune responses at sites where 
many disease causing agents invade their host, making it advantageous over 
systemic vaccination, which has been shown to induce mainly systemic and very 
low to no mucosal responses. This concept has been based on the fact that the 
systemic and mucosal immune systems are thought to function independent of 
one another due to differential regulation and structural compartmentalization. 
The delivery of mucosal vaccines has been proven difficult and several 
strategies have been developed to allow successful vaccine administration. Such 
strategies include oral, plant-based vaccines (Streatfield, 2005), and those 
administered via the nasal, rectal, genito-urinary and pulmonary mucosa. These 
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strategies include live attenuated micro-organisms, attenuated toxins, or 
nanocarriers and microparticles (Shahiwala et al., 2006; Vyas and Gupta, 2007). 
To increase the immune response, highly immunogenic adjuvants such as CT and 
E. coli lymphotoxin (LT) have been employed to trigger adequate immune 
responses. However, as they are toxic and not acceptable for human use, 
alternative adjuvants such as aluminium have been used. In humans, there are 
currently several vaccines licenced for mucosal administration, including the live 
attenuated oral polio vaccine, cholera vaccine, live attenuated monovalent 
rotavirus vaccine, and live attenuated influenza vaccine (Holmgren and 
Czerkinsky, 2005).  
 
 
1.2.2.4 Regulation of Immune Tolerance and Autoimmunity in the Intestine 
The intestinal mucosa has a complex immune structure and regulatory mechanism 
that involves various cell populations. Among these, regulatory T cells (T regs) and 
Th17 cells play a significant role in maintaining mucosal tolerance and 
autoimmunity respectively. 
The role of regulatory T cells has been shown in forkhead box P3 (FoxP3) 
deficient mice, which experienced multiorgan inflammation (Fontenot et al., 2003). 
Naturally occurring CD4+CD25+FoxP3+ T regs have been found in the thymus (Itoh 
et al., 1999). However, FoxP3+ T regs can be generated from naïve T cells in the 
presence of respective antigens or ligands. This is in contrast to CD4+ memory T 
cells, which are resistant to FoxP3 induction (Wang et al., 2009). In fact, CD4+ 
memory T cells were shown to inhibit regulatory T cell conversion of naïve T cells.  
In particular within the intestine, T regs play an important role in the regulation of 
tolerance to commensal bacteria and food antigens by preventing autoimmune 
responses. In that respect, intestinal DCs seem to play a significant role in the 
induction of T regs responses and tolerance. Benson et al. (2007) were able to 
use RA to generate T regs in vitro that are able to home in vivo to the small 
intestinal lamina propria. 
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Coombes et al. (2007) defined a new population of CD103+ MLN DCs that are 
able to induce FoxP3+ T reg cells. This T reg development was dependent on 
transforming growth factor (TGF-β) and RA. Similarly, Sun et al. (2007) showed 
that small intestinal DCs promote de novo generation of FoxP3 regulatory T cells 
in the presence of RA. More specifically, exposure of T cells to RA increases 
expression and phosphorylation of SMAD3 (Huehn et al., 2009), which then leads 
to an increase in TGF-β-induced FoxP3 expression while preventing the 
differentiation of Th17 cells (Xiao et al., 2008). However, FoxP3 expression may 
not be specific for regulatory T cells as shown by Wang et al. (2007). They showed 
that although murine CD4+CD25- T cells induced FoxP3 expression upon TCR 
stimulation, these cells lacked suppressor function. Experimental evidence 
suggests that some pathogens may have evolved to manipulate regulatory T cells 
to immunosuppress the host. For example, regulatory T cell activity has been 
reported to increase in several infections including HIV (Suchard et al., 2010). 
These data reveal the complexity in the identification and induction regulatory T 
cells and their role in intestinal immunology. 
Interestingly, it was shown that CD4+CD25+FoxP3+ T cells may have the 
potential to differentiate into IL-17 producing cells through epigenetic modulation of 
foxp3 expression (Koenen et al., 2008). Th17 cells were first described on the 
basis of IL-17 production (Langrish et al., 2005), and it was shortly after that 
Harrington et al. (2005) showed that IL17-producing CD4+ effector T cells develop 
via a lineage distinct from the Th1 and Th2 cells. Th17 cells have been implicated 
in autoimmune diseases and in the protection against extracellular bacteria, 
viruses, and fungal species (Khader et al., 2009). Within the intestine, Th17 cells 
have been implicated in maintaining immunological homeostasis. As shown by 
O’Connor et al. (2009), IL-17 plays a significant role in the protective mechanism 
of the intestine, as the lack of IL-17 led to enhanced colitis. Likewise, a loss of 
Th17 cells in the gastrointestinal (GI) tract has been associated with HIV infection 
(Brenchley et al., 2008).  
The role of intestinal DCs in the regulation of Th17 cells has been considered of 
great importance. In addition, a new set of lamina propria macrophages has been 
identified, which induced differentiation of FoxP3 T regulatory cells (Denning et al., 
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2007). Those cells are in contrast to CD11b+ DCs, which produce IL-17. The 
balance between these and other cells, as well as factors such as RA, influences 
the balance between Th17 and T reg responses within the intestine. 
 
Within the mucosal tissue of the intestine two populations of regulatory T cells, T 
helper 3 cell (Th3) and Tr1 cells, have been suggested to play an important role in 
maintaining mucosal homeostasis by suppressing inflammation (Groux et al., 
1997). 
Th3 cells are involved in mucosal immunity and protecting mucosal surfaces in the 
gut from nonpathogenic non-self antigens (Lan et al., 2007). They mediate this 
non-inflammatory environment by secreting TGF-β and IL-10, which promote class 
switch to low concentrations of IgA. At the same time Th3 inhibits Th1 and TH2 
cell responses. Interestingly, Th3 cells have different cytokine requirements for 
their growth from natural CD25+CD4+ Treg cells. While, the survival of CD25+CD4+ 
Treg cells is dependent upon IL-2 (Sakaguchi et al., 2006), differentiation of Th3 
cells is enhanced by TGF-β, IL-4, and IL-10. It was previously shown that TGF-β 
was produced by intestinal dendritic cells (Johansson and Kelsall, 2005; Iwasaki, 
2007), which has been considered to be the source of cytokines for the induction 
of Th3 cells in the intestine.  
In contrast, Tr1 cells differ from natural T regs and Th3 cells in that they do not 
express Foxp3 nor large amounts of CD25 (Shevach, 2006). As Tr1 cells are 
abundant within the intestine, it has been suggested that they may play a role in 
the induction of oral tolerance (Battaglia et al., 2004). Tr1 cells have been shown 
to produce large amounts of IL-10 and TGF-β.  
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1.3 DC Biology 
1.3.1. DC Differentiation 
Dendritic cells differentiate during embryonic development and also during 
postnatal life from bone marrow progenitor cells (Geissmann, 2007). Within the 
bone marrow, undifferentiated CD34+ precursor cells give rise to two progenitor 
cell lines, consisting of the “common myeloid progenitor cell” and the “common 
lymphoid progenitor cell” (Ardavín et al., 2001). These cell lines give rise to 
myeloid DCs and plasmacytoid DCs respectively. These progenitor cells 
subsequently seed the blood and tissue where they differentiate into their 
respective DC subtype. Different subsets of DCs can be distinguished based on 
their cellular origin, half-life in peripheral tissues and the mechanisms by which 
they are renewed (Geissmann, 2007; Merad et al., 2002). 
 
 
1.3.2 DC Life Cycle 
The life span of DCs can be separated into two stages, consisting of the 
“immature” and “mature” phases. Not only do immature and mature DCs differ in 
their phenotype but also in their biological function and ability to process and 
present antigen to immune cells. Immature DCs are characterised by their ability 
to ingest and process foreign antigens, while mature DCs, which are found in the 
peripheral lymphoid tissues are potent stimulators of naïve T cells. 
 
 
1.3.2.1 DC Precursors and Immature DCs 
Newly generated DC precursors migrate from the bone marrow into the blood 
stream, from where they disperse to various peripheral sites, including most 
surface epithelia such as the skin, and mucosal tissues, including the 
gastrointestinal tract. Within these sites, DCs fully differentiate into their respective 
immature phenotype. 
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Immature DCs not only differ from mature DCs in their ability to take up and 
process antigen but they also have a different phenotype. Antigen uptake by 
immature DCs is mediated by non-selective macropinocytosis, which allows 
internalization of large volumes of fluid (Sallusto et al., 1995). In addition, 
immature DCs have been shown to express the mannose receptor, which allows 
the efficient and continuous uptake of mannosylated glycoproteins (Stahl and 
Ezekowitz, 1998). At the same time, expression of FcγRI (CD64) and FcγRII 
(CD32), which mediate uptake of IgG-antigen complexes, have been shown on 
blood-derived myeloid DCs (Fanger et al., 1996). However, DCs share with 
macrophages the ability to recognize and take up foreign pathogens through 
receptors that recognize features common to microbial surfaces. DCs are very 
active in taking up pathogens by phagocytosis using receptors such as the dectin 
DEC205. 
 
The immature DC phenotype is associated with low levels of surface major 
histocompatibility complex (MHC) proteins, empty cell-surface class II MHC 
proteins (Santambrogio et al., 1999) and high intracellular MHC Class II (Mellman 
and Steinman et al., 2001). Also, immature DCs lack co-stimulatory molecules 
such as CD80 and CD86, rendering them unable to stimulate naïve T cells. 
Typical of immature DCs are the LCs in the skin, which are actively phagocytic. 
Upon infection they mature and migrate to the spleen or regional lymph nodes, 
where they present antigen to naive and memory lymphocytes, thereby inducing a 
secondary immune response. 
 
 
1.3.2.2 Immature DC Activation and Maturation 
Maturation of DCs can be achieved through either antigenic stimulation from 
pathogens, i.e. LPS, or via cytokines (Figure 1.5). When an infection occurs, DCs 
become activated and migrate to the local lymphoid tissues via the lymphatics 
where they function in the presentation of processed antigenic peptides to immune 
cells. This maturation or activation process is not only associated with changes in 
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the ability of DCs to ingest and present antigen but also triggers changes in the 
expression of cell surface molecules.  
Activation of DCs can be achieved through TLR-mediated signalling. It has been 
shown that LPS-mediated maturation causes DCs to lose their ability to take up 
and process antigen (Granucci et al., 1999). At the same time DCs have been 
shown to up-regulate the expression levels of new MHC molecules and their half-
life to allow efficient peptide presentation to T cells (Cella et al., 1997). DC 
maturation also involves the up-regulation of CD40 and co-stimulatory molecules 
CD80, CD83, and CD86, which enables DCs to activate naïve T cells (Sallusto et 
al., 1995).  
Upon maturation, DC migration to the lymph nodes is mediated by various 
chemokines. Stimulation of DCs results in high expression of CCR7 and 
responsiveness to its ligand, EBI1 ligand chemokine (ELC or CCL19) (Sallusto et 
al., 1998), which is produced in lymphoid organs. 
 
 
      IL-10 
       Pathogens,  
  cytokines, T cells 
 
 
Immature DC               Mature DC 
High intracellular MHC Class II   High surface MHC class II 
Endocytosis, including FcR   Low endocytosis and FcR 
Low CD80, 83, 86     High CD80, 83, 86 
Low CD54, 58, p55     High CD54, 58, p55, DC-SIGN 
Low CD40, CD25, IL-12    High CD40, CD25, IL-12 
DEC205      High ICAM-1, -2, LFA-1 
 
Figure 1.5: DCs activation leads to changes in phenotype and function. 
Activation of immature DCs can be induced by various agents, including cytokines and pathogens. 
This process leads to DC maturation and change in cell surface marker expression pattern. Figure 
adapted from Banchereau and Ralph M. Steinman (1998). 
 
 
Tissues DCs that have not been activated by foreign antigens and reach the end 
of their life span also migrate via the lymphatics to the local lymphoid tissues. 
However, as they do not express the required co-stimulatory molecules to activate 
T cells, they induce tolerance to any self antigens that they display which are 
derived from the peripheral tissue. 
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1.3.3 The Intrinsic Network of DCs 
DCs comprise a vast and complex network of different sub-populations that 
localize to different tissues and organs within the human body, where they play a 
major role in immune regulation. DCs have been implicated in linking the innate 
and adaptive immune response by activating cellular and humoral immune 
responses upon recognition of foreign pathogens. However, DCs not only induce 
adaptive immune responses, they also play a role in tolerizing T cells to self 
antigens. Based on the expression of different surface molecules, tissue location 
and origin, DCs can be categorised into various sub-populations. 
 
 
1.3.3.1 Biology of Skin LCs 
LCs can be found within the epidermis, in particular within the basal and 
suprabasal layers (Merad et al., 2002). However, LCs have also been identified in 
foreskin, vaginal, and oral mucosa (Hussain and Lehner, 1995). Since LCs reside 
within the epidermis they are considered to have the first interaction with skin 
invading pathogens. The density of LCs in most areas of the human skin is 
approximately 400-1000 cells/ mm2 (Chen et al., 1985, Berman et al., 1983) where 
they constitute about (3−8 %) of epidermal cells (Katz et al., 1979). Under steady 
state conditions, LCs reside up to three weeks within the skin, after which they are 
replaced by self-renewal of radioresistant precursors located within the skin 
(Merad et al. 2008). As LCs represent a very dynamic cell population the 
immediate LC precursor during steady state conditions has not yet been identified. 
However, mice studies have suggested that blood-derived monocytes with high 
expression of the monocyte marker Gr-1 (Ly-6c/G) are direct precursors of 
epidermal LCs during inflammation (Ginhoux et al., 2006).  
 
Skin LCs were first discovered by Paul Langerhans in 1868 (Langerhans, 1868) 
who thought they were members of the nervous system. Later, they were regarded 
as melanocytes that had lost the capacity to synthesize the melanin pigment 
(Breathnach, 1963; Zelickson, 1965; Mishima, 1966). However, their role as 
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antigen presenting cells was described only in 1985 (Schuler and Steinman, 
1985), when LCs were shown to be immature DCs and have the potential to 
mature into potent immunostimulatory DCs. 
 
LCs are characterised by the expression of Langerin (CD207) and of Birbeck 
granules, which were first described by Birbeck as “rod- and tennis racket-shaped” 
organelles (Birbeck et al., 1961). These findings were later confirmed by Schwartz 
(2007) who showed that the surface marker Langerin is selectively expressed on 
LCs where it forms a major component of Birbeck granules. With respect to 
infection, it is thought that Langerin may act as an antigen binding receptor, as the 
only microbial ligand that has been identified for Langerin to date, is the HIV-1 
gp120 (Turville et al., 2002). In addition, early research on LCs confirmed their 
expression of Fc- and complement receptors (Stingl et al., 1977). In the same 
year, LCs were further shown to express MHC class II molecules (Klareskog et al. 
1977, Rowden et al., 1977). Other LCs markers include the recently identified 
epithelial cell adhesion molecule (EpCAM) (Bursch et al., 2007) and the skin 
homing antigen CLA (Ross et al., 1994). Further studies have shown epidermal 
LCs not only to express Langerin and CCR6 but also that they are resistant to ultra 
violet (UV) radiation and slowly self-replicating (Merad et al., 2002).  
Although LCs are able to stimulate T cells and detect antigens, their role in 
generating an in vivo immune response has been questioned. Until recently it was 
assumed that cutaneous antigens were recognized and processed by epidermal 
LCs which then become activated to mature and migrate into draining lymph 
nodes for efficient antigen presentation to T cells. However, several studies have 
questioned the role of LCs in antigen presentation as antigen-specific T cell 
activation remains intact in LC deficient murine models. Using Langerin-DTA mice, 
Kaplan and colleagues (2005) were able to show that mice still developed contact 
sensitivity when challenged with the haptens dinitrofluorobenzene (DNFB) and 
oxazalone, suggesting LCs not to be required. Similarly, it was shown that LCs 
were dispensable for triggering hapten-specific effector T cells through skin 
immunization (Kissenpfennig et al., 2005). In contrast, it has been demonstrated 
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that topical administration of antigen results in inefficient transportation to draining 
LNs in the absence of LC (Bennett et al., 2007).  
In fact, LCs may only play a significant role in the transfer of antigen from the skin 
to the lymph node, where they transfer antigen to LN DCs for presentation, as CTL 
priming in HSV infection was mediated by LN-resident DCs rather than migrating 
LCs (Allan et al., 2006). These observations are in agreement with previously 
published data showing LN-resident CD8+ DCs, rather than LCs, to play a role in 
CTL priming during intradermal HSV, influenza and vaccinia virus administration 
(Belz et al., 2004). However, in the context of HIV-1 vaccine development and 
HIV-1 biology, one needs to consider the possibility that epidermal LCs may 
indeed play a role in antigen presentation and T cell stimulation.  
 
 
1.3.3.2 Biology of Dermal DCs 
As their name suggests, dermal DCs are located within the dermal layer of the 
skin and are considered analogous to “interstitial DCs” found in the connective 
tissue. Under steady state conditions, 2–3 % of human dermal DCs actively cycle 
in and out of human skin (Bugonovic et al., 2006) and are continuously 
replenished by self-replicating, radiosensitive cells (Merad et al., 2002; 
Shklovskaya et al., 2008).  
Human dermal DCs typically express the C-type lectins DC-SIGN (CD209) and 
Mannose Receptor (CD206). In contrast to LCs, dermal DCs have generally been 
considered Langerin (CD207) negative (Valladeau et al., 2000). In addition, dermal 
DCs have been described to express the myeloid markers CD11c and CD1c 
alongside human leukocyte antigen (HLA) -DR and the human clotting factor XIII 
subunit A (FXIIIA) (Meunier et al., 1993). However, FXIIIA is not a specific marker, 
as can also be found on endothelial cells (Suvarna and Cotton, 1993).  
 
At least two subgroups of dermal DCs have been described based on the 
expression of CD14 and CD1a. Within the dermis, CD14-CD207-CD1a+ (15% to 
20% of total dermal DC) and CD14+CD207-CD1a- (10% to 15% of total dermal 
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DC) have been identified (Nestle et al., 1993; Klechevsky et al., 2008). A third 
population has been identified that express neither CD1a nor CD14 (65% to 70% 
of total dermal DCs). Phenotypic analysis showed that CD1a+ dermal DCs express 
higher levels of HLA-DR, CD40, CD80, and CD86 and located to the upper layers 
of the dermis (Angel et al., 2006).  
Furthermore, it was shown (Angel et al., 2006) that human CD14-CD1a+ dermal 
APCs have the capacity to migrate in response to LN chemokines and prime naive 
T cells. Based on the fact that the previously identified CD14+CD1a- DCs were 
unable to migrate in response to such chemokines and failed to stimulate naive T 
cells, they concluded that CD1a+ dermal DCs represent antigen presenting cells in 
the dermis. Alternatively, CD14+CD1a- cells were suggested to represent 
cutaneous macrophages (Larregina et al., 2001). 
 
Within the past years, new data has emerged on the heterogeneity of dermal DCs. 
Studies in mice have led to the identification of a new population of Langerin+ DCs 
in the dermis and skin draining lymph nodes.  
Reconstituting irradiated mice with bone-marrow cells from mice in which the 
enhanced green fluorescent protein (EGFP) was under the control of the langerin 
promoter, Poulin et al. (2007) were able to identify Langerin+ DCs in the dermis. 
These cells repopulated the dermis and the dermal lymph nodes at a much faster 
rate than the LCs, suggesting that dermal Langerin+ cells are radiosensitive and 
distinct from epidermal LCs. Using a similar mouse model, Ginhoux and 
colleagues (2007) showed Langerin+ DCs to repopulate cutaneous draining lymph 
nodes (DLNs) and the dermis before the reappearance of LCs in the epidermis. 
This proposes the existance of a separate population of cells that gives rise to 
Langerin+ dermal DCs. Similar to the previous studies, Bursch et al. (2007) 
described Langerin+ DCs in the dermis, where they showed dermal Langerin+ DCs 
to be required for optimal hypersensitivity responses. This not only suggests that 
epidermal LCs are not required for the induction of these responses but also that 
Langerin+ dermal DCs may have different regulatory functions. Likewise, 
Shokloskaya and colleagues (2008) showed that radiosensitive murine dermal 
DCs could be subdivided into three subsets on the basis of differential expression 
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of Langerin and CD11b (Langerin+CD11blow, Langerin–CD11blow, and Langerin–
CD11b+ dDC). 
A similar discovery was made in human skin with the identification of CD1ahigh 
Langerin+CD14– dermal LCs (Angel et al., 2006). Overall, these studies suggest 
the existence of dermal Langerin+ DCs, alongside epidermal Langerin+ and 
Langerin- dermal DCs.  
 
 
1.3.3.3 Biology Blood-derived myeloid Dendritic Cells (mDCs) 
Newly generated myeloid DCs emigrate from the bone marrow into the blood 
stream where they reside as immature DCs. Human blood DCs are 
heterogeneous in their expression of various cell surface markers, but many of 
these populations reflect differences in the maturation or activation states of DCs 
rather than separate sublineages (Hart, 1997). Peripheral blood-derived DCs 
consist of two major categories comprising CD303+CD11c- plasmacytoid DCs 
(pDCs) and CD11c+ conventional or mDCs, which can be further distinguished 
from pDCs based on the expression of CD1c+ (BDCA-1). Distribution studies have 
shown that the percentage of myeloid CD1c+ DCs in cord blood of healthy 
newborns did not significantly differ when compared to those in peripheral blood of 
healthy adults. However, the percentages of BDCA-2+ (CD303) and BDCA-4+ 
(CD304) DCs of newborns were significantly lower when compared to peripheral 
blood of adults (Darmochwal-Kolarz et al., 2004). 
Freshly isolated CD11c+ blood mDCs have been shown to lack expression of 
CD40, CD80 and CD86 (Thomas and Lipsky, 1994) as well as CD1a (Robinson et 
al., 1999). Up-regulation of such markers only occurred after in vitro differentiation. 
Phenotypic analysis has further shown that blood mDCs expressed levels of HLA-
DR, CD40, CD86, and CD83 that were similar to those observed with monocyte-
derived dendritic cells (MoDCs). CD209 was present on MoDCs but not on blood 
CD11c+ DCs (Osugi, et al., 2002). In addition, blood CD11c+ DCs generated a 
lower proliferative mixed leukocyte response (MLR) than Mo-DCs. 
In mice, CD8α+ and CD8α- DC are thought to represent cells of lymphoid and 
myeloid origin, respectively (Merad et al., 2000), and both DC lineages have been 
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shown to take up foreign antigen and migrate into T cell areas (Sousa et al., 
1997). This suggests that blood mDCs do have the ability to process foreign 
antigen and stimulate T cell responses. 
It has been proposed that the CD1a+CD11c+ subset of human blood DCs functions 
as a direct precursor of LCs (Ito et al., 1999). Based on the expression of CD11c 
and CD1a, they identified two populations of CD11c+ blood DCs, comprising 
CD1a+CD11c+ and CD1a-CD11c+ cells. Both populations expressed myeloid 
markers such as CD13 and CD33, and the receptor for GM-CSF. In addition, 
CD1a+CD11c+ DCs quickly differentiated into Langerin+ E-cadherin+ and Birbeck 
granules+ cells when cultured in the presence of granulocyte macrophage colony-
stimulating factor (GM-CSF), IL-4, and TGF-β1. 
These observations stand in contrast to O'Doherty et al. (1994) who suggested 
CD11c- blood DCs to give rise to LCs, which would explain the low expression 
levels of CD11c on LCs in vivo (Romani et al., 1989). In contrast, CD11c+ DCs 
were suggested to reside in tissues and upon antigen-mediated activation migrate 
into the spleen or lymph nodes. 
 
 
1.3.3.4 Biology of Gut Mucosal DCs 
One of the remarkable characteristics of the mucosal immune system of the 
intestine is to recognize and distinguish between commensal bacteria, food, and 
infectious agents in order to generate and balance specific immune responses. 
This supports the notion that DCs in gut mucosal tissue possess unique functions 
that allow them to regulate mucosal immune responses. The role of intestinal DCs 
in the induction of mucosal immune responses has been of great interest; 
however, intestinal DCs comprise a large network that yet has to be fully 
investigated. Appreciating the diversity of mucosal DCs, the origin of intestinal 
DCs has been under careful investigation. Within the LP, PP, MLNs, as well as 
isolated lymphoid follicles (ILFs) antigen presenting cells function to regulate the 
intestinal immune response. To date, most of the knowledge regarding intestinal 
DCs has been drawn from murine studies.  
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Trying to identify the origin of mucosal DCs, numerous studies have been 
conducted in mice and rats. In mice, two populations of intestinal DCs have been 
characterised based on their expression of CD103 and CX3CR1 (Bogunovic et al., 
2009). It has been shown that CD11b-CD103+CX3CR1− lamina propria DCs arise 
from macrophage-DC precursors, while CD11b+CD103low/-CX3CR1+ lamina 
propria DCs were generated from Ly6Chi monocytes (Bogunovic, et al., 2009; 
Varol et al., 2009). Consistent with these observations was the differentiation of 
CX3CR1+ monocytes to tissue migratory DCs in rats (Yrlid et al., 2006).  
DCs within the mucosal tissue seem to exhibit unique functional properties 
which allow them to play an important role in the induction of gut homing T cells. 
Iwata et al. (2004) were the first to published data on the potential of murine DCs 
from MLNs and PPs to produce RA from retinol.  
Further studies have shown that, in particular, CD103+ DCs present within 
mucosal tissue of the intestine play an important role in regulating mucosal 
responses, as they have the ability to de novo synthesise RA (Coombes et al., 
2007; Sun et al., 2007). This characteristic to generate RA is likely to be linked to 
their ability to express retinoic synthesising enzymes. DCs in Peyer’s patches and 
MLNs have been shown to express aldehyde dehydrogenase (ALDH) 1A1 and 
ALDH1A2, which would allow them to generate RA from retinal. However, as 
suggested by Coombes et al (2007), it is only the CD103+ DCs which express 
ALDH1A2. These finding coincide with published data on functional studies, which 
have shown CD103+ but not 103- DCs to promote expression of the gut homing 
receptor CCR9 on CD4+ T cells (Annacker et al., 2005, Jaensson et al., 2008). 
Similar observations were made by Johansson-Lindbom et al. (2005), who showed 
that CD103+ DCs from the MLN and small intestinal LP have an enhanced ability 
to induce CCR9 expression on CD4+ and CD8+ T cells. 
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Figure 1.6: Subsets of intestinal APCs. 
Murine studies have identified several subsets of intestinal DCs that are phenotypically and 
functionally distinct. In particular, CD103
+
 DCs seem to be able to synthesize vitamin A and induce 
gut homing lymphocytes. Figure modified from Manicassamy and Pulendran (2009). 
 
 
Lamina Propria DCs were as potent as DCs derived from the MLN in triggering an 
up-regulation of α4β7 on CD8+ T cells and more efficient in inducing CCR9 surface 
expression.  
Interestingly however, intestinal macrophages have also been shown to express 
high levels of ALDH1A1 and ALDH1A2 relative to their splenic counterparts. 
Furthermore, Molenaar et al., (2009) showed MLN stromal cells showed 
expression of vitamin A converting enzymes allowing production of RA by these 
cells. Alternatively, DCs may already transport RA that has been derived from 
dietary carotenoids or other vitamin A derivatives by intestinal epithelial cells 
(Figure 1.6).  
In addition, mucosal DCs play a significant role in the regulation of autoimmunity 
and tolerance. It has been shown that human primary CD103+ DCs isolated from 
MLNs have the ability to drive T regs differentiation (Iliev et al., 2009). In a similar 
way, studies have shown murine intestinal DCs to have the potential to induce 
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Th17 cells. It was reported by Denning et al. (2007) that CD11b+CD103- DCs were 
able to induce Th17 cells, while CD103+CD11b- were not very efficient. These 
observations are in agreement with the notion that CD103+ DCs are able to 
synthesize retinoic acid, and that retinoic acid inhibits Th17 differentiation. 
Overall, comparison to systemic DCs has shown gut mucosal DCs to 
produce the anti-inflammatory cytokines IL-10, TGF-β (Iwasaki et al., 2001), and 
IL-6 (Sato et al., 2001). In addition, mucosal DCs have been shown to polarize 
antigen-specific T cells to produce Th2 and Th3 cytokines (Iwasaki and Kelsall, 
1999), T regs (Bilsborough et al., 2003), or IgA-secreting gut homing B cells (Mora 
et al., 2006) and T cells (Mora et al., 2003). These are characteristics that clearly 
differentiate mucosal DCs from DCs found in the periphery (Figure 1.7).  
 
 
a)       b)         c)          d) 
 
Figure 1.7: Differences in immune Induction by mucosal and peripheral DCs. 
a) In response to pathogen-associated molecular patterns (PAMPs) or T cells, mucosal DCs 
secrete anti-inflammatory cytokines, while systemic DCs secrete proinflammatory signals. b) 
Antigen presentation to T helper cells by mucosal DCs induces Th2, Th3, or T regs, while systemic 
DCs induce Th1. c) Mucosal DCs can instruct B cells to undergo isotype switching to IgA. d) 
Mucosal DCs play a role in the induction of gut homing markers on lymphocytes, while systemic 
DCs instruct naive CD8 T cells to home to the skin. Figure according to Iwasaki (2007). 
 
 
In the context of this thesis, in all subsequent sections the term “mucosal” refers to 
the mucosa found within the small and large intestine. 
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1.3.4 In Vitro Models of Systemic DCs 
Due to the difficulty in readily isolating large numbers of epidermal or dermal DCs 
from human tissues, different in vitro models have been developed that allow the 
production of reasonable numbers of DCs required for their study. In addition, in 
vitro-generated DCs can be used as a model for the study of various pathogens, 
including HIV-1 (Mallon et al., 1999). Most of our knowledge regarding human DCs 
subsets has been obtained from in vitro studies involving the generation of DCs 
from precursor cells. 
 
 
1.3.4.1 The Nature of MoDCs 
The in vitro generation of MoDCs from CD14+ monocytes was first described by 
Sallusto and Lanzavecchia (1994). In the presence of GM-CSF and IL-4 they were 
able to establish DCs in vitro that maintained the antigen capturing and processing 
capacity characteristic of immature DCs in vivo. Similarly, it was shown by Romani 
et al. (1994) that large numbers of DCs could be generated in vitro in the presence 
of IL-4 and GM-CSF from human peripheral blood.  
It has been suggested that monocytes give rise to DCs or macrophages 
depending on their tendency to migrate across endothelium (Randolph et al., 
1998). Using an in vitro transendothelial-migration model, they were able to show 
that monocytes can migrate across an endothelial barrier in vitro and differentiate 
into either macrophages or DCs, which have the potential to migrate back across 
the endothelial layer. Additional in vitro studies have shown (Randolph et al., 
2002) that CD14+CD16+ human peripheral-blood monocytes preferentially 
differentiate into DCs.  
The phenotype of MoDCs has been shown to resemble that of human dermal DCs 
in that they are both CD1a+CD14-CD206+DC-SIGN+Langerin- (Grassi et al., 1998).  
Although existence of MoDCs in vivo at the steady-state is not certain, the 
existence of inflammatory MoDCs in vivo has previously been documented 
(Randolph et al. 1999; Naik et al., 2006). In addition, data has suggested that TLR 
activation triggers differentiation of monocytes into dendritic-like cells (Krutzik et 
al., 2005). 
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Hence, the fact that they are an in vitro model should be remembered when 
experimental data derived from the use of MoDCs is interpreted 
 
 
1.3.4.2 Umbilical cord CD34+-derived LCs and dermal-like DCs (dDCs) 
The in vitro generation of LCs and dDCs from CD34+ hematopoietic stem cells 
was first described by Caux et al. (1996). Culturing of CD34+ progenitor cells in the 
presence of GM-CSF, Flt3L, SCF, and TNF-α led to the differentiation into two 
populations that could be distinguished by their CD1a and CD14 expression 
profile. CD14+CD1a- precursor cells differentiate in the presence of IL-4 and GM-
CSF to give rise to dDCs. In addition, Flt3L plays an important role in the 
proliferation, survival, and differentiation of early human hematopoietic precursor 
cells (Shurin et al., 1998) and was initially added to the dDC culture. Their 
phenotype shows a remarkable similarity to MoDCs, which has previously been 
reported by Grassi et al., (1998). Dermal DCs, like MoDCs, were shown to be 
positive for the surface expression of CD1a, CD11b, CD206 and DC-SIGN. In 
contrast, CD14-CD1a+ precursor cells were shown to differentiate in the presence 
of GM-CSF and TGF-β into LCs, which are representative of those cells present in 
the epidermis (Caux et al., 1996). As confirmed by Strobl et al. (1996), TGF-β plus 
GM-CSF, TNF-α, and SCF strongly induces CD34+ differentiation in vitro. Similarly, 
Strunk and colleagues (1996) generated human LC from CD34+ hematopoietic 
progenitor cells (HPCs) isolated from peripheral blood. They showed that in vitro 
culture with GM-CSF and TNF-α led to their differentiation into leukocytes some of 
which express CD1a and anti-MHC class II reactivity (Strunk et al., 1996). 
 
 
1.3.4.3 Monocyte-derived Langerhans Cells (MoLCs)  
The in vitro-generation of LCs from CD14+ monocytes in the presence of GM-CSF, 
IL-4, and TGF-β has previously been shown (Geissman et al., 1998). Although 
monocyte-derived LCs (MoLCs) are thought to mimic epidermal LCs, differences in 
receptor expression and IL-12 production have been reported upon stimulation 
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with CD40L in vitro (Peiser et al., 2004). However, in mice it has been 
demonstrated in vivo that during inflammation, circulating monocytes migrate to 
inflamed skin where they differentiate to give rise to LCs (Ginhoux et al., 2006). In 
particular, Gr-1+ (Ly-6c/G) monocytes were recruited to the inflamed skin and 
differentiated into LCs, suggesting Gr-1hi monocytes as the direct precursors for 
LCs in vivo. Furthermore, they showed that the induction of LCs was dependent 
on colony stimulating factor-1.  
The differentiation of peripheral blood-derived CD14+ monocytes in the presence 
of GM-CSF, IL-4, and TGF-β led to the generation of LCs that expressed a 
phenotype similar to that of LCs derived from CD34+ progenitor cells derived from 
cord blood. These cells were CD1a+, E-cadherin+, CLA+, Birbeck granules+, Lag+.  
Although these two LC models provide the basis for studying LCs in vitro, they are 
not entirely reflective of human epidermal LCs and it is unclear whether they 
reflect the biology of Langerin+ dermal-DCs in vivo.  
 
 
Figure 1.8: Differentiation pathways of human DC subsets. 
DC precursors arise from myeloid and lymphoid progenitors within the bone marrow from where 
they migrate via the blood to peripheral tissues. Within the tissue, differentiation of myeloid and 
lymphoid precursors into immature DCs is regulated by endogenous cytokines. Subsequent DCs 
activation and maturation is induced by exogenous stimuli in form of microbial or viral products. It is 
likely that there are multiple subtypes within each of the five groups of DCs shown here. 
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1.4 DC Interaction with T cells 
1.4.1 Antigen Presentation to T cells by DCs 
T cells cannot recognize antigenic peptides alone or when represented in the 
context of the wrong MHC complex. Instead, they rely on antigen presentation by 
antigen presenting cells, such as DCs, which are essential for the activation of the 
adaptive immune response. DC precursors are generated in the bone marrow, 
from which they migrate to the peripheral tissue. Within the peripheral tissues, 
DCs function in surveying the local area for invading pathogens. Upon infection, 
immature DCs capture invading pathogens in the peripheral tissues and migrate to 
lymphoid tissue where they present peptide antigens in the context of MHC class I 
and II molecules to CD8+ T cells (CTLs) and CD4+ T helper cells respectively. 
 
 
1.4.1.1 Activation of CD8+ T cells by MHC Class I Expressing DCs 
Upon entry of cytosolic or intracellular pathogens, antigens are degraded within 
the cytosol of the DCs. The peptides presented in the context of MHC class I 
complexes are derived from intracellular proteins and cytosolic pathogens that are 
degraded within the cytosol of the infected cell via proteolysis (Hershko and 
Ciechanover, 1998). The proteasome itself is a complex present in the cytoplasm 
of the cell and consists of several subunits. Aside from lysosomes, proteasomes 
are the major sites of adenosine triphosphate (ATP)-dependent proteolytic activity 
within the cell. Naturally, the function of proteasomes includes the degradation of 
cellular proteins and misfolded proteins. Such proteins, including viral antigens, 
are broken down into smaller peptides, which are subsequently transported to the 
endoplasmic reticulum (ER). This process requires the hydrolysis of ATP. 
Transporter associated with antigen presentation (TAP1 and TAP2) are 
polypeptides, which combine to form a heterodimer that constitutes a channel 
within the membrane of the ER to allow peptides to be transported from the 
cytosol into the lumen of the ER. Within the ER, the peptides are loaded onto MHC 
class I molecules. This process seems to be dependent on the protein tapasin, 
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which links TAP and MHC class I complexes within the ER. Newly synthesized 
MHC class I molecules are synthesized in the cytosol and then translocated to the 
lumen of the ER and held within the ER in a partly folded state until they bind a 
peptide. During that stage, they interact with calnexin and calreticulin, two 
chaperones that bind partly folded members of the immunoglobulin superfamily 
and retain them in the ER until folding is completed (Ou et al., 1993; Wada et al., 
1995). 
Once the peptide has been loaded onto the MHC class I molecule, the molecule is 
released from the ER to migrate through the Golgi apparatus to the cell surface. 
The degraded peptides are then presented to CD8+ T cells in the context of an 
MHC class I peptide complex. MHC class I complexes that are transported to the 
surface without antigen are unstable at 37° C and will be degraded. Eventually, 
presentation of peptides on MHC class I from intracellular pathogens facilitates 
recognition and killing of infected cells by CD8+ CTL cells. 
 
 
 
Figure 1.9: Antigen processing and presentation in the context of MHC class I and II. 
a) MHC class I molecules present peptides from intracellular pathogens that have been degraded 
within the cytosol by proteasomes. b) MHC class II molecules present proteins that enter the cell 
through the endocytic route. c) DCs can endocytose antigens and cross-present them to CD8
+
 
cytotoxic T lymphocytes. Figure taken from Heath and Carbone (2001). 
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1.4.1.2 Immune activation of CD4+ T cells in the context of MHC class II 
On the contrary, intravesicular or extracellular pathogens are degraded in acidified 
endocytic vesicles (i.e. lysosomes) by acid-dependent proteases. These 
phagosomes then fuse with vesicles that contain MHC class II molecules 
generated in the ER. Upon translation, the MHC class molecule α and β chains 
associate within the ER where they are complexed with a polypeptide known as 
the invariant chain. This chain binds and thereby blocks the peptide-binding cleft to 
prevent it from binding cellular peptides or peptides from the endogenous 
pathway. In addition, the invariant chain facilitates the export of class II MHC from 
the ER through the Golgi and subsequent vesicle fusion with a late endosome 
containing endocytosed, degraded proteins. The invariant chain is then broken 
down in stages by proteases called cathepsins, leaving only a small fragment 
known as CLIP which maintains blockage of the peptide binding cleft on the MHC 
molecule. An MHC class II-like structure, HLA-DM, facilitates CLIP removal and 
allows the binding of peptides with higher affinities. The MHC class II and peptide 
comples are then expressed on APCs. 
Antigen presentation in the context of MHC class II then leads to the activation of 
CD4+ T cells that secrete cytokines, which have numerous effects including 
activation of macrophages that can phagocytose and kill pathogens. CD4 T cells 
also provide help to MHC calss II expressing B cells to secrete immunoglobulins 
(MacLennan et al., 2006). 
 
 
1.4.1.3 Antigen Cross Presentation 
For a long time, it has generally been accepted that MHC class I molecules 
present peptides derived from endogenous proteins degraded in the cytosol of 
APCs. Concurrently, MHC class II molecules were considered to present peptides 
from exogenous pathogens. However, the concept of antigen presentation has 
been reformulated with the discovery of antigen cross presentation. Cross 
presentation of antigen provides a route by which exogenous antigens can enter 
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the MHC class I pathway. Two antigen cross-presenting pathways have been 
proposed. 
The “Canonical cytosolic pathway” proposes that antigens are first taken up into 
endosomes where they are degraded before they are being released into the 
cytosol of the cell (Lin et al., 2008). These degraded peptides are then loaded onto 
MHC class I molecules using the traditional MHC class I machinery before they 
are presented on the cell surface. 
The second pathway is referred to as the “alternative vacuolar pathway”, which 
functions independent of the proteins normally involved in the MHC class I loading 
process (TAP 1 and 2, tapasin, calnexin, and calreticulin). Exogenous proteins are 
thought to be degraded within the phagosome where they are loaded onto MHC 
class I molecules. Loaded MHC class I molecules are then transported to the cell 
surface for presentation. 
The biologic relevance of antigen cross presentation has been thought to lie within 
a fallback mechanism for viruses that evade CTL activity.  
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1.4.2 Regulation of Homing Tropism on T cells by DCs 
Aside from activating naive and memory T cells, DCs have the ability to regulate 
expression of tissue specific homing receptors on T cells. Within the skin, DCs 
have been shown to metabolize Vitamin D into the active metabolite 1,25(OH)2D3, 
which in turn is thought to play a role in the induction of CCR10 expression on T 
cells, directing them to the skin (Sigmundsdottir et al., 2007). Similarly, expression 
of CCR4 by T cells is thought to direct migrating cells to the skin. As shown by 
(Berg et al., 1991), interaction of CLA with its ligand E-selectin is characteristic of 
lymphocytes directed towards the skin. For a more detailed description of T cells 
homing to the skin please refer to section 1.5.3. 
 
 
 
1.5 Lymphocyte Migration to the GI Tract and Skin under 
Physiological Conditions 
Lymphocyte migration within and to the skin and small intestine is regulated by 
different tissue-specific adhesion molecules such as selectins and chemokines 
(Fabbri et al., 1999). Depending on the tissue within which naïve T cells encounter 
the antigen and are activated, they either migrate to peripheral sites such as the 
skin or intestinal mucosa. T cells that become activated within peripheral skin-
draining lymph nodes preferentially home to the skin (Robert and Kupper, 1999), 
while T cells activated in the GALT, PPs, or MLN, preferentially migrate to the 
small intestine (Iwata, 2009).  
 
 
1.5.1 The Mechanism of Lymphocyte Migration 
Over the past years, the mechanism underlying lymphocyte migration has been 
thoroughly investigated. Today, there is general consensus supporting a “multistep 
paradigm” (Fabbri et al., 1999) by which lymphocytes migrate from the site of 
activation to the target tissue (Figure 1.10). Initially, lymphocytes in the blood 
vessel collide with the vascular endothelium in high endothelial venules (HEV) 
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generating tethering contacts that lead the cells to adopt a rolling behavior (Salmi 
and Jalkanen, 1999). This rolling or tethering along the endothelium is mediated 
by the interaction of selectins expressed on the endothelium and their respective 
carbohydrate ligands on leukocytes. While effector and memory T cells express 
various ligands such as glycoproteins, PSGL-1 or various integrins, naïve T cells 
primarily rely on the interaction of L-selectin with its tissue specific ligand (Figure 
1.10). 
 
 
 
Figure 1.10: Multistep paradigm of lymphocyte migration. 
Lymphocyte migration is described as a “multistep paradigm”, which involves four distinct adhesion 
steps that are followed by diapedesis across the endothelial wall. Tethering and rolling allows the 
cells to come into close proximity with the endothelium. The interaction of specific chemokines and 
their receptors allows lymphocyte activation and to undergo firm adhesion with the endothelium. G-
protein-coupled receptors can bind specific chemoattractants, such as a chemokine, leading to the activation 
of a transmembrane signal that induces rapid activation of β2 and/or α4 integrins. Cellular arrest is mediated 
through various integrins and their ligands. During these processes, a number of molecules can interact 
with more than one partner (symbolized by arrows). Figure taken from Kogan and von Adrian (2008). 
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Activation oflymphocytes is mediated through 7 transmembrane receptors (TMR) 
that can be activated via chemoattractants or even complement factors. Upon 
acitvation, lymphocytes use tissue specific integrins to firmly bind to the 
endothelium. Upon binding, the cell then migrates across the endothelium via 
interendothelial junctions into the underlying basement membrane of the target 
tissue (diapedesis). There it receives other directional signals which help it to 
move within the tissue stroma. 
 
 
1.5.2 Lymphocyte Homing to the GI Tract 
Lymphocyte homing to mucosal surfaces such as the GI tract is dependent on the 
expression of selectins, specific integrins (α4β7) and chemokine (C-C motif) 
receptors (CCR9 and CCR10) that differ from those mediating lymphocyte 
migration to and within the skin.  
 
The initial, tethering or rolling process of lymphocytes along the intestinal 
endothelium is dependent on the interaction of selectins and integrins on 
lymphocytes with respective ligands expressed or produced by endothelial cells.  
However, as naive lymphocytes express only low levels of α4β7 (Bargatze et al., 
1995), a heterodimer involved in the tethering and adhesion of lymphocytes to the 
gut endothelium, they depend on the interaction of L-selectin with its ligand, a 
carbohydrate-modified version of mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) (Berg et al., 1993). The importance of L-selectin in mucosal homing 
of naive lymphocytes has been shown by Hamann et al. (1991) in that treatment 
with anti-L-selectin antibodies leads to a reduction in naive lymphocyte homing to 
PPs. Respectively, MAdCAM-1 is expressed on mucosal endothelium, and its 
importance in lymphocyte homing has been confirmed by Streeter et al. (1989) 
who showed anti-MAdCAM-1 specific antibodies reduced the number of MALT 
homing lymphocytes. 
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Comparative studies have revealed differences in the homing mechanisms of 
naive and memory cells. As mature lymphocytes have been imprinted with a gut 
homing phenotype, they do not depend on L-selectin mediated tethering and 
therefore can skip the initial L-selectin mediate tethering process (Hamann et al., 
1994). Expression of α4β7, which has been shown to be specific for the migration 
of lymphocytes to the lamina propria (Berlin et al., 1995), allows lymphocytes to 
directly bind to the endothelium. The integrin α4β7, in particular β7, seems to be 
characteristic of lymphocytes homing to the intestine.  
T cell homing to the gut is initiated by the interaction of α4β7 with the mucosal 
addressin cell adhesion molecule-1 (MAdCAM-1). Upon antigen recognition and 
activation by DCs, T cells up-regulate α4β7, which then binds to MAdCAM-1 
present on HEVs in PPs, MLNs, and postcapillary venules in the LP (Miles et al., 
2008). Interestingly, α4β7 functions at various steps of the multistep migration 
cascade (Bargatze et al., 1995). Initially, the interaction between α4β7 and 
MAdCAM-1 slows lymphocytes down causing them to roll along the endothelium. 
As shown by Miles et al. (2008) MAdCAM-1 and VCAM-1 support lymphocyte 
rolling and firm adhesion. This is followed by the firm interaction with the 
endothelium and leukocyte flattening leading to their migration between the 
endothelial cells 
 
The lymphocyte function associated antigen 1 (LFA-1; L2) functions at a later 
stage of the multistep cascade. LFA-1 has been shown to interact with ICAM-1 
and ICAM-2 (Simmons et al., 1988; Stauton et al., 1989) located on the endothelial 
lining of the intestine, as well as ICAM-3 present on resting leukocytes (Fawcett et 
al., 1992). However, there have been controversial data on the significance of 
LFA-1 in lymphocyte homing. It has been shown that lymphocyte homing to the 
LNs depends on LFA-1 (Hamann et al., 1988; Berlin-Rufenach et al., 1999). 
However, there have been publications showing that a lack in LFA-1 does not 
completely abrogate lymphocyte homing. For example, Woolf et al. (2007) showed 
LFA-1 deficient cells to exhibit only slightly impaired abilities to home to the 
intestine. 
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In addition, it has been shown that the interaction of αEβ7 with its ligand E-
cadherin plays a role in the retention of IELs within the intestinal mucosa. As 
shown by Farstad et al. (1996), more than 90% of IELs express αEβ7, while in the 
GALT only a few cells were positive for αEβ7. However, studies on effector CD8
+ T 
cell recruitment to the intestine have shown (Lefrançois et al., 1999) that E-/- 
(CD103) cells were equally as efficient as wild type T cells in homing to, and 
remaining in, the small intestine, suggesting a less significant role for E in T cell 
recruitment to the small intestine. This theory was further supported by Pauls et al. 
(2001) who showed Eβ7 to play a role in the localization of CD8+ T cells to the 
epidermis in psoriatic skin.  
 
With regard to the GI tract, the small and large intestine were previously 
considered to be part of a common intestinal immune system (Brandtzaeg et al., 
1999). However, with the discovery of differences in the expression of the 
chemokine TECK/CCL25 in the small and large intestine, it is now thought that 
there may be distinct mechanisms in the induction and regulation of lymphocyte 
homing at these two sites. As reviewed by Kunkel et al. (2003), the CCL25-specific 
C-C chemokine receptor 9 (CCR9) is expressed on nearly all small intestinal T 
cells ( > 90 %), whereas its expression levels on T cells from the colon (< 20 %) 
and stomach (< 10 %) are significantly lower. This suggests a specialization of the 
small intestine with respect to the recruitment of CCR9+ lymphocytes.  
 
The general role of CCR9, aside from mediating lymphocyte migration to the 
intestine, is not well understood. CCR9 is expressed on a distinct subset of CD4+ 
and CD8+ T cells, which also express the intestinal homing receptor α4β7 (Zabel 
et al., 1999). Furthermore, CCR9 expression can be used to distinguish gut 
homing 4+7+ memory T cells from CCR9-CLA+ (cutaneous lymphocyte-
associated antigen) memory T cells that home to non-gut lymphoid organs (Zabel 
et al., 1999). Albeit being considered a “homing receptor” specific for the small 
intestine, CCR9 can also be found on immature and mature thymocytes, a few 
circulating α4+β7+ lymphocytes, and T cells in the colon. CCR9 is not only 
expressed on intestinal T cells, but also has been reported on IgA-secreting cells 
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(Bowman et al., 2002) and plasmacytoid DCs (Wendland et al., 2007). Other 
peripheral blood cells such as natural killer (NK) cells, monocytes, neutrophils, 
basophils, eosinophils and DCs seem to lack CCR9 (Zabel et al., 1999). 
Nonetheless, CCR9 is primarily seen on T cells in the small intestine, and the 
ability of T lymphocytes to home to the small intestine correlates with CCR9 
expression. This observation coincides with the continuous expression of CCL25 
within the small intestine, but weak or no expression in the colon and other 
mucosal tissues. Interestingly however, Stenstad et al. (2007) have shown that 
there is a difference between the CCL25 expression levels along the small 
intestine, with CCL25 expression being lower in the distal compartment compared 
to the proximal compartment. Although, Stenstad et al. (2006) showed that CCR9 
was required for the maximal uptake of CD4+ T cells into the LP of the small 
intestine, they further showed that T cell migration to the small intestine could also 
be mediated by α4+β7+, CCR9-/- CD4+ T cells. These data suggest that T cells 
homing to the GALT can be mediated via a CCR9-dependent as well as –
independent mechanism. 
 
Lymphocyte migration to the large intestine seems to be regulated in a manner 
that differs from that seen in the small intestine. This difference in homing 
mechanism is due to the physiological difference seen within the large intestine. 
While the process of extravasion seems to be the same for the large and small 
intestines, CCR9 binding to its ligand thymus-expressed chemokine (TECK; 
CCL25) seems to play a less significant role in lymphocyte homing to the large 
intestine. Kunkel et al. (2000) were able to show that there is no significant CCL25 
activity in the colon, suggesting a diminutive role for CCR9 in mediating 
lymphocyte homing to the large intestine. Lefrançois et al., (1999) showed that 
activated CD8+T cells can enter the mucosa of the large intestine via a 7-
dependent mechanism. Instead, it has been proposed that CCR10 may be 
involved in the recruitment of lymphocytes to the large intestine. It has been shown 
that the CC chemokine ligand 28 (CCL28) functions as a signal for CCR10 
expressing IgA+ and IgM+ plasmablasts and T cells (Kunkel et al., 2003) to migrate 
to the gastrointestinal tract. 
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Overall, T cell imprinting and homing is regulated and controlled by a delicate 
mechanism that can be influenced by shifts in concentrations of chemoattractants. 
Data from mouse DCs isolated from MLNs and PPs, but not from spleen and PLN, 
increase expression of the mucosal homing receptor α4β7 (Mora et al., 2003; 
Iwata et al., 2004) and CCR9 (Mora et al., 2003) on memory T cells, and 
orchestrate effector/memory CD8+ T cells to home preferentially to the intestinal 
epithelium. Notably, DC imprinting of gut homing specificity has recently been 
shown to involve RA, which is uniquely produced by intestinal DCs, but not by DCs 
from other lymphoid organs (Iwata et al., 2004). Overall, these observations 
suggest that DCs play a pivotal role in the regulation of gut homing T cells. 
 
 
1.5.3 Lymphocyte Homing to the Skin 
As previously shown with the regulation of naive and memory lymphocytes homing 
to the intestine, there are also differences in receptor usage between naive and 
memory lymphocytes homing to peripheral tissue. The initial contact and rolling 
process of naive lymphocytes has been shown to depend on the interaction of L-
selectin (lymphocyte) with peripheral node addressins (PNAd) such as Gly-CAM 
(Lasky et al., 1992) or CD34 (Baumhueter et al., 1993).  
Migration of memory lymphocytes into the periphery and skin is regulated by the 
expression of CLA, P-selectin glycoprotein ligand-1 (PSGL-1), the integrin 41 
(very late antigen 4; VLA-4), and LFA-1, which bind vascular E-selectin, P-selectin, 
vascular cell adhesion molecule 1 (VCAM-1) and intracellular cell adhesion 
molecule 1 and 2 (ICAM-1, -2) respectively (Santamaria Babi et al., 1995; Fabbri 
et al., 1999). Eventually, these interactions lead to the rolling of lymphocytes along 
the endothelium and subsequent transmigration into the skin. The initial up-
regulation of CLA, PSGL-1 and CCR4 signals T cells within the blood to migrate 
into the dermis. Binding of CLA to E-selectin (CD62E) and PSGL-1 to P-selectin 
leads to E-selectin- and P-selectin-dependent tethering and rolling within 
cutaneous venules respectively (Asa et al., 1995). Subsequent firm adhesion of 
lymphocytes is mediated by the integrin 41, which also has been implicated to 
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mediate lymphocyte homing to inflamed skin (Rivera-Nieves et al., 2005). 
Diapedesis is subsequently instigated by the interaction of LFA-1 with ICAM-1/2. 
 
Interaction between CCR4 and CCL17 is then required for T cell migration into the 
dermal layer of the skin (Santamaria-Babi et al., 1995). The generation of 
epidermotropic T cells is induced by up-regulating cell surface markers CLA, 
CCR4, and CCR10 (Sigmundsdottir and Butcher, 2008). Once T cells have 
migrated into the dermal layer of the skin, CCR10 seems to be involved in the 
recruitment of lymphocytes from the dermis to the epidermis by binding to CCL27, 
which is expressed and secreted by keratinocytes of the epidermis 
(Sigmundsdottir et al., 2007). Hence, CCR10 has been proposed to be the main 
regulator of ‘epidermotropism’. 
However, with regard to the role of CCR10 and its implications in T cell homing to 
the skin conflicting observations have been made. Soler et al. (2003) showed that 
CLA+CCR4+CCR10+ TH cells do not have any significant advantage over 
CLA+CCR4+CCR10- cells with respect to skin homing abilities. Even if CCR10 is 
required for the initial phases of T cell homing to the skin, CCR10 is down-
regulated once the T cell has migrated into the skin. This differs from CCR4 cell 
surface expression, which is unaltered in TH cells from the blood compared to 
those from the skin (Kunkel et al., 2000).  
It is believed that vitamin D plays an important role in mediating T cell homing to 
the skin, as vitamin D can influence surface receptor expression on T cells. In the 
presence of 1,25 dihydroxycholecalciferol (1,25(OH)2D3), the active form of vitamin 
D, surface expression of skin homing markers is induced and up-regulated. As 
shown by Sigmundsdottir et al. (2007), addition of 1,25(OH)2D3 to cultures of 
activated T cells, led to the up-regulation of CCR10 and a down-regulation of 
47. Within the skin, DCs are believed to convert calciferol (Vitamin D3) to 
1,25(OH)2 Vitamin D3, which induces expression of CCR10. CCR10 then binds to 
CCL27 and promotes epidermotropism.  
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Figure 1.11: Differential regulation of lymphocyte migration to the intestinal mucosa and 
skin. 
Lymphocyte migration to and within anatomically different tissues depends on the interaction of 
specific homing receptors with their respective ligands. Migration of lymphocytes to the intestine, 
primarily depends on α4β7 and CCR9 expression, while lymphocytes homing to the skin express 
CLA, CCR4, and CCR10. L-selectin-mediated rolling is used by naive lymphocytes (green), while 
imprinted lymphocytes use α4β7 and CLA to enter the intestinal mucosa and skin respectively 
(blue). α4β1 and LFA-1 (red) also play a role in inflammation. Figure based on Fabbri et al., (1999). 
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1.6 Vitamin A and its Biological Significance in Humans  
There are three types of vitamin A, which are denoted vitamin A1, A2, and A3. 
While vitamin A1 can be found in plants, animals and salt-water fish, vitamin A2 is 
found in fresh-water fish, and plays a negligible role for mammals. Vogt and 
Kirschfeld (1984) have shown the existence of third type of vitamin A (A3) which 
forms the basis of visual systems of a wide variety of animals. As vitamin A2 and 
A3 only play a negligible role for mammals, in the context of this thesis, the term 
vitamin A will refer to vitamin A1.  
Generally speaking, vitamin A is a broad term that includes several 
biochemically related forms, including pro-vitamin A carotenoids such as β-
carotene, and the vitamin A (retinol) metabolites retinal and RA (McCullough et al., 
1999). Depending on the physiological process and anatomical location, different 
metabolites of vitamin A play the active role. 
 
 
1.6.1 The Role of Vitamin A and its Metabolites in Vision 
There are several factors that influence vision, including age and genetic 
predisposition. However, vitamin A has been shown to play a crucial role in the 
development and functional regulation of vision (Pirie, 1956) and it has been 
documented that patients suffering impaired vision often experience vitamin A 
deficiency (VAD). Rather than retinol, it is its photosensitive metabolite retinal that 
plays the biologically active role in vision (Wald, 1933). In order to detect light, 11-
cis-retinal is covalently bound to opsin to form the visual pigment rhodopsin. When 
struck by a photon (light), 11-cis retinal undergoes photoisomerization to all-trans 
retinal (Bernstein et al., 1987), thereby activating the opsin molecule.  
 
 
1.6.2 The Role of Vitamin A in Cellular Differentiation and Development 
The vitamin A metabolic pathway also plays a role in cellular differentiation, 
development, proliferation, and reproduction. Early developmental studies have 
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shown that VAD in female parents during pregnancy is associated with severe 
congenital malformations during fetus development and tissue growth. Wilson and 
Warkany (1950) were able to show that VAD in rats was associated with defects 
during heart development. Similarly, Lohnes et al. (1994) showed null mutations in 
RAR to be associated with craniofacial and skeletal abnormalities in mice. In 
addition, it has been shown (Chytil, 1996) that retinoids are crucial for perinatal 
lung development. RA given to neonatal rats was shown (Massaro and Massaro, 
1996) to cause significant increase in the number of pulmonary alveoli. With 
regards to reproduction, it has been shown that the lack of vitamin A is a reason 
for testicular atrophy (Mason, 1933) and decreased ovarian size (Panda et al., 
2001). Although vitamin A deficient rats can conceive, depending on the degree of 
vitamin A deficiency, rats give birth to dead or malformed offspring (Takahashi et 
al., 1975).  
In humans, an imbalance in vitamin A levels can have analogous effects. 
Human hypovitaminosis A may lead to growth inhibition, restraint reproduction, 
membrane disruption and eventually death (Bendich and Langseth, 1989). Vitamin 
A also plays an important role in regulating the development of immune cells. It 
has been shown that retinoid deficiency negatively affects lymphocyte 
development and maturation (Zhou et al., 2008), as well as T cell activation and 
antibody production due to missing B cell stimulus (Carman et al., 1989). Aside 
from regulating the development of immune cells, RA has been shown to play a 
role in eye development, where it regulates eye segment development and growth 
of the ventral retina (Matt et al., 2005). 
 
 
1.6.3 Vitamin A in Immunity and Infection 
Much research has been conducted on the role of vitamin A and its metabolites in 
modulating the immune system. As reviewed by Ross and Stephensen (1996), it 
was in the 1920s when vitamin A was first suggested to play a role in regulating 
the immune system. Today, vitamin A, also known as the anti-infective vitamin, is 
thought to play a crucial role in eliciting specific immune responses and that its 
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deficiency predisposes to infections. Based on McCullough et al. (1999), vitamin A 
seems to have two main functions in preventing infection. Firstly, it has a direct 
effect on the immune system and secondly, it has an effect on maintaining 
epithelial surfaces. 
 
The clinical relevance of vitamin A is strengthened by the observations that VAD 
severely compromises host defence. Within the intestine, vitamin A functions to 
ensure the integrity of the gut mucosa. However, in cases of malnutrition, VAD can 
lead to enhanced viral infections (Ahmed et al., 1990), which may be the result of 
VAD-induced decrease in the numbers of B and T cells in the small intestine 
(Iwata, 2009). Furthermore, vitamin A is thought to increase IgA responses in the 
intestine (Mora et al., 2006).  
Other studies have been shown a link between VAD and respiratory infections 
(Vijayaraghavan et al., 1990). It has been shown that in vitamin A-deficient 
animals a reduction in mucociliary cells takes place, which is replaced by a 
keratinized layer (Chytil, 1999). Supplementation of vitamin A in the diet restores 
the bronchopulmonary network back to normal (Wolbach and Howe, 1933). 
Hence, the role of vitamin A in regulating cell-mediated and humoral immunity, as 
well as mucosal homeostasis, emphasizes its value for the human body and 
immunity. 
In addition, RA is known to play a role in maintaining the Th17 – regulator T cell 
balance. In mice, Uematsu et al. (2008) showed that low concentrations of RA 
might be required for efficient development of Th17 cells. These observations 
were confirmed by Cha et al. (2010) who showed that vitamin A-deficient mice 
showed a decrease in IL-17 producing CD4+ T cells. More specifically, RA was 
shown to inhibit Th17 cells and to promote FoxP3 expression via the RAR-α (Elias 
et al., 2008). These data coincide with other publications that reported RA to have 
an impact on the differentiation of inducible regulatory T cells (Benson et al., 
2007). 
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Figure 1.12: Differentiation of naïve CD4
+
 T cells into Th cells in the presence of RA. 
Naive CD4
+
 T cell differentiation into Th17 cells in mice is controlled by the presence of TGF-β and 
IL-6, while Th17 development from naive CD4 T cells in humans has been suggested to depend on 
IL-1, IL-6, TGF-β and IL-23. Retinoic acid is implicated in the repression of Th17 responses, while 
inducing regulatory T cells. Figure adapted from Mora et al. (2008) and Di Cesare et al. (2009).   
 
 
 
With respect to T cell responses, RA has been suggested to inhibit the production 
of proinflammatory cytokines that favour a Th1 response, while promoting the 
production of cytokines that favour a Th2 response. RA has been shown (Kang et 
al., 2000) to enhance secretion of IL-10 and block TNF-α and IL-12 synthesis. 
 
 
1.6.5 Modulatory Effect of Vitamin A on Lymphocyte Homing 
The capacity of small intestinal DCs to trigger α4β7 and CCR9 surface expression 
on T and B cells is thought to be linked to their ability to metabolize and synthesize 
RA. RA is produced by DCs in the gut-related lymphoid organs, PPs of the GALT, 
MLN, and LP of the small intestine. It has also been proposed that macrophages 
in the LP may be able to produce RA. 
Using mouse models, it has been shown that the ability of Gut-Associated 
Lymphoid Tissue-derived DCs (GALT-DCs) to induce expression of CCR9 and 
integrin α4β7 on T cells is associated with their ability to synthesize RA. As shown 
by Iwata et al. (2004) in the absence of GALT-DCs, exogenously added RA 
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induces differentiation of gut-homing T cells that express CCR9 and α4β7. 
Furthermore, RARs have been shown to regulate the homing properties of 
intestinal lymphocytes. In vitro experiments have shown that DCs from PPs and 
MLNs convert all-trans retinol to all-trans retinoic acid (ATRA), which preferentially 
activates RAR-α, resulting in enhanced expression of CCR9 and α4β7 (Iwata et 
al., 2004; Delescluse et al., 1991). Similarly, Mora et al. (2006) demonstrated that 
the addition of RA to activated murine spleen B cells leads to the expression of 
α4β7 and CCR9. More specifically, they showed that the imprinting of gut-homing 
tropism by MLN-DCs depended on the presence of RA. In vitro experiments 
showed that in the presence of RA, porcine DCs significantly up-regulated 
transcription of β7 and CCR9 encoding genes in lymphocytes after co-culture with 
MoDCs (Saurer et al., 2007). 
 
 
1.6.4 Vitamin A Metabolism 
1.6.4.1 Dietary Uptake of Vitamin A and Liver Storage 
Within the intestine, enterocytes convert provitamin A carotenoids to 
retinalaldehyde, of which the majority is reduced to retinol (McCullough et al., 
1999) which can then either be transported to the liver or taken up by the intestinal 
mucosa. Vitamin A cannot be produced by the human body and needs to be taken 
up via the diet. Primarily, vitamin A is taken up as precursor molecules in form of 
retinyl esters or provitamin A, which are animal- and plant-derived respectively. 
Once ingested, both, retinyl esters and -carotene are converted to retinol in the 
small intestinal mucosa. Reduction of -carotene to retinal is mediated by -
carotene 15,15’- dioxygenases (Figure 1.13). Retinal is then further reduced to 
retinol by retinaldehyde reductases (Tomkin and Hussey, 1989). Respectively, 
retinyl esters are reduced to retinol by pancreatic esterases (Figure 1.13b). 
Synthesized retinol is then either absorbed or re-esterified for transport to and 
storage in the liver. Inside the liver, retinyl esters will be stored in the form of retinyl 
palmitate (Tomkins and Hussey, 1989). To maintain homeostatic levels of blood 
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retinol, these esters will be hydrolysed and released into the blood stream (1-2 
M) (Iwata, 2009). 
 
a) 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
Figure 1.10: Synthesis of retinol from retinyl esters and β-carotene. 
The conversion of -carotene to retinol is a 2-step enzymatic process, which takes place primarily 
in the intestinal mucosa (a). The conversion of retinyl esters to retinol is mediate by pancreatic 
esterases such as β-C15,15-dioxygenase and short chain dehydrogenase/reductases (SDR) (b). 
Figure is based on data by Tomkinson and Hussey (1989). 
 
 
1.6.4.2 Intestinal Absorption and Metabolism of Vitamin A  
Retinol absorption is dependent on the presence of several enzymes, including the 
retinol binding protein (RBP), which binds retinol at a ratio of 1:1 (Kanai et al., 
1968). Subsequent entry of retinol into mucosal cells depends on the binding of 
RBP to the surface of the target cell. Alternatively, absorption of retinol into 
enterocytes has been suggested to be based on simple diffusion (Harrison, 2005).  
 
Due to their lipophilic character, retinoids associate with specific proteins within the 
plasma and cytoplasm that allow stabilization and delivery to target tissues. After 
cellular uptake, retinol is bound by cellular retinol-binding proteins (CRBPs) 1 and 
2, which are thought to play a role in the metabolism of retinol, by regulating the 
intracellular concentration of retinol, retinal, and RA (Roos et al., 1998). 
Oxidation of retinol takes place within the cell cytoplasm and requires the activity 
of several enzymes. Members of the alcohol dehydrogenase and short-chain 
dehydrogenase/reductase enzyme families catalyse the reversible and rate-
Retinol Retinyl esters 
Pancreatic 
esterases 
Retinol 2 Retinaldehyde 1 -Carotene 
SDR 
-C 15,15’-
dioxygenase 
ADH 
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limiting conversion of retinol to retinal. In contrast, enzymes catalysing the 
irreversible oxidation of retinal to RA belong to the ALDH and cytochrome P450 
enzyme families (Duester, 1996). Due to the reversibility of the retinol to retinal 
conversion, it is more difficult to determine whether an enzyme will mediate 
oxidation of retinol or reduction of retinal. However, it has been shown that alcohol 
dehydrogenase (ADH) is more efficient in retinol oxidation that reduction (Yang et 
al., 1994). Also, enzyme preferences for coenzymes nicotinamide adenine 
dinucleotide (NAD+; retinol oxidation) or NADH (retinal reduction) helps identify the 
metabolic function of an enzyme. As the levels of free cytoplasmic NAD+ exceed 
those of NADH (Veech et al., 1969), ADHs are likely to perform retinol oxidation.  
 
While it was initially thought that class 3 ADHs are not involved in retinol 
metabolism (Beisswenger et al., 1985), human class 1, 2 and 4 ADHs have been 
shown to catalyse retinol oxidation in vitro (Yang et al., 1994; Kedishvili et al., 
1995; Boleda et al., 1993). Generation of systemic retinal is partially provided by 
ADH1, which is primarily expressed in the liver and is thought to play a role in 
minimizing vitamin A toxicity by eliminating excess retinol (Molotkov et al., 2002). 
On the contrary, ADH4 has been suggested in retinal synthesis during vitamin A 
deficiency during development (Haselbeck and Duester, 1997). Although 
enzymatically less efficient, ubiquitous expression of ADH3 has been proposed to 
be the main enzyme that leads to the synthesis of systemic retinal (Molotkov et al., 
2002b). As shown in mice, expression of class 4 ADH coincides with sites of RA 
detection (Ang et al., 1996). Within the cell, ADHs 1, 2, and 4 have been shown to 
metabolize all-trans retinol, 9-cis retinol, and 13-cis retinol (Bhat and Samaha, 
1998; Labrecque et al., 1995). In relation to the gut immune system, the potential 
of local RA synthesis was first suggested when high levels of ADH1 expression 
were reported in mice (Haselbeck and Duester, 1997). 
 
Upon synthesis, retinal is oxidised to RA by retinal dehydrogenases (RALDHs) or 
cytochrome p450 enzymes. To date, three classes of ALDH have been identified. 
A role for ALDH class 1 in the oxidation of retinal to RA has previously been 
described (Lee et al., 1991; Duester, 1998), while class 2 and 3 ALDHs play no 
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significant role in retinal oxidation (Lee et al., 1991). Among the p450 enzyme 
family, p450 1A1 and 1A2 have been identified to oxidize retinal (Raner et al., 
1996). Synthesized RA is then bound by cytoplasmic retinoic acid binding proteins 
(CRABP) 1 and 2, which are known to be involved in the synthesis, degradation, 
and control of steady-state levels of RA. More specifically, CRABP1 and 2, which 
regulate RA bioavailability and delivery to RARs respectively (Dong et al., 1999). 
RA can then be further degraded to products such as 4-oxo-RA, 4-OH-RA, 18-OH-
RA and 5,8-epoxy-RA (Roos et al., 1998; Maden, 2002), which are then excreted. 
 
 
   PLASMA        CYTOPLASM 
  
 
Figure 1.11: Vitamin A metabolic pathway. 
Conversion of retinol to retinal is mediated by members of the ADH family, while subsequent 
oxidation of retinal to RA is catalysed by ALDHs and cytochrome P450 enzymes. During this 
process, retinoids are bound by specific proteins that promote stabilization and delivery of the 
various retinoids. 
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1.7 Vitamin D and its Biological Significance for Humans 
Vitamin D is a fat-soluble prohormone, which means that it has no physiologically 
significant activity. Vitamin D can be synthesized by humans with exposure to 
sunlight and therefore is only mistakenly classified a vitamin. Several forms of 
vitamin D have been identified. However, the two prevalent forms are vitamin D2 
(ergocalciferol) and vitamin D3 (cholecalciferol). While, vitamin D2 is produced by 
invertebrates, fungi and plants, it is not produced by vertebrates. On the contrary, 
vitamin D3 is produced naturally within the animal skin upon exposure to sunlight 
(Holick, 1995). In the context of this thesis, all further references with regard to 
vitamin D will refer to vitamin D3 and its active metabolite 1,25(OH)2D3.  
 
 
1.7.1 The Role of Vitamin D in Immunity and Infection 
The role of vitamin D in immunity and cellular differentiation has been well 
documented. The immune modulatory function of vitamin D has been documented 
in that it affects immune cells such as macrophages by promoting phagocytosis 
(Bar-Shavit et al., 1981). In addition, vitamin D has been suggested to play a role 
in autoimmune diseases and shown to exert anti-tumour activity in vitro and in 
vivo. 1,25(OH)2D3 has been shown to play a role in regulating DC responses, and 
inducing regulatory T cells (Prietl et al., 2010). In murine models of inflammatory 
bowel disease, the absence of vitamin D has been shown to enhance disease 
severity (Cantorna et al., 2000). 
The ability of vitamin D to kill cancer cells is thought to be associated with its 
function as a ligand for nuclear transcription factors which allows it to induce death 
of vitamin D receptor (VDR) expressing cancer cells (Welsh et al., 2002). At the 
same time, a decrease in serum 1,25(OH)2D3 level has been associated with 
increased risk of breast cancer (Garland et al., 2006) and newly developed vitamin 
D analogues such as EB1089 have been shown to possess anti-tumour activity 
(Colston et al., 1992). Vitamin D has further been shown to prevent and reverse 
coronary disease, as vitamin D deficiency has been associated with an increase in 
high blood pressure and cardiovascular risk (Wang et al., 2008).  
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One of the main functions of vitamin D is the regulation of calcium absorption in 
the gut. Active vitamin D increases calcium concentration in serum by promoting 
intestinal absorption, leading to an increased deposition of calcium in bones and 
teeth. The deficiency of vitamin D has been well documented in children, leading 
to the development of rickets and impaired bone mineralization that might be 
contributing to osteoporosis.  
In otherwise healthy individuals, vitamin D deficiency can be due to inefficient 
vitamin D uptake or lack of sunlight exposure. Alternatively, heredity disorders can 
lead to limited vitamin D absorption or defects that impair the conversion of vitamin 
D into active metabolites. In addition, vitamin D has been suggested to play role in 
aging by slowing down the turnover of leukocytes and telomere shortening 
(Richard et al., 2007).  
Vitamin D deficiency has been linked to increased rates of infection. In humans, 
activation of direct antimicrobial pathways in monocytes and macrophages is 
mediated by vitamin D-dependent production of the antimicrobial peptide 
cathelicidin (Liu et al., 2006). The role of cathelicidin was first shown (Nizet et al., 
2001) in cathelicidin knockout mice that experienced increased susceptibility to 
skin infection. Activation of TLR1/2 induces expression of the 25D-1α-hydroxylase 
CYP27B1, which converts inactive 25-dihydroxyvitamin D3 to bioactive 
1,25(OH)2D3 (Zehnder et al., 1999). In turn, this leads to the up-regulation of 
VDRs. As the cathelicidin gene contains as cis-acting vitamin D receptor response 
element (VDRE), activated VDRs will induce transcription of the cathelicidin gene 
(Liu et al., 2006). Cathelicidin is synthesized and secreted by a variety of immune 
cells (Agerberth et al., 2000; Di Nardo et al., 2003) and decreased expression has 
been reported in leukemia (Yang et al., 2003).  
 
 
1.7.2 Modulatory Effect of Vitamin D on Lymphocyte Homing 
In the context of DC biology, VDR ligands have been shown to affect maturation, 
differentiation, and migration of DCs and inhibit DC-dependent T cell activation, 
resulting in an overall state of immunosuppression (Penna and Adorini, 2000). 
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However, vitamin D has also been shown to play an important role in regulating 
immune responses, such as the regulation of homing receptors on T cells. In the 
presence of 1,25(OH)2D3 chemokine-induced migration of naive cells to the lymph 
nodes was inhibited (Topilski et al., 2004). Migration of lymphocytes to the skin 
has been associated with cell surface markers such as CLA (Bos et al., 1993), 
CCR4 (Campbell et al., 2007), and CCR10 (Soler et al., 2003). Yamanaka et al. 
(2008) showed that vitamin D plays a significant role in the regulation of CLA 
surface expression on T cells by selectively down-regulating CLA expression. 
Vitamin D has also been shown to have an effect on the production of CCL22, a 
CCR4 ligand. It was shown that CCL22 production by MoDCs is markedly 
enhanced in the presence of 1,25(OH)2D3 (Adorini et al., 2004). Likewise, 
1,25(OH)2D3 has been shown to instruct T cells to express CCR10, which enabled 
them to migrate to the skin-specific chemokine CCL27 secreted by keratinocytes 
of the epidermis (Sigmundsdottir et al., 2007). On the other hand, 1,25(OH)2D3 
was shown to suppress the gut homing receptors α4β7 and CCR9. 
 
 
1.7.3 Vitamin D Metabolism 
In contrast to vitamin A, vitamin D is not a true vitamin, as it is actively produced 
by humans through the combined effect of substrate specific enzymes and UV 
exposure. The active form of vitamin D3, 1,25-dihydrocholecalciferol, is produced 
from cholesterol (Figure 1.15a). Synthesis of vitamin D3 from 7-dehydrocholesterol 
takes place within the stratum basale and spinosum of the epidermis in response 
to UVB radiation. 
Within the liver and kidneys vitamin D3 is converted to its biologically active form 
1,25 dihydroxyvitamin D, (1,25(OH)2D3), which is also referred to as calcitriol 
(Prosser and Jones, 2004). In the liver, a hydroxy group (OH) is placed on carbon 
atom number 25 (Figure 1.15b) to generate 25 – hydroxycholecalciferol. In the 
kidneys a further OH group is placed onto carbon number 1. The synthesized 
hormone is called 1,25-dihydroxycholecalciferol, the active form of vitamin D 
(Holick et al., 1981). 
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a) 
 
 
 
 
b) 
 
  
 
Figure 1.12: Vitamin D3 metabolism to 1,25-dihydroxycholecalciferol. 
a) Cholecalciferol is generated from cholesterol in the presence of 7-dehydrocholesterol reductases 
and UV radiation within the epidermis. b) Cholecalciferol is converted to the metabolically active 
from of vitamin D3 1,25-dihydroxycholecalciferol (1,25-(OH)2D3 or 1,25(OH)2D). With longer 
exposure to sunlight, equilibrium is established and the vitamin is degraded as fast as it is 
generated. Figure adapted from Lin et al. (2003). 
 
 
Notably, increases in skin melanin concentration prolongs the exposure time to 
solar UV radiation required to maximize the formation, but not the total content, of 
provitamin D3 (Holick et al., 1981). In contrast, it was shown that increased skin 
pigment can greatly reduce the UV ratiation-mediated synthesis of vitamin D3 
(Clemens et al., 1982). 
 
Cholecalciferol (Vitamin D3) 25-Hydroxycholecalciferol 1,25-Dihydroxycholecalciferol 
Cholesterol 7-Dehydrocholesterol Cholecalciferol (Vitamin D3) 
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1.8 Regulation of Gene Transcription by Vitamins A and D 
1.8.1 Expression and Role of Human RARs and Retinoid X Receptors (RXR) 
RARs are RA-inducible transcription factors that belong to the superfamily of 
steroid/thyroid nuclear receptors (Krust et al., 1989). In humans, three distinct 
RAR have been identified. Petkovich et al. (1987) were among the first to 
characterise hRAR-α (isoforms α1-2) and hRAR-β (β1-4), while hRAR-γ (γ1-2) 
was characterised by Krust et al. (1989). In mice, all three equivalent mRARs (α, 
β, γ) were identified by Zelent et al. (1989). Studies on the distribution of these 
receptors in adult mice have shown that while mRAR-α is ubiquitously expressed 
and mRAR-β at low levels in most tissues, mRAR-γ can be found almost 
exclusively and at comparatively high levels in the skin (Zelent et al., 1989). In 
contrast, during embryonic development, the expression patterns of RAR-β and 
RAR-γ are more restricted than that of RAR-α (Mollard et al., 2000). Similarly, 
Redfern and Todd have shown (1992) that RAR-α and RAR-γ can readily be found 
in keratinocytes and fibroblasts, while RAR- is undetectable. In addition, they also 
showed that RA can rapidly induce expression of RAR-β.  
On a cellular level, the RAR isomers α1 and γ1 are both constitutively expressed 
on human T and B cell lines or adenoidal T and B cells, while detection of RAR-β2 
and RAR-α2 is only possible after treatment with ATRA (Ballow et al., 2003). 
However, the RAR isoforms -β1, - β3, and -γ2 were not inducible with ATRA, 
highlighting the differential effects of ATRA on RARs and possible variation in 
receptor function. Similarly, it has been shown that RAR-α and RAR-γ, but not 
RAR-β, are expressed by T cell hybridomas as well as murine thymocytes and 
thymic stromal cells (Meco et al., 1999, Tóth et al., 2001). 
 
RAR-γ has been implicated in promoting CD8+ T cell responses. Mice lacking 
RAR-γ have been shown to mount a defective memory and effector CD8+ T cell 
response (Dzhagalov et al., 2007). RAR-γ2 is only expressed at low levels in 
human lymphocytes and its expression is not induced by treatment with ATRA, 
while RAR-1 and RAR-3 are not expressed in B or T cells under any conditions 
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(Ballow et al., 2003). Besides, it has been suggested that RAR-α is necessary for 
TGF-β1-mediated induction of FoxP3 (Elias et al., 2008). 
The RXR family also contains three members (RXRα-γ), which only interact with 9-
cis RA. With respect to RXRs, the generation of mice carrying mutations in RARα 
were shown to experience sever defects in the immune system (Du et al., 2005).  
 
 
1.8.2 Expression and Role of VDRs 
The discovery of the VDR was reported by Haussler and Norman (1969) when 
they provided evidence for the existence of a chromosomal protein capable of 
binding the biologically active form of vitamin D. Like RARs, nuclear VDRs belong 
to the steroid/thyroid hormone family of nuclear receptors that function as ligand 
inducible transcription factors (Minghetti and Norman, 1988). VDRs are 
continuously expressed by immune cells (Yu et al., 1991). In particular, VDR 
expression has been reported for T and B lymphocytes (Veldman et al., 2000) and 
monocytes differentiating into DCs (Brennan et al., 1987).  
Unlike RARs, only one VDR isomer has been described. However, a single 
nucleotide polymorphism in the initiation codon results in an alternate translation 
start site three codons downstream. Alternative splicing results in multiple 
transcript variants encoding the same protein (NM_000376; RefSeq).  
 
 
1.8.3 Receptor Dimerization and Regulation of Gene Expression by Vitamin 
A and Vitamin D 
RA signalling is mediated by nuclear receptors of the RAR and RXR families. More 
specifically, depending on the stereoisomer, RA can signal through RXR/RAR 
heterodimers or RXR/RXR homodimers (Zhang et al., 1992; Rowe, 1997). While 
ATRA shows a high affinity for and activation of RARs, it shows little binding 
affinity for RXRs (Levin et al., 1992). In contrast, 9-cis RA is known to signal 
through RXRs as well as RARs (Allenby et al., 1993). 
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Each receptor isoform contains two transcriptional activation components located 
in the N-terminal and C-terminal region. These domains can act either 
synergistically or differentially to activate RA response elements (RAREs). In 
cases where RXR monomers complex to form homodimers binding and activation 
of the retinoid x response element (RXRE) takes place. Similarly, the VDR 
functions by heterodimerizing with RXRs which then selectively bind and activate 
VDREs.  
 
The ability of RXRs to heterodimerize with receptors responsive to a variety of 
ligands emphasizes its significance in hormonal signalling. Yet, formation of the 
different receptor complexes depends on ligand availability and receptor 
concentration. Depending on the type of ligand interaction, as well as on the 
availability of co-activators and co-repressors, nuclear receptor-ligand complexes 
perform either transcriptional activation or repression of target genes. 
 
When RAR ligands such as ATRA (9-cis RA) are not present, the RAR-RXR 
heterodimers (RXR-RXR homodimers) are constitutively bound to the RARE 
(RXRE) attracting corepressors and histone deacetylases to repress gene 
expression. Respectively, in the absence of vitamin D, the VDR-RXR heterodimer 
is constitutively bound to the VDRE, leading to the recruitment of corepressors and 
histone deacetylases that block gene expression (Figure 1.16a). 
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a) 
 
 
b) 
 
 
Figure 1.13: Control of gene expression by retinoids and vitamin D. 
a) In the absence of agonists or in the presence of antagonists, RAR*-RXR heterodimers bind to 
DNA and recruit co-repressors to block gene expression. b) Agonist binding leads to a 
conformation change in the RAR ligand binding domain, which results in the release of the co-
receptors and recruitment of co-activators. Some co-activators interact with the transcription 
machinery, while others induce chromatin remodelling. * Instead of RAR, another RXR receptor 
may bind to form a homodimer that binds to a RXRE. Alternatively, the vitamin D receptor (VDR) 
can dimerize with RXR to regulate gene expression through the VDRE. Figure modified from 
Niederreither and Dollé (2008). 
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When RAR ligands become available, i.e. when RA is produced by intestinal DCs, 
these ligands enter cells where they activate RAR-RXR or RXR-RXR dimers 
(Kelsall, 2008). Similarly, vitamin D activates VDR in a ligand dependent manner 
to regulate gene expression. Receptor binding is followed by conformational 
changes leading to the release of corepressors and recruitment of coactivators. 
This in turn, attracts histone acetyl transferases, resulting in the conformational 
opening of the chromosome and activation of gene transcription (Kurokawa et al., 
1995). Subsequent activation of gene transcription can lead to changes in 
proliferation, differentiation, and immunomodulatory functions that either can be 
immune stimulating or immune suppressive.   
 
Notably, there have been controversies regarding the mechanism by which RA 
exerts its functions. Although it has been generally believed, that RA acts on the 
regulation of gene transcription in a direct fashion, there have been suggestions 
that changes in RA-induced gene regulation may be due to RA-dependent 
initiation of mRNA translation rather than to RA-induced gene expression. As 
shown by Lal et al. (2005) ATRA treatment of leukemia cells is associated with the 
deactivation of 4E-binding protein 1 (4E-BP1) and its subsequent dissociation from 
the eukaryotic initiation factor-4E (eIF4E) complex, leading to cap-dependent 
translation. 
Similarly, it has been shown that RA can stimulate phosphorylation and activation 
of signal transducers and activators of transcription 1 (STAT1) (Gianni et al., 1997) 
so rapidly that it is unlikely that its effect is mediated by transcriptionally activated 
RARs. Alternatively, it has been suggested (Si and Collins, 2002) that activated 
STAT5 directly binds to RAR/RXR and triggers a conformational change thereby 
mimicking the action of vitamin D.  
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1.9 Aims and Hypothesis 
The ability of intestinal DCs to induce T cells expressing a gut homing phenotype 
has been linked to their ability to metabolize vitamin A. RA is thought to induce 
expression of intestinal homing marker α4β7 and the small intestinal homing 
marker CCR9 on lymphocytes. In the context of HIV infection and vaccine 
development, induction of a strong CTL response within the intestinal mucosa 
would allow a reduction in viral titre. In turn, this would reduce the rate of CD4+ T 
cells killing and time of disease progression. Based on the nature and function of 
mucosal DCs, systemic vaccination has aimed at the induction a mucosal immune 
response by non-mucosal DCs. Here, we hypothesize systemic DCs to hold the 
potential to induce mucosal T cells. The specific aims of this thesis were as listed 
below: 
 
1. To establish in-vitro methods for the generation of MoDCs, dDCs, and LCs and 
to develop a protocol for the isolation of dermal and epidermal LCs from human 
skin explants. Furthermore, we aimed to characterize the various DC subtypes by 
phenotypic analysis and comparison (chapter 3). 
 
2. To investigate the effects of RA and systemic DCs on α4β7 and CLA expression 
on total, naive, and memory CD4+ and CD8+ T cells (chapter 4). 
 
3. To assess the effect of retinol and retinal on α4β7 and CLA expression in the 
context of systemic DCs and to determine the potential of systemic DCs to 
metabolize these retinoids (chapter 5). 
 
4. To assess the effects of vitamin D on the expression of skin and gut homing 
receptors on CD4+ and CD8+ T cells in the context of systemic DCs (chapter 6). 
 
5. To analyse the effect of RAR and dehydrogenase inhibitors on α4β7 and CLA 
expression of T cells cultured in the presence of systemic DCs (chapter 7). 
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Chapter 2 
 
 
 
 
 
Materials and Methods 
 
 
 
2.1 Chemical Reagents 
Unless otherwise stated, experiments involving water or phosphate buffer saline 
(PBS) were performed using sterile dH2O and PBS under aseptic conditions. 
RPMI1640, HEPES-modified RPMI, DMEM, and sterile PBS were all obtained 
from Sigma-Aldrich, UK. Serum free StemX-Vivo medium was obtained from R&D 
Systemic, UK. 
 
 
2.1.1 Solutions and Buffers 
1 M HCl 
0.5 ml 12 M HCl  
5.5 ml dH2O 
 
1 x Tris-Borate EDTA (TBE) Buffer 
1/5 dilution of 5 x TBE in dH2O. 
 
2 % RPMI Medium 
500 ml bottle RPMI 1640 (HEPES modification) 
5 ml FCS 
2 mM L-Glutamine 
100 IU/ ml Penicillin 
100 µg/ ml Streptomycin 
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4 mM HCl 
1 ml FCS 
40 µl of 1 M HCl 
8960 µl dH2O 
The solution was filter-sterilized before being used. 
 
5 x TBE Buffer 
89 mM Tris 
89 mM Boric Acid 
2 mM EDTA 
 
10 % AB-RPMI 
90% RPMI 1640 Medium 
10 % AB Serum (H4522, Sigma) 
 
10 % GIBCO Medium (CD34+ cells) 
90 % RPMI 1640 Medium 
10 % FCS (GIBCO) 
2 mM L-Glutamine 
100 IU/ ml Penicillin 
100 µg/ ml Streptomycin 
 
10 % RPMI 1640 Medium 
500 ml bottle RPMI 1640 (buffered with NaHCO3) 
50 ml FCS 
2 mM L-Glutamine 
100 IU/ ml Penicillin 
100 µg/ ml Streptomycin 
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10 % DMEM Medium 
500 ml bottle DMEM 
50 ml FCS 
2 mM L-Glutamine 
100 IU/ ml Penicillin 
100 µg/ml Streptomycin 
 
50% Percoll 
107 ml of 70 % Percoll  
43 ml unsupplemented HANKS balanced salt solution (HBSS; Sigma-Aldrich, UK). 
 
70% Percoll 
145 ml Percoll (Sigma-Aldrich, UK) 
85 ml Percoll Mix Solution. 
 
CD40 Ligand/TRAP 
CD40L (Z02022, GenScript USA Inc.) was resuspended in PBS at 20 µg/ ml. 
 
DNase (cell culture) 
A stock was prepared in PBS at 10,000 U/ ml (Roche, UK). DNase was used at a 
working concentration of 10 U/ ml. 
 
DNase Buffer (reverse transcription) 
150 μl per sample/ per column. 
15 μl of 10 x DNase buffer (Promega) 
135 μl of dH2O 
 
FACS Buffer 
2 % FCS  
2 mM EDTA (8.0 pH) 
5 ml of 10 % NaN3 
 Make up to 500 ml with non-sterile PBS. 
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Freeze Mix 
90 % FCS 
10 % DMSO (Sigma Aldrich, UK) 
 
LPS 
A stock solution of Ultra-Pure LPS (0111:B4; InvivoGen) was prepared at 1mg/ ml. 
 
MACS Buffer 
500 ml sterile PBS (Sigma, UK) 
2 % FCS  
2 mM EDTA (pH8) 
 
Non-sterile Phosphate Buffered Saline (PBS) 
Non-sterile PBS was prepared by diluting Dulbecco’s PBS powder (D5773-10L, 
Sigma) in 10 L dH2O. The solution was placed on a magnetic stirrer until all the 
powder was dissolved.  
 
Percoll Mix Solution 
60 ml of 10 x PBS  
176 ml H2O. 
 
Serum free StemX-Vivo 
2 mM L-Glutamine 
100 IU/ ml Penicillin 
100 µg/ml Streptomycin 
 
Trypan Blue 
Trypan Blue Solution 0.4 % (T8154; Sigma, UK) was diluted with PBS at 9:1 ratio. 
The solution was filter-sterilized and stored at 4 °C.   
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2.1.2 Cytokines 
Flt-3/Flk-2 Ligand 
Stock solutions (308-FKN, R&D Systems) were prepared in 2 % RPMI 1640 
Medium at 5 µg/ml. Aliquots of 200 µl were stored at - 80°C. 
 
GM-CSF 
A stock (215-GM; R&D Systems) of 20 µg/ ml was prepared in 2 % RPMI and 
stored at -80 °C. 
 
IL-4 
A stock (204-IL; R&D Systems) of 200 000 U/ ml was prepared in 2 % RPMI, 
aliquoted, and stored at -80 °C. 
 
rhSCF 
A stock (255-SC; R&D Systems) of 5 µg/ ml was prepared in 2 % RPMI, aliquoted, 
and stored at -80 °C. 
 
rhTGF-β1 
A stock of 1 µg/ ml was prepared (240-B; R&D Systems) in 4 mM HCl, aliquoted, 
and stored at -80 °C. 
 
rhTNF-α 
A stock was prepared in PBS at 1 ng/ µl (210-TA; R&D Systems), aliquoted, and 
stored at -80 °C. 
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2.2 Cell and Tissue Culture  
2.2.1 Cell Count 
Cells were resuspended in an appropriate volume of 10 % RPMI 1640 Medium, 
MACS Buffer, or PBS, depending on the nature of the experiment. For the cell 
count of dendritic cells and lymphocytes, cell dilutions of 1:2 and 1:10 in trypan 
blue were prepared respectively. For the count of cells from percoll interface (PIs) 
and percoll pellet (PPs) isolated from buffy coats or cones (section 2.2.4.2), 
dilutions of 1/40 were prepared. Ten microliters of the resulting dilution were 
loaded onto the counting chambers of a disposable haemocytometer (Biostat, UK). 
The degree of cell viability was determined by trypan blue exclusion. The cell 
count was defined as the number of live cells within nine squares. The total 
number of cells was determined using the formula present below: 
 
Total Number of live cells  
= cell count x 104 x dilution factor x volume (ml) 
 
 
2.2.2 Resurrecting Cells 
Cells (1 ml aliquots) were defrosted in a 37 °C water bath before being added 
drop-wise to 10 ml 2 % RPMI medium. Subsequently, the cells were pelleted for 5 
minutes at 1200 rpm in a ROTINA 46 (Hettich, Zentrifugen) at room temperature 
(RT) to remove residual dimethyl sulfoxide (DMSO). The cells were then washed 
once more in 2 % RPMI medium for 5 min. at 1200 rpm. The pellet was then 
resuspended in 2-3 ml of fresh, 10 % FCS-supplemented RPMI medium. The cells 
were subsequently treated with 1 μl DNase per 1 ml cells and incubated for 1-2 hrs 
at 37 ºC. Finally, the DNase was washed off and cell viability determined as 
described in section 2.2.1. Cells were either incubated to grow or differentiate or 
immediately used in further experiments.  
 
 
  Chapter 2 
   
95 
2.2.3 Cryo-Preservation and Long-term Storage of Cells 
For long-term storage, cells were pelleted and resuspended at a concentration of 3 
x 107 cells per 1 ml freeze mix. The cells were placed in cryovials transferred to 
Nalgene cryo freezing containers (Nunc, Roskilde, Denmark) containing 2-
isopropanol (Sigma Aldrich, UK) and stored overnight at -80 C, before being 
transferred to liquid nitrogen for long-term storage. 
 
 
2.2.4 In-vitro Generation of Systemic DC Subsets 
2.2.4.1 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
Buffy Coat Blood Bags (50 ml each) or lymphocyte cones (~ 30 ml) from healthy 
individuals were obtained from the National Blood Services (Colindale, UK). One 
buffy coat bag or lymphocyte cone was equally divided into five or three 50 ml 
conical tubes respectively and each 10 ml blood sample was subsequently diluted 
in 20 ml of PBS. The diluted blood was then underlaid with 20 ml Histopaque 1077 
(Sigma Aldrich, UK) and spun for 25 minutes at 2000 rpm (ROTINA 46, Hettich 
Zentrifugen) with no brake. PBMCs were subsequently harvested from the 
Histopaque interface and washed twice with 50 ml PBS for 7 minutes at 1200 rpm. 
PBMCs were then either frozen for long-term storage or used for the separation of 
lymphocytes from non-lymphocytic cells. 
 
2.2.4.2 Separation of PBMCs into Lymphocyte and non-Lymphocyte rich Fractions 
PBMCs were obtained as described in section 2.2.4.1. The cells were underlaid 
with 5 ml of 50 % percoll and the samples were spun for 30 minutes at 300 rcf 
(ROTINA 46, Hettich Zentrifugen) with no brake. Both, the PI, a monocyte/ DC-
enriched fraction, and the PP, consisting of a lymphocyte enriched fraction, were 
harvested. The PI was removed and cells washed twice with 50 ml PBS to remove 
any residual percoll. Cell viability was determined by trypan blue exclusion, prior to 
the cells being frozen and labelled “PI” (percoll interface). The PP was 
resuspended in 20 ml PBS and layered onto 2 x 5 ml Histopaque in 15 ml conical 
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tubes. The samples were spun for 20 min. at 2000 rpm (ROTINA 46, Hettich 
Zentrifugen) without brake to remove residual red cells. The supernatant was 
discarded and the pellet washed in PBS twice. As before, cell viability was 
determined by trypan blue exclusion. The cells were then frozen or used 
immediately in subsequent experiments. 
 
 
2.2.4.3 Generation of MoDCs from CD14+ Progenitor Cells 
CD14+ monocytes were isolated from Histopaque-separated PBMCs or 
lymphocyte enriched fractions (percoll interface) using immunomagnetic beads 
and MACS separation columns as recommended by the manufacturer (Miltenyi 
Biotec, Bisley, UK). Briefly, PI cells or PBMCs were pelleted by centrifugation for 5 
min. at 1580 rpm and then resuspended in 0.5 ml of MACS buffer. Cells were 
subsequently labelled with 20 µl of anti-CD14 magnetic beads and FcR blocking 
reagent (Miltenyi Biotec) per 107 cells for 15 minutes at 4 °C. Subsequently, 
unbound antibody was washed off by centrifugation at 1580 rpm for 5 minutes. 
CD14-labelled cells were resuspended in 0.5 ml MACS buffer and passed through 
an MS separation column (Miltenyi Biotec) that had been pre-wetted with 0.5 ml 
MACS buffer. The column was rinsed twice with 0.5 ml MACS buffer and the 
CD14+ monocytes eluted using a plunger (2 x 1.5 ml MACS buffer). Cellular 
differentiation took place by culturing purified CD14+ cells at 3-5 x 106 cells/ ml in 
10 % supplemented RPMI medium in the presence of IL-4 (1000 U/ ml) and GM-
CSF (100 ng/ ml) for 5-7 days (Figure 2.1). Cells were fed with additional GM-CSF 
and IL-4 every other day. Fresh medium was added when necessary. After 5-7 
days, a population of immature MoDCs were harvested.  
Depending on the nature of the experiment, MoDCs were also generated in 
StemX-Vivo serum free Dendritic Cell Base medium (R&D Systems) 
supplemented with 100 IU/ ml penicillin and 100 µg/ ml streptomycin. Generation 
of MoDCs in serum free medium followed the same protocol with the exception 
that no serum was added to the medium.    
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                   MoDCs 
 
 
Figure 2.2: Differentiation of MoDCs from CD14
+
 progenitor cells. 
PBMCs were separated from human peripheral blood and isolated CD14
+
 progenitor cells were 
cultured in the presence of IL-4 (1000 U/ ml) and GM-CSF (100 ng/ ml) for 5-7 days at 37 C to 
give rise to immature MoDCs. Cells were fed on day 1 and then every other day of the 
differentiation process. 
 
 
 
2.2.4.4 Generation of dDCs and LCs from CD34+ Progenitor Cells 
Dermal-like DCs and LCs were generated from umbilical cord blood samples, 
obtained from consented mothers in full term labour. Fresh blood was collected in 
citrate-phosphate-dextrose solution with adenine (CPDA) (C4431; Sigma, UK) and 
the same day. Dermal-like DCs and LCs were generated from CD34+ 
hematopoietic progenitor cells isolated from human cord blood mononuclear cells 
(CBMCs) by immunomagnetic separation [MACS separation columns (Miltenyi 
Biotec)]. First, CBMCs were isolated from umbilical cord blood by diluting 10 ml 
blood in 20 ml PBS and underlying the sample with 20 ml Histopaque 1077 
(Sigma, UK) and spun for 25 minutes at 2000 rpm (ROTINA 46, Hettich 
Zentrifugen) with no brake. CBMCs were subsequently harvested from the 
Histopaque interface and washed twice with 50 ml PBS for 5 minutes at 1200 rpm. 
CD34+ progenitor cells were then harvested from the interface by positive, 
magnetic selection using the CD34+ Isolation Kit (Miltenyi Biotec).  
 
CD34+ progenitor cells were incubated for 30 minutes at 4 °C in the presence of 
100 µl anti-CD34 beads per 108 cells and FcR blocking reagent (Miltenyi Biotec). 
The cell suspension was then washed in MACS buffer at 1200 rpm for 5 minutes, 
the supernatant removed and the cells were again resuspended in 0.5 ml MACS 
buffer. The cell suspension was then applied to an MS separation column that had 
been pre-wetted with 0.5 ml MACS buffer. Non-labelled cells were allowed to pass 
IL-4 
GM-CSF 
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through the column, followed by 2 x washes with 0.5 ml MACS buffer. Finally, 
CD34+ cells were eluted by pushing 2 x 0.5 ml 10 % GIBCO medium through the 
column. Eluted cells were then cultured in the presence of GM-CSF (100 ng/ ml), 
TNF-α (5 ng/ ml), Flt3L (25 ng/ 100 l), and SCF (25 ng/ 100 µl) (all R&D Systems, 
UK).  
 
Two distinct populations developed after 6 days (Figure 2.2). These populations 
were separated based on the expression of CD14, using CD14-specific 
immunomagnetic beads. CD14+CD1a- precursors were then cultured for an 
additional 5 to 7 days (day 12-14) in the presence of GM-CSF (100 ng/ ml) and IL-
4 (1000 U/ ml) to give rise to dDCs. CD14-CD1a+ were grown for 5 to 7 days in the 
presence of GM-CSF, TNF-α, and TGF-β (5 ng/ ml, R&D Systems) to give rise to 
LCs. TNF-α was only added to LCs on day 6. Finally, dDCs and LCs were purified 
using anti-CD1a magnetic beads.  
 
 
 
 
 
 
 
 
 
 
 
 
CD34+ Progenitor Cells                
 
 
 
 
 
 
Figure 2.2: Growth of dDCs and LCs from CD34
+
 progenitor cells. 
Isolated CD34
+
 cells were grown for 6 days as described in section 2.2.4.2. CD34
+
 cells were fed 
on day 1, 3, and 5. On day 6, cells were separated into CD14
+
 and CD14
-
 populations. CD14
+
 cells 
were further differentiated to give rise to dDCs, while CD14
-
 precursors were differentiated into 
LCs. On day 13, CD1a positive dDCs and LCs were harvested and isolated (Miltenyi, UK).   
Day 12-14 
CD14+CD1a- 
CD14-CD1a+ LCs 
dDCs 
Day 1 Day 6 
TGF-β 
GM-CSF 
IL-4 
GM-CSF 
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2.2.4.5 CD1a Purification of DCs 
Dermal-like DCs, LCs, MoDCs, and epidermal LCs were CD1a-purified before 
being used in co-culture experiments, phenotyping or polymerase chain reaction 
(PCR). Briefly, dendritic cells were pelleted by centrifugation at 1200 rpm for 5 
minutes in MACS buffer. The supernatant was removed and cells incubated at 4 
°C for 15 minutes in the presence of 20 µl anti-CD1a magnetic beads and 20 µl 
FcR blocking reagent per 107 cells (Miltenyi Biotec). The cells were then washed in 
MACS buffer and CD1a-labelled cells were isolated by passing the cell suspension 
over a MS column (Miltenyi Biotec). CD1a+ cells were eluted by washing the 
column with 2 x 0.5 ml MACS buffer as previously described. 
 
 
2.2.5 Isolation of DC Subsets from Human Peripheral Blood and Skin 
2.2.5.1 Isolation of LCs from Human Epidermis 
All skin samples were obtained from consented healthy individuals undergoing 
plastic surgery at the Chelsea and Westminster Hospital. Skin was prepared as 
previously described by Lenz et al. (1993) and Piskin et al. (2006). The individual 
skin sections were collected in sterile PBS containing Streptomycin (100 µg/ ml) 
and Penicillin (100 IU/ 500 ml). First, the skin samples were prepared by removing 
subcutaneous fat tissue. The specimens were subsequently cut into thin 25 mm2 
pieces and rinsed twice in PBS before incubation in 0.2 % Dispase II (Roche, UK) 
at 4 ºC over night. The following day, the epidermis and dermis were mechanically 
separated by carefully pulling them apart using sterile forceps. The epidermis was 
washed in PBS before incubation for 72 hrs in 10 % RPMI medium at 37 ºC to 
allow LCs to migrate into the culture medium. In addition, GM-CSF (100 ng/ ml) 
was added to the cells on day 1. The culture medium was harvested and the cells 
washed twice in PBS. LCs were separated from cellular debris and epidermal cells 
by CD1a selection using magnetic beads (Miltenyi Biotec) (2.2.5.4).  
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a)         b)                  c)                       d) 
           
 
e)       f)                  g)       h) 
           
Figure 2.3: Skin separation and LCs isolation from the epidermis. 
Human Skin Samples were collected in PBS supplemented with 1 % Glutamine, 1 % Penicillin and Streptomycin (a). Initially, the tissue was rinsed and 
surplus fat tissue was removed (b). The samples consisting of dermis (white) and epidermis (brown) were then dissected into smaller (~ 1 cm
2
) pieces (d) 
before incubated overnight at 4 °C in 0.2 % dispase (e). The two layers were carefully separated the following day (f). Subsequently, the epidermis was 
incubated in a 6-well plate for 48 hrs at 37 C (g), with each well containing 3 ml supplemented RPMI 1640. In addition, each well received GM-CSF (100 ng/ 
ml) and epidermal LCs were obtained through a “walk-out” process (h). 
Dermis 
Epidermis Fat 
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2.2.5.2 Isolation of Dermal DCs from Human Dermis 
Dermal DCs were isolated from the dermis as described by Piskin et al., (2003). 
The dermis was separated into little pieces and incubated in PBS containing 0.2% 
collagenase D (Boehringer Mannheim), 40 U/ ml DNase I (Boehringer Mannheim) 
and 2 % foetal calf serum (FCS) for 3 hrs at 37 °C under constant rotation 
(MACSmix tube rotator, Miltenyi Biotec). Subsequently, the mixture was filtered 
through a cell strainer to remove tissue debris. The remaining skin and connective 
tissue were incubated in 0.2 % collagenase D for an additional hour to isolate 
remaining cells. The cell suspension was then washed twice in 2 % RPMI followed 
by phenotypic analysis using flow cytometry. 
 
 
2.2.5.3 Isolation of mDCs from Peripheral Blood 
Myeloid dendritic cells were isolated from percoll interphase cells using the BDCA-
1 kit (Miltenyi Biotec) following manufacturer’s guidelines. This kit involves the 
depletion of CD19+CD1c+ B cells prior to the positive selection of CD1c+ mDCs. 
Initially, the cells were resuspended in 200 l of MACS buffer per 108 cells and 
incubated with 100 l of FcR Blocking reagent, 100 l of anti-CD19 microbeads, 
and 100 l of biotinylated BDCA-1 (CD1c) antibody for 15 minutes at 4 C. The 
samples were then washed in cold MACS buffer and spun for 5 minutes at 1200 
rpm before the supernatant was removed. The pellet was then resuspended in 500 
l MACS buffer. An LD column (Miltenyi Biotec) was set up and rinsed with 2 ml of 
MACS buffer before the cell suspension was added dropwise and allowed to flow 
through. The column was subsequently washed twice with 2 ml MACS buffer. The 
effluent containing the B cell depleted fraction was collected and centrifuged at 
1200 rpm for 5 minutes T cells were then resuspended in 400 l of MACS buffer 
per 108 cells and 100 l of anti-biotin microbeads per 108 cells. The sample was 
then left at 4 C for 15 minutes. Unbound anti-biotin microbeads were 
subsequently washed off and cells resuspended in 1 ml MACS buffer. The 
suspension was then passed through an LS column, which had been prewashed 
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with 1 ml MACS buffer. Once the entire sample had passed through, the column 
was washed twice with 1 ml of MACS buffer. The column-bound CD1c+ mDC 
population was flushed with 1.5 ml of MACS buffer using the supplied plunger. To 
increase the purity of mDCs, the cells were further depleted of CD19+, CD14+ and 
CD3+ cells using Dynal® magnetic beads (Invitrogen, UK) at 4 x 108 beads/ ml. 
Myeloid DCs were then cultured overnight in medium supplemented with IL-4 
(1000 U/ ml) and GMC-SF (100 ng/ ml) before being used in experiments. 
 
 
2.2.6 Isolation of CD4+ and CD8+ T Lymphocyte Populations 
Human CD4+ and CD8+ T cells were isolated from either umbilical cord blood or 
adult peripheral blood using magnetic cell sorting according to the manufacturer’s 
recommendations (Miltenyi Biotec). 
 
 
2.2.6.1 Isolation of total T cells (Pan T) from Human Peripheral Blood 
Untouched total T cell populations were isolated from human PBMCs through an 
indirect magnetic labelling system using the Pan T Cell Isolation Kit II (Miltenyi 
Biotec). Briefly, PBMCs or the lymphocyte-enriched fraction were resuspended in 
40 µl MACS buffer per 107 cells and incubated for 10 minutes at 4 °C with 10 µl of 
Biotin-Antibody Cocktail per 107 cells. Afterwards, 20 µl of Anti-Biotin MicroBeads 
per 107 cells were added and the cell suspension incubated for an additional 15 
minutes at 4 °C. Labelled cells were subsequently washed with MACS buffer and 
resuspended in 0.5 ml MACS buffer. The cell suspension was then applied to a 
MS column (Miltenyi Biotec) and untouched Pan T cells were collected in the 
effluent. For higher purity yield, the sample was passed over a second MS column.  
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2.2.6.2 Isolation of Naïve CD4+ T Cells from Umbilical Cord Blood 
Naïve CD4+ T helper lymphocytes were obtained from umbilical cord blood and 
isolated using the “Naïve CD4+ T Cells Isolation Kit” (Miltenyi Biotec). The CD34-
depleted fraction of cord blood mononuclear cells (CBMCs) was isolated on a 50 
% percoll pellet gradient by centrifugation for 30 minutes at 300 rcf (ROTINA 46, 
Hettich Zentrifugen) with no brake. The supernatant was discarded and the pellet 
washed twice in PBS. The cells were then either frozen as described in section 
2.2.3 or used for naïve CD4+ T cell isolation. Briefly, isolation of CD4+ naïve T cells 
was performed by magnetic depletion of memory T cells, CD8+ T cells, B cells, NK 
cells, γ/δ T cells, monocytes, DCs, granulocytes, platelets, and erythroid cells 
using a cocktail of biotinylated antibodies against phenotypic cell surface markers 
of the above-mentioned cell populations. Cells were then labeled with anti-Biotin 
MicroBeads for 15 minutes at 4 °C and the cell suspension was subsequently 
passed through two MS columns (Miltenyi Biotec) as previously described, 
resulting in an enriched population of naïve CD4+ T cells. 
 
 
2.2.6.3 Isolation of naive CD8+ T Cells from Umbilical Cord Blood 
Like CD4+ naive T cells, naive CD8+ T cells were isolated from the CD34+-
depleted percoll pellet fraction of umbilical cord blood. Isolation of naive CD8+ T 
cells was performed using the “Naive CD8+ T Cell Isolation Kit” (Miltenyi Biotec). 
The isolation of naive CD8+ T cells was performed in a two-step procedure. First, 
total naive T cells were enriched by depletion of non-naive T cells and NK cells 
according to the manufacturer’s protocol. This was followed by the positive 
selection of naive CD8+ T cells using “naive CD8+ T cells MicroBeads” (Miltenyi 
Biotec). Briefly, resurrected or freshly isolated cells were resuspended in 40 µl 
MACS buffer per 107 cells and 10 µl of Naive CD8+ T Cell Biotin-Antibody Cocktail 
per 107 cells. The cell solution was mixed and incubated for 15 min. at 4 °C. 
Afterwards, 20 µl of Anti-Biotin MicroBeads per 107 cells were added and left at 4 
°C for an additional 15 minutes. The cells were then washed and resuspended in 
500 μl MACS buffer. Non-naive CD8+ T cells were depleted using an LD 
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separation column (Miltenyi Biotec). The effluent was subsequently collected and 
resuspended in 80 µl MACS buffer and 20 µl anti-CD8 MicroBeads. The cell 
suspension was then incubated for 15 minutes at 4 °C. Anti-CD8 microbead-
labelled cells were resuspended in 500 μl MACS buffer and passed through an MS 
separation column that had been pre-wetted with 500 μl MACS buffer (Miltenyi 
Biotec). The column was rinsed twice with 500 μl MACS buffer and the CD8+ 
fraction eluted using a plunger (2 x 1.5 ml MACS buffer). 
 
 
2.2.6.4 Isolation of memory CD4+ and CD8+ T cells from Peripheral Blood 
CD4+ and CD8+ memory T cells were isolated from the percoll pellet cells derived 
from peripheral blood using either the “Memory CD4+ T cell Isolation Kit” or the 
“Memory CD8+ T Cells Isolation Kit” respectively (Miltenyi Biotec). This method 
involves the indirect magnetic labelling of non-CD4+ and non-CD8+ cells for the 
isolation of untouched CD4+ and CD8+ memory T cells. Briefly, percoll pellet cells 
were counted and resuspended in 40 l MACS buffer per 107 cells. The cell 
suspension was subsequently incubated with 10 l per 107 cells of the respective 
memory T Cell Biotin-Antibody Cocktail for 10 minutes at 4 °C. The cells were then 
washed in 1-2 ml MACS buffer per 107 cells at 1200 rpm for 5 minutes to remove 
unbound antibodies. Subsequently, 30 l of MACS buffer per 107 cells were 
added, followed by the addition of 20 l of Anti-Biotin MicroBeads per 107 cells. 
The sample was mixed and incubated at 4 °C. After 15 minutes the cells were 
washed as described before and resuspended in 0.5 ml MACS buffer. The cell 
suspension was then applied to a pre-wetted MS separation column (Miltenyi 
Biotec). The column was washed with 2 x 500 l MACS buffer and the effluent, 
containing the respective memory T cells, was collected. For increased purity, the 
cell suspension was subsequently passed through another MS column as 
described above. 
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2.2.7 Cell Culture of A549 Cell Line 
Upon resurrection, A549 cells (~ 5 x 106 cells) were resuspended in 10 % FCS 
Dulbecco’s Modified Eagle’s Medium (DMEM) and cultured in a 75 mm2 flask at 37 
°C until confluent. They were then passaged and expanded by placing them into a 
175 mm2 flask. Depending on the extent of cellular proliferation, cells were 
passaged every 3rd or 4th day. Briefly, A549 cells were passaged by pipetting off 
the medium and rinsing the monolayer with 10 ml PBS carefully rocking the flask 
back and forth. Subsequently, the PBS was removed and 5 ml of 0.05 % Trypsin-
EDTA solution (GIBCO, Invitrogen) added to the flask, swirled, then 3 ml were 
removed. The remaining solution was equally dispersed throughout the flask and 
left to incubate for approximately 1 minute while slightly tapping against the flask 
side to cause the cells to detach. Once the cells had detached from the flask, they 
were resuspended in 8 ml of 10 % DMEM, split at a 1/5 or 1/10 ratio again using 
DMEM, and seeded at the appropriate numbers in new tissue culture flasks.  
 
 
2.2.8 Mixed Leukocyte Reactions (MLRs) 
2.2.8.1 Preparation, Storage, and Use of Retinoids and Vitamin D3 
Stock solutions of 0.1 M all-trans retinol (R7632, Sigma-Aldrich) and all-trans 
retinal (R2500, Sigma-Aldrich) were prepared in DMSO and stored in 20 µl 
aliquots at -80 °C. Similarly, 10 mM ATRA (R2625, Sigma-Aldrich) stock solutions 
were prepared in DMSO and stored in 20 µl aliquots at -80 °C. For each 
experiment, a new vial was resurrected and dilutions were prepared in sterile PBS 
to reach respective working concentrations. Vitamin D3 (1,25(OH)2D3) (D1530, 
Sigma-Aldrich) stock solutions of 0.1 mM were prepared by re-suspending the 
reagent in DMSO. All work involving retinoids or vitamin D3 was done under 
subdued light conditions. 
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2.2.8.2 Preparation, Storage, and Use of Blocking Reagents 
Ro41-5253 and CD2665 were used to block RAR-α and RAR-β/γ respectively. 
Stock solutions of 0.01 M Ro41-5253 (GR-110; Biomol International, USA) were 
prepared by resuspension in DMSO. Aliquots of 10 µl were stored at -20 °C. 
Likewise, stock solutions of 0.1 M CD2665 (3800; Tocris Bioscience, UK) were 
prepared by resuspending the reagent in DMSO. Aliquots of 10 µl were stored at -
20 °C. To obtain the desired working concentrations, dilutions were prepared in 
PBS. The blocking reagents were added to the DCs prior to ATRA and T cells. 
The co-cultures were then incubated for 4 days at 37 °C before T cells were 
analysed for receptor surface expression by flow cytometry.  
Citral was used to block dehydrogenase activity. Liquid 95 % Citral (C8, 300-7; 
Aldrich, UK) was stored at RT. For each experiment, fresh dilutions of citral were 
prepared in PBS. 
 
 
2.2.8.3 Preparation, Storage, and Use of Antigens 
Tetanus Toxoid (TT) was obtained from Calbiochem-Merck, UK and a stock 
solution of 2 µg/ ml was prepared in PBS. TT was used at a final concentration of 
10 ng/ 100 µl cells.  
Diphtheria toxin (CRM mutant, 322327) was obtained from Calbiochem, 
USA. The lyophilized reagent was reconstituted in 1 ml dH2O and aliquots of 100 
μl were stored at – 80 °C. Diphtheria toxin was used at a working concentration of 
100 ng/ 100 µl cells.  
Pertussis toxin from Bordetella pertussis (516562, 50 µg; Calbiochem., 
USA) was resuspended in PBS to a stock concentration of 0.1 µg/ µl and stored at 
4 °C. The pertussis toxin was used at a working concentration of 100 ng/ 100 µl 
cells.  
Measles Virus (Edmonton Strain) (AR00130SU-N) was obtained from Acris 
Antibodies GmbH, Germany. The liquid lysate (1.86 mg/ ml) was diluted in PBS to 
yield a final stock concentration of 1 µg/ μl. Cells were stimulated with a final 
concentration of 100 ng measles antigen per 100 µl cells.  
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Live Influenza (Strain X31) was kindly donated by Dr Rod Daniels (National 
Institute of Medical Research, NIMR). Live Influenza virus was heat-inactivated for 
30 minutes at 56 °C before it was added to the culture at a concentration of 20.48 
HA/ ml.  
Cytomegalovirus (CMV) antigen was obtained from Dade Behring Inc. The 
antigen was produced from human tissue cell cultures infected with CMV and 
subsequently lyophilized after inactivation and addition of a stabilizer compound. 
The CMV antigen used in experiments was reconstituted in PBS and its 
concentration determined using a Nanodrop (Thermo Scientific; see section 
2.2.7.5). CMV was used at a working concentration of 100 ng/ 100 µl cells.  
SEB from Staphylococcus aureus (S4881) was obtained from Sigma, UK 
and used at a working concentration of 100 ng/ ml or 500 ng/ ml. 
 
 
2.2.8.4 Measuring Protein and DNA concentrations 
To determine the protein and DNA concentrations of our samples we used a 
Nanodrop 1000 Spectrophotometer by Thermo Scientific Inc. Protein and DNA 
concentrations were calculated using ND-1000 V3.7.1 software (Thermo Fisher 
Scientific Inc). Before and after measuring the concentrations of our samples, the 
instrument was primed with dH2O to ensure a consistency of measurements. 
Following calibration of the instrument with dH2O, one µl of the sample was 
carefully pipetted onto the measurement lever and spectral measurement was 
initiated. For proteins, absorbance was measured at 280 nm, while absorbance for 
DNA was measured at 260 nm.  
 
 
2.2.8.5 Preparation and Use of T Cell Activation Beads 
T-cell Activation/Expansion Kit was obtained from Miltenyi Biotec. T-cell activation 
beads were prepared by mixing 500 µl Anti-Biotin MACSiBead Particles with 100 
µl of each biotinylated antibody (anti-CD2, anti-CD3, and anti-CD28) and 200 µl of 
MACS Buffer to reach a final volume of 1 ml. The mixture was then incubated for 2 
   Chapter 2 
   
 108 
hrs at 4 °C under constant rotation on the MACS mix tube rotator (Miltenyi Biotec). 
Finally, the beads were then stored at 4 °C and used within 4 months of their 
preparation.  
T cell activation beads were used at a concentration of 2.5 x 106 beads (~ 25 µl) 
per 5 x 106 cells. For each experiment, the required amount of beads was 
prepared by washing them in 100-200 µl of fresh medium at 13000 rpm for 5 
minutes (MicroCentaur Plus; MSE), after which they were resuspended in fresh 
RPMI supplemented with 10 % FCS at a concentration of 2.5 x 104 beads/ µl. 
 
 
2.2.8.6 Allogeneic DC - T Cell Co-culture 
For co-cultures, DCs were harvested and re-suspended in 10 % RPMI medium at 
a concentration of 105 cells/ ml. Cells were seeded in 96 well plates at 104 cells 
per well either in the presence or absence of corresponding concentrations of 
retinoids, 1,25(OH)2D3, or blocking reagents. In all experiments, 1,25(OH)2D3, 
retinoids, and blocking reagents were added once at the beginning of the culture 
before addition of allogeneic T cells. Purified T cells (naive, memory, TPan, or total 
T cells) were resuspended in 10 % supplemented medium at 106 cells/ ml and 
added to DCs at 105 cells/ well (ratio of 1:10). In some experiments DCs were 
matured overnight in the presence of LPS (Sigma-Aldrich) (1 g/ ml). 
 
 
2.2.8.7 Establishment of Autologous MLRs 
Immature MoDCs were harvested after 5 days of culture and resuspended in 10 % 
FCS RPMI medium. Approximately 3 x 106 cells were pulsed with 500 ng/ ml 
Staphylococcal Enterotoxin B (SEB) and matured with 100 ng/ ml LPS (InvivoGen) 
for 3-4 hrs at 37 ºC. Cells were subsequently washed and resuspended in fresh 10 
% FCS RPMI medium at a concentration of 105 cells/ ml and added to 96 well 
plates at 104 cells per well. Autologous T cells were resuspended at 106 cells/ ml 
and 105 cells were added to each well. Cells only matured with LPS served as a 
negative control.  
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2.2.8.8 CFSE Staining Experiments 
Stock aliquots of 5 mM of CFSE were stored at -80 °C. For each experiment a new 
vial was thawed. Lymphocytes that were used in CFSE experiments were 
resurrected the previous day and left overnight in DNase. The following day, total 
T cells or purified T cell populations were counted by trypan blue exclusion and 
resuspended in PBS at a concentration of 107 cells/ ml. 1 % of FCS was then 
added to the cells. Subsequently, 2 µM of CFSE were added to the cells in the 
dark while vortexing. The tube was then sealed and incubated at RT in the dark on 
the Miltenyi rotor for precisely 5 minutes. Afterwards, the sample was washed 
twice in 10 % FCS RPMI 1640 medium. Finally, the cells were resuspended in 10 
% AB-RPMI at a concentration of 106 cells/ ml for subsequent use in co-culture 
experiments. 
 
   Chapter 2 
   
 110 
2.3 Cell Staining and Flow Cytometric Analysis 
2.3.1 Cell Surface Staining 
Monoclonal antibodies and their respective isotype controls were used to stain and 
phenotype different types of DCs and lymphocytes. The various antibodies used 
are listed in table 2.1. A minimum of 2 x 105 cells were washed in 2 ml FACS 
buffer and spun for 5 minutes at 1200 rpm in an ROTINA 46 centrifuge (Hettich, 
Zentrifugen). The supernatant was discarded and the cell pellet resuspended in 
100 µl FACS Buffer/antibody solution. Cells were labelled with 5 µl of each 
appropriate fluorochrome-conjugated antibody and left at 4 °C for 30 minutes. 
Cells were then washed with 2 ml FACS Buffer at 1200 rpm for 5 minutes before 
being fixed with 200 µl of 2 % PFA (Sigma Aldrich, UK). Flow cytometric analysis 
was performed on an LSRII using Becton Dickinson (BD) FACSDiva Software. 
20,000 events within the live gate were collected. 
 
 
2.3.2 Gating Strategy for Flow Cytometry Analysis of DCs and T cells 
Initially, a gate was placed on a forward scatter vs side scatter plot to identify live 
cells (live gate). For dDCs an additional gate was placed on CD1a+ cells. LCs 
were gated on Langerin+CD1a+ cells. For the analysis of skin-derived DCs, a gate 
was placed on CD1a+ epidermal LCs and CD1a+HLA-DR+ dermal DCs due to 
lower purity when isolating cells. 
 
Analysing receptor surface expression on T cells, a gate was placed on a forward 
vs side scatter plot to identify live cells (live gate). We subsequently gated on 
CD4+CD3+ cells to distinguish CD4+ T cells from CD8+ T cells. CLA expressing 
cells were identified by placing a gate on α4β7 expressing CD4+ and CD8+ T cells. 
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Table 2.1: List of antibodies used for cell surface staining. Antibodies were obtained from 
Becton Dickinson (UK), Beckman-Coulter (USA), and R&D Systems (UK). All antibodies were used 
at 5 µl per tube. APC - Allophycocyanin; APC-Cy7 – Allophycocyanin-Cyanine 7; FITC - 
Fluorescein isothiocyanate; PE - phycoerythrin; PerCP - Peridinin chlorophyll protein; PE-Cy7 - 
Phycoerythrin-Cyanine 7. 
Surface Marker Conjugate Clone Isotype Supplier 
CD1a APC HI149 Mouse IgG1 BD 
CD1a FITC HI149 Mouse IgG1 BD 
CD3 PerCP SK7 Mouse IgG1 BD 
CD3 APC-Cy7 SK7 Mouse IgG1 BD 
CD4 PE SK3 Mouse IgG1 BD 
CD4 PE-Cy7 SK3 Mouse IgG1, κ BD 
CD8 APC-Cy7 SK1 Mouse IgG1, κ BD 
CD11c PE S-HCL-3 Mouse IgG2b BD 
CD11b PE ICRF44 Mouse IgG1 BD 
CD14 PE M5E2 Mouse IgG2a BD 
CD14 PerCP M5E2 Mouse IgG2a BD 
CD45RA APC HI100 Mouse IgG1 BD 
CD45RO PE UCHL1 Mouse IgG2a BD 
CD45RO FITC UCHL1 Mouse IgG2a BD 
CD49d (Alpha 4) PE 9F10 Mouse IgG1 BD 
CD56 PE B159 Mouse IgG1 BD 
CD56 PE-Cy7 B159 Mouse IgG1 BD 
CD57 FITC HNK-1 Mouse IgG1 BD 
CD80 PE L307.4 Mouse IgG1 BD  
CD83 PE HB15e Mouse IgG1 BD  
CD86 APC 2331 Mouse IgG1 BD  
CD103 (Alpha E) PE Ber-ACT8 Mouse IgG2a BD  
CD206 FITC 19.2 Mouse IgG1 BD 
CD207 (Langerin) PE DCGM4 Mouse IgG1 Immunotech 
CD209 (DC-SIGN) FITC DCN46 Mouse IgG2b BD 
HLA-DR PerCP L243 Mouse IgG2a BD 
Beta 7 Integrin APC FIB504 Rat IgG2a BD 
CCR4 FITC 205410 Mouse IgG2B R&D Systems 
CCR10 PE 314305 Rat IgG2a R&D Systems 
CLA FITC HECA-452 Rat IgM BD 
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2.3.3 Flow Cytometric Detection of ALDH Activity 
2.3.3.1 Preparation of ALEFLUOR Substrate 
ALDH activity was detected using the ALDEFLUOR® kit provided by ALDAGEN, 
Inc. (Stemcell Technologies; North Carolina, USA). All kit reagents were allowed to 
come to RT before use. The ALDEFLUOR reagent was activated through the 
addition of 25 µl to the vial of dry ALDEFLUOR powder. The vial was incubated for 
1 minute at RT. Subsequently, 25 µl of 2N HCl were added and the vial mixed. 
The vial was left for 15 minutes at RT before 360 l of ALDEFLUOR buffer were 
added to the vial. The activated ALDEFLUOR substrate was then aliquoted (25 µl) 
and stored at -20 C. 
 
 
2.3.3.2 DC Stimulation 
DCs were incubated overnight in the presence of ATRA alone (10 nM), LPS alone 
(50 µg/ 105 cells), CD40L alone (200 ng/ 105 cells), or LPS and CD40L. The cells 
were harvested the following day and centrifuged at 1200 rpm for 5 minutes. The 
supernatant was then removed and the cells were resuspended in ALDEFLUOR 
buffer at 106 cells/ ml.  
 
 
2.3.3.3 ALDEFLUOR Assay 
Five l of activated ALDEFLUOR substrate were added to each millilitre of sample 
with the exception of the negative control. Each sample was mixed immediately 
and incubated at 37 C for no longer than 45 minutes The negative control was 
prepared by adding 5 µl of diethylaminobenzaldehyde (DEAB) solution to the 
sample before adding 5 µl of the activated ALDEFLUOR substrate. The negative 
control was subsequently also placed at 37 C for the same amount of time. 
Following incubation, surface staining for HLA-DR, CD11c and CD1a molecules 
was performed. Cells were stained as described in section 2.3.1 for 15 minutes at 
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4 C. Subsequently, cells were washed in PBS and resuspended in 0.5 ml of 
ALDEFLUOR Assay Buffer. The samples were subsequently analysed by flow 
cytometric analysis using an LSRII machine (BD) and FACSDiva Software. 
 
 
 
 
Figure 2.4: Schemtic illustration of the ALDEFLUOR assay. 
ALDEFLUOR is used to identify cells that express high levels of ALDH. a) The fluorescent 
ALDEFLUOR reagent (BAAA) freely diffuses into cells and is a non-toxic substrate for ALDH. The 
amount of fluorescent ALDH reaction product that accumulates in cells is directly proportional to 
the ALDH activity in these cells. The negative charge of BAA prohibits its diffusion from cells, 
however it can be actively exported via the ATP-binding cassette (ABC) transporter system. This 
active efflux can be inhibited by the ALDEFLUOR Assay Buffer. Hence the ALDEFLUOR reaction 
product will only be retained by cells with intact membranes and fixed, permeabilized or dead cells 
will appear ALDH negative. b) DEAB blocks the conversion of BAAA to BAA by ALDH. Therefore, 
cells will not fluoresce and appear negative on the FACS plot.  
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2.4 DNA Analysis and Cloning Techniques 
2.4.1 RNA Extraction and complementary DNA (cDNA) Synthesis 
2.4.1.1 RNA Extraction and oligo dT-bead annealing 
RNA Extraction and cDNA synthesis were performed using the μMACS™ One-
step cDNA Kit (Miltenyi Biotec). cDNA synthesis took place in micro columns 
placed in the thermoMACS separator. Lysis/binding buffer and Wash Buffer were 
prewarmed to RT before use. In summary, cells were thawed and resuspended in 
lysis/binding buffer at a concentration of 107/ ml cells and vortexed at maximum 
speed for 3-5 minutes in order to dissolve the cell pellet. The lysate was then 
added to “lysate clear columns” and spun for 3 minutes at 13000 rpm in a 
MicroCentaur Plus (MSE). Fifty µl of oligo dT-beads were added per 107 lysed 
cells to the lysateClear flow-through. The micro columns were rinsed with 100 μl 
lysis/binding buffer and the lysateClear flow-through was added to the column. 
The column was then washed twice with 200 μl lysis binding buffer and 4 x 100 μl 
Wash Buffer. Additionally, a DNase step was included to remove any 
contaminating genomic DNA, whereby the columns were washed with 100 μl of 
DNase Buffer. Next, 1 μl (2 U) of DNase was added to 50 μl of DNase Buffer and 
transferred to the column (Promega, UK). Subsequently the sample incubated for 
2 minutes before the column was washed 2 x with 200 μl Lysis Buffer followed by 
4 x with 100 μl Wash Buffer. 
 
 
2.4.1.2 cDNA Synthesis 
First, the column was washed twice with 100 μl Equilibrium/Wash Buffer. The 
lyophilised enzyme mix (MLV reverse transcriptase) was dissolved in 20 μl 
resuspension buffer and gently mixed. Twenty μl of enzyme were then added per 
column and the column was carefully sealed with a drop (~1 μl) sealing solution to 
cover the sample. The thermoMACS apparatus (Miltneyi Biotec) was then set to 
42 ºC and the sample left to incubate for 1 hr. Afterwards, the column was washed 
twice with 100 μl Equilibrium/Wash Buffer. 20 μl of cDNA clean solution were then 
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added to the column and incubated for 10 minutes at 42 ºC. cDNA was eluted with 
50 μl elution buffer (2 x 25 μl) and stored at -20 ºC.  
 
 
2.4.2 Experimental Conditions of PCR 
Polymerase chain reactions were performed using the GoTaq® Flexi DNA 
Polymerase Kit (M8305, Promega). Each PCR sample was prepared according to 
the components listed in table 2.2.  
 
 
Table 2.2: PCR reaction mix. Each PCR tube 
contained 25 μl of PCR reaction Mix. Primers were 
used at a molarity of 10 M. cDNA Template was 
added last to the reaction. All samples were prepared 
on ice. 
Substance Amount (in μl) 
5 x Green Buffer 5 
Reverse Primer 0.5 
Forward Primer 0.5 
dNTPs (10 nM) 0.5 
Template 0.5 
Taq polymerase (5 unit/l) 0.125 
Mg2+ (25 mM) 1.5 
ddH2O 16.375 
 
 
The forward and reverse primers used in our PCR reactions are summarized in 
table 2.3. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as 
positive control for the PCR. The PCR set up for ADH1 and ALDH1A2 
amplification is shown in table 2.4. 
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Table 2.3: Specific primer pairs used in PCRs. ADH1 and ALDH1A2 primer pairs 
were obtained from Eurofins MWG Operon (Germany). 
Name Forward and Reverse Primer 
Sequences 
Amplicon Size 
ADH1 AACCCTCAAGACTACAAGAAA 
TCTTAGCCATAAAATCAGCCAC 
291 bp 
ALDH1A2 CCATTGGAGTGTGTGGACAG 
GATGAGGGCTCCCATGTAGA 
151 bp 
GAPDH ATGGAGAAGGCTGGGGCTC 
AAGTTGTCATGGATGACCTTG 
190 bp 
 
 
Table 2.4: PCR cycle for ADH1 and ALDH1. Optimized conditions were used for the  
amplification of ADH1 and ALDH1 from cDNA-RNA hybrid. 
Step Temperature Time (minutes) 
Initial Denaturation 94 °C 4 
Denaturation 94 °C 0.5 
Annealing 61 °C 1 
Extension 72 °C 1.5 
Final Extension 72 °C 5 
Hold 4 °C Until end 
 
 
 
2.4.3 Agarose Gel Electrophoresis 
Agarose gels were made with 1-1.5 % agarose dissolved in 1 x TBE. SYBR Safe 
DNA gel stain (10,000X, Invitrogen™) was used for sample visualization under UV 
light at a concentration of 1μl/ 10 ml. Samples were mixed with agarose gel 
loading buffer before loading and running in 1 x TBE running buffer at 80 V for 
approximately 45 minutes, before visualization on a UV trans-illuminator. 
Depending on the expected size of the DNA fragment, 1 kbp, 500 bp (both from 
Promega), or low molecular weight (25 – 766 bp) (N3233S, BioLabs, New 
England) DNA ladders were used as markers. 
   Chapter 2 
   
 117 
 
2.4.4 PCR Fragment Gel Purification 
DNA fragments were purified from agarose gel using the GENECLEAN® SPIN Kit 
(Q Biogene). Briefly, 400 µl GENECLEAN® SPIN GLASSMILK® were added to 
the SPIN filter together with the isolated gel fragment and incubated at 55 C until 
the gel had fully dissolved. The sample was then centrifuged at 13,000 rpm for 1 
minute. The flow through was discarded and 500 l of GENECLEAN® SPIN NEW 
Wash was added to the filter. The tube was then centrifuged for another 30 
seconds at 13,000 rpm. To dry the pellet, the sample was then centrifuged for 
another 2 minutes before the SPIN filter was transferred to a fresh Catch Tube. 
Fifteen l of GENECLEAN® SPIN Elution Solution was then added to the Spin 
Filter and thoroughly mixed to resuspend the GENECLEAN® SPIN GLASSMILK®. 
Finally, the sample was spun at 13,000 x g for 30 seconds to transfer eluted DNA 
to a clean collection tube. DNA sequence analysis was performed by Eurofins 
MWG Operon (UK) using Custom DNA Sequencing. 
 
 
2.5 Statistics 
Statistical analyses were carried out using GraphPad Prism 5 (GraphPad Software 
Inc., USA). For all data, means and standard errors of the mean (SEM) of sample 
groups were calculated and compared using a two-tailed Student’s t test (Wilcoxon 
signed rank test). Results were considered statistically significant with a p-value of 
≤ 0.05. In this thesis, for the Wilcoxon signed rank test, a p-value of ≤ 0.05 is 
shown through “*”, while p-values of < 0.05 and < 0.005 are represented by “**” 
and “***” respectively.  
In cases where comparative analyses were made across the different DC 
subtypes Two-Way ANOVA plus Bonferroni correction post-tests were used. 
Results were considered statistically significant when p < 0.05. For the Two-Way 
ANOVA test p-values of < 0.01 and < 0.001 are indicated by “**” and “***” 
respectively. 
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Chapter 3 
 
 
 
 
 
Isolation, Differentiation, and Phenotypic Characterization 
of in vitro-generated Human DC Subsets, blood-derived 
mDCs, and Skin-derived DCs 
 
 
 
3.1 Background and Aims 
DCs have been described as the “sentinels” of the immune system that have the 
ability to function in the capturing and processing of invading pathogens. Their 
ability to subsequently mediate antigen presentation to naïve and memory T cells 
(Banchereau and Steinman, 1988) enables them to establish a linkage between 
the innate and adaptive immune system. However, the capacity of DCs to present 
antigens and induce immune responses does depend on their phenotype and 
location within the different tissues. 
Immature DCs (iDCs) are continuously produced from hematopoetic stem 
cells within the bone marrow. In humans, two major DC pathways have been 
described, consisting of the myeloid and plasmacytoid lineage (Banchereau et al., 
2006). In vivo, the myeloid pathway includes blood myeloid DCs, as well as LCs 
and interstitial DCs (intDCs), which are primarily located within the different strata 
of the skin. However, the diverse function of DCs in immune regulation depends 
on the diversity of DC subsets and lineages (Liu, 2001). 
Although DCs were first described by Paul Langerhans in the late 19th 
century, it was not until 1973, when Steinman and Cohn (1973) first introduced the 
term “dendritic cell”. It was only twenty years later with the first description of 
human MoDCs that a distinct subset of DCs would be generated in vitro (Sallusto 
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and Lanzavecchia, 1994). As circulating DCs are rare (< 1 % of human PBMCs) 
and difficult to maintain in culture, the development of this in vitro system has ever 
since offered great assistance in the study of human DCs.  
Other groups (Caux, et al., 1996) have developed systems in which CD34+ 
progenitor cells can be differentiated to give rise to LCs and interstitial or dDCs in 
vitro, representing human skin DCs. Addition of specific cytokines to the culture 
stimulates CD34+ progenitor cells to give rise to two distinct subpopulations of 
CD14+ and CD14- DC precursors. These cells can be further differentiated to give 
rise to dDCs and LCs respectively. This model is validated by the finding that 
human CD34+ common myeloid progenitor cells differentiate into CD11c+CD1a+ 
and CD11b+CD1a- immature DCs in vivo. CD11c+CD1a+ subsequently migrate 
into the epidermis to become LCs, while CD11b+CD1a- migrate to the dermis and 
other tissues to become dDCs or intDCs (Ito et al., 1999). 
A third type of in vitro system has shown the generation of LCs from 
monocytes. Adult peripheral blood CD14+ monocytes were differentiated into LCs 
(CD1a+, E-cadherin+, CLA+, Birbeck granules+, Lag+) in the presence of GM-CSF, 
IL-4, and TGF-β (Geissmann et al., 1998).  
Although the development of such in vitro systems has allowed the scientific 
community to investigate the biology of different DC subsets in vitro, the 
dissimilarities between those systems need to be considered when drawing 
comparative conclusions regarding DC phenotype and function. In addition, these 
systems are naturally limited in their capacity to differentiate into representative 
cells found in vivo.  
 
The aim of the experiments described in this chapter was to differentiate and 
phenotype three models of systemic in vitro-generated human DC subsets, blood-
derived mDCs, and skin-derived DCs. MoDCs, dDCs and LCs were differentiated 
in vitro and their phenotype confirmed by cell surface staining and subsequent flow 
cytometric analysis. Blood-derived mDCs were isolated from human peripheral 
blood by means of CD1c selection and stained for their surface markers. Finally, to 
investigate the phenotype of human skin dendritic cells ex vivo, we aimed to 
establish a protocol that would allow isolation of dermal DCs and epidermal LCs 
from healthy human skin explants followed by their phenotypic characterization. 
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3.2 Results 
3.2.1 Differentiation and Phenotypic Analysis of MoDCs 
3.2.1.1 Generation of MoDCs in Supplemented Medium 
MoDCs were grown from CD14+ progenitor cells for 5 days in the presence of GM-
CSF (100 ng/ ml) and IL-4 (1000 U/ ml) as described in Chapter 2.2.4.3. On day 5, 
the cells were harvested and phenotyped by FACS. Phenotypic characterization of 
membrane antigens on MoDCs was carried out for several markers including C-
type lectins, myeloid markers and activation markers. As shown in Figure 3.1b and 
Figure 3.1e, MoDCs stained positive for the glycoprotein CD1a (98.1 %) and HLA-
DR (66.9 %), which is characteristic for APCs. Also, MoDCs stained positive for 
DC-SIGN (97.6 %) and the mannose receptor (CD206) (86.9 %). As expected, 
MoDCs stained positive for the myeloid markers CD11b and CD11c. When 
staining for activation markers, MoDCs stained negative for CD83 (1.1 %), while 
48.1 % stained positive for CD80 and 23 % stained positive for CD86. In contrast, 
MoDCs stained negative for the cell surface marker Langerin (Figure 3.1d). 
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a)               b)        c)                   d)    e) 
      
 
f)               g)        h)                   i)             j) 
     
 
k)               l) 
Figure 3.1: Phenotypic analysis of immature MoDCs. 
MoDCs were differentiated in culture from CD14
+
 progenitor cells in the presence of GM-CSF 
(100 ng/ ml) and IL-4 (1000 U/ ml) for 5 days (chapter 2.2.4.3) before being harvested and 
phenotyped by cell surface staining. MoDCs were stained for the expression of C-type lectins, 
myeloid markers, and co-stimulatory molecules. Histograms were gated on live cells. Respective 
isotype controls can be found in Figure A.1 of the Appendix. 
98.1 % 0.1 % 66.9 % 
99.8 % 48.1 % 1.1 % 97.6 % 
86.9 % 
53.8 % 
99.8 % 
23 % 
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3.2.1.2 Generation of MoDCs in Serum Free Medium 
Fetal calf and human sera have been described to contain endogenous 
concentrations of retinoids, including RA (Tang and Russell, 1990; Semba, 1997). 
To ensure that the FCS present in the supplemented culture medium used for the 
differentiation and growth of DCs does not influence their phenotype and/or ability 
to regulate expression of homing receptors on T cells, MoDCs were also 
generated in StemX-Vivo serum free Dendritic Cell Base medium (R&D Systems) 
and phenotyped before being used in co-culture experiments with T cells in the 
presence of exogenously added RA. Phenotypic analysis showed MoDCs 
generated in serum free medium to have a phenotype comparable to that of 
MoDCs generated in supplemented medium. As presented in Figure 3.2, MoDCs 
generated in serum free medium stained positive for CD1a (88.9 %) and HLA-DR 
(97.8 %). 97.1 % of the cells stained positive for DC-SIGN and most of them were 
also positive for CD206 (96 %). When analysing for myeloid markers CD11b and 
CD11c, 95.4 % and 99.9 % of the harvested cells stained positive respectively. 
MoDCs also stained positive for the activation markers CD80 (29.7 %) and CD86 
(90 %), whereas CD83 was barely detected (0.4 %). As expected, MoDCs stained 
negative for Langerin (0.8 %) (Figure 3.2d). 
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a)               b)         c)                    d)             e) 
      
f)               g)         h)                    i)      j) 
     
k) 
Figure 3.14: Phenotypic analysis of immature MoDCs differentiated in serum free medium. 
CD14
+
 cells were differentiated in the presence of GM-CSF (100 ng/ ml) and IL-4 (1000 U/ ml) for 5 days in serum free 
medium (R&D Systems) (chapter 2.2.4.3). The resulting population was characterised by cell surface staining for different DC 
cell surface markers by flow cytometric analysis. The harvested cells were stained and gated on live cells. Respective isotype 
controls can be found in Figure A.2 of the Appendix. 
 
 
29.7 % 97.1 % 0.4 % 95.4 % 99.9 % 
90 % 
88.9 % 96 % 97.8 % 0.8 % 
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3.2.2 In vitro Generation of dDCs and LCs from Human CD34+ Progenitor 
Cells 
Due to the limitations associated with the isolation of large numbers of LCs and 
dDCs from human skin, dDCs and LCs were differentiated in vitro from human 
CD34+ hematopoietic stem cells isolated from human umbilical cord blood by 
immunomagnetic selection (Chapter 2.2.4.4). In the presence of SCF, Flt-3L, GM-
CSF, and TNF-α, CD34+ progenitor cells were cultured for 6 days to give rise to 
two distinct populations of DC precursor cells (Figure 3.3a). These populations 
were mutually distinct in their expression of the cell surface markers CD1a and 
CD14. The two populations were magnetically separated based on the cell surface 
expression of CD14 as originally described by Caux et al. (1996). As previously 
observed by our lab, there were more CD14- cells on day 6, suggesting a skewing 
towards the development of CD14-CD1a+ precursors. CD14+CD1a- and CD14-
CD1a+ were subsequently sub-cultured for an additional 6-8 days to further 
differentiate into dDCs and LCs respectively (Figure 3.3b and c). CD14+CD1a- 
were cultured in the presence of GM-CSF, IL-4, Flt-3L, and SCF to give rise to 
dDCs, while CD14-CD1a+ cells were differentiated in the presence of GM-CSF, 
TGF-β, and TNF-α into LCs. On day 13, dDCs and LCs were harvested and their 
phenotype confirmed by cell surface staining and flow cytometric analysis (Figure 
3.4 and 3.5).  
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             a) 
       DAY 6 
 
 
 
 
b)        c) 
 
     DAY 12                  DAY 12 
           
 
       dDCs               LCs 
 
 
Figure 3.3: In vitro-generation of dDCs and LCs from CD34
+
 progenitor cells. 
CD34
+
 cells were magnetically isolated from umbilical cord blood and differentiated as described in 
section 2.2.4.4. a) On day 6, cells were separated based on the expression of CD14. b) 
CD14
+
CD1a
-
 cells were cultured for an additional 6-8 days in the presence of IL-4 (1000 U/ ml) and 
GM-CSF (100 ng/ ml) to give rise to dDCs. c) CD14
-
CD1a
+
 cells were grown in the presence of 
GM-CSF and TGF- for an additional 6-8 days to give rise to LCs. Respective isotype controls can 
be found in Figure A.3 of the Appendix. 
 
 
As previously seen with MoDCs, phenotypic characterization of in vitro-generated 
dDCs and LCs was carried out by staining for surface expression of various C-type 
lectins, myeloid markers, and activation markers. As shown in Figure 3.4, isolated 
dDCs stained positive for CD1a (73.6 %) and HLA-DR (87.4 %), two markers 
characteristic of DCs. Furthermore, dDCs stained positive for the C-type lectins 
IL-4, GM-CSF, 
SCF, Flt3L TNF-α (day 6), 
GM-CSF, TGF- 
84.3 % 94.6 % 11 % 
3.1 % 1.6 % 
1.1 % 
3.7 % 0.7 % 
CD14
+
CD1a
-
 
CD14
-
CD1a
+
 
84.3 % 
2.9 % 
84.3 % 
11.7 % 
23.5 % 
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DC-SIGN (81.4 %) and CD206 (89.0 %) (Figure 3.4). However, similar to MoDCs, 
dDCs stained negative for Langerin (1.4 %) (Figure 3.4d). Also, dDCs stained 
positive for the myeloid markers CD11b (69.9 %) and CD11c (99.5 %). The 
phenotypic maturation/activation status of dDCs was assessed by cell surface 
staining for CD83, and the co-stimulatory molecules CD80 and CD86. As shown in 
panels i-k, the expression levels for the activation markers CD80 and CD83 were 
low (5.6 % and 1.5 % respectively), while 35.1 % of dDCs stained positive for 
CD86. Only a minority of dDCs stained CD14+ (9.8 %) (Figure 3.4l). 
 
Like dDCs, in vitro-generated LCs were harvested after 13 days and 
phenotypically characterized by flow cytometry. Similar to dDCs, in vitro-generated 
LCs stained positive for CD1a and HLA-DR (Figure 3.5b and e). However, when 
staining for the C-type lectin DC-SIGN, LCs showed a staining pattern that was 
distinct from that of MoDCs and dDCs in that they stained DC-SIGN negative 
(Figure 3.5f). At the same time, 8.2 % of LCs stained positive for CD206 (Figure 
3.5c). As expected, LCs stained positive for Langerin (92.8 %) (Figure 3.5d). 
When analysing the expression pattern of the myeloid markers on LCs, they were 
found to express CD11c (99 %), while staining low positive for the expression of 
CD11b (12.8 %). Subsequent staining for activation markers and co-stimulatory 
molecules showed LCs to be positive for CD80 (71.9 %). Concurrently, LCs 
stained negative for CD83 (6.3 %) and CD40 (3.3 %), and low positive for CD86 
(23.6 %) (Figure 3.5j, m, k). Furthermore, LCs stained low positive for the 
expression of CD14 (9.8 %) (Figure 3.5l). 
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a)                 b)             c)                 d)             e) 
     
 
f)         g)             h)                 i)             j) 
      
 
k)         l) 
 
Figure 3.15: Phenotypic analysis of immature dDCs. 
dDCs were differentiated from CD34
+
 precursor cells. On day 6, CD14
+
 cells were isolated 
and sub-cultured for an additional 6-8 days before the cells were CD1a-purified and 
phenotyped. dDCs were analysed for the expression of C-type lectins, myeloid markers, and 
co-stimulation related molecules. Histograms were gated on live cells. Respective isotype 
controls can be found in Figure A.4 of the Appendix. 
 
35.1% 9.8% 
87.4% 73.6% 
81.4% 
89.0% 1.4% 
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a)               b)        c)          d)            e) 
      
 
f)              g)        h)           i)             j) 
     
 
k)               l)                 m) 
 
Figure 3.5: Phenotypic analysis of immature LCs. 
LCs were generated from CD34
+
 precursors as described in 
chapter 2.2.4.2. LCs were harvested on day 13, CD1a
+
 purified, 
and phenotyped. LCs were analysed for the expression of C-type 
lectins, myeloid markers, and co-stimulatory molecules. The LC 
population analysed was gated on live cells. Respective isotype 
controls can be found in Figure A.5 of the Appendix. 
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3.2.4 Isolation of Dermal DCs and Langerhans Cells from Human Skin 
3.2.4.1 Isolation of Dermal DCs from Human Dermal Tissue 
Although there are close similarities between in vitro-generated dDCs and LCs 
and skin-derived dermal and epidermal DCs, in vitro systems are limited in their 
capacity to generate DCs that match the exact characteristics of DCs found in 
vivo. Therefore, human dermal DCs were isolated from healthy human skin as 
described in chapter 2.2.4.4 and characterised by cell surface staining for C-type 
lectins and activation markers. As presented in Figure 3.6b, only a small fraction 
(41.7 %) of the isolated cells stained positive for CD1a and HLA-DR. These cells 
expressed low levels of Langerin (9 %) (Figure 3.6e) and slightly higher levels of 
CD206 (13.8 %) (Figure 3.6f). When analysed for the expression of maturation 
markers and co-stimulatory molecules, we were unable to detect expression of 
CD80 (0.8 %) and CD83 (0.5 %). Only low levels of CD86 expressing dermal DCs 
were detected (6.1 %). 
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a)     b) 
   
 
 
c)       d)            e)       f) 
    
 
 
     g)     h)           i) 
   
 
Figure 3.616: Phenotypic analysis of skin-derived dermal DCs. 
Dermal DCs were isolated from healthy human skin by collagenase digestion. The dermis cut into 
small pieces and incubated with collagenase D for 3-4 hrs at 37 °C under constant rotation 
(Miltenyi rotor). Cells were subsequently harvested and phenotyped by receptor surface staining. 
Due to the low purity of cells, a gate was placed on CD1a
+
HLA-DR
+
 cells (b). Respective isotype 
controls can be found in section A.6 of the Appendix. 
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3.2.4.2 Isolation of mature LCs from Human Epidermis 
Epidermal LCs were isolated from human skin samples by the tissue digestion and 
“walk-out” method (chapter 2.2.5.1). Initially, the processed skin samples were 
incubated overnight in 0.2 % dispase at 4 °C. The following day, the dermis and 
epidermis were separated by carefully pulling apart the two layers. The epidermis 
was subsequently processed to isolate epidermal LCs. Higher purity of 
Langerhans cells was achieved by positive selection of cells expressing CD1a 
epidermal LCs. For FACS analysis, the gate was placed on the CD1a+ population 
and these cells were shown to express HLA-DR (Figure 3.7). In contrast to 
MoDCs, dDCs, and dermal DCs, epidermal LCs stained for Langerin+ (98 %; 
Figure 3.7d) but were negative for CD206, DC-SIGN (Figure 3.7e and f) and the 
myeloid marker CD11b (0.7 %). They were positive for CD11c (41.4 %). Epidermal 
LCs stained positive for the maturation marker and costimulatory molecules CD80, 
CD83, and CD86 (Figure 3.7i-k), suggesting that they were matured by the “walk 
out” or “migration” method of isolation. 
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a)                b)                  c)              d)       e)   
     
 
f)               g)                   h)    i)        j) 
      
 
k) 
Figure 3.717: Phenotypic analysis of skin-derived epidermal LCs. 
LCs were isolated from human epidermal sheets as described in chapter 2.2.5.1. Migrated cells were harvested from the 
supernatant and CD1a purified by means of direct positive selection. The cells were subsequently washed and phenotyped 
by cell surface staining. Matching isotype controls can be found in Figure A.7 of the Appendix. 
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3.2.3 Isolation and Phenotyping of mDCs from Human Peripheral Blood 
Human mDCs were magnetically isolated from peripheral blood and further 
purified using DYNAL beads as described in section 2.2.4.5 of Materials and 
Methods. mDCs were subsequently left to rest overnight in 10 % supplemented 
RPMI medium in the presence of GM-CSF (100 ng/ ml) and IL-4 (1000 U/ ml). The 
following day, mDCs were phenotyped, staining for the expression of cell surface 
markers by flow cytometry. 
 
As presented in Figure 3.8a, mDCs stained positive for HLA-DR (99.3 %). Similar 
to MoDCs and dDCs, mDCs stained positive for the C-type lectins DC-SIGN (17.8 
%) and CD206 (9.8 %). At the same time, mDCs stained negative for Langerin 
(Figure 3.8d). CD14 was expressed only at low levels (10.9 %). The expression 
pattern for the myeloid markers was 25.5 % for CD11b, whereas most cells 98.9 % 
stained CD11c+. Finally, mDCs stained positive for the activation markers CD80, 
CD83 and CD86 (Figure 3.8i-k). 
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a)               b)                  c)                    d)             e) 
         
 
f)                g)                  h)                     i)      j) 
          
 
k) 
Figure 3.818: Phenotypic analysis of over-night cultured blood-derived mDCs. 
Human mDCs were magnetically isolated from the percoll interphase of Buffy Coats and further purified using DYNAL beads. 
The isolated cells were then cultured overnight in the presence of GM-CSF (100 ng/ ml) and IL-4 (1000 U/ ml) at 37 °C. 
Cultured mDCs were then surface stained for the expression of C-type lectins, myeloid markers, and activation markers. 
Histograms were gated on live cells. Respective isotype controls can be found in Figure A.8 of the Appendix. 
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3.2.5 The Effect of ATRA on MoDCs 
Treatment of DCs with retinoids can have an effect on their proliferation and 
survival capacity. Bedford and Knight (1989) showed that DC isolated from RA-
treated cultures were less stimulatory when added to allogeneic lymphocytes. 
Similarly, it has been shown that the percentage of DCs is markedly lower in 
ATRA treated cells (Tao et al., 2006). Hence, ATRA was evaluated as to its effects 
on the phenotype of MoDCs. To determine whether ATRA treatment had an effect 
on the levels of cell surface marker expression on DCs, MoDCs were incubated 
overnight in the absence or presence of ATRA (10 nM or 1000 nM). MoDCs were 
subsequently analysed for the cell surface expression of CD1a, HLA-DR, DC-
SIGN, and the activation markers CD80, CD83, and CD86 (Figure 3.9). In the 
absence of ATRA, 93.4 % of MoDCs expressed CD1a (Figure 3.9b). However, in 
the presence of 10 nM (Figure 3.9i) and 1000 nM (Figure 3.9p) ATRA, there was a 
slight decrease in CD1a+ MoDCs. This trend was also observed for the percentage 
expression of HLA-DR and DC-SIGN. Overnight-treatment of MoDCs in the 
presence of 10 nM or 1000 nM decreased the percentage of HLA-DR+ MoDCs to 
87.7 % and 86.4 % respectively (Figure 3.9j and q). Untreated MoDCs showed 
DC-SIGN expression levels of 89.4 % (Figure 3.9d). Addition of 10 nM (Figure 
3.9k) and 1000 nM (Figure 3.9r) ATRA induced a slight reduction in DC-SIGN 
expressing cells. Interestingly, ATRA treatment did affect CD80 and CD83 
expression much more severely. As shown in Figure 3.9e and f, in the absence of 
RA the levels of CD80 and CD83 expressing cells were 88 % and 53.5 % 
respectively. However, in the presence of only 10 nM ATRA, we observed a 
reduction in CD80 expression to 63.9 % (Figure 3.9l). This reduction was even 
more severe in the case of CD83 expression, decreasing from 53.5 % to 2.3 % in 
the presence of 10 nM ATRA (Figure. 3.9m). On the contrary, MoDCs treated with 
ATRA experienced an increase in CD86+ (Figure 3.9n and u) cells when compared 
to untreated cells (Figure 3.9g). Overall, the increased levels if CD83 expression 
could be indicative of partial MoDC activation during differentiation.  
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a)              b)                 c)                   d)            e)               f)                 g) 
        
 
h)              i)                 j)                   k)    l)      m)         n) 
        
 
o)      p)                q)                   r)    s)      t)         u) 
        
 
Figure 3.919: Treatment of MoDCs with ATRA. 
MoDCs were generated as described in chapter 2.2.4.3. MoDCs were then overnight cultured in the absence (a-g) or presence of 10 nM (h-n) or 1000nM (o-u) 
ATRA. Cells were subsequently harvested and stained for the expression of CD1a, HLA-DR, DC-SIGN, and the activation markers CD86. Histograms were 
gated on live cells. Respective isotype controls can be found in Figure A.9 of the Appendix.    
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3.3 Discussion 
The aim of this chapter was to establish a reliable method that allowed the 
isolation and differentiation of human CD34+ and CD14+ precursor cells into 
models of systemic DCs. As there are limitations in the isolation of large numbers 
of immature DCs from human skin, the development of such in vitro systems 
greatly facilitates the study of DC biology. Immature MoDCs, as well as LCs and 
dDCs were generated in vitro from CD14+ progenitor cells and CD34+ progenitor 
cells respectively, and their phenotypes and maturation status compared to dermal 
DCs and epidermal LCs directly isolated from human skin. 
 
 
3.3.1 In vitro Generation and Characterisation of MoDCs 
In vitro generation of immature MoDCs from PBMCs was first published by 
Sallusto and Lanzavecchia, (1994). Using GM-CSF and IL-4 they were able to 
establish DCs that maintained the antigen capturing and processing capacity 
characteristic of immature DCs ex vivo. To generate MoDCs, we isolated CD14+ 
precursor cells from peripheral blood and differentiated them in the presence of 
GM-CSF and IL-4. Immature DCs are characterized by a CD1a-/lowCD11chighCD83-
CD86lowHLA-DRlow phenotype, while DC maturation is accompanied by the up-
regulation of cell surface markers including MHC class I and II, as well as co-
stimulatory molecules such as CD80, CD86 and CD40 (Liu et al., 2001; Ardeshna 
et al., 2000). Other groups (Beckebaum et al., 2003) confirmed that MoDCs 
cultured in GM-CSF and IL-4 displayed the phenotype of differentiating but not yet 
mature cells with low MFI of CD83 and CD80, moderate expression of CD86. 
These publications agree with the data presented in Figure 3.1, where we showed 
MoDCs to have a DC-SIGN+CD86+HLA-DR+CD83-Langerin- phenotype. Our data 
show immature MoDCs to be CD83- (1.1 %), CD86+ (23 %), and CD80+ (48.1 %). 
These observations concur with publications by Waeckerle-Men et al. (2004). 
More specifically, Ardeshna et al. (2000) characterised immature MoDCs to be 
approximately 26.9 % CD80+, 34.8 % CD83+, and 11.4 % CD86+. Although our 
values for the level of CD80 expression (1.1 %) are lower than those published by 
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Ardeshna et al. (2000), other groups have also shown that immature DCs are 
CD83 negative. Janjic et al. (2002) showed immature DCs to be CD83- and 
CD80lowCD86lowCD40lowMHC class IintMHC class IIint.  
 
The presence of ATRA in human sera has been shown by different groups (De 
Leenheer at al. 1982, Napoli et al., 1985). Similarly, Tang and Russell (1990) 
confirmed the occurrence of 13-cis-RA as an endogenous component in human 
serum. For the purpose of subsequent experiments and to test whether fetal calf 
serum had an effect on the phenotype of MoDCs, CD14+ precursors were 
differentiated in serum free medium to give rise to MoDCs. Our results indicate 
that the absence or presence of fetal calf serum in the medium did not significantly 
affect the differentiation and phenotype of MoDCs. MoDCs generated in serum 
free medium expressed similar percentages of surface receptors tested as MoDCs 
generated in supplemented medium (Figure 3.1). Slight differences were detected 
in the expression levels of HLA-DR and CD86. MoDCs generated in supplemented 
medium showed lower levels of HLA-DR expression (66.9 % vs 97.8 %) as well as 
CD86 expression (23 % vs 90 %). However, these differences could be attributed 
to differences in the antibody isotypes used in each experiment. 
These findings suggest that MoDCs generated in serum free medium do not 
significantly differ in their phenotype from those MoDCs generated in 
supplemented medium. However, we have not analysed cytokine production by 
MoDCs generated in either one of the two media. Further experimentation is 
required to fully conclude on the differences or similarities between MoDCs 
generated in supplemented and serum free medium. 
 
Various immunoregulatory roles have been ascribed to retinoids, including the 
regulation of DC differentiation, maturation and antigen presentation (Walsh et al., 
1988; Bedford and Knight, 1989). While lymphocyte activation relies on the 
presentation of antigens by DCs in the context of MHC complexes in combination 
with costimulatory molecules, it has been shown that retinoids can affect that 
function of MoDCs. In particular, the impact of RA on human MoDCs has been 
evaluated (Geissmann et al., 2003), showing that retinoids have the ability to 
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enhance expression of MHC class II and CD86 on MoDCs. To test whether ATRA 
has an effect on the phenotype of MoDCs and therefore potentially their immune 
function and associated ability to regulate homing receptors on T cells, we cultured 
MoDCs in the presence of ATRA and subsequently analysed them for the 
expression of CD1a, HLA-DR, the C-type lectin DC-SIGN, and the activation and 
costimulatory molecules CD80, CD83, and CD86 (Figure 3.9). As presented in 
Figure 3.9, there was a slight decrease in the percentages of CD1a, DC-SIGN, 
and HLA-DR expressing MoDCs when ATRA was added to the cells. A more 
dramatic decrease was observed with CD80 and CD83. At the same time, RA 
increased the percentages of CD86 expressing MoDCs. These results suggest 
that ATRA may have a stimulating effect on MoDCs. The activation of LCs after 
administration of RA has previously been reported (Meunier et al., 1994; 
Manickasingham et al., 1996), which is consistent with the observed increase in 
CD86 expressing MoDCs. 
However, a decrease in CD1a, CD-Sign, HLA-DR, CD80, and CD83 suggests 
ATRA to have an inhibitory effect on MoDCs. Since the presence of RA led to a 
slight decrease in the levels of CD83 and HLA-DR expression, one might suggest 
RA to have a slight inhibitory effect on DCs. As previously shown by Bedford and 
Knight (1989), treatment of DCs with RA inhibited their capacity to stimulate 
allogenic responses. Similarly, it was previously shown by Zapata-Gonzales et al. 
(2007) that 9-cis-retinoic acid is able to interfere with the normal differentiation 
process of human monocyte leading to the generation of mature DCs with a less 
stimulatory phenotype. Yet, other groups have shown that the phenotype of RA-
treated MoDCs with respect to MHC class II or CD80/86 expression did not 
change (Sauer et al., 2007). Our data suggest that RA mediates only a slight 
increase in CD86 expression and decrease in CD1a, HLA-DR, and DC-SIGN, 
whereas CD80 and CD83 expression were much more severely affected. To 
determine the overall effect of RA on DCs further experiments are required, that 
include such as the differentiation of MoDC precursors in the presence of 
exogenously added RA. 
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3.3.2 Generation and Characterization of dDCs and LCs relative to Skin-derived 
Dermal DCs and Epidermal LCs 
Although MoDCs are widely used as an in vitro DC model their phenotype differs 
from human epidermal LCs. Hence, we used an alternative in vitro model for the 
generation of LCs and dDCs. As shown by Caux et al. (1992) representative DCs 
of the dermis (dDCs) and epidermis (LCs) can be grown in vitro from CD34+ 
progenitor cells. Caux et al. (1992) were able to show that CD34+ progenitor cells 
differentiated to give rise to two distinct DC subtypes comprising dDCs and LCs. 
Similarly, Klechevsky et al. (2008) showed that models of dDCs and LCs could be 
generated in vitro by culturing CD34+ hematopoietic progenitor cells (HPCs) for 9 
days before sorting them into CD1a+CD14- (LCs) and CD1a-CD14+ (CD14+ dDCs) 
populations. These publications are supported by our data (Figure 3.3) showing 
the differentiation of CD34+ progenitor cells into dDCs and LCs.  
Phenotypic analysis not only showed that CD34+-derived LCs differ from MoDCs 
but also confirmed expression of cell surface receptors characteristic for each of 
the two populations. As expected, CD34+ progenitor could be differentiated into 
two mutually exclusive populations, CD1a-CD14+ and CD1a+CD14- cells, which 
were separated by magnetic labelling and further differentiated into dDCs and LCs 
(Figure 3.3b and c). dDCs, which are characteristically defined as being Langerin-
DC-SIGN+CD11b+, stained negative for Langerin (1.4 %), and positive for DC-
SIGN (81.4 %) and CD11b (69.9 %). dDCs also stained positive for HLA-DR and 
CD1a, and the myeloid marker CD11c. These observations are in concordance 
with data showing Langerin- DCs present within the human dermis to have a 
CD11c+CD1a+ phenotype (reviewed by Merad et al., 2008). Furthermore, dDCs 
stained positive for CD206, which coincides with data published by Geijtenbeek et 
al. (2000), who detected DC-SIGN expression only on dermal DC from skin 
sections. dDCs also stained negative/low for CD83 (1.5 %) and CD80 (5.6 %), and 
for CD86 (35.1 %) (Figure 3.4), which is characteristic for immature DCs 
(Banchereau and Steinman, 1998). These findings confirm the similarity in 
phenotype between MoDCs and dDCs (Grassi et al., 1998) and the representative 
status of in vitro-generated MoDCs for human dermal DCs. 
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It was Paul Langerhans, who first described DCs resident in the skin, in particular 
the epidermis. In his paper “Über die Nerven der menschlichen Haut” published in 
1868, Langerhans first described non-pigmentary DCs or stellate corpuscles, 
which are now known as LCs. It was Valladeau et al. (2000) who characterized 
Langerin, a lectin specifically expressed by LCs. Using a CD1a monoclonal 
antibody, Fithian et al. (1981) were the first to demonstrate expression of CD1a on 
human LCs from human epidermis. These observations were later confirmed by 
Grassi et al. (1998) who showed that LCs are immature DCs that express a 
CD1a+HLA-DR+ phenotype. As presented in Figure 3.5, we were able to generate 
immature LCs that were CD1a+, Langerin+, HLA-DR+, and DC-SIGN-. Further 
analysis showed that LCs stained positive for the myeloid marker CD11c and 
expressed low levels of CD11b. The lack of CD11b expression on LCs has also 
been described by Jaksits et al. (1999). However, low levels of CD11b expression 
could be explained by a heterogeneous population of LCs. More recently, Soulas 
et al. (2006) showed that human CD34+CD11b− cells differentiate in culture into 
CD34−CD11b− precursors that in turn generate CD34−CD11b+ cells. These cells 
are enriched in LC precursors, leading to the generation of a mixture of CD11b− 
and CD11b+ LC in vitro.  
In addition, in vitro-generated LCs stained positive for the activation marker CD80, 
and showed low expression levels for CD83 and CD86, which is characteristic of 
immature LCs (Banchearau and Steinman, 1998). Although the expression of the 
skin homing CLA on LCs was not investigated, it has been shown (Ross et al., 
1994) that LCs specifically express CLA. Overall, these data showed that LCs 
could be successfully generated in vitro. 
 
The human skin contains at least three subpopulations of DCs. Within the dermis, 
CD14-Langerin-CD1a+ and CD14+Langerin-CD1a+ have been identified, while in 
the epidermis, a single CD14-Langerin+CD1a+ has been described (Klechevsky et 
al., 2008). As shown by Klechevsky et al. (2008), human epidermal sheets contain 
CD1a+HLA-DR+ cells expressing Langerin. Phenotypic analysis of epidermal LCs 
isolated from epidermal sheets showed that most of the isolated cells were HLA-
DR+Langerin+CD1a+, confirming the findings published by Klechevsky et al. (2008) 
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and those observed with in vitro-generated LCs. Several other groups have also 
shown that human LCs share CD1a expression with DCs generated in vitro. In 
concordance with our results, Klechevsky et al. (2008) showed that skin LCs 
expressed Langerin and high amounts of costimulatory molecules (CD80, CD86, 
and CD40). Although epidermal LCs were successfully isolated from epidermal 
sheets, the various processing steps and isolation method are likely to have 
contributed to the activation of LCs and thus up-regulation of activation markers 
and costimulatory molecules. The isolation of mature LCs by the “epidermal 
migration” method has previously been described by Morelli et al. (2005). 
Evidently, LCs were expected to have a mature phenotype, which was reflected by 
high CD83 and CD86 expression levels. This stands in contrast to the in vitro 
model of LCs, which has the advantage of generating phenotypically immature 
LCs. 
 
Within the human skin, DCs have been identified to express the myeloid marker 
CD11c. Epidermal LC (Langerin+CD11c+CD1a+), dermal DCs (CD11c+CD1a+/-
Langerin-), and dermal DC (Langerin+CD11c+CD1a+) all express CD11c (Merad et 
al., (2008); Liu, (2001). Expression levels of CD11c on epidermal LCs were 
moderate (41.4 %; Figure 3.7h) and much lower than on in vitro-generated LCs 
(99 %; Figure 3.5h). One feasible explanation might be the treatment of skin 
sheets with collagenase and dispase. As highlighted by Henri et al. (2010) 
collagenase and dispase digestion tend to affect CD11c expression on DCs. 
Further analysis showed that skin-derived epidermal LCs stained negative for the 
C-type lectins DC-SIGN and CD206, two receptors that are restricted to MoDCs, 
dDCs, and DCs of the dermis (Figures 3.1, 3.4, 3.6). The absence of DC-SIGN 
and CD206 on isolated epidermal Langerin+ LCs is in agreement with findings 
(Ochoa et al., 2008) showing DC-SIGN+ cells to lack expression of Langerin. Also, 
this observation coincides with data obtained for in vitro-generated LCs and 
detection of CD206 on skin-derived dermal DCs. As shown by Geijtenbeek et al. 
(2000), DC-SIGN is only expressed on dermal DC, whereas CD1a positive LCs in 
the epidermis are DC-SIGN negative. In addition, they showed that in vitro 
differentiation of monocytes into immature DC in the presence of GM-CSF and IL-
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4 coincides with DC-SIGN expression. These findings not only explain the lack of 
DC-SIGN on LCs but also validate expression of DC-SIGN on MoDCs and dDCs, 
which both are generated in the presence of GM-CSF and IL-4. 
Expression of CD206 has been regarded a hallmark of immature DCs, whereas 
monocytes and mature DCs as well as epidermal LCs are mannose receptor 
negative (Kato et al., 2000). As shown, skin-derived dermal DCs were CD206+ and 
showed low expression levels of activation markers and costimulatory molecules, 
whereas LCs isolated from human epidermal sheets stained negative for CD206. 
However, controversial data have been published on the expression pattern of 
CD206 by epidermal LCs. Generally, freshly isolated LCs have been shown to not 
express detectable levels of CD206 (Geijtenbeek et al., 2000; Mommaas et al., 
1999; Sallusto et al., 1995; Kato et al., 2000). However, Condaminet et al. (1998) 
showed strong macrophage mannose receptor staining of human CD1a+ LC but 
not CD1a- populations. Wollenberg et al., (2002) more specifically showed that 
inflammatory epidermal DCs but not LCs express CD206. 
Based on the cell surface analysis, dDCs and LCs generated in vitro expressed a 
phenotype remarkably similar to that of dermal DCs and LCs isolated from human 
skin, suggesting CD34+ derived dDCs and LCs to be a good model system for 
studying the nature and role of dermal DCs and LCs ex vivo. However, the in vitro 
system needs further validation as two major characteristics of epidermal LCs 
have recently been described.  
 
First, using transgenic mice, Kissenpfennig et al. (2005) showed that Langerin 
alone is not a reliable marker to identify LC-derived DCs outside the skin, as most 
CD8α+ DCs present in CLNs, MLNs, and the spleen express Langerin. Data 
published by Poulin et al. (2007) further revealed that there are at least two 
populations of Langerin+ LCs in mice, which originate from two different 
developmental pathways. In humans, Langerin+ cells have also been found in the 
dermis (Angel et al., 2007), as well as in mucosal tissue of the lung, liver and 
kidneys (Merad et al., 2008). Using DCs from murine epidermis, Borowski et al. 
(1996) demonstrated that gp40, the homologue of EpCAM, was selectively 
expressed on isolated LCs, cultured LCs and LCs migrated from skin sections, 
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while lower levels of gp40 were present on DC from gut-associated lymph nodes. 
In addition, Bursch et al. (2007) have reported that the expression of EpCAM can 
be used to distinguish epidermal LCs from Langerin+ dDCs, which are EpCAM 
negative.  
A second characteristic of epidermal LCs is their resistance to UV radiation. As 
shown by Merad et al. (2002) cells ensuring epidermal LC renewal are radiation 
resistant, and after lethal irradiation and bone marrow transplantation, epidermal 
LCs found in CLNs remain of host origin. This stands in contrast to all other DC 
subtypes, including Langerin+ dermal DCs, which are radiosensitive and display a 
distinct cell surface phenotype (Bursch et al., 2007). Hence, in order to fully 
phenotype skin-derived LCs and test the validity of the in vitro systems currently 
used, radiation experiments would need to be conducted.  
 
 
3.3.3 Isolation and Characterization of mDCs 
Hematopoietic progenitors in the bone marrow (BM) give rise to circulating DC 
precursors that home to blood as well as non-lymphoid and lymphoid tissues, 
where they reside as immature cells. The human blood contains at least three 
phenotypically and functionally distinct subpopulations of DCs, of which myeloid 
and plasmacytoid DCs constitute the majority of DCs. Blood mDCs have been 
characterized based on the expression of CD1c (BDCA-1) and CD141 (BDCA-3). 
CD11chighCD1a+CD64+CD123low CD1c+ mDCs are thought to constitute an 
immediate precursor of LCs (Ito et al., 1999) and are with a frequency of 0.6 % the 
major DC population in the blood. We therefore isolated and analysed mDCs for 
their phenotype and compared them to in vitro-generated and skin-isolated DCs. 
Out data show the successful isolation of mDCs and their positive staining for 
HLA-DR and CD11c (Figure 3.8). The expression levels for the activation markers 
CD83 and CD86 were higher than what was observed for MoDCs. As suggested 
by Osugi et al., (2002) mDCs express similar levels of CD83 and CD86 as 
MoDCs. However one explanation for the high levels of CD83 and CD86 
expression could be the overnight culture of mDCs. As suggested by MacDonald 
et al., (2002) culturing of mDCs in vitro leads to the up-regulation of surface 
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receptors such as CD123, which is normally only weakly expressed. Cell surface 
staining further showed blood CD1c+ DCs to express low levels of DC-SIGN (17.8 
%). These levels were much lower than those observed with MoDCs (97.6 %) 
confirming data published by Osugi et al. (2002) who detected CD209 on MoDCs 
but not on blood CD11c+ DCs. Similarly, a low level of CD14 expression was 
detected (10.9 %), confirming data published by MacDonald et al., (2002), who 
showed that the blood myeloid population expresses CD11c and low levels of 
CD14. Expression levels of CD11b were moderate (25.9 %; Figure 3.8g). As 
previously shown by our lab (Patterson et al., 2005) purified blood mDCs cultured 
in vitro with GM-CSF and IL-4 differentiate into two distinct populations. The major 
population is CD11b+, CD1a+, and DC-SIGN+ and expresses moderate levels of 
MHC class II and low levels of costimulatory molecules. The second population is 
CD11b-/low and lacks CD1a and DC-SIGN but expresses high levels of MHC class 
II and costimulatory molecules. Hence, moderate expression of DC-SIGN and 
CD11b, as well as elevated expression of costimulatory molecules suggests 
mDCs maturation. With respect to DC-SIGN expression, phenotypic analysis of 
mDCs showed similarity to LCs. However, clear differences in Langerin expression 
were also detected. 
 
In conclusion, we have shown data on the generation and phenotyping of MoDCs 
in supplemented and serum free medium and confirmed their equivalent 
phenotypes. Furthermore, we showed that addition of ATRA led to a slight change 
in MoDC phenotype. 
For the in vitro generation of dDCs and LCs, we were able to use a model 
representative for dermal and epidermal DCs respectively. However, keeping in 
mind the diversity of DCs present in the skin, using this model does not take into 
account the Langerin+ DCs present within the dermis. Therefore, we looked into 
the isolation of DCs directly from human skin explants. Here, we were able to 
establish a protocol for the isolation of dermal and epidermal LCs from human 
skin. 
Finally, blood-derived myeloid DCs (mDCs) were characterized based on the 
expression of CD11b, HLA-DR. However, myeloid DCs are only one population of 
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DCs found in human peripheral blood. Additional analysis of plasmacytoid DCs 
(pDCs) might be required in order to understand the role of blood derived DCs in 
the regulation of the immune system. 
 
Mucosal DCs have been characterised into two major sub-populations of DCs 
consisting of CD103+ and CD103- cells. In particular CD103+ DCs, which express 
high levels of TGF-β are thought to regulate homing of gut T cells. Based on our 
data, we propose that in vitro-generated LCs may have the highest potential 
among the systemic DCs to induce gut homing T cells through the production of 
TGF-β. Hence, they may provide a good target for skin vaccines. 
 
Although we were able to generate systemic DCs in vitro, isolate mDCs from 
blood, and DCs from dermal and epidermal tissue, these DC populations 
represent only a small fraction of DCs that can be found within the human body. In 
addition, the human Langerin+ DC network within the skin seems much more 
complex than initially anticipated. Hence, much work needs to be put into the 
identification and analysis of additional human DC subsets, which may have 
implications for the development of systemic and mucosal vaccines. 
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Chapter 4 
 
 
 
 
 
Induction of a Mucosal Homing Phenotype on T cells by 
Systemic DCs in the Presence and Absence of ATRA as 
determined by the Expression of 47 and CLA 
 
 
 
4.1 Background and Aims 
Foreign antigens are encountered and selectively taken up into highly structured 
sites for the initiation of systemic and mucosal immune responses. It has long 
been thought that the systemic immune system is separate from the mucosal 
immune system and that the “common mucosal immune system” induces the 
homing of antigen-specific lymphocytes to mucosal effector sites other than the 
site where initial antigen exposure occurred. However, within the past years, the 
general consensus that systemic vaccination only induces systemic immune 
responses has been challenged by new data that have shown systemic 
vaccination to induce mucosal immune responses (Fuller et al., 2002, Belyakov et 
al., 2004, Schoenly et al. 2007, Reinhardt et al., 2001, Masopust et al., 2001, 
Tatsis et al. 2007, Berry et al., 2004, Trumpfheller et al., 2006). The discovery that 
systemic vaccination may hold the potential to induce a mucosal homing 
phenotype on lymphocytes not only questions the existence of a “common 
mucosal immune system” (McGhee et al., 1992) but has also led to the 
consideration of novel vaccine delivery systems such as skin vaccination and 
immunomodulatory strategies in order to induce mucosal immune responses. 
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T cell migration to the intestinal mucosa is regulated by various homing receptors, 
two of which include the α4β7 integrin and CCR9. Expression of α4β7 has been 
shown (Springer, 1990; Streeter et al., 1988; Mora et al., 2006) to play an 
important role in the homing process of lymphocytes to the mucosa of the 
intestine. In contrast, lymphocyte homing to the skin is regulated by cell surface 
receptors that differ from those expressed on B and T cells in the intestinal 
mucosa. As shown by Fuhlbrigge et al. (1997), lymphocyte trafficking to the skin 
is, in part, dependent on the expression of CLA.  
 
Activation of the adaptive immune response is absolutely dependent on antigen 
recognition by professional APC such as DCs. Systemic and mucosal DCs are 
both required for the initiation of primary immune responses (Hart, 1997; Iwasaki 
and Kelsall, 1999). Nonetheless, it has long been thought that systemic DC are 
only able to induce systemic immune responses, while mucosal DCs have the 
potential to induce mucosal as well as systemic immune responses. Over the past 
years, the role of intestinal and MALT DCs in inducing and regulating mucosal 
immune responses as well as maintaining intestinal homeostasis has been under 
intense investigation. Various subpopulations of mucosal DCs have been 
identified, with the CD103+ cells in the PP and MLNs being of particular 
significance since they have been found to induce gut homing lymphocytes. 
Several groups have shown (Stagg et al., (2002); Jaensson et al., (2008); Mora et 
al., (2006); Johansson-Lindbom et al., (2005)) that these mucosal DCs have the 
capacity to induce expression of gut homing receptors α4β7 and CCR9 on 
lymphocytes. The mechanism underlying this property is attributed to the ability of 
these DCs to metabolize Vitamin A to RA (reviewed by Iwata, 2008). Retinoic acid 
then acts as a regulator of gene transcription, leading to the up-regulation of the 
gut homing receptors α4β7 and CCR9. For further details on the molecular 
mechanism and regulation of gene transcription by RA please refer to chapter 1.8. 
Although more than 25 different vaccines are available for use in humans, most 
vaccines are only licensed for non-mucosal administration such as subcutaneously 
or intramuscularly (Ogra et al., 2001).  
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These include intramuscular vaccines against diseases such as diphtheria, 
whooping cough (pertussis), TT, influenza (flu), and subcutaneous vaccines such 
as measles which commonly enter the body at mucosal surfaces. Thus we asked 
whether systemic vaccination with these antigens induced mucosal homing 
lymphocytes. To answer this question we tested whether these vaccine antigens 
could trigger expansion CD4+ memory T cells expressing 47. This was 
investigated by pulsing human MoDCs with vaccine antigen, co-culturing with 
autologous lymphocytes and analysing expanded antigen specific CD4+ memory T 
cells for expression of 47. The results and conclusions drawn from these 
experiments further led us to examine the role of different human DC subtypes in 
initiating a mucosal immune response. Specifically we analysed the ability of 
MoDCs, CD34-derived LCs and dDCs, LCs isolated from skin, and BDCA-1 blood 
mDC to induce expression of α4β7 on purified naïve and memory CD4+ and CD8+ 
T cells in the presence and absence of RA. In addition we analysed expression of 
CLA to see whether there is reciprocal reduction in expression as α4β7 levels are 
increased.  
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4.2 Results 
4.2.1 Proliferation of Memory CD4+ T Cells and Induction of Mucosal Homing 
Phenotype in the Presence of Systemic Vaccine Antigens  
4.2.1.1 In vitro Generation of Secondary Immune Response by Systemic Antigens 
in the Presence of Autologous MoDCs 
Most vaccines are licensed for use only via a nonmucosal route, which either 
involves subcutaneous, intravenous or intramuscular administration (Lambert and 
Laurent, 2008). Therefore, we firstly address the question of whether in vitro-
generated human systemic DCs have the potential to induce a specific CD4+ 
memory T cell response to various antigens that are normally used in systemic 
vaccination and secondly, whether antigen delivery would induce proliferation of T 
cells expressing a 4+7+ phenotype. In vitro-generated MoDCs were co-cultured 
with purified populations of autologous CD4+ memory T cells in the presence of 
antigens including TT, flu, measles, CMV, diphtheria and pertussis. Antigen-
specific T cell proliferation (% CFSE) and the percentage of α4β7 expressing cells 
were measured on day 4 by flow cytometric analysis (Figure 4.1 and 4.2).  
As expected, culturing T cells alone (0.7 %) or MoDC-T cells (3.1 %) only 
showed low levels of T cell proliferation (Figure 4.1). The extent of T cell 
proliferation detected for MoDC-T cells alone was set as the background. As 
expected, stimulation with Staphylococcus aureus Enterotoxin B (SEB) 
superantigen always led to high levels of CD4+ memory T cell proliferation. In the 
vaccine antigens-stimulated CD4+ T cells, lower levels of memory CD4+ T cell 
proliferation were observed on stimulation with TT (5.1 %), diphtheria (3.9 %), and 
measles (4.5 %). Stimulation with flu led to higher levels of proliferation (7 %) 
whilst CMV and pertussis generally triggered the highest CD4+ T cell memory 
proliferation response. 
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a)               b)         c)      No Stimulus         d)         TT            e)    Diphtheria 
     
 
e)         Flu             f)       Pertussis      g)         Measles         h)       CMV           i)          SEB 
     
 
j)      T cells 
Figure 4.1: Antigenic stimulation of isolated CFSE-labelled CD4
+
 memory T cells. 
Purified CFSE-labelled CD4
+
 memory T Cells were co-cultured for 4 days in the presence of either tetanus toxoid (10 ng/ 100 
µl), diphtheria (100 ng/ 100 µl), pertussis (100 ng/ 100 µl), heat-inactivated influenza (20.48 HA/ ml), CMV (100 ng/ 100 µl), or 
measles (100 ng/ 100 µl) -  pulsed MoDCs. SEB-stimulation (100 ng/ ml) was used as positive control. T cells only (j) and 
MoDC-T cells (c) were used as negative control. The percentage of proliferating memory CD4
+
 T cells and 47 expressing T 
cells were measured by flow cytometric analysis using an LSRII. Resprective isotype controls can be found in Figure B.1 of 
the Appendix.  
29.4% 48.1% 4.5% 90.2% 
0.7% 
3.1% 5.1% 3.9% 
34.5% 
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a)               b)                  c)       No Stimulus          d)         TT             e)     Diphtheria 
     
 
e)         Flu             f)        Pertussis       g)         Measles          h)       CMV             i)          SEB 
     
 
j)      T cells 
Figure 4.2: α4β7 expression on proliferating CD4
+
 memory T cells. 
Purified CFSE-labelled CD4
+
 memory T Cells were co-cultured for 4 days in the presence of either tetanus toxoid (10 ng/ 100 
µl), diphtheria (100 ng/ 100 µl), pertussis (100 ng/ 100 µl), heat-inactivated influenza (20.48 HA/ ml), CMV (100 ng/ 100 µl), or 
measles (100 ng/ 100 µl) -  pulsed MoDCs. SEB-stimulation (100 ng/ ml) was used as positive control. T cells only (j) and 
MoDC-T cells (c) were used as negative control. The percentage of proliferating 47 expressing T cells were measured by 
flow cytometric analysis using an LSRII. Respective isotype controls can be found in Figure B.2 of the Appendix. 
 
 
21.6 % 29 % 31 % 
28.5 % 51.1% 56.6 % 80.3 % 60.5 % 
10.6 % 
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Figure 4.20: Antigen-mediated induction of α4β7 on proliferating CD4
+
 memory T cells. 
a) CFSE-labelled CD4
+
 memory T Cells were co-cultured for 4 days with antigen-stimulated 
MoDCs. Antigen-specific T cell proliferation was measured based on the percentage of CFSE low 
CD4
+
 T cells. b) Mean percentage of α4β7 expression on proliferating (CFSE low) CD4
+
 memory T 
cells. * p < 0.05; ** p < 0.005; statistics were performed using the Wilcoxon matched pairs test. 
 
 
As summarized in Figure 4.3, our data showed that pulsing of T cells with SEB 
induced high mean percentages of proliferating T cells (73.44 % ± 4.57 %). 
Comparing the mean percentage of T cells stimulated by MoDCs alone (no toxin) 
(3.44 % ± 0.65) with antigen-pulsed T cells, we were able to observe a significant 
increase in the mean percentages of proliferating memory CD4+ T cells. Pertussis 
(21.80 % ± 4.37 %), Flu (15.51 % ± 6.12 %), and CMV (20.42 % ± 5.51 %) 
generally induced good proliferation (Figure 4.3a). Although T cell proliferation was 
detected in the presence of TT (14.49 % ± 5.13 %; p = 0.6250), diphtheria (12.02 
% ± 5.27 %; p = 0.5992) and measles (11.41 % ± 6.22 %; p = 0.1563), there was 
no significance between these antigen-pulsed T cells and those cultured in the 
presence of MoDCs alone (Figure 4.3a). 
There was a lack of correlation between proliferation and α4β7 expression. In the 
absence of exogenously added antigens, the mean percentage of proliferating 
CD4+ memory T cells expressing the surface marker 47 was 14.28 % ± 2.73 % 
(Figure 4.3b; white bar). Although stimulation with pertussis, flu, and CMV led to a 
significantly higher mean percentage of proliferating CD4+ memory T cells (Figure 
4.3a), a significant increase in 47 expression on proliferating T cells was only 
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recorded for Pertussis (p < 0.005) and Flu (p < 0.05) but not CMV (p = 0.2188) 
(Figure 4.3b). T cells pulsed with pertussis showed a mean percentage of 33.89 % 
± 5.92 %, while T cells pulsed with flu had a mean value of 39.24 % ± 7.48 %. 
Interestingly, although SEB induced the highest level of proliferating memory CD4+ 
T cells, expression of 47 on proliferating T cells (24.65 % ± 6.24 %) was not 
significantly higher when compared to T cells co-cultured with MoDCs alone (p = 
0.4961). Similarly, T cells pulsed with TT (p = 0.5469), diphtheria (p = 0.1953), 
CMV (p = 0.2188), or measles (p = 0.1094) did not show a significantly higher 
mean of 47 expression, however, an upward trend was noticeable. 
 
 
4.2.2 Induction of α4β7 Expressing T cells by different Human Systemic DC 
Subtypes in the Presence of ATRA 
4.2.2.1 Titration of ATRA 
To determine the optimal range of concentration of ATRA for our in vitro 
experiments, 10-fold dilutions of ATRA were prepared, ranging from 10-1 nM to 104 
nM. It was titrated into cultures of MoDCs and allogeneic T cells, not separated 
into naïve and memory populations, and incubated for 7 days followed by staining 
for α4β7 and CLA. In the absence of exogenously added ATRA, the percentage 
range of 47 expressing CD4+ and CD8+ T cells was very broad, ranging from 5 
% to 25 % for CD4+ T cells (Figure 4.4a) and 5 % to 50 % for CD8+ T cells (Figure 
4.4b). With the addition of ATRA to the culture medium 24 hrs prior to the addition 
of T cells, we were able to detect an increase and decrease in the number of 47 
and CLA expressing T cells respectively (Figure 4.4). Only a slight increase in 
47 positive T cell populations could be detected on addition of 0.1nM ATRA 
(Figure 4.4). For most samples there was maximal of 4β7 expression at 10 nM 
ATRA.  
In contrast to α4β7 where there were only slight increases induced by 0.1 nM 
ATRA, this concentration induced a very marked reduction in the percentage of 
cells expressing CLA with maximum reduction observed at 1 nM for most samples 
for both CD4+ (Figure 4.4c), and CD8+ T cells (Figure 4.4d).  
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a)    CD4+ T cells          b)  CD8 + T cells 
 
 
c)    CD4+ T cells           d)  CD8 + T cells 
   
Figure 4.421: Titration of ATRA on MoDCs in the presence of percoll pellet cells. 
MoDCs (n = 5-6) were incubated with total T cells from Percoll Pellet in the presence of increasing 
concentrations of all-trans retinoic acid (ATRA) for 7 days. The percentage of 47 (a – CD4 T 
cells and b – CD8 T cells) and CLA (c – CD4 T cells and d – CD8 T cells) expressing T cells was 
subsequently measured by flow cytometry. 
 
 
To investigate whether ATRA influenced the mean expression levels of 7 and 
CLA on CD4+ and CD8+ T cells, MFI data of each receptor were analysed. As 
shown in Figure 4.5a and 4.5b, the presence of 0.1 nM ATRA increased 7 
surface expression on CD4+ and CD8+ T cells at 0.1 nM; however, significance 
was only reached at a concentration of 10 nM ATRA. The mean MFI for CD4+ T 
cells increased from 3934 ± 2093.23 in the absence of ATRA to 6699 ± 2927 in 
the presence of 10 nM ATRA (n = 7). The mean MFI for CD8+ T cells increased 
from 4653 ± 2444 to 7330 ± 3371 (n = 7). 
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At the same time, a slight decrease in MFI of CLA on 7+CD4+ and 7+CD8+ T 
cells was observed that was inversely proportional to the concentration of ATRA 
used (Figure 4.5c and d). In the presence of 10 nM ATRA, we measured a decline 
in the mean MFI of CLA+CD4+ (1520 ± 299 to 1450 ± 298) and CLA+CD8+ (2211 ± 
682 to 1482 ± 406) T cells, however, this was not significant likely due to 
insufficient sample size (n = 5; p < 0.125). 
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Figure 4.5: ATRA increases β7 and decreases CLA surface expression. 
MoDCs (n = 5-7) were cultured with or without ATRA for 24 hrs before total allogeneic percoll pellet 
cells were added to the culture. After 7 days, CD4
+
 and CD8
+
 T cells were stained for 7 surface 
expression (a and b) and CLA expression on 7
+
 CD4
+
 (c) and CD8
+
 T cells (d). * p < 0.05; 
statistics were performed using the Wilcoxon matched pairs test. 
 
Based on these findings and to ensure the regulatory effect of ATRA, 
concentrations of ATRA between 10 nM and 1000 nM were used in subsequent 
experiments.  
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4.2.2.2 ATRA induces α4β7 Surface Expression on CD4+ and CD8+ T Cells 
Stimulated with Activation Beads 
Initially, we set up an experiment in which purified total T cells were isolated from 
percoll pellets and stimulated with anti-CD2, anti-CD3, and anti-CD28 activation 
beads (Miltenyi, UK) in the absence or presence of ATRA (10 nM – 1000 nM). In 
the absence of ATRA, low mean percentages of α4+β7+CD4+ and CD8+ T cells 
were detected (Figure 4.6a). T cell stimulation in the absence of ATRA supported 
α4β7 percentage values of 34.7 % ± 4.74 % for CD4+ T cells and 50.41 ± 7.96 % 
for CD8+ T cells. However, in the presence of 10 nM ATRA a significant increase 
in α4+β7+CD4+ (64.06 % ± 7.00 %) and CD8+ (72.58 % ± 5.04 %) T cells was 
observed.  
The regulation of CLA expressing T cells was inversely proportional to the amount 
of ATRA added to the culture. In the absence of ATRA, low levels of CLA 
expressing CD4+ (6.11 % ± 1.33 %) and CD8+ (11.92 % ± 2.89 %) T cells were 
seen (Figure 4.6b). In the presence of 10 nM ATRA, the percentages of CLA+CD4+ 
and CLA+CD8+ T cells significantly decrease to 0.53 % ± 0.16 % and 0.78 % ± 
0.17 % respectively. 
 Aside from an increase in α4β7 positive and a decrease in CLA positive 
CD4+ and CD8+ T cells, ATRA also modulated the density of β7 and CLA surface 
expression. As detected for α4+β7+CD4+ T cells, in the absence of ATRA the mean 
MFI was 4812.29 ± 905.83, which increased to 8111 ± 1900.08 in the presence of 
10 nM ATRA (Figure 4.6c). Similarly, addition of 10 nM ATRA led to a significant 
increase in the mean β7 surface expression on CD8+ T cells from 5792.29 ± 
1168.20 to 9709.57 ± 2087.25 (Figure 4.6c). 
As expected, the presence of ATRA in the culture led to a significant reduction in 
CLA surface expression on CD4+ and CD8+ T cells (Figure 4.6d; p < 0.05). The 
mean MFI for CD4+ T cells changed from 2005.67 ± 318.18 to 1522.17 ± 312.90, 
while the mean MFI for CD8+ T cells declined from 2854.33 ± 447.40 to 1766.17 ± 
305.44. 
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Figure 4.6: Total T cells cultured in the presence of activation beads. 
T cells were cultured and expanded in the presence of biotinylated antibodies against human CD2, 
CD3, and CD28 (100 µg / ml) for 14 days in the presence of all-trans retinoic acid (ATRA). a) Cells 
cultured with or without ATRA were analysed for the expression of α4β7 on CD4
+
 (n = 8) and CD8
+
 
(n = 8) T cells. b) CD4
+
 (n = 10) and CD8
+
 (n = 10) T cells were stained for CLA expression on β7
+
 
cells. c) MFI data were analysed for the surface expression of β7 on CD4
+
 (n = 7) and CD8
+
 (n = 7) 
T cells. d) Expression of CLA on β7
+
CD4
+
 (n = 6) and β7
+
CD8
+
 (n = 6) T cells. * p < 0.05; ** p < 
0.005; statistics were performed using the Wilcoxon matched pairs test. 
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4.2.2.3 ATRA increases α4β7 Expression on Pan T Cells cultured with Systemic 
DCs 
Initial experiments with MoDCs and percoll pellet T cells showed a general up-
regulation in the percentage of α4β7 expressing CD4+ and CD8+ T cells when co-
cultured in the presence of 10 nM ATRA (Figure 4.7). Whole allogeneic percoll 
pellet cells were added to MoDCs in the presence of ATRA for 7 days. Gating on 
CD4+CD3+ and CD8+CD3+ T cells revealed an up-regulation in the percentage of 
α4β7 expressing T cells (Figure 4.7).  
Once we had investigated the effect of MoDCs in conjunction with ATRA on the 
expression of α4β7 on CD4+ and CD8+ T cells from whole percoll pellet, we 
examined different systemic in vitro-generated DC subtypes for their capacity to 
up-regulate the surface marker α4β7 on purified total T cells in the absence or 
presence of ATRA. Aside from testing in vitro-generated DCs, we also examined 
systemic CD1c DCs directly isolated from peripheral blood (mDCs) or DCs directly 
isolated from human skin (epidermal LCs). In addition, we examined LCs and 
dDCs generated from CD34 umbilical cord stem cells. The various DC subtypes 
were subsequently used in allogeneic mixed leukocyte reactions (MLRs) with 
purified total T cells for 7 days in the absence or presence of ATRA.  
The representative diagrams in Figure 4.7, show that all DCs have an intrinsic 
ability to support low levels of α4β7 expressing T cells in the absence of ATRA.  
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Figure 4.7: α4β7 expression on CD4
+
 and CD8
+
 T cells from whole percoll pellets.  
Whole percoll pellet was co-cultured with dDCs in the absence or presence of 10 nM ATRA for 7 days. In the absence of ATRA, low levels of 4
+
7
+ 
T cells 
were supported. 10 nM ATRA caused an increase in the number of 4
+
7
+
 CD4
+
 and CD8
+
 T cells. Respective isotypes can be found in Figure B.3 of the 
Appendix 
15.1 % 44.7 % 
10.8 % 54 % 
CD4+ T cells 
CD8+ T cells 
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Figure 4.8: α4β7 surface detection on CD4
+
 and CD8
+
 T cells. 
Pan T cells were co-cultured with systemic DCs in the absence or presence of retinoic acid and subsequently stained for α4β7 surface expression on CD4
+
 
and CD8
+
 T cells. In the absence of ATRA, CD4
+
 and CD8
+
 T cells stained positive for α4β7, while ATRA caused an increase in the number of α4β7 positive 
T cells. Respective isotypes can be found in Figure B.4 of the Appendix. 
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Co-culture of total T cells (Pan T) with MoDCs in the absence of ATRA supported 
low levels of α4β7 expressing CD4+ (14.03 % ± 2.49 %) and CD8+ (18.69 % ± 4.55 
%) T cells (Figure 4.9a and b). However, these levels were not significantly higher 
than those obtained for unstimulated T cells alone (grey bar). The percentages of 
α4β7 expressing CD4+ T cells and CD8+ T cells increased in the presence of 10 
nM to 33.47 % ± 4.58 % and 35.47 % ± 5.14 % respectively. No significant 
difference between 10 nM and 1000 nM ATRA was observed.  
To test whether the maturation status of the DC had an effect on the 
number of α4β7 positive T cells and β7 surface expression, DCs were LPS-
matured overnight before being used in co-cultures with T cells. As shown with 
MoDCs, the maturation status did have a significant effect on the extent of α4β7 
expressing CD4+ T cells (Figure 4.9a). LPS-matured MoDCs were able to trigger a 
higher mean percentage of α4β7 expressing CD4+ T cells in the presence of 10 
nM ATRA (33.47 % ± 4.58 % vs 47.7 ± 5.79 %). Although no significance could be 
detected for CD8+ T cells (p = 0.2210), there was a trend, suggesting LPS-
matured MoDCs to have a greater potential than immature MoDCs to induce 
α4+β7+CD8+ T cells. 
 
When comparing dDCs – stimulated T cells with unstimulated T cells alone, we 
were able to observe a significant difference in α4β7 expressing T cells (Figure 
4.9c and d). Unstimulated CD4+ and CD8+ T cells expressed low mean percentage 
levels of α4β7 expression (4.4 % ± 0.27 % and 4.81 % ± 0.76 % respectively) 
(grey bars). However, T cell stimulation with immature dDCs induced significantly 
higher levels of α4β7 expressing T cells in the absence of ATRA, with mean 
values of 13.80 % ± 3.62 % for CD4+ T cells and 18.99 % ± 4.58 % for CD8+ T 
(Figure 4.9c and d). 
In the presence of 10 nM a significant up-regulation in the mean percentages of 
α4β7 expressing CD4+ (50.43 % ± 2.58 %) and CD8+ (47.99 % ± 4.50 %) T cells 
was observed. Concentrations of 100 nM and 1000 nM did not have a significantly 
different effect than 10 nM ATRA.  
In the absence of ATRA, LPS-matured dDCs induced similar levels of CD4+ (15.15 
% ± 5.77 %) and CD8+ (22.97 % ± 6.98 %) T cells, suggesting that the maturation 
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status did not significantly affect the potential of dDCs to induce α4β7 expressing 
T cells. Interestingly, dDCs showed the highest percentage change in α4β7 
expression between untreated and ATRA-treated cells (Figure 4.9c and d). 
 
Overall, immature and mature LCs showed the greatest ability to stimulate α4+β7+ 
T cells in the absence of ATRA (Figure 4.9e and f). When comparing the extent of 
α4β7 surface expression on CD4+ and CD8+ T cells stimulated with immature LCs 
in the absence of ATRA, a mean percentage of 22.38 % ± 3.4 % was observed for 
CD4+ T cells (Figure 4.9e), while CD8+ T cells showed a mean of 31.77 % ± 5.67 
%. These values were significantly higher compared to 7.75 % ± 1.43 % for CD4+ 
and 11.72 % ± 1.57 % for CD8+ T cells alone. In the presence of 10 nM ATRA, 
immature LCs were also able to support a significant increase in the mean 
percentage of α4β7 expressing T cells. CD4+ T cells had a mean percentage of 
45.58 % ± 6.11 %, while CD8+ T cells had a value of 42.53 % ± 3.67 %. 
Compared to immature LCs, mature LCs did not significantly influence the extent 
to which α4β7 expressing T cells were supported in the absence or up-regulated in 
the presence of ATRA. However, ATRA did increase the mean percentage of 
47 expressing CD4+ T cells from 28.01 % ± 5.26 % to 52.75 % ± 5.00 % (Figure 
4.9e) and the mean percentage of 47 expressing CD8+ T cells from 32.5 % ± 
5.18 % to 45.99 % ± 4.49 % (Figure 4.9f). 
To investigate the ex vivo effect of blood-derived mDCs and skin-derived 
epidermal LCs, co-culture experiments were set up as previously described with in 
vitro-generated DCs. As expected, in the absence of ATRA and mDCs there were 
low levels of 47 expressing CD4+ and CD8+ T cells (4.69 % ± 0.68 % and 5.74 
% ± 1.25 %). Stimulation of T cells with mDCs in the absence of ATRA induced 
α4β7 mean percentages of 14.91 % ± 2.93 % and 18.51 % ± 4.84 % for CD4+ and 
CD8+ T cells respectively (Figure 4.9g). Addition of 10 nM ATRA to the culture 
induced a significant up-regulation in the mean percentages of α4β7 expressing T 
cells to 36.78 % ± 5.21 % and 28.39 % ± 5.43 % respectively. Similar observations 
were made for epidermal LCs (Figure 4.9h).  
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Figure 4.922: ATRA up-regulates the percentage of α4β7 expressing CD4 and CD8 T cells. 
DCs were cultured in the presence of total allogeneic T cells with increasing concentrations of 
ATRA, ranging from 10 nM to 1000 nM for 7 days at 37°C. MoDCs (a and b), dDCs (c and d), and 
LCs (e and f) were used either as immature DCs or were LPS-matured overnight before T cells 
were added. a) CD4
+
 T cells stimulated with immature (n = 13, purple) or mature (n = 9, blue) 
MoDCs in the absence of presence of ATRA. b) CD8
+
 T cells cultured with immature (n = 14) or 
mature (n = 11) MoDCs; c) CD4
+
 T cells cultured with dDCs in the absence (n = 8) or presence of 
LPS (n = 6); d) CD8
+
 T cells co-cultured with immature (n = 10) or LPS-matured (n = 6) dDCs; e) 
CD4
+
 T cells stimulated with LCs in the absence (n = 8) or presence of LPS (n = 10); f) CD8
+
 T 
cells cultured in the presence of immature (n = 7) and mature (n = 7) LCs; g) mDCs cultured with 
total T cells in the absence of LPS and gated on CD4 (n = 10, purple) and CD8 (n = 9, green) T 
cells; h) Epidermal LCs co-cultured with total T cells in the absence of LPS. Gated on CD4 (purple) 
and CD8 (green) T cells (both n = 10). * p < 0.05; ** p < 0.005; *** p < 0.0005; statistics were 
performed using the Wilcoxon matched pairs test. 
 
 
To investigate the effect of ATRA on the level of β7 on the cell surface, we looked 
at the mean fluorescence intensity (MFI) on CD4+ and CD8+ T cells. On the whole, 
the MFI of 7 on CD4+ and CD8+ T cells increased in the presence of ATRA 
(Figure 4.10).  
For CD4+ and CD8+ T cells stimulated with immature MoDCs (n = 7-8) in the 
absence of ATRA, the mean β7 MFI was 5500 ± 1950.76 and 2989.25 ± 505.05 
respectively (Figure 4.10a and b). CD4+ T cells alone, showed MFI expression 
values of 2929.25 ± 635.53 (p = 0.13), while CD8+ T cells alone showed 
significantly lower MFI values (2039.00 ± 278.42) than MoDC-stimulated T cells. 
Addition of 10 nM ATRA increased the MFI to 8156.88 ± 2603.72 for CD4+ T cells 
and to 5420.75 ± 1030.16 for CD8+ T cells. Interestingly, the maturation status did 
not seem to significantly affect the mean MFI values. 
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Figure 4.10: Induction of β7 on CD4
+
 and CD8
+
 T cells in the presence of ATRA. 
ATRA (10 nM) induced a significant increase in 7 surface expression on CD4
+
 and CD8
+
 T cells 
when co-cultured with the different DC subtypes. Mean MFI values are shown for T cells stimulated 
with MoDCs (a and b), dDCs (c and d), LCs (e and f), mDCs (g) and epidermal LCs (h). * p < 0.05; 
** p < 0.005; statistics were performed using the Wilcoxon matched pairs test.   
MoDCs 
dDCs 
LCs 
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In the absence of ATRA, immature dDCs induced mean β7 MFI values of 4180.10 
± 364.54 for CD4+ (n = 10) and 4503.40 ± 699.73 for CD8+ (n = 10) T cells. As 
shown (grey bars), these values were significantly higher than what was observed 
for CD4+ and CD8+ T cells alone (2889.00 ± 343.60 and 3361.00 ± 563.10). In the 
presence of ATRA, these values significantly increased to 11403.20 ± 711.46 and 
10969.70 ± 1197.94 respectively (Figure 4.10c and d).  
 
As shown in Figures 4.10e and f, LCs supported mean MFI levels that were 
significantly higher than those of T cells alone. In the absence of ATRA, LCs 
induced MFI values of 5877.73 ± 737.50 for CD4+ T cells (n = 8) and 5855.63 ± 
580.25 for CD8+ T cells (n = 8) (Figure 4.10e and f). In the presence of 10 nM 
ATRA, the mean values for both T cell types increased (CD4+ T cells: 9725.13 ± 
1086.96; CD8+ T cells: 9745.38 ± 1487.42). However, the values induced by LCs 
were lower than those obtained for dDC-stimulated CD4+ and CD8+ T cells. Again, 
the maturation status of the LCs did not significantly influence the extent to which 
β7 was up-regulated (Figure 4.10e and f). 
Blood-derived mDCs and epidermal LCs induced the lowest amounts of β7 
expression on T cells. For mDCs-stimulated T cells (n = 8), mean values of 
2948.38 ± 563.85 and 2919.75 ± 580.51 were recorded for CD4+ and CD8+ T cells 
respectively (Figure 4.10g). Although the mean values were lower than those 
observed for in vitro-generated DCs, we were still able to detect a significant 
increase in the mean MFI when grown in the presence of ATRA. Again, the MFI 
values of T cells alone (grey bars) were significantly lower than those of mDC-
stimulated T cells. 
Finally, epidermal LCs (n = 7) were tested for the ability to up-regulate β7 
on T cells in the presence of ATRA. As shown in Figure 4.10h, CD4+ and CD8+ T 
cells alone, showed low MFI values of 1383.00 ± 76.51 and 1633.00 ± 225.00 
respectively. In contrast, mean MFI values of 1847.43 ± 226.99 and 1860.00 ± 
183.35 were recorded for epidermal LC-stimulated CD4+ and CD8+ T cells 
respectively. Addition of ATRA to the culture did cause a significant increase in the 
mean MFI values for CD4+ and CD8+ T cells (2632.86 ± 345.55 and 2252.86 ± 
261.07). 
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Overall, the β7 MFI values obtained for dDC-stimulated T cells in the presence of 
ATRA were the highest (Figure 4.10c and d). In addition, the overall change in the 
mean MFI was the greatest for dDCs, which correlates with the high mean α4β7 
percentage values shown in Figure 4.9. In addition, the maturation status only 
played a significant role in the case of MoDC-mediated T cell stimulation (Figure 
4.9a and b). 
 
 
4.2.2.4 ATRA increases the Percentages of α4β7 expressing Naïve CD4+ T Cells 
stimulated with Systemic DCs 
In the previous section the ability of DC subpopulations with and without ATRA to 
up-regulate expression of α4β7 on total T cell populations containing both memory 
and naïve T cells was examined. Since vaccines aimed at stimulating mucosal 
immunity would be required to induce mucosal homing on naïve T cells we have 
examined the ability of in vitro-generated MoDCs, dDCs or LCs and blood-derived 
mDCs and epidermal LCs to induce α4β7 expression on naïve CD4+ T cells. 
Naive CD4+ T cells were isolated and purified from umbilical cord blood as 
described in section 2.2.6.2 of Materials and Methods and tested for their purity 
before being used in co-culture experiments. As shown in Figure 4.11, more than 
90% of CD4+ T cells stained positive for the naive T cell marker CD45RA, while 
being negative for the memory marker CD45RO. 
 
 
a)            b)           c) 
       
Figure 4.11: Isolation of naive CD4
+
 T cells from human umbilical cord blood. 
Naive CD4
+
 T cells were isolated by MACS separation from whole cord blood mononuclear cells 
(CBMCs). Cells were subsequently stained for expression of CD45RA and CD45RO to confirm 
their purity. More than 95 % were CD3
+
CD4
+
 T cells (b) and of those 91.9 % were of the naïve 
phenotype (c). Isotypes can be found in Figure B.5 of the Appendix. 
97.7% 
91.9% 
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Isolated naïve CD4+ T cells were used in co-culture experiments with the various 
DC subtypes in the absence or presence of ATRA (10 nM - 1000 nM). As 
exemplified in Figure 4.12, treatment of LCs with 10 nM ATRA 24 hrs before the 
addition of naïve CD4+ T cells triggered an increase in α4β7 expressing T cells 
from 33.6 % to 83.3 %. 
 
 
       a)             b)                c) 
           
 
       d)             e)                f) 
           
Figure 4.12: ATRA-enhanced expression of α4
+
β7
+
CD4
+
 naive T cells. 
LCs were co-cultured with purified naïve CD4
+
 T cells for 7 days in the absence or presence of 10 
nM ATRA. a) Whole live gate. b) CD4
+
 naïve T cells comprise 89.6% of the lymphocyte population. 
c) Freshly isolated naive CD4
+
 T cells expressing α4β7. d) α4β7 positive naïve CD4
+
 T cells in the 
absence of ATRA (50.9 %). e) α4β7 positive naïve CD4
+
 T cells in the presence of 10nM ATRA 
(65.8 %). f) T cells were cultured in the absence of LCs and ATRA. Respective isotypes can be 
found in Figure B.6 of the Appendix. 
 
 
As there was variation in the percentages of α4β7 expression on CD4+ and CD8+ 
T cells alone, all subsequent results in this section are presented as relative 
means, calculated as the ratio of stimulated T cells to T cells alone.  
As summarized in Figure 4.13a, the presence of different DCs in the culture did 
have an effect on the relative means of naïve α4+β7+CD4+ T cells. T cells grown in 
the absence of DCs showed lower mean percentages of α4β7 expressing T cells. 
65.8 % 23.6 % 50.9 % 
11.1 % 
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Co-culture of DCs with T cells in the absence of ATRA triggered an increase in 
α4β7 expressing T cells. In particular, in vitro-generated LCs induced a relative 
mean of 4.92 ± 0.72 that was significantly higher than the means induced by the 
other DC subtypes (Two-way ANOVA, p < 0.05). In the presence of 10 nM ATRA 
a significant increase in the relative means of α4β7 expressing naïve CD4+ T cells 
was detected (Figure 4.13a). This was true for all DC subtypes, with the exception 
of epidermal LCs, here the sample number was too small to obtain significance (n 
= 3). However, there was an apparent trend suggesting ATRA to exert an up-
regulatory effect on naïve CD4+ T cells co-cultured with epidermal LCs but this 
was not as marked as that induced by other T cells subsets. 
Further comparison showed, that dDCs (7.60 ± 1.76) and LCs (7.14 ± 0.99) 
were able to induce the highest relative means of α4β7 expressing naïve CD4+ T 
cells in the presence of ATRA (Figure 4.13a). The relative mean values for MoDCs 
(4.67 ± 0.67), mDCs (4.21 ± 1.43) and epidermal LCs (2.44 ± 0.49) were much 
lower. Statistical analysis of the different DCs showed that dDCs were able to 
induce a significantly higher relative mean of α4β7 expressing naïve CD4+ T cells 
than MoDCs (p < 0.05), mDCs or epidermal LCs (p < 0.001) (Two-way ANOVA). 
Similarly, LCs had significantly higher mean values than mDCs (p < 0.05) and 
epidermal LCs (p < 0.001) (Two-way ANOVA). No significant difference was 
observed between the other DC subtypes in the presence of ATRA. Although, in 
vitro-generated LCs were able to induce the highest relative mean of α4β7 positive 
naïve CD4+ T cells in the absence and presence of ATRA, the overall change was 
greatest for dDCs followed by MoDCs (Figure 4.13a).  
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Figure 4.13: ATRA induces α4β7 surface expression on naive CD4
+
 T cells. 
CD4
+
 naive T cells co-cultured with different DC subtypes in the absence or presence of ATRA. 
After 7 days cells were harvested and stained for CD4, CD3, and 47 expression. a) Naïve CD4
+
 
T cells were incubated with either MoDCs (n = 10), dDCs (n = 7), LCs (n = 7), mDCs (n = 8) or 
epidermal LCs (n = 3) in the absence or presence of ATRA. Results are shown as the relative 
mean of 47 expressing T cells; b) MFI of naïve CD4
+
 T cells stimulated with MoDCs (n = 8), 
dDCs (n = 10), LCs (n = 6), mDCs (n = 6) or epidermal LCs (n = 3). * p < 0.05; ** p < 0.005; 
statistical analysis was performed using the Wilcoxon matched pairs test.  
 
 
The mean values of β7 surface expression in the absence and presence of ATRA 
are shown in Figure 4.13b. In the absence of ATRA, mean MFI values ranged 
between 3726.00 ± 2616.00 for epidermal LCs and 6271.60 ± 1005.57 for in vitro-
generated LCs. In the presence of ATRA, there was a significant increase in β7 
surface expression for all DCs tested. However, the range was much wider in the 
presence than in the absence of ATRA. 
As presented, the mean MFIs of in vitro-generated DCs were the highest in 
the presence of ATRA, with LCs showing the maximum values (11682.00 ± 
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1840.77). dDCs (10608.40 ± 1543.13) and MoDCs (10455.00 ± 2280.45) also 
induced high levels of β7 expression, though the standard error mean was higher 
for MoDCs. With mean values of 7032.83 ± 1963.15 and 4667.67 ± 2505.46, 
mDCs and epidermis-derived LCs showed the lowest mean MFIs. Comparison 
between the individual DC subtypes did not show any significant differences in 
their ability to induce β7 surface expression in the absence or presence of ATRA. 
 
 
4.2.2.5 ATRA increase α4β7 Expression on purified Naïve CD8+ T Cells 
As previously shown by Lefrançois et al., (1999) naïve CD8+ T cells depend on β7 
integrin expression to migrate to the Peyer’s patches. Once we had investigated 
the influence of ATRA on α4β7 on purified naïve CD4+ T cells in the presence of 
systemic DCs, we looked into the effect of ATRA on α4β7 expression on naïve 
CD8+ T cells in combination with different DC subtypes.  
 
 
a)                 b)                      c)                  d) 
       
Figure 4.14: Isolation of naïve CD8
+
 T cells from umbilical cord blood. 
Naïve CD8
+
 T cells were magnetically isolated and stained for the expression of CD8, CD45RO, 
CD56, CD57, and CCR7. Cells were subsequently analysed using an LSRII. Respective isotypes 
can be found in Figure B.7 of the Appendix. 
 
 
Isolated naïve CD8+ T cells were initially tested for their purity before being used in 
co-cultures with DCs in the absence or presence of ATRA (Figure 4.14). As 
expected, isolated naïve CD8+ T cells stained CD8+CD45RO-CD57-CD56-
CD45RA+. In addition, cells also stained CCR7+ (data not shown). 
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As exemplified in Figure 4.15c, stimulation of T cells with dDCs in the absence of 
ATRA supported basal levels (23.8 %) of α4β7 expressing T cells. Addition of 10 
nM led to an increase in α4β7 expressing T cells (54.5%) (Figure 4.15d). 
As presented in Figure 4.16a, T cells alone expressed low levels of α4β7 
expressing T cells. However, when co-cultured in the presence of MoDCs, dDCs, 
LCs, or mDCs, higher relative means of naïve CD8+ T cells expressing α4β7 were 
detected. In the absence of exogenously added ATRA, LCs showed the highest 
values (64.09 ± 30.72) but were not significantly different from those obtained for 
dDCs (29.80 ± 15.54) and mDCs (48.82 ± 18.67). In contrast, MoDCs supported 
comparatively low levels (3.29 ± 0.50).  
 
 
a)                   b)                     c)    0 nM ATRA        d)   10 nM ATRA 
       
Figure 4.15: ATRA enhanced expression of α4β7 positive CD8
+
 naive T cells. 
dDCs were co-cultured with purified naïve CD8
+
 T cells in the absence or presence of ATRA. a) 
Whole live gate. b) CD8
+
 naïve T cells comprise c) α4β7 positive naïve CD8
+
 T cells in the absence 
of ATRA (23.8 %). d) α4β7 positive CD8 naïve T cells in the presence of 10nM ATRA (54.5 %). 
Respective isotypes can be found in Figure B.8 of the Appendix. 
 
 
In the presence of 10 nM ATRA, there was a significant increase in the relative 
means of α4+β7+CD8+ T cells (Figure 4.16a). However, in general the capacity of 
the different DCs to stimulate naïve CD8+ T cells remained the same. Again, LCs 
induced the highest relative mean of α47 expressing T cells (150.69 ± 76.66), 
while MoDCs recorded the least (5.62 ± 0.93). Cross-coparative analysis showed 
that in the presence of ATRA, MoDCs supported significantly lower levels of α4β7 
expressing T cells than the other DC subtypes (p < 0.01 for LCs; p < 0.001 for 
mDCs; p < 0.05 for dDCs) (Two-way ANOVA). Overall, the relative mean values 
for naïve α4+β7+CD8+ T cells were much greater than those observed for naïve 
CD4+ T cells (Figure 4.13a). 
23.8 % 54.5 % 
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Subsequently, the capacity of the individual DCs to mediate an increase in β7 
surface expression in the presence of ATRA was investigated (Figure 4.16b). All 
DC subtypes tested were able to support a significant increase in the β7 MFI (p < 
0.05 for mDCs; p < 0.005 for MoDCs, dDCs, and LCs). Based on the low levels of 
α4+β7+CD8+ T cells induced by MoDCs, we were not surprised to see MoDCs to 
support the lowest levels of β7 surface expression (2287 ± 297) in the absence 
and presence (2699 ± 313) of ATRA. Interestingly, dDCs showed the greatest 
relative increase of β7 surface expression rising from 2574 ± 566 in the absence 
of ATRA to 5372 ± 1181 in the presence of ATRA. Myeloid DCs showed slightly 
higher levels than LCs in the absence (3027 ± 488 vs 2479 ± 800) and presence 
(4163 ± 575 vs 3773 ± 1055) of ATRA, however, both DC subtypes showed a 
nearly parallel capacity to increase β7 surface expression. The difference in MFI 
values in the presence of ATRA, reached statistical significance for dDCs and 
MoDCs (p < 0.05). 
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Figure 4.16: α4β7 surface expression on naive CD8
+
 T cells.  
CD8
+
 naive T cells were used in co-culture experiments with in vitro-generated DCs in the 
presence of ATRA and with or without LPS. After 7 days cells were harvested and stained for CD4, 
CD3, and α47 surface expression. a) MoDCs incubated with CD4
+
 naïve T cells (n=7). b) dDCs 
(n=7) c) In vitro-generated LCs (n=8). * p < 0.05; ** p < 0.005; statistical analysis was performed 
using the Wilcoxon matched pairs test.     
 
 
4.2.2.6 ATRA increases α4β7 Expression on purified CD4+ Memory T Cells 
Next, we examined the effect of in vitro-generated immature and LPS-matured 
DCs, mDCs, and epidermal LCs on α4β7 expressing CD4+ memory T cells in the 
absence and presence of ATRA. To do this, memory CD4+ T cells were isolated 
from percoll pellets and checked for purity before being used in co-cultures with 
DCs. The majority of the isolated T cells stained CD4+CD45RO+ (Figure 4.17c). 
 
 
a)             b)         c) 
     
Figure 4.17: Isolated and purified memory CD4
+
 T cells. 
Memory CD4
+
 T cells were isolated as described in chapter 2.2.6.4. CD4
+
 memory T cells were 
identified by flow cytometry based on the expression of CD45RA and CD45RO. Respective 
isotypes can be found in Figure B.9 of the Appendix. 
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Similarly to naïve CD4+ and CD8+ T cells, the number of α4β7 positive CD4+ 
memory T cells was up-regulated in the presence of 10 nM ATRA. As illustrated in 
Figure 4.18, the presence of 10 nM ATRA up-regulated the percentage of α4+β7+ 
T cells co-cultured with LCs from 7.1 % to 21.1 %. 
 
 
a)                  b)                    c)    0 nM ATRA         d)   10 nM ATRA 
       
Figure 4.18: LCs co-cultured with CD4
+
 memory T cells. 
LCs were co-cultured with CD4
+
 T cells in the absence (c) and presence of ATRA (d) for 7 days, 
before being surface stained for α4β7 expression. In the presence of 10 nM ATRA an up-regulation 
in the percentage of α4β7 expressing CD4
+
 memory T cells was observed. Respective isotypes 
can be found in Figure B.10 of the Appendix. 
 
 
Overall, co-culture of in vitro-generated DCs, mDCs, and epidermal LCs with CD4+ 
memory T cells in the presence of ATRA resulted in a significant increase in the 
relative means of α4+β7+CD4+ memory T cells (Figure 4.19a) and β7 MFI (Figure 
4.19b). Our data showed mDCs to most efficiently support α4+β7+CD4+ memory T 
cells in the absence (6.90 ± 1.08) and presence (12.88 ± 1.63) of ATRA (Figure 
19a; yellow bar). In vitro-generated MoDCs (1.23 ± 0.18), dDCs (1.94 ± 0.27), and 
LCs (3.20 ± 0.64) showed lower relative mean values in the absence of ATRA. 
Likewise, the level for epidermal LCs was 2.00 ± 0.33. Additional comparison 
between the DC subtypes (Two-Way ANOVA) revealed mDCs to significantly 
differ in their ability to stimulate α4+β7+CD4+ memory T cells in the absence of 
ATRA. 
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Figure 4.19: ATRA increases the relative mean of α4
+
β7
+
CD4
+
 memory T cells and β7 surface 
expression. 
CD4
+
 memory T cells were co-cultured with in vitro-generated MoDCs (n=9), dDCs (n=7), LCs 
(n=9), mDCs (n=11), or epidermal LCs (n=3) in the absence or presence of 10 nM ATRA. a) 
Relative mean of α4
+
β7
+
CD4
+
 memory T cells co-cultured with various DC subtypes in the absence 
and presence of ATRA. b) 7 MFI of CD4
+
 memory T cells. * p < 0.05; ** p < 0.005; statistical 
analysis was performed using the Wilcoxon matched pairs test. 
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While mDCs were significantly better than LCs (p < 0.05), dDCs (p < 0.01), and 
MoDCs (p < 0.001) in the induction of α4β7 on CD4+ memory T cells, they were 
not significantly superior to epidermal LCs, possibly due to insufficient data point 
for epidermal LCs (n=3). 
Addition of ATRA mediated a significant increase in the relative means of 
α4+β7+CD4+ memory T cells, with dDCs having the lowest value (4.52 ± 0.94). 
However, it was not significantly lower than those values obtained for MoDCs 
(6.55 ± 2.35), LCs (8.41 ± 1.86) or epidermal LCs (5.81 ± 0.41). Again, mDCs 
were significantly different from MoDCs (p < 0.001), dDCs (p < 0.001), LCs (p < 
0.01), and epidermal LCs (p < 0.05) in their ability to induce α4β7 expressing T 
cells. 
 
Comparative analysis of β7 MFI values further revealed that mDCs (n = 11) 
showed the lowest mean β7 surface expression in the absence (2917 ± 701) and 
presence (3886 ± 878) of ATRA (Figure 4.19b). In vitro-generated LCs and 
epidermal LCs showed the highest and nearly identical MFI values in the absence 
(5497 ± 674 and 5518 ± 1772) and presence (9189 ± 1422 and 9402 ± 3833) of 
ATRA.  
Although MoDCs showed a significantly higher (p < 0.05) mean MFI than mDCs in 
the presence of ATRA, the increase in MFI was similar to that of dDCs. For 
MoDCs, we were able to detect a change in MFI from 4928 ± 726 to 7404 ± 1150, 
whereas dDCs underwent a rise from 3407 ± 566 to 5658 ± 1552. While in vitro-
generated LCs induced higher levels of β7 MFI than mDCs (p < 0.001), they 
showed MFI values that were nearly identical to those of epidermal LCs. 
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4.2.2.7 ATRA increases α4β7 Expression on purified Memory CD8+ T Cells 
Once we had determined the effect of ATRA on α4β7 expression pattern on pure 
memory CD4+ T cells, we further investigated the effect of ATRA on α4β7 
expression on purified memory CD8+ T cells. Prior to the co-culture experiments 
untouched memory CD8+ T cells were isolated as described in chapter 2.2.6.4 of 
materials and methods and analysed for their purity. As shown in Figure 4.20, 98.4 
% of the isolated cells stained CD8+CD56-CD45RA-CD57-, confirming successful 
depletion of non-CD8+ T cells and CD8+ T cells with a different phenotype. The 
reason why we opted to not stain for CD45RO to identify CD8 memory T cells is 
that CD45RO is expressed on most thymocytes, activated and memory T cells, a 
subset of resting peripheral blood T lymphocytes, monocytes, macrophages and 
granulocytes (Naeim et al., 2008). Also, upon activation naïve T cells first acquire 
CD45RO, and then lose CD45RA (Picker et al., 1993). 
 
 
a)         b)               c) 
     
Figure 4.20: Isolated and purified CD8
+
 memory T cells. 
Memory CD8
+
 T cells were isolated from human PBMCs using the CD8
+
 Memory T Cell Isolation 
Kit (Miltenyi, UK). Untouched CD8
+
 T cells were isolated using an indirect magnetic labelling 
system and subsequently stained for the expression of surface markers such as CD8, CD56, 
CD57, and CD45RA. Respective isotypes can be found in Figure B.11 of the Appendix. 
 
 
Upon purification, memory CD8+ T cells were used in co-culture experiments with 
the various systemic DCs in the absence or presence of 10 nM ATRA. A 
representative graph of the effect of RA on α4β7 expressing T cells is shown in 
Figure 4.21.  
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a)                  b)                   c)    0 nM ATRA       d)   10 nM ATRA 
       
Figure 4.21: MoDCs were co-cultured with CD8
+
 memory T cells. 
LCs were co-cultured with CD8
+
 T cells in the absence (c) or presence of 10 nM ATRA (d). After 7  
days, an ATRA-mediated increase in the percentage of α47 expressing CD8
+
 memory T cells was  
observed. Respective isotypes can be found in Figure B.12 of the Appendix.  
 
 
In the absence of ATRA, the relative means of α4+β7+CD8+ memory T cells 
stimulated with various DCs was low (Figure 4.22a). MoDCs (2.73 ± 0.81), dDCs 
(2.35 ± 0.66), and LCs (1.95 ± 0.29) showed lower levels than mDCs (6.27 ± 
2.16). However, no statistical significance was observed between the different DC 
subtypes in the absence of RA (ANOVA; p > 0.05). Incubation of cells in the 
presence of ATRA resulted in significantly higher amounts of α4β7 expressing T 
cells. The relative mean values for MoDCs and dDCs increased significantly (p < 
0.005) to 5.25 ± 2.24 and 5.69 ± 1.44 respectively. Although the increase in 
α4+β7+CD8+ memory T cells was significant (p < 0.05), LCs showed the lowest 
mean values (4.81 ± 1.65) and mDCs (9.16 ± 2.83) the highest in the presence of 
ATRA. Overall, there was no statistical significance between the DCs with respect 
to their capacity to support α4β7 induction on T cells in the presence of RA. 
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Figure 4.22: ATRA increases α4β7 expressing memory CD8
+
 T cells. 
MoDCs (n = 9), dDCs (n = 8), LCs (n = 12), mDCs (n = 7) and epidermal LCs (n = 1) were co-
cultured in the presence of ATRA for 24 hrs before untouched CD8
+
 memory T cells were added to 
the co-culture. Cells were incubated at 37 C for 7 days before being harvested and stained for 
α47 surface expression. * p < 0.05; ** p < 0.005; statistical analysis was performed using the 
Wilcoxon matched pairs test. 
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Consistent with the relative means of α4+β7+ expressing CD8+ memory T cells, 
mDCs showed the highest mean in β7 MFI in the absence (6054 ± 1761) and 
presence of ATRA (7689 ± 2187) (Figure.4.22b), while the other DC subtypes 
induced lower, yet similar levels of mean β7 surface expression, ranging from 
1693 ± 187 (LCs) to 2981 ± 674 (dDCs) in the absence of ATRA and 1871 ± 203 
(LCs) to 3975 ± 1021 (MoDCs) in the presence of ATRA. Although no statistical 
significance was observed between the relative means of the various DCs (Figure 
4.22a), mDCs showed significantly higher MFI values than MoDCs (p < 0.05) and 
LCs (p < 0.01) in the absence of ATRA. In the presence of ATRA, mDCs induced 
significantly higher values not only than MoDCs (p < 0.05) and LCs (p < 0.001), 
but also dDCs (p < 0.05) (Figure 4.22b). 
 
 
4.2.3 Surface Expression of CLA on Different T Cell Populations in the 
Presence of Systemic DCs and ATRA 
4.2.3.1 ATRA decreases the Percentage of CLA expressing total T cells and CLA 
Surface Expression 
Lymphocyte trafficking to the skin is, to some extent, dependent on the interaction 
between CLA and its ligand E-selectin. Therefore, we analysed the effect of ATRA 
in the context of stimulating with systemic DCs on the percentage of CLA 
expressing CD4+ and CD8+ T cells and the level of CLA surface expression. Total 
T cells (Pan T) were isolated from percoll pellets and co-cultured with different 
DCs in the presence or absence of ATRA. We then determined the differential 
effects of various in vitro-generated as well as blood- and skin-derived DCs on 
CLA surface expression on CD4+ and CD8+ T cells. Overall, a general reduction in 
CLA expressing T cells was observed when 10 nM ATRA were added to the 
culture (Figure 4.23). 
As summarized in Figure 4.24, we were able to detect CLA expressing CD4+ and 
CD8+ T cells when co-cultured with DCs in the absence of any exogenously added 
ATRA. Dermal-like DCs were most potent in supporting CLA expression on CD4+ 
and CD8+ T cells in the absence of ATRA, reaching mean values of 16.33 % and 
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28.75 % respectively (Figure 4.24). MoDCs and LCs showed slightly lower levels 
than dDCs, while mDCs and epidermal LCs induced the lowest levels of CLA 
expressing T cells. Overall, the mean percentages of CD8+ CLA expressing T cells 
was higher than the mean percentages of CD4+ T cells, with the exception for 
mDCs, which supported a similar percentages of CD4+ and CD8+ T cells. 
However, a general reduction in the number of CLA+CD4+ and CD8+ T cells was 
observed when co-cultured in the presence of 10 nM ATRA and the respective DC 
subset. Low levels of CLA expressing T cells were measured across the different 
DC subtypes, reaching percentages of below 2 %. This reduction was independent 
of the DC subtype used in the co-culture. This further showed that there was no 
proportional correlation between the initial percentage of CLA expressing T cells in 
the absence of ATRA and the percentage of CLA expressing T cells in the 
presence of ATRA.  
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Figure 4.23: ATRA decreases the number of CLA expressing T cells and CLA surface expression on T cells. 
The different DCs were co-cultured with total T cells in the absence or presence of 10 nM retinoic acid (ATRA) for 7 days at 37 °C. Subsequently, the cells 
were analysed for CLA expression on CD4
+
 and CD8
+
 T cells by flow cytometry. Each blot is a representative of DC-T cell co-culture. MoDCs (a-d), dDCs (e-
h), LCs (i-l), mDCs (m-p), and epidermal LCs (q-t) all supported induction of CLA
+
CD4
+
 and CLA
+
CD8
+
 T cells in the absence of ATRA. In the presence of 
ATRA, a reduction in the percentages of CLA
+
 T cells was observed. Respective isotypes can be found in Figure B.13 of the Appendix. 
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As shown in Figure 4.24, the overall greatest reduction was observed in dDCs 
cultures, whereas epidermal LCs showed the lowest reduction for CLA+CD4+ T 
cells (Figure 4.24a) and mDCs the lowest for CLA+CD8+ T cells (Figure 4.24b). 
Interestingly, T cell stimulation by DCs was required for the expression of CLA 
(Figure 4.24) as T cells alone showed only low levels of CLA expression. 
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Figure 4.24: ATRA decreases the percentage of CLA expressing CD4
+
 and CD8
+
 T cells. 
Various DCs (MoDCs, n = 11; dDCs, n = 6; LCs, n = 6; mDCs, n = 6; epidermal LCs, n = 8) were 
co-cultured with Pan T cells in the absence or presence of ATRA (10 nM). After 7 days, the 
percentage of CLA
+
CD4
+
 T cells (a) and CLA
+
CD8
+
 T cells (b) was determined by flow cytometry. * 
p < 0.05; ** p < 0.005; *** p < 0.0005.statistical analysis was performed using the Wilcoxon 
matched pairs test. 
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In addition, we observed a significant reduction in CLA surface expression (MFI) 
on CD4+ and CD8+ T cells in the presence of ATRA (Figure 4.25). The basal levels 
of CLA surface expression in the absence of ATRA were highest for in vitro-
generated DCs (Figure 4.25). MoDCs and LCs supported the highest levels of 
CLA expression on CD4+ T cells, whereas mDCs and epidermal LCs showed the 
lowest amount. A similar trend was observed for CD8+ T cells in the presence of 
10 nM with a significant reduction in the mean MFI values. At the same time, we 
found no significant difference in the number of CLA+ T cells regardless of the 
maturation status of the DC used in the experiment. CD4+ T cells cultured without 
LPS showed comparable levels of CLA+ levels as CD4+ T cells cultured with LPS-
matured DCs. Similar results were obtained for CD8+ T cells (data not shown). 
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Figure 4.25: ATRA decreases CLA expression on total CD4
+
 and CD8
+
 T cells. 
MoDCs (n = 11), dDCs (n = 6), LCs (n = 6), mDCs (n = 6), and epidermal LCs (n = 8) were co-
cultured with total Pan T cells in the absence or presence of ATRA for 7 days before CLA surface 
expression was detected on β7
+
CD4
+
 (a) and CD8
+
 (b) T cells by flow cytometry. * p < 0.05; ** p < 
0.005; statistical analysis was performed using the Wilcoxon matched pairs test. 
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4.2.3.2 ATRA decreases CLA Surface Expression on Naïve CD4+ T Cells 
To determine whether CLA expression on naive CD4+ T cells was influenced by 
ATRA and systemic DCs, we co-cultured purified human naive CD4+ T cells in the 
presence of MoDCs, dDCs, LCs, mDCs, or epidermal LCs with or without ATRA 
concentrations, ranging from 10 nM to 1000 nM.  
As represented (Figure 4.26), ATRA reduced the number of CLA expressing CD4+ 
T cells co-cultured with LCs from 11.9 % to 0.1 %. This reduction could also be 
observed at ATRA concentrations of 100 nM and 1000 nM (data not shown). 
 
 
a)             b)       0 nM ATRA          c)       10 nM ATRA 
     
Figure 4.26: Detection of CLA expressing naïve CD4
+
 T cells in the absence of ATRA. 
Purified naïve CD4
+
 T cells were co-cultured with LCs in the absence or presence of ATRA and 
subsequently stained for CLA surface expression. CLA
+
 cells were gated on α47 and β7 positive 
CD4
+
 T cells. In the absence of ATRA, CD4
+
 T cells stain positive for CLA (b), while 10 nM ATRA 
caused a decrease in the percentage of CLA
+
CD4
+
 T cells (c). Respective isotypes can be found in 
Figure B.14 of the Appendix. 
 
 
A down-regulation in CLA+ naïve CD4+ T cells was also observed when T cells 
were stimulated with the other DC subtypes (Figure 4.27) in the presence of 
ATRA. Together with MoDCs (104.30 ± 45.45) and LCs (108.70 ± 31.24), dDCs 
showed the highest relative mean (177.80 ± 79.07) in the absence of ATRA. A 
significant decrease in CLA+CD4+ T cells was observed in the presence of 10 nM 
ATRA. This trend was also observed for mDCs (38.63 ± 15.74) and epidermal LCs 
(29.75 ± 8.25). However their relative means were much lower in the absence of 
ATRA than those obtained for in vitro-generated DCs. Sample size did not enable 
us to achieve statistical significance for mDCs (p = 0.2500) and epidermal LCs (n 
= 2) (Figure 4.27a). Cross-comparative analysis of the various DC subtypes 
11.9 % 0.1 % 
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showed that dDCs supported significantly higher relative means of CLA+CD4+ T 
cells than mDCs and epidermal LCs (ANOVA; p < 0.05). 
Correspondingly, the CLA (FITC) MFI mean values for MoDCs (2850 ± 410), LCs 
(3427 ± 1037), and dDCs (3102 ± 663) were the highest when compared to those 
for mDCs (2355 ± 165) and epidermal LCs (1614 ± 363) and showed a significant 
decrease in the mean CLA surface expression when cultured in the presence of 
10 nM ATRA (p < 0.05) (Figure 4.27b). Again, sample size was too small to obtain 
statistical significance for mDCs and epidermal LCs – stimulated T cells.   
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Figure 4.27: ATRA decreases the mean and MFI of CLA expressing naïve CD4
+
 T cells. 
MoDCs (n = 6), dDCs (n = 7), LCs (n = 6), mDCs (n = 3), and epidermal LCs (n = 2) were co-
cultured in the presence of ATRA for 24 hrs before purified naive CD4
+
 T cells were added to the 
culture. Cells were incubated for 7 days at 37  C before being stained for 47 and CLA surface 
expression on T cells. * p < 0.05; ** p < 0.005; statistical analysis was performed using the 
Wilcoxon matched pair test. 
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4.2.3.3 ATRA decreases CLA Surface Expression on Naïve CD8+ T Cells 
The effect of ATRA on the expression pattern of CLA on purified naive CD8+ T 
cells was investigated. Again, co-cultures were established and T cells were 
analysed for their CLA expression pattern. As examplified in Figure 4.28c, dDCs 
supported CLA expressing T cells in the absence of ATRA. However, 10 nM 
abrogated CLA expression and reduced the percentage from 29.7 % to 0.5 % 
(Figure 4.28d). 
 
 
a)                b)                     c)    0 nM ATRA        d)   10 nM ATRA 
    
Figure 4.28: CLA surface detection on α4
+
β7
+
CD8
+
 naïve T cells. 
Purified naïve CD8
+
 T cells were co-cultured with in vitro-generated dDCs in the absence or 
presence of 10 nM ATRA. CLA expression on α4β7
 
and β7 positive T cells was determined after 7 
days using flow cytometry. Respective isotypes can be found in Figure B.15 of the Appendix. 
 
 
Our results show that naïve CD8+ T cells can be stimulated by systemic DCs to 
express the surface marker CLA. As shown in Figure 4.29a, culturing naïve T cells 
alone did support only low or undetectable levels of CLA+CD8+ expressing cells. 
However, when co-cultured in the presence of DCs, an increase in the relative 
mean of CLA+CD8+ naïve T cells was observed. Overall, in the absence of ATRA 
dDCs showed the statistically highest relative mean (17.00 ± 7.56) (p < 0.001), 
whereas MoDCs (1.61 ± 0.67), LCs (2.35 ± 0.64), and mDCs (3.00 ± 1.07) showed 
similar, yet much lower levels than dDCs.  
In the presence of ATRA, all DC subtypes supported a significant decrease in the 
relative mean of CLA+CD8+ naïve T cells (p < 0.05). The relative mean values for 
dDCs (0.76 ± 0.47) and LCs (0.86 ± 0.39) were similar, while MoDCs (0.12 ± 0.06) 
and mDCs (0.34 ± 0.19) showed the lowest relative means (Figure 4.29a). Yet, in 
0.5 % 29.7 % 
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the presence of ATRA, there was no statistical difference between the individual 
DC subtypes.  
Subsequent analysis of the MFI for CLA showed that in the absence of ATRA 
naïve CD8+ T cell stimulation with dDCs led to mean MFI values (3610 ± 1139) 
that were significantly greater than those obtained for the other DC subtypes (p < 
0.5 for LCs, p < 0.005 for MoDCs and mDCs) (Figure 4.29b). Lower mean MFI 
values were obtained for LCs (1946 ± 395) and mDCs (1444 ± 389), while MoDCs 
had the mean minimum MFI (1099 ± 435). 10 nM ATRA reduced these values 
significantly to mean values ranging from 1069 ± 339 for dDCs to 615 ± 186 for 
MoDCs. However, in the presence of ATRA, there was no difference between the 
DC subtypes with respect to their ability to modulate CLA expression (MFI). 
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Figure 4.29: ATRA decreases the percentage of CLA expressing naïve CD8
+
 T cells. 
MoDCs (n = 8), dDCs (n =7), LCs (n = 6), or mDCs (n = 8) were co-cultured with purified naïve 
CD8
+
 T cells in the presence of 10 nM ATRA for 7 days. Cells were harvested and stained for CLA 
surface expression. For the purpose of the analysis CLA
+
 cells were identified by gating on β7
+
 
cells. * p < 0.05; ** p < 0.005; statistical analysis was performed using the Wilcoxon matches pair 
test. 
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4.2.3.4 ATRA decreases CLA Surface Expression on Memory CD4+ T Cells 
Once we had examined the effect of ATRA on CLA expression on naïve CD4+ T 
cells, we turned to determining the effect of ATRA on CLA surface expression on 
CD4+ memory T cells. Hence, co-culture experiments with DCs and purified CD4+ 
memory T cells were established. The culturing of purified memory CD4+ T cells 
with LCs in the absence of ATRA supported high levels of CLA expressing T cells 
(36.1 %) that declined in the presence of 10 nM ATRA (3.0 %) (Figure 4.30). 
 
 
a)             b)        0 nM ATRA        c)       10 nM ATRA 
   
Figure 4.30: CLA expressing CD4
+
 memory T cells decrease in the presence of ATRA. 
LCs were co-cultured with CD4
+
 memory T cells in the absence (b) or presence (c) of ATRA for 7 
days after which T cells were stained for the expression of CLA on α4
+
β7
+
 and β7
+
 T cells. 
Respective isotypes can be found in Figure B.16 of the Appendix. 
 
 
Analysis of the effect of the various DC subtypes on CLA expression in the 
absence and presence of ATRA showed similar relative means of CLA+CD4+ 
memory T cells (Figure 4.31a). In vitro-generated MoDCs (5.11 ± 0.95), dDCs 
(4.64 ± 1.81), LCs (4.94 ± 1.16), mDCs (6.04 ± 1.01), and epidermal LCs (4.02 ± 
0.82) supported similar levels of CLA+CD4+ memory T cells in the absence of 
ATRA.  
In the presence of ATRA, CLA was significantly down-regulated for MoDCs, LCs, 
and mDCs. Due to the small sample size for dDCs and epidermal LCs, no 
statistical significance could be reached. However, for dDCs (n = 4; p = 0.1250), a 
trend was detected. Comparison between the different DC subtypes did not 
suggest that they were significantly different with respect to their capacity to down-
regulate CLA on CD4+ memory T cells.  
34.6 % 3.1 % 
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The MFI values for CLA surface expression (Figure 4.31b) showed MoDCs (2948 
± 415) and LCs (2303 ± 317) to induced the highest levels in the absence of 
ATRA, followed by mDCs (2296 ± 153), dDCs (2037 ± 723), and epidermal LCs 
(1524 ± 1013). In the presence of ATRA, the mean MFI for MoDC- and LC-
stimulated T cells decreased significantly (p < 0.005). This trend was also 
observed for mDCs (p < 0.05). Although the same trend was observed for dDCs, a 
p-value of only 0.1250 was reached. Overall, there was no significant difference 
between the DC subsets to abrogate CLA expression on CD4+ memory T cells in 
the presence of ATRA. 
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Figure 4.31: The number and CLA expressing CD4
+
 memory T cells decrease in the 
presence of ATRA. 
DCs were co-cultured in the presence of purified CD4
+
 memory T cells for 7 days after which T 
cells were stained for the expression of CLA. a) MoDCs (n = 8), dDCs (n = 4), LCs (n = 7), mDCs 
(n = 6), and epidermals (n = 2) induced similar levels of CLa+CD4+ memory T cells in the absence 
of ATRA. However, the relative means of CLA expressing T cells were reduced in the presence of 
ATRA. b) ATRA reduces the MFI of CLA
+
 T cells stimulated with MoDCs (n = 9), dDCs (n = 3), LCs 
(n = 10), mDCs (n = 6), and epidermal LCs (n = 2). * p < 0.05; ** p < 0.005; statistical analysis was 
performed using the Wilcoxon matched pair test.  
  Chapter 4 
   
195 
4.2.3.5 ATRA decreases CLA Surface Expression on Memory CD8+ T Cells 
To test whether memory CD8+ T cells could be induced to down-regulated CLA 
expression in the presence of ATRA, memory CD8+ T cells were isolated from 
umbilical cord blood and used in co-cultures with systemic DCs and ATRA. As 
represented in Figure 4.32, CD8+ memory T cells expressed CLA when stimulated 
with dDCs in the absence of ATRA. However, CLA expression was abrogated in 
the presence of 10 nM ATRA (Figure 4.32d). 
 
 
a)        b)                      c)    0 nM ATRA        d)   10 nM ATRA 
          
Figure 4.32: CLA expressing CD8
+
 memory T cells decrease in the presence of ATRA. 
dDCs were co-cultured with purified CD8
+
 memory T cells in the absence (c) or presence (d) of 
ATRA. After 7 days the cells were harvested and stained for the expression of CLA on α4β7 and 
β7 positive CD8
+
 T cells. Respective isotypes can be found in Figure B.17 of the Appendix.  
 
 
As shown in Figure 4.33a, stimulation of T cells was required for the detection of 
CLA. There were few CLA positive T cells when they were cultured alone. 
However, stimulation with various DC subtypes allowed the expansion of 
CLA+CD8+ memory T cells. Co-culturing of T cells with LCs (15.45 ± 5.73) and 
dDCs (15.04 ± 5.59) in the absence of ATRA generated the highest relative 
means, while mDCs showed slightly lower levels (10.22 ± 5.50) whilst MoDCs 
supported the least (3.17 ± 1.27). Addition of ATRA significantly reduced the 
number of α4+β7+CD8+ memory T cells to levels as low as 0.85 ± 0.42 (dDCs) 
(Figure 4.33a). MoDCs showed a slightly higher levels (0.92 ± 0.19), while mDCs 
(1.35 ± 0.35) and LCs (1.68 ± 0.96) showed the highest numbers in the presence 
of ATRA. As only a single experiment was performed with epidermal LCs, no 
mean values were obtained or statistical tests performed. Comparison of the 
18.4 % 0 % 
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different DC subtypes showed that in the absence of ATRA, dDCs and LCs 
induced significantly higher relative means of α4+β7+ T cells than MoDCs (Figure 
4.33a, ANOVA, p < 0.05). 
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Figure 4.33: The number and MFI of CLA expressing CD8
+
 memory T cells decrease in the 
presence of ATRA. 
DCs were co-cultured with purified CD8
+
 memory T cells in the absence or presence of 10 nM 
ATRA. a) Relative mean expression levels of CLA expressing T cells induced by different DCs. b) 
Mean CLA MFI values induced by DCs. * p < 0.05; ** p < 0.005; statistical analysis was performed 
using the Wilcoxon matched pair test. 
 
 
Additionally, MFI values of CLA were obtained and analysed for CD8+ memory T 
cells. Epidermal LCs induced the highest level of CLA expression, however as this 
data is based on one sample only, no comparative conclusion can be drawn 
relative to the other DC subtypes. Nevertheless, it was shown that in the absence 
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of ATRA, epidermal LCs are able to induce CLA expressing T cells. In the 
absence of ATRA, MoDCs (1177 ± 257) and LCs (1602 ± 390) showed the lowest 
MFI values, while the values for mDCs (2111 ± 456) and dDCs (2177 ± 351) were 
nearly identical. In the presence of ATRA, the steepest decline in CLA expression 
was observed for mDCs (905 ± 156) and dDCs (840 ± 139). There was almost a 
parallel correlation between LCs and MoDCs, reaching values as low as (869 ± 
209) and (489 ± 51) respectively.  
 
 
 
 
4.2.4 MoDCs generated in Serum Free Medium support a Gut Homing 
Phenotype in the Presence of ATRA 
The expression of α4β7 in the absence of added ATRA may have been influenced 
by the possible presence of retinoic acid in the FCS. To exclude this possibility we 
first showed that DC generated in serum-free medium had the expected 
phenotype. MoDCs generated in serum-free medium were then used in serum-
free co-culture experiments with total T cells and the effect of adding retinoic acid 
examined. In the absence of added ATRA α47 expressing CD4+ (13.94 % ± 1.85 
%) and CD8+ (19.82 % ± 4.36 %) T cells were generated.  
As shown in Figure 4.34a, co-culturing of MoDCs generated in serum free medium 
with T cells in the presence of retinoic acid did not abrogate the up-regulatory 
effect of ATRA on the percentage of α47 expressing CD4+ and CD8+ T cells. In 
the presence of 10 nM ATRA a significant rise in the mean percentage of α47 
expressing T cells was observed (CD4+: 20.27 % ± 2.16 %; CD8+: 29.16 % ± 4.17 
%). This increase was also observed with respect to the amount of 7 surface 
expression (Figure 4.34c). For CD4+ T cells, we observed an increase in the mean 
7 MFI from 1691 ± 156 to 2297 ± 297, whereas CD8+ T cell increased from 1717 
± 349 to 2000 ± 377.  
 CLA expression was inversely regulated in the presence of ATRA. Initial 
levels of 5.33 % ± 1.90 % for CD4+ T cells and 4.37 % ± 1.38 % for CD8+ T cells 
fell to 2.42 % ± 0.73 % and 1.01 % ± 0.31 % in the presence of ATRA (Figure 
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4.34b). Similarly, there was a significant decline in the mean CLA MFI for both, 
CD4+ and CD8+ T cells when 10 nM ATRA were added to the culture (Figure 
4.34d).  
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Figure 4.34: α4β7 up-regulation on T cells grown stimulated with MoDCs generated in serum 
free medium in the absence or presence of ATRA. 
CD14
+
 precursor cells were differentiated and grown in serum free medium before incubated in the 
presence of ATRA and Pan T cells for 7 days at 37 °C. Cells were subsequently harvested and 
stained for a) α4β7 (n = 10-13) and b) CLA (n = 6-7) expression. Additionally, β7 (n = 12-13) and 
CLA (n = 6-7) mean MFI were examined. * p < 0.05; ** p < 0.005; *** p < 0.0005; statistical analysis 
was performed using the Wilcoxon matched pair test. 
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4.2.5 ATRA induces α4β7 and down-modulates CLA Expression on SEB-
stimulated Autologous T cells 
To ensure that the up-regulation of α4β7 and down-regulation of CLA was not a 
result of the allogeneic T cell stimulation by DCs, autologous co-cultures 
stimulated with SEB were established. Using MoDCs with total T cells in 
autologous culturing systems, we were able to record a similar trend as previously 
seen with allogeneic stimulation of T cells. As presented in Figure 4.35a, in the 
absence of ATRA, MoDCs were able to support basal levels of α4β7 expressing 
CD4+ and CD8+ T cells with mean percentage values of 16.61 % ± 2.50 % and 
15.71 % ± 4.11 % respectively. In the presence of ATRA, a significant up-
regulation in α4β7 expressing CD4+ (34.83 % ± 3.10 %) and CD8+ (34.03 % ± 3.65 
%) T cells was observed (Figure 4.35a).  
As previously seen with allogeneic co-culturing systems, in the presence of 10 nM 
ATRA a significant decrease in the mean percentages of CLA+ CD4+ and CD8+ T 
cells could be detected (Figure 4.35b). For CD4+ T cells the initial levels fell from 
11.43 % ± 2.93 % to 0.67 % ± 0.21 %, while CD8+ T cells experienced a decrease 
from 23.65 % ± 6.40 % to 2.83 % ± 0.40 %. 
Furthermore, MFI data revealed that ATRA markedly increased β7 cell 
surface expressions on CD4+ and CD8+ T cells to a similar level (Figure 4.35c). 
The mean MFI values for CD4+ T cells increased from 7085 ± 1984 in the absence 
of ATRA to 12664 ± 2364 in the presence of ATRA. Likewise, the mean MFI for 
CD8+ T cells increased from 7598 ± 2161 to 12437 ± 2990.  
Correspondingly, we were able to detect a significant decline in the mean 
MFI of CLA for both, CD4+ (from 2069 ± 258 to 1475 ± 282) and CD8+ (2846 ± 106 
to 1989 ± 267) T cells (Figure 4.35d) when cultured in the presence of 10 nM 
ATRA.  
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Figure 4.35: Autologous MoDC-T cell co-cultures support α4β7 and CLA expression. 
Autologous MoDCs and T cells were co-cultured in the absence or presence of ATRA. a) Mean 
percentage of autologous α4β7 and CLA positive CD4
+
 and CD8
+
 T cells (n = 6) in the absence 
and presence of ATRA. b) Mean β7 (n = 6) and CLA (n = 7) cell surface expression (MFI) on CD4
+
 
and CD8
+
 T cells. * p < 0.05; ** p < 0.005; statistical analysis was performed using the Wilcoxon 
matched pair test.  
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4.3 Discussion 
For many years, vitamins have been known to hold the potential to regulate 
cellular growth and differentiation, and modulate immune responses. In particular, 
vitamin A (retinol) and its metabolites (retinal and RA) have been shown to 
modulate immune responses such as functional differentiation of lymphocytes and 
lymphocyte trafficking (Tomkins and Hussey, 1989). 
Retinoic acid exerts an effect on various cell types of the immune system, 
including DCs and lymphocytes. In the context of lymphocyte activation, RA has 
been shown to enhance T cell proliferation and inhibit B cell proliferation (Bosma 
and Sidell, 1988). In addition, Wiedermann et al. (1993) showed that RA deficiency 
caused a decreased Th2 response, while RA supplementation blocked Th1 
cytokines. Furthermore, RA has been shown to induce regulatory T cell 
differentiation (Coombes et al., 2007; Wang et al., 2009), while blocking Th17 
polarization (Elias et al., 2007). However, over the past years, emphasis has been 
placed on the role of RA in lymphocyte trafficking to gut mucosal tissue. While 
naïve lymphocytes migrate mainly through secondary lymphoid organs, effector 
and memory lymphocytes depend on the expression of homing molecules that 
allow them to migrate to selective tissues. Effector and memory lymphocytes that 
migrate to the small intestine have been shown to require the expression of α4β7 
(Hamann et al., 1994; Lefrançois et al., 1999, Svensson et al., 2002) and CCR9 
(Wurbel et al., 2000; Kunkel et al., 2000). On the other hand, skin homing T cells 
use CLA and its subsequent interaction with E-selectin. 
 
As shown by Iwata et al. (2004), RA is necessary and sufficient to induce gut-
homing receptors on T cells stimulated with antibodies to CD3 and CD28. 
Similarly, it has been shown that DCs from MLNs, in the presence of antigen or 
anti-CD3 antibody induce gut tropism on T cells (Stagg et al., 2002; Johansson-
Lindbom et al., 2003). The fact that we were able to detect an increase in α4β7 
expression on T cells cultured in the presence of activation beads and RA 
confirmed the up-regulatory effect RA has on α4β7 expression (Figure 4.6). In 
addition, we investigated the expression of the skin homing marker CLA and were 
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able to show a down-regulation in the mean percentage of CLA expressing T cells 
as well as a down-regulation in CLA surface expression when cultured with ATRA. 
However, to investigate the effect of systemic DCs on α4β7 and CLA expression 
DC – T cell co-cultures were established. 
 
 
4.3.1 Antigenic Stimulation of α4+β7+CD4+ Memory T Cells 
Many pathogens initiate infection through a mucosal surface and thus induction of 
a mucosal cellular immune response, particularly for HIV-1, is considered to be a 
fundamental requirement of any preventative vaccine candidate. Many studies 
suggest that mucosal homing can only be achieved with a mucosal antigenic 
stimulus (Campbell and Butcher, 2002). This notion is supported by the 
observation that mucosally activated B cells preferentially express the gut homing 
marker α4β7 and thus migrate to mucosal sites, whereas cells activated at 
systemic sites express receptors (L-selectin) that allow migration to peripheral 
tissues (Quiding-Järbrink et al., 1997). Similarly, other studies have shown that 
memory T cells stimulated by mucosal intestinal rotavirus infection preferentially 
expressed the gut homing marker α4β7 (Rott et al., 1997). Nonetheless, several 
groups have shown that a mucosal immune response can be achieved through 
systemic vaccination (Masopust et al., 2001; Kaufman et al., 2008). We therefore 
aimed to investigate the possibility that antigens commonly used in systemic 
vaccination to induce mucosal responses in vitro. In order to do so, purified CD4+ 
memory T cells were stimulated with various antigens in the presence of 
autologous MoDCs.  
As presented in Figure 4.2, we were able to record proliferation of memory 
CD4+ T cells that had been pulsed with antigens commonly used in systemic 
vaccination. These observations coincide with data published by Benlahrech et al. 
(2009), who showed that stimulation of T cells with TT, influenza, or SEB induced 
proliferation of α4+β7+CD4+ T cells. Overall, these results not only confirm basal 
expression of α4β7 by unstimulated memory T cells but also the ability of MoDCs 
to support proliferation of antigen-specific CD4+ memory T cells in vitro. More 
specifically, it highlights the ability of these antigens to induce proliferation of α4β7 
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expressing T cells. This suggests that systemic vaccination has the potential to 
induce a mucosal immune response, and more specifically trigger T cells that 
express a tropism for the intestine. 
However, we need to bear in mind that the proliferative responses we detected 
with memory CD4+ T cells could be due to previously experienced natural 
infections rather than to antigenic stimulation by vaccination. These findings have 
led us to investigate whether systemic DCs can modulate mucosal homing 
properties of T cells. 
 
 
4.3.2 ATRA-induced up-regulation of α4β7 on CD4+ and CD8+ T cells is 
independent of DC Subtype 
In this section we showed that ATRA increases the mean percentages and relative 
means of α4β7 expression on CD4+ and CD8+ T cells from total T cells, purified 
naive and memory T cells, when co-cultured with systemic DCs. Although the 
overall up-regulation was independent of the type of DC present in the co-culture, 
the individual DC subtype did influence the extent to which this up-regulation 
ensued. Co-expression of α4 and β7 integrin expression has also been shown on 
central memory T cells (Kader et al., 2009). Notably, the staining for α4 and β7 co-
expression appeared, on all our data, to be on the diagonal axis. This observation 
is likely to be due to β7 only forming complexes with α4 rather than over 
compensation. A similar staining pattern for α4β7 was shown by Kader et al 
(2009). 
 
In co-culture experiments with total T cells all DCs were able to support modest 
levels of basal α4β7 expression on T cells in the absence of ATRA. However, the 
various DC subtypes differentially influenced the extent to which up-regulation took 
place in the presence of ATRA. Our results showed that in vitro-generated LCs 
were most potent in supporting α4β7 expressing T cells in the absence of ATRA 
(Figure 4.9e and f). However, in the presence of 10 nM dDCs showed the highest 
overall percentage and relative increase in α4β7 expressing T cells (Figure 4.9c 
and d).  
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These data suggest that ATRA promotes expression of α4β7 on T cells stimulated 
to proliferate and that the level of expression is influenced by the type of DC 
present in the co-culture. 
 
Mucosal DCs are characterised by their ability to induce gut homing T cells and 
their preference to secrete IL-10, TGF-β and IL-6 (Iwasaki, 2007). In 2007, Sauer 
et al. showed that RA-treated MoDCs release TGF-β into the culture medium 48 
hrs after treatment and that TGF-β has an up-regulating effect on β7. Since our in 
vitro model of LCs is based on the addition of TGF-β to the culture medium, this 
could have an up-regulatory effect on α4β7 T cells. However, cells were washed 
several times before being used in co-culture experiments. Hence, we propose 
that LCs may have an inherent ability to produce TGF-β and therefore to stimulate 
α4β7 T cells. Hence, trying to explain the relatively high mean percentages of 
α4β7 expressing CD4+ and CD8+ T cells co-cultured with LCs in the absence of 
ATRA, we hypothesise that either TGF-β from the LCs culture medium has effects 
on the induction of β7 or that LCs may intrinsically release increased levels of 
TGF-β compared to the other DC subtypes. As shown by Gruschwitz and 
Hornstein (1992), LCs of healthy individuals produce TGF-β, which plays a 
significant role in immunoregulation and T cell development (Letterio and Roberts, 
1998). The modulatory effect of TGF-β on β7 has previously been described by 
Lim et al. (1998), who showed that the β7 gene promoter (Itgb-7) is responsive to 
TGF-β and functions in a tyrosine phosphorylation dependent manner. Activation 
of this pathway subsequently leads to the stimulation of TGF-β1 response regions 
(TGFBRR1 and 2) upstream of the 7 gene promoter, triggering an increase in β7 
expression. 
Similarly, it has previously been shown that αEβ7 expression on gut IEL-derived T 
cell lines can be up-regulated by TGF-β (Parker et al., 1992). In the context of 
mucosal immune regulation release of TGF-β by enterocytes may be the cue for 
lymphocytes to alter integrin surface expression and therefore accumulate 
preferentially within the intestinal mucosa. 
However, this explanation fails to explain the ability of dDCs to mediate the highest 
relative induction of α4β7 expressing T cells, the overall highest percentage of 
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α4β7 expressing T cells (Figure 4.9), and high levels of β7 surface expression in 
the presence of ATRA (Figure 4.10).  
This suggests that LCs may produce and release greater amounts of TGF-β 
in response to ATRA than the other subtypes. The positive effect of RA on the 
expression of TGF-β has previously been shown in vitamin A-deficient rats (Glick 
et al., 1991). TGF-β could then act on the β7 promoter to increase gene 
expression on T cells. Alternatively, dDCs may express higher levels of RAR 
receptors than the other DC subtypes, which would allow a greater response to 
retinoic acid stimulation and subsequent TGF-β expression.  
Alternatively, ATRA may influence the interaction between dDCs and T cells, 
allowing T cells to more effectively respond to dDCs and ATRA. Gene expression 
studies have shown (Kang et al., 2011) that expression of the integrin α4 chain in 
T cells requires RA, whereas transcription of β7 genes requires TGF-β. This may 
suggest dDCs to mediate induction of α4β7 on T cells through the combined 
effects of TGF-β and ATRA.  
T cell stimulation in the presence of mDCs or epidermal LCs induced much lower 
levels of α4β7 expressing T cells and β7 surface expression than stimulation with 
in vitro-generated DCs (Figure 4.8-4.10). It has been shown in mice that RA can 
induce expression of TGF-β in the intact epidermis in vivo (Glick et al. 1989), this 
may suggest that epidermal LCs and mDCs are less responsive to ATRA and 
produce lower amounts TGF-β that could otherwise increase α4β7 expression on 
T cells. 
However, in addition to considering the differential effects of DCs on T cell 
stimulation and receptor expression, we also need to consider the direct effect of 
ATRA on T cells. RA has been shown to enhance T cell proliferation probably by 
enhancing IL-2 secreting and signalling in T cells (Ertesvag, 2002). Therefore, we 
need to consider the possibility that addition of ATRA to the culture medium 
triggered the proliferation of α4β7 T cells rather than de novo expression of α4β7. 
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4.3.3 The Effect of LPS-mediated DC Maturation on α4β7 and CLA 
Expression 
We were interested in determining whether the DC maturation status played a 
significant role in the induction of α4β7 expressing T cells. As shown by 
Caradonna et al. (2000) inflammatory bowel disease (IBD) is characterised not 
only by T cell migration to the intestine but also by elevated plasma LPS and 
plasma LPS binding protein levels. This suggests that the increase in α4β7 
expressing T cells may be associated with an increase in the presence of LPS. 
Also, since DC maturation is associated with a change in surface receptor 
expression pattern (Ardeshna et al., 2000) and an increase in the ability to present 
antigens, we were interested in determining whether DC maturation had an effect 
on modulating the surface expression of α4β7 and CLA in the presence of ATRA. 
MoDCs, dDCs, and LCs were LPS-matured and co-cultured with whole percoll 
pellets (Figure 4.9), naïve CD4+ T cells or memory CD4+ T cells (data not shown). 
Overall, induction of α4β7 and reduction of CLA expressing cells was not 
significantly different when compared to immature DCs, with the exception of CD4+ 
T cells co-cultured with MoDCs (Figure 4.9a). The significantly higher induction of 
α4+β7+CD4+ T cells suggests an additive effect of ATRA and LPS on β7 
expression. This observation concurs with data published by Reinhardt et al. 
(2001), who showed that intravenous vaccination of the antigen in conjunction with 
LPS led to enhanced mucosal T cell migration. 
 
 
4.3.4 Differential effects of ATRA on Naïve and Memory T Cells in the 
Presence of Systemic DCs 
Naïve and memory T lymphocytes are two clearly distinct T cells populations that 
differ in their immunological response to antigens. Naïve T cells have never 
encountered their specific antigen and thus have never mediated an immune 
response to it. However, memory T cells are more sensitive to antigens than naïve 
T cells as they have become adapted to mediate immunological memory. Upon re-
exposure, memory T cells respond rapidly to the antigen that originally induced 
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them. This immunological difference implies a clear difference between the biology 
of naïve and memory T cells.  
With regard to the induction of T cells that express a mucosal homing 
phenotype we were able to not only show that in vitro-generated DCs are capable 
of up-regulating the percentage of naïve and memory α4β7 positive T cells in the 
presence of ATRA, but also that there are differences in the degree to which this 
up-regulation occurs. Likewise, using ATRA-treated porcine MoDCs Sauer et al. 
(2007) were able to induce imprinting of β7 on naïve and memory T cells. 
Expression of α4β7 naïve CD4+ T cells was relatively low in the absence of ATRA, 
with the exception of LCs (Figure 4.13a). In the presence of ATRA, a significant 
increase was observed for naïve CD4+ and CD8+ T cells (Figure 4.13 and 4.16). 
For naïve CD4+ T cells, dDCs and LCs seemed most efficient in supporting α4+β7+ 
T cells, while LCs, dDCs, and mDCs efficiently induced naïve α4+β7+CD8+ T cells. 
This supports the hypothesis that systemic DCs can induce a CD8+ T cell 
response directed towards the intestinal mucosa. The stronger induction of α4β7 
by LC may indicate skin vaccination could mediate a mucosal T cell response. 
 
Higher levels of α4β7 expression were induced on naïve than memory T cells. 
One reason for the high number of naïve T cells may be that naïve T cells are not 
yet committed towards either a mucosal or systemic homing phenotype. The 
presence of ATRA may hence induce a stronger mucosal T cell response on these 
cells. At the same time, the number of induced memory T cells expressing a 
mucosal homing phenotype is lower as these cells may have previously been 
primed to elicit a systemic homing response.  
 
 
4.3.5 ATRA down-regulates CLA Expression on α4β7 T Cells in the Presence 
of Systemic DCs 
CLA is a major ligand for dermal vascular E-selectin and promotes T cell entry into 
the skin (Fuhlbrigge et al., 1997). Hence, expression regulation and modulation of 
this homing receptor may play a significant role in directing T cells to or away from 
the skin. At the same time, T cell activation depends on stimulation by APCs. The 
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interplay between these two parameters may be of immense importance in the 
initiation of either a systemic or mucosal immune response. Although the role of 
ATRA in the induction of a mucosal immune response has been described (Iwata 
et al., 2004), its effect on modulating skin homing markers in the context of various 
systemic DCs has been less frequently investigated. Additionally, the induction of 
CLA on naïve and memory T cells stimulated with systemic DCs in the presence of 
ATRA has not been explored. Hence, the aim of this section was to determine the 
effect of ATRA on CLA expression in the context of stimulation by various 
systemic DC subtypes. In addition to modulating α4β7 expression, ATRA was 
found to down-regulate the human T cell skin homing marker CLA on β7+ CD4 and 
CD8 T cells. 
 
Using activation beads on total T cells (Figure 4.6) we initially reproduced findings 
by Picker et al. (1993), showing that in vitro stimulation of T cells with anti-CD3 
antibody in the presence of IL-2 up-regulates CLA. Examining the in vitro effects of 
different systemic DCs on CLA expression, we showed that in the absence of 
ATRA, all the different DC subtypes supported CLA expression on total CD4+ and 
CD8+ T cells. Our results showed dDCs to be most potent in inducing CLA 
expression on CD4+ and CD8+ T cells from co-cultures with total T cells (Figure 
4.24). As T cells alone showed very low levels of CLA expression, this not only 
suggests a requirement for DCs in the induction of CLA but also a modulatory role 
of DCs in the regulation of CLA expression. 
 
Ni and Walcheck (2009) successfully showed induction of CLA expression by 
newly activated naive and memory T cells. Here, we further investigated whether 
DCs would be able to support CLA expression and examined the effect of ATRA 
on CLA expression in the context of these DCs. Naive T cells do not express CLA 
(Picker et al., 1993; Lichtman et al., 1997), however in vitro stimulation with anti-
CD3 antibody in the presence of IL-2 has been shown to up-regulate E-selectin 
ligands and CLA (Picker et al., 1993). Using activation beads (Figure 4.6) we 
initially reproduced these findings using total T cells. Additionally, we investigated 
the effect of ATRA on CLA expression on naïve T cells in association with various 
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systemic DC subtypes. Our data showed that dDCs were the most potent 
stimulators of CLA expressing naïve CD4+ and CD8+ T cells in the absence of 
ATRA (Figures 4.27 and 4.29). They also induced the highest levels of CLA 
surface expression. 
Circulating memory T cells in healthy individuals commonly express CLA 
(Picker et al., 1993; Lichtman et al., 1997) and in the blood, 10-15 % of T cells are 
CLA+ (Picker et al., 1990). Clark et al. (2006) even suggested that 98% of CLA 
expressing effector memory T cells reside in normal skin. However, when 
examining purified memory CD4+ and CD8+ T cells for expression of CLA, levels 
were very low. However, whether this was influenced by handling of T cells during 
the experiment is not clear. Here we showed that CLA expression increases on 
memory CD4+ and CD8+ T cells when co-cultured in the presence of DCs. Overall, 
there was no single DC subtype that showed superior capacity to induce CLA 
expression.  
The down-modulatory effect of ATRA on CLA expression is supported by 
Yamanaka et al. (2008) who were able to show that vitamin A is a potent inhibitor 
of CLA expression. The down-regulatory effect of ATRA on CLA expression is 
thought to be associated with a blockage in its synthesis. 
 
On the whole, these findings suggest differences between the regulation of CLA 
expression of naïve and memory T cells in response to DCs stimulation and 
ATRA. As dDCs seem to have the greatest potential to modulate CLA expression 
in the absence of ATRA on naïve T cells, they may play a crucial role when it 
comes to vaccine development and delivery through the skin. The ability of ATRA 
to abrogate CLA expression could also have clinical implications in that it could be 
used to modulate the homing of T cells away from the skin. 
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4.3.6 Regulation of α4β7 and CLA Expression on T cells stimulated with 
MoDCs differentiated in Serum Free Medium and Autologous MoDCs 
As human and fetal calf serum contain RA (De Leenheer et al., 1982; Tang et al., 
1990), we wanted to confirm that the basal expression levels and subsequent up-
regulation of α4β7 were due to exogenously added ATRA rather than medium or 
serum-derived ATRA. Hence, MoDCs were generated in serum free medium and 
phenotyped before they were used in co-cultures with T cells. 
We were able to show that MoDCs generated in serum free medium still had the 
potential to support basal levels of β7 and CLA expression in the absence of 
ATRA (Figure 4.34). In the presence of ATRA, MoDCs supported up-regulation of 
pre-existing levels of α4β7 and down-regulation of CLA expressing CD4+ and 
CD8+ T cells. Although the trend was the same, the extent of receptor modulation 
was slightly lower than that of MoDCs generated in supplemented medium (Figure 
4.9a and b). This suggests that RA present in fetal calf serum may have some 
effect on the level but does not affect the overall outcome of the experiment. Kang 
et al. (2010) showed that the overall integrin β7 expression pattern of the CD8+ T 
cells cultured in a serum-free medium was similar to that cultured in a serum-
containing medium. However, the background expression level of β7 was higher in 
the serum-containing medium compared with the serum-free medium.  
Although MoDCs and T cells were washed several times before being used 
in the co-cultures with supplemented medium, this may suggest that MoDCs can 
take up and store ATRA from the medium, which then acts to regulate β7 and CLA 
expression. This theory has been addressed by Sauer et al. (2007) who showed 
that MoDCs are capable of taking up and storing ATRA. 
 
In order to show that the up-regulation of α4β7 was not an artefact of allogeneic T 
cell stimulation, we set up SEB-stimulated autologous culturing systems with 
MoDCs in the absence and presence of ATRA. Stimulation of autologous T cells 
by MoDCs in the absence of ATRA supported basal levels of α4β7 expression on 
CD4+ and CD8+ T cells (Figure 4.35) that were slightly but not significantly lower 
than those obtained with allogeneic T cells (Figure 4.9a and b). In the presence of 
10 nM ATRA, MoDCs supported a significant increase in α4β7 expression on 
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autologous T cells. These observations are similar to those published by Sauer et 
al. (2007) who were able to induce β7 expression on autologous T cells stimulated 
with MoDCs in the presence of 1000 nM ATRA. Nonetheless, they were unable to 
observe a significant increase in β7 expression when MoDCs had been pre-
treated with only 10 nM ATRA. This discrepancy could be due to sample size (n = 
5) or the fact that MoDCs were washed several times before co-cultured in the 
presence of T cells, removing all the exogenously added ATRA. Hence, up-
regulation of β7 must have been due to ATRA initially taken up and stored by 
MoDCs. De novo synthesis of ATRA could be excluded as treatment of DCs with 
citral did not prevent them to exert an up-regulatory effect on β7 integrin. 
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Chapter 5 
 
 
 
 
 
The Vitamin A Metabolites Retinol and Retinal influence 
47 and CLA Expression on T Cells in the Presence of 
Different Systemic DC Subtypes 
 
 
 
5.1 Background and Aims 
Vitamin A has the unique property in that it functions in numerous biological 
pathways, including reproduction and development, light absorption for vision, and 
gene regulation (Duester, 2000). As presented in chapter 4, addition of ATRA to 
the DC-T cell co-cultures led to an increase in the expression of α4β7 expressing 
T cells and decrease in CLA expressing T cells. This suggests that ATRA can act 
on systemic DC by regulating gene transcription involved in the modulation of 
homing receptors on lymphocytes. Iwata et al. (2004) were the first to show that 
the vitamin A metabolite RA imprints T cells with gut-homing properties, and that 
vitamin A is essential for orchestrating T cells to the mucosa of the small intestine. 
Hence, in order to function on a molecular level, vitamin A (retinol) and its 
immediate metabolite retinal first need to be converted to the metabolite RA.  
 
Studies have exposed a complex and intricate network of enzymes involved in the 
metabolism of vitamin A. Generally, synthesis of RA from stored dietary retinol 
occurs in a two-step reaction consisting of the conversion of retinol to retinal 
followed by the transition of retinal to RA. The dehydrogenases that catalyse the 
reversible interconversion of retinol to retinal are members of either the ADH 
family or SDR family (Duester et al., 1996) and depending on their catalytic 
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efficiencies, they either participate in the oxidation of retinol or its storage. To date, 
the alcohol dehydrogenases ADH1 and ADH4 seem to play an important role in 
the conversion of retinol to retinal in vivo (Duester, 2000).  
Dehydrogenases that catalyse the irreversible oxidation of retinal to RA 
belong to the ALDH and cytochrome P450 enzyme families (Duester et al., 1996; 
White et al., 1996). The ability of the ALDH family to convert retinal to RA has 
previously been described by Dockham et al. (1992). However, while the major 
cytosolic aldehyde dehydrogenase isozyme ALDH1 exhibits strong activity for 
oxidation of retinal to RA, mitochondrial ALDH2 and stomach cytosolic ALDH3 
have no retinal metabolizing activity (Vasiliou et al., 2000; Yoshida et al., 1992). 
Further molecular analysis has shown that the alcoholdehydrogenase family can 
be further subdivided into subfamilies such as ALDH1A1 and ALDH1A2, which, to 
date, have been allocated important roles in the conversion of retinal to RA 
(Duester, 2000).  
 
As previously shown (Iwata et al., 2004), ALDH expression and activity are 
essential for the RA-producing capacity of DCs in GALT. Unlike systemic DCs and 
DCs from other mucosal tissues, DCs in PPs and MLNs have been shown to 
express ALDH1A1 and ALDH1A2 respectively. Furthermore, Iwata et al. (2004) 
showed that PP-DCs express mRNA for ADH1 and ADH4. Within the MLNs, 
Coombes et al. (2007) more specifically showed that CD103+ DCs but not CD103- 
DCs express ALDH1A2. These findings were supported by Uematsu et al. (2008) 
who reported DCs within the lamina propria to express ALDH1A2. Additionally, it 
was confirmed that dehydrogenases play a crucial role in the oxidation of vitamin 
A to RA for the induction of gut homing T cells as dehydrogenase blocking 
experiments failed to induce gut homing T cells. 
 
RA is known to modulate β7 and CLA expression on T cells in vitro (Sauer et al., 
2007; Yamanaka et al., 2008). In addition, upon T cell stimulation, it enhances 
CCR9 expression on T cells, imprinting them with gut tropism specific for the small 
intestine. Furthermore, Iwata et al. (2004) showed that the ability of MLN- and PP-
derived DCs to convert retinol to RA led to the expression of α4β7 on T cells. 
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Therefore, we conclude that the capacity of intestinal DCs to induce α4β7 and 
CCR9 on T cells seems to be linked to their ability to express functional vitamin A 
metabolizing enzymes and oxidize vitamin A to its biologically active form RA. 
Overall, this suggests that the expression of vitamin A converting enzymes by 
intestinal DCs is an absolute requirement in the metabolism of vitamin A. 
As systemic DCs are not thought to express ALDH1A1 or ALDH1A2, and 
only low levels of ADH isoenzymes, they are believed to lack vitamin A 
metabolizing activity. Detection of such enzymes in systemic DCs would provide 
new evidence for their potential to metabolize vitamin A and modulate mucosal 
immune responses. 
 
Given that RA is the active metabolite of retinol and retinal responsible for 
regulating gene expression, the objective of this chapter was to investigate 
whether systemic DCs have the potential to metabolize the penultimate and 
ultimate RA precursors retinol and retinal, and if so, whether this would lead to an 
up-regulation in the gut homing marker α4β7 and a down-regulation in the skin 
homing marker CLA on total T cells. Initally, we investigated in vitro-generated 
DCs for their ability to influence α4β7 and CLA surface expression on T cells in the 
presence of retinol and retinal. In addition, we tested blood-derived mDCs and 
epidermal LCs for their ability to metabolize RA precursors and modulate α4β7 
and CLA expression on T cells. Finally, in vitro-generated MoDCs and LCs were 
analysed for the expression of ADH1 and ALDH1A2 by RT-PCR. To confirm 
expression of functional dehydrogenases, MoDCs, dDCs and LCs were examined 
for their ALDH enzymatic activity by flow cytometry.  
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5.2 Results 
5.2.1 Retinal increases the Mean Percentages of α47 Expressing CD4+ and 
CD8+ T Cells in the Presence of Systemic DCs 
Firstly, immature and mature, LPS-stimulated, DC subtypes and allogeneic total T 
cells were co-cultured in the absence or presence of increasing concentrations of 
retinal indicated by an up-regulation of α4β7. The data presented in Figure 5.1 
clearly show a dose-dependent correlation between the fold increase of α4β7 
expressing T cells and the concentration of retinal added. As we observed 
variation across the different T cell samples regarding background expression of 
α4β7, all data are presented relative to T cells alone. As shown in Figure 5.1, in 
the absence of retinal, all three types of DCs supported baseline levels of α4β7 
expressing T cells, which were higher than what was observed for T cells alone 
(Figure 5.1; grey bars). Stimulation of T cells with MoDCs in the absence of retinal 
induced a fold increase in α4β7 expressing CD4+ and CD8+ T cells of 8.07 ± 3.02 
and 3.88 ± 1.28 respectively (Figure 5.1a and b). However, addition of 0.01 µM 
retinal led to a significant, fold increase in α4β7 expressing CD4+ T cells (11.75 ± 
3.59), while 0.1 μM significantly increased α4+β7+CD8+ T cells (5.35 ± 1.51) 
(Figure 5.1b). At the same time, we failed to detect a significant increase in the 
relative numbers of α4+β7+ CD4+ (n = 3) and CD8+ (n = 4) T cells stimulated with 
LPS-matured MoDCs in the presence of retinal (Figure 5.1a and b, red and blue).  
T cell stimulation in the presence of immature dDCs without retinal yielded a fold 
increase of 1.92 ± 0.49 for CD4+ T cells and 3.66 ± 0.97 for CD8+ T cells (Figure 
5.1c and d). Again, these levels were higher than for T cells alone. Addition of 0.1 
μM retinal led to a significant rise in α4β7 expressing CD4+ and CD8+ T cells, 
increasing by 3.83 ± 0.95 and 7.90 ± 2.22 respectively when compared to T cells 
alone. As seen with MoDCs, maturation of dDCs did not significantly affect their 
capacity to induce α4β7 expressing T cells in the absence or presence of retinal (n 
= 4-5). In the absence of retinal, the relative increase of α4β7 expressing T cells 
stimulated with matured dDCs was 3.91 ± 0.93 for CD4+ T cells and 3.79 ± 1.79 
for CD8+ T cells. These values increased with higher concentrations of retinal 
being added to the culture. Interestingly, for CD4+ T cells we were able to detect a 
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trend, suggesting a difference between the ability of immature DCs and LPS-
matured DCs to up-regulate α4β7 expression (n = 0.0625) (Figure 5.1c). 
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Figure 5.1: Retinal induces α4β7 expressing T cells in the presence of systemic DCs. 
Immature and LPS-matured MoDCs (n = 11 and 3), dDCs (n = 6 and 4), and LCs (n = 7-11 and 3) 
were overnight-stimulated with increasing concentrations of retinal before total T cells were added. 
The co-cultures were incubated for 7 days at 37 °C before cells were harvested and stained for 
α4β7 expression on CD4
+
 and CD8
+
 T cells. Results are shown as fold increase. * p < 0.05; ** p < 
0.005; statistical analysis was performed using the Wilcoxon matched pair test.  
MoDCs 
dDCs 
LCs 
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A slower and more gradual increase in α4β7 expression was induced by in vitro-
generated LCs when co-cultured with total T cells (Figure 5.1e and f). In addition, 
the fold increase of α4β7 expression was lower than what was observed with 
MoDCs and dDCs. T cell stimulation with immature LCs in the absence of retinal 
triggered an increase of 2.03 ± 0.30 for CD4+ T cells and 2.25 ± 0.33 for CD8+ T 
cells (Figure 5.1e and f). Addition of 0.1 µM retinal to the co-culture significantly 
increased the numbers of CD4+ and CD8+ T cells to 3.18 ± 0.70 and 3.36 ± 0.76 
respectively. Stimulation of T cells by LPS-matured LCs seemed to induce slightly 
higher levels of α4β7 expressing T cells, yet we were unable to detect a significant 
difference (p = 0.1250). As shown with CD4+ T cells, there was a fold increase of 
α4β7 expressing CD4+ T cells from 2.84 ± 0.54 in the absence of retinal to 6.22 ± 
1.64 in the presence of 0.1 µM retinal (Figure 5.1e; p = 0.1250). Similarly, in the 
absence of retinal, CD8+ T cells stimulated with mature LCs showed a fold 
increase of 2.20 ± 0.46 (Figure 5.1f), that was further increased in the presence of 
retinal. However, as seen before, this increase was not significant (p = 0.5000). 
These values are all slightly higher than those obtained with immature LCs, 
suggesting that the maturation status of LCs, similar to dDCs, influences their 
capacity to module the percentage α4β7 expressing T cells. Conversely, for MoDC 
and dDCs there was no apparent correlation between the maturation status of the 
DCs and their ability to support an up-regulation in α4β7 expressing T cells.  
Generally, retinal concentrations of 0.01 to 1 μM were required to induce a 
significant fold increase in α4β7 expressing T cells. Even so, MoDCs seemed to 
be most efficient in the induction of a fold increase in α4β7 expressing T cells, in 
particular CD4+. MoDCs and dDCs seemed equally capable to induce α4β7 
expressing CD8+ T cells. Overall, LCs were the least efficient DC subtypes to 
induce a fold increase in α4β7 expressing T cells. Notably, in some cases these 
concentrations of retinal required to mediate a significant fold increase in α4β7 
expressing T cells were 100-fold greater than for ATRA (chapter 4; Figure 4.9). 
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In addition to investigating the effect of in vitro-generated systemic DCs on α4β7 
expressing T cells in the presence of retinal, we isolated and tested blood-derived 
mDCs and epidermal LCs for their ability to support induction of α4β7 expressing 
T cells when co-cultured in the presence of retinal. Immature mDCs (Figure 5.2a) 
were used to stimulate total T cells in the absence and presence of increasing 
retinal concentrations. Again, the data are represented as fold increase of α4β7 
expressing T cells. In the absence of retinal, mDCs were able to support baseline 
levels of α4β7 expressing T cells of 1.19 ± 0.13 for CD4+ T cells and 1.08 ± 0.23 
for CD8+ T cells that were only slightly higher than those of T cells alone (grey 
bars). Addition of 0.1 μM retinal induced a significant increase in α4β7 expressing 
CD4+ T cells to 4.06 ± 0.66. Similarly, addition of 0.1 μM retinal significantly 
increased the percentage of α4β7 expressing CD8+ T cells to 1.81 ± 0.34 (Figure 
5.2a).  
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Figure 5.2: Retinal decreases α4β7 expressing T cells co-cultured in the presence of mDCs 
and epidermal LCs. 
mDCs (a; n= 7) and epidermal LCs (b; n = 4) were cultured for 24 hrs in the absence or presence 
of retinal, ranging from 0 – 1 μM before total T cells were added. The cells were incubated at 37  C 
for 7 days before being stained for 47 surface expression. Results are shown as fold increase. * 
p < 0.05; ** p < 0.005; statistical analysis was performed using the Wilcoxon matched pair test. 
 
 
As shown in Figure 5.2b, the use of epidermis-derived LCs in co-culture 
experiments with total T cells in the presence of retinal also led to a dose-
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dependent increase in the fold expression levels of α4+β7+ T cells. In the absence 
of retinal, epidermal LCs supported a fold increase of 1.35 ± 0.23 and 1.15 ± 0.15 
CD4+ and CD8+ T cells respectively. Like mDCs, epidermal LCs cultured in the 
presence of 0.1 μM retinal showed a rise in the fold increase of α4β7 expressing T 
cells. However, the overall fold increase was lower even when compared to in 
vitro-generated DCs. Also, we were unable to determine significance (p = 0.2500). 
 
Overall, these results showed that DCs are able to support a dose-dependent fold 
increase in α4β7 expressing T cells when co-cultured in the presence of retinal. 
Furthermore, this leads us to propose systemic DCs can metabolize retinal to RA. 
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5.2.2 Retinal decreases the Mean Percentages of CLA Expressing CD4+ and 
CD8+ T Cells in the Presence of Systemic DCs 
To determine whether CLA expression is also altered in the presence of retinal 
and whether DCs influence the extent to which CLA expression on β7+ T cells is 
regulated, the different systemic DCs were co-cultured with total T cells in the 
presence of increasing concentrations of retinal, ranging from 0.1 nM to 1 μM 
(Figure 5.3). In parallel, the effect of DC maturation on the regulation of CLA was 
examined. CLA expression was found to be dependent on T cell stimulation and 
that the percentages of CLA expressing T cells were significantly reduced in the 
presence of retinal (Figure 5.3).  
Stimulation of T cells with MoDCs in the absence of retinal showed low levels of 
CLA expression on α4+β7+CD4+ and α4+β7+CD8+ T cells (Figure 5.3a and b). 
While MoDCs induce a fold increase of 5.91 ± 0.58 for α4+β7+CD4+ T cells, the 
increase of CLA expression on α4+β7+CD8+ T cells was 4.63 ± 0.89 when 
compared to T cells alone (grey bars). Addition of 0.01 μM retinal led to a 
significant decrease in CLA expression on β7+ T cells.  
 
CLA expression on α4+β7+CD4+ T cells was significantly reduced in the presence 
of 0.01 µM retinal, however, there was still a 1.35 ± 0.22 fold increase when 
compared to T cells alone. In comparison, CD8+ T cells experienced a clear 
reduction to 0.89 ± 0.29 that was below the levels of T cells alone. Analysis of T 
cell stimulation with LPS-matured MoDCs suggested that the maturation status 
could play a role in the regulation of CLA expression on T cells (n = 1). 
 
Stimulation of T cells with retinal in the presence of dDCs triggered a fold increase 
in CLA expressing CD4+ T cells by 4.27 ± 1.20 and 4.29 ± 1.22 for CD8+ T cells 
(Figure 5.3c and d). To significantly down-regulate the numbers of CLA expressing 
T cells, dDCs required a ten-fold higher concentration of retinal (0.1 μM) than 
MoDCs. Addition of retinal induced a change in CLA expression of 0.51 ± 0.26 and 
0.87 ± 0.70 fold for CD4+ and CD8+ T cells respectively. At the same time, mature 
dDCs did not have a significantly greater capacity to regulate CLA expression on T 
cells in the absence or presence of retinal (Figure 5.3c and d; red and blue bars).  
  Chapter 5 
   
221 
Comparative analysis between the different in vitro-generated DC models further 
showed LCs to support similar fold increases in CLA+α4+β7+ T cells as MoDCs 
and dDCs in the absence as well as presence of retinal (Figure 5.3e and f). As 
previously observed, the levels of CLA expression were low on T cells alone (grey 
bars). T cells stimulated with immature LCs in the absence of retinal increased the 
percentages of CD4+ and CD8+ T cells by 5.47 ± 1.27 and 4.69 ± 0.63 fold. As 
observed with MoDC-stimulated T cells, T cells stimulated with immature LCs 
experienced a significant reduction in the percentages of CLA expressing CD4+ 
and CD8+ T cells when cultured in the presence of 0.1 μM retinal. Yet, this 
expression was 1.76 ± 0.62 and 1.47 ± 0.58 fold higher than for T cells alone. As 
seen with dDCs, the maturation status of LCs did not significantly influence the 
extent to which LCs induced CLA expression in the absence of retinal or regulated 
CLA expression in the presence of retinal. 
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Figure 5.3: Retinal decreases the mean percentages of CLA expressing α4
+
β7
+
CD4
+
 and 
α4
+
β7
+
CD8
+
 T cells in the presence of systemic DCs. 
Immature and mature MoDCs (a and b; n = 8-9 or 1), dDCs (c and d; n = 6 or 4) and LCs (e and f; 
n = 11 or 3) were tested for their ability to support CLA
+
α4
+
β7
+
 T cells in the presence and absence 
of retinal. DC-T cell co-cultures were incubated for 7 days at 37 °C before stained for CLA 
expression on α4
+
β7
+
 T cells. Results are shown as fold increase. * p < 0.05; ** p < 0.005; 
statistical analysis was performed using the Wilcoxon matched pair test. 
MoDCs 
dDCs 
LCs 
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Next, we tested the effect of mDCs and epidermal LCs on CLA+α4+β7+ T cells 
when co-cultured in the presence of increasing concentrations of retinal. As shown 
in Figure 5.4, the DCs alone induced a fold increase in CLA expression on 
α4+β7+CD4+ and α4+β7+CD8+ T cells that was inversely proportional to the retinal 
concentrations present in the co-culture. 
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Figure 5.4: Down-regulation of CLA expression on α4
+
β7
+
 T cells in the presence of retinal 
when co-cultured with human systemic DCs. 
a) Myeloid DCs (mDCs) (n = 7) and b) epidermal LCs (n = 3) were cultured in the presence of 
increasing concentrations of retinal. Samples were incubated at 37 °C for 7 days before being 
stained for CLA expression on α4β7 expressing CD4
+
 and CD8
+
 T cells. Results are shown as fold 
increase. * p < 0.05; statistical analysis was performed using the Wilcoxon matched pair test. 
 
 
Stimulation with mDCs alone (Figure 5.4a) induced a fold increase in the 
percentage of CD4+ T cells by 8.20 ± 2.96 and 12.76 ± 4.44 for CD8+ T cells when 
compared to unstimulated T cells (grey bars). For both, CD4+ and CD8+ T cells, 1 
μM and 0.1 μM retinal were required to significantly decrease the mean of 
CLA+α4+β7+ T cells to 1.05 ± 0.26 and 1.99 ± 0.41 fold above the background. 
Similar observations were made for T cells stimulated with epidermal LCs (Figure 
5.4b). Although a trend towards a down-regulation of CLA+ T cells was observed 
statistical significance was not obtained (n = 3; p = 0.2500).  
mDC
s 
Epidermal LCs 
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5.2.3 Retinol increases the Mean Percentages of α4β7 Expressing CD4+ and 
CD8+ T Cells in the Presence of Systemic DCs 
Vitamin A (retinol) is the penultimate precursor of RA. Hence, conversion of retinol 
to RA first requires retinol to be converted to retinal followed by the oxidation of 
retinal to RA. To test whether the different DC subtypes are capable of 
metabolizing retinol to RA we incubated DCs with various concentrations of retinol 
in the presence of total T cells. Similar to the effect of ATRA (Figure 4.8 and 4.9), 
and retinal (Figure 5.1 and 5.2), retinol was able to induce an up-regulation of 
α4β7 expressing T cells (Figure 5.5) when co-cultured with systemic DCs. Again, 
data are represented as fold increase of α4β7 expression relative to unstimulated 
T cells. Stimulation of T cells with immature MoDCs in the absence of retinol, led 
to an increase in the levels of CD4+ T cells by 2.94 ± 1.07 and 2.99 ± 0.62 for 
CD8+ T cells (Figure 5.5a). Stimulation of T cells with immature MoDCs in the 
presence of increasing retinol concentrations led to a further increase in α4β7 
expressing T cells. As seen with CD4+ T cells, in the presence of 0.1 μM retinol, 
there was a 7.25 ± 1.66 fold increase in the percentage of α4β7 expressing T 
cells. To significantly up-regulate α4β7 expression on CD8+ T cells by 7.31 ± 0.92 
fold, 1 μM retinol was required (Figure 5.5a). This increase was similar to that 
observed for CD4+ T cells. 
Similarly, stimulation of T cells with dDCs led to an increase in α4β7 
expressing T cells. However, the relative increase was less than what was 
observed for MoDCs. In the absence of retinol, dDCs alone induced an increase in 
α4β7 expressing CD4+ and CD8+ T cells by 1.72 ± 0.49 and 1.97 ± 0.65 
respectively. For both, CD4+ and CD8+ T cells, 1 μM retinol was required to 
achieve a significant increase in α4β7 expressing T cells when co-cultured with 
dDCs (Figure 5.5b). This increase was 6.84 ± 2.96 and 3.68 ± 1.07 relative to T 
cells alone. Also, it seemed that 1-10 μM retinol induced a sudden surge in the 
fold increase of α4β7 expression, in particular on CD4+ T cells.  
 
Analysing the ability of in vitro-generated LCs to induce an increase of α4β7 
expressing T cells, we observed comparable levels as seen with MoDCs and 
dDCs. In the absence of retinol, LCs amplified the relative expression of α4β7 for 
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CD4+ by 2.44 ± 0.42, which is below MoDCs but slightly above dDCs. However, 
for CD8+ T cells, LCs stimulated α4β7 expressing T cells by just 1.06 ± 0.08 
(Figure 5.5c). Although addition of 1 µM retinol to the culture did lead to a 
significant increase in α4β7 expressing T cells by 3.05 ± 0.51 and 1.89 ± 0.39, the 
overall fold increase induced by LCs remained low compared to MoDCs and 
dDCs. 
 
Having studied the effect of in vitro-generated DCs on α4β7 expressing T cells in 
the presence of retinol, we investigated the influence of mDCs and epidermal LCs 
and their potential to up-regulate α4β7 expression in the presence of retinol. As 
shown in Figure 5.5d, in the absence of retinol, mDCs supported levels of CD4+ 
and CD8+ T cells that were 1.98 ± 0.25 and 2.38 ± 0.96 times higher than T cells 
alone. Addition of 1 µM retinol triggered a significant rise in the fold increase of 
CLA expression on β7+ T cells (4.11 ± 0.89 and 3.43 ± 0.96 respectively). These 
levels of fold increase are analogous to those seen with in vitro-generated DCs.  
 
Finally, to test the ability of naturally occurring skin DCs to metabolize retinol and 
regulate homing receptor expression, we investigated epidermal LCs for their 
ability to induce α4β7 (Figure 5.5e). Although levels of basal α4β7 expression 
were similar to those seen with the other DC subtypes, we only obtained a 
significant increase in α4β7 expressing CD4+ and CD8+ T cells when 10 μM retinol 
were added to the culture. Moreover, epidermal LCs mediated a fold increase in 
α4β7 expressing T cells that was below yet similar to the fold increase observed 
with in vitro-generated LCs. In the absence of retinol, epidermal LCs triggered a 
fold increase in α4β7 expressing CD4+ and CD8+ T cells by 1.56 ± 0.18 and 1.17 ± 
0.15 respectively. In the presence of 10 µM retinol, a significant increase in α4β7 
expressing T cells was observed (3.41 ± 0.72 and 1.42 ± 0.16 respectively). 
Notably, we found that retinol concentration as high as 100 M reduced the 
number of α4β7 expressing T cells due to a decrease in cell viability (data not 
shown).  
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Overall, we were able to show that addition of retinol to the culture led to an 
increase in α4β7 expressing T cells when co-cultured in the presence of in vitro-
generated and tissue-derived systemic DCs. Although no significance was 
obtained, MoDCs and dDCs seemed most potent in regulating a fold increase in 
α4β7 expressing T cells, while LCs and epidermal LCs showed lower levels of 
stimulation. 
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Figure 5.5: Retinol enhances the mean percentages of α4β7 expressing CD4
+
 and CD8
+
 T 
cells when co-cultured with systemic DCs. 
a) MoDC (n = 11-12), b) dDC (n = 6), c) LC (n = 9-10), d) mDC (n = 10-11), and e) epidermal LCs 
(n = 5-7) were co-cultured with allogeneic T cells in the presence of increasing concentrations of 
retinol to examine their capacity to induce α4β7
 
expressing T cells. Cells were harvested after 7 
days and stained for α4 and β7 cell surface expression. Results are shown as fold increase. * p < 
0.05; ** p < 0.005; statistical analysis was performed using the Wilcoxon matched pair test. 
MoDCs dDCs 
LCs mDCs 
Epidermal LCs 
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5.2.4 Retinol mediates a down-regulation of CLA Expressing CD4+ and CD8+ 
T Cells when co-cultured in the Presence of Systemic DCs 
The positive effect of retinol on α4β7 expressing cells suggest that simultaneously 
it may suppress expression of CLA+α4+β7+ T cells. Hence, the effect of retinol on 
CLA surface expression on β7 expressing T cells co-cultured with immature 
systemic DCs was investigated (Figure 5.6). Our data show that the absence of T 
cell stimulation by DCs was accompanied by a lack in CLA expressing T cells 
(grey bars). However, upon T cell stimulation with systemic DCs, moderate levels 
of CLA expressing T cells were detected regardless of the DC subtypes present in 
the culture.  
 
In the absence of retinol, MoDCs were able to support an increase in CLA 
expressing cells by 23.69 ± 10.42 and 58.77 ± 23.79 for CD4+ and CD8+ T cells 
respectively (Figure 5.6a). Addition of retinol to MoDC-T cell co-cultures triggered 
a decrease in CLA expressing T cells. 1 μM retinol induced a significant decline in 
CLA+CD4+α4+β7+ T cells to 1.95 ± 0.48 relative to unstimulated T cells. To 
mediate a significant decline in the CLA+CD8+α4+β7+ T cell population only 0.1 nM 
retinol were required (23.07 ± 15.65). 
 
Likewise, T cell stimulation with dDCs induced increased levels of CLA expression 
when compared to T cells alone (Figure 5.6b). The levels of CLA expression for 
CD4+ T cells were comparable to those induced by MoDCs (26.33 ± 7.47 vs 23.69 
± 10.42). However, the fold increase of CD8+ T cells induced by dDCs seemed 
slightly lower than that for MoDCs (35.03 ± 8.39 vs 58.77 ± 23.79). In the presence 
of 1 μM, a significant reduction in CLA+ CD4+ and CD8+ T cells was observed. 
These levels were still 2.63 ± 0.54 and 4.08 ± 1.17 times higher than for T cells 
alone. 
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Figure 5.6: Retinol decreases the mean percentages of CLA expressing α4
+
β7
+
CD4
+
 and 
β7
+
CD8
+
 T cells in the presence of systemic DCs. 
a) MoDCs (n = 6-7), b) dDCs (n = 6), c) LCs (n = 7-8), d) mDCs (n = 10), and e) epidermal LCs (n 
= 6) were cultured in the presence of retinol for 24 hrs before total T cells were added. Samples 
were incubated at 37 °C for 7 days before being harvested and stained for CLA surface 
expression. * p < 0.05; ** p < 0.005; statistical analysis was performed using the Wilcoxon matched 
pair test. 
MoDCs dDCs 
LCs mDCs 
Epidermal LCs 
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Analysis of T cells stimulated with LCs showed that LCs are relatively weak 
inducers of CLA expression in the absence and presence of retinol (Figure 5.6c). 
In the absence of retinal LCs induced percentages of CLA expressing CD4+ T cells 
by 11.11 ± 3.61 and CD8+ T cells by 18.85 ± 7.13 fold, which was considerably 
lower than what was achieved with MoDCs and dDCs. However, addition of 1 μM 
retinol to the culture did also significantly reduced expression of CLA+α4+β+ CD4+ 
and CD8+ T cells to levels 5.02 ± 2.09 and 4.40 ± 1.90 above background. 
 
Subsequently, isolation of mDCs followed by their use in co-culture with retinol 
induced low levels of CLA expressing T cells in the absence of retinol (Figure 
5.6d). However, mDCs supported even lower increases in the level of CLA 
expression than LCs. The fold increase of CLA expression for CD4+ T cells was 
only 5.42 ± 1.36, making it the lowest overall. With 6.25 ± 3.52, CD8+ T cells 
induced slightly higher levels of CLA expressing cells in the absence of retinol. 
However, in the presence of 1 μM retinol the levels of CLA expressing cells was 
reduced to 1.71 ± 0.77 and 1.07 ± 0.34 fold above T cells alone. 
 
Finally, epidermal LCs were examined for the ability to support CLA expression in 
the absence and presence of retinol. As shown in Figure 5.6e, in the absence of 
retinol epidermal LCs supported a fold increase of 24.12 ± 10.75 for CLA+CD4+ T 
cells which was similar to what was seen with MoDCs and dDCs. A higher fold 
increase was obtained for CLA+CD8+ T cells (35.87 ± 11.00), a trend that had also 
been seen with MoDCs and dDCs. However, to significantly reduce CLA 
expressing T cells, 10 μM retinol were required. In the presence of 10 µM retinol, 
epidermal LCs still induced levels of CD4+ and CD8+ T cells that were 1.13 ± 0.79 
and 9.54 ± 3.72 fold above the level of T cells alone. 
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5.2.5 Detection of Dehydrogenases in Systemic DCs by RT-PCR and Enzyme 
Activity 
5.2.5.1 Detection of ADH1 and ALDH1A in in vitro-generated MoDCs and LCs by 
RT-PCR  
Retinol is oxidized to RA by a two-step oxidation pathway that involves the 
enzymatic function of ADHs and ALDHs. It is believed that it is RA that 
subsequently functions in the regulation of gene transcription by binding RARs 
and/or RXRs. However, in vitro competition experiments (Repa et al., 1993) have 
shown that high concentrations of retinol can compete with RA for binding to 
RARs. To exclude the possibility that the observed up-regulation of α4β7 
expressing and down-regulation of CLA expressing T cells was merely due to 
receptor binding by retinal and/or retinol, we therefore examined the ADH1 and 
ALDH1 expression profile of systemic DCs by PCR. Total mRNA was isolated and 
purified from MoDCs and LCs, reverse transcribed into cDNA, and before 
subsequently used in PCRs to test for the expression of ADH1 and ALDH1A.  
Using ADH1A specific primer pairs, we were able to detect a band slightly 
above the 200 bp mark (Figure 5.7; blue box). The expected size of the PCR 
amplicon was 291 bp. We subsequently isolated and purified the band. Sequence 
analysis confirmed that it was ADH1A specific (Eurofins, MWG).  
ALDHs constitute the enzyme family required for the oxidation of retinal to 
RA. Hence, the ability of DCs to support induction of α4β7 expression on T cells in 
the presence of increasing concentrations of retinal suggests that they express the 
enzyme required to metabolize retinal to RA. Testing MoDCs and LCs for the 
expression of ALDH1A2, we were able to amplify the ALDH1A2 gene using 
ALDH1A2 specific primer pairs (Eurofins, MWG). The expected size of the PCR 
amplicon was 151 bp. 
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a) 
                                 
    
 
b) 
                                
 
 
Figure 5.7: Detection of ADH1A and ALDH1A2 in MoDCs and LCs. 
RNA was isolated from respective dendritic cells and reverse transcribed using One-step cDNA 
synthesis kit (Miltenyi, UK) (Chapter 2.4.1). a) MoDC-derived cDNA was used in PCR reactions to 
amplify ADH1 and ALDH1A2. b) Detection of ADH1 and ALDH1A in CD1a-purified LCs. Lanes 1 
and 8 contain the Low Molecular Weight Marker (LMW) and 100 bp respectively. GAPDH 
functioned as the positive control, while lane 5 – 7 served as negative controls.  
 
1      2      3      4       5      6       7      8 
1       2      3      4      5     6       7       8 
500 bp 
200 bp 
150 bp 
500 bp 
200 bp 
150 bp 
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Here, we were able to visualize a band for MoDCs and LCs in the range of 150bp 
to 200bp (Figure 5.7; yellow). The 150 bp fragments were isolated, purified, and 
subsequently sequenced (Eurofins, MWG). Sequence alignment of the isolated 
fragment with the ALDH1A2 DNA sequence confirmed its identity. Throughout the 
experiments, GAPDH served as a positive control (Figure 5.7; row 4). Negative 
controls consisted of primers only (row 6 and 7) or template only (row 7). Rows 1 
and 8 represent molecular weight markers. 
 
Based on our results, we conclude that MoDCs and LCs do express ADH1 and 
ALDH1A2, which belong to the enzyme families required for the conversion of 
retinol and retinal to RA. 
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5.2.5.2 Detection of ALDH1 Activity in MoDCs, dDCs, and LCs by Flow Cytometry  
To demonstrate enzymatic activity of ALDH1 in MoDCs, dDCs, and LCs, we used 
the ALDEFLUOR® reagent system in which ALDH converts a soluble 
aminoacetaldehyde substrate into an insoluble fluorescent aminoacetate product 
(Figure 5.8). The amount of fluorescent ALDH reaction product that accumulated 
in cells directly correlates to ALDH activity. Respective DC subtypes were cultured 
overnight at 37 °C in the absence of any stimulus (unstimulated) or in the 
presence of either 10 nM ATRA, LPS alone, CD40L alone, or LPS and CD40L. 
DEAB, a specific inhibitor of ALDH, was used to treat cells serving as negative 
control, while A549 cells were used as a positive control. All data are presented as 
a ratio of the conditioned DC sample relative to its respective negative control 
(DEAB-treated DCs) (sample/ negative control). 
 
 
 
a)                   b)             c) 
     
 
 
 
 
 
Figure 5.8: Detection of ALDH activity in systemic DCs. 
CD1a-purified DCs were cultured overnight in the absence (unstimulated) or presence of ATRA (10 
nM), LPS (50 μg/ 10
5
 cells), CD40L (200 ng/ 10
5
 cells), or LPS and CD40L. The following day, DCs 
were stained for ALDH activity using the Aldefluor® reagent system. DCs incubated with Aldefluor 
substrate were analysed by flow cytometry. For the purpose identifying the DC populations, we 
initially gated on live cells (live gate) followed by gating on CD1a
+
HLA-DR
+
 cells. Each plot 
represents a single experiment of MoDCs (c-i), dDCs (j-p), and LCs (q-w).  
 
 
Unstimulated DEAB 
0.2 % 19.6 % 
continued 
A549 Cells 
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d)  MoDCs          e)                f)          g)   h)      i)                 j) 
       
 
k)  dDCs            l)                m)                  n)   o)      p)                q) 
       
 
r)  LCs               s)                t)          u)   v)      w)                 x) 
       
 
5 % 12.4 % 8.6 % 10.5 % 12.2 % 0.1 % 
1.3 % 8.5 % 47.5 % 1.1 % 9.4 % 0.8 % 
1.1 % 1.4 % 3.5 % 1.7 % 13.5 % 0.8 % 
Unstimulated ATRA LPS CD40L LPS + CD40L DEAB 
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As shown in Figure 5.9, unstimulated DCs showed low but detectable levels of 
ALDH activity. Based on the individual flow cytometry blots, MoDCs seemed the 
most efficient in expressing ALDH. Interestingly however, dDCs were most 
responsive to LPS, leading to a remarkable increase in ADLH activity. 
Unstimulated MoDCs showed the highest relative mean of ALDH+ cells with 15.94 
± 7.49. Both, dDCs and LCs showed much lower levels of ALDH+ cells (2.15 ± 
0.38 and 3.74 ± 0.49 respectively). Although MoDCs seemed to promote 
significantly higher ALDH activity, we were unable to detect a statistically 
significant difference. As promoter activity of human ADH3 was shown to be 
activated by RA (Duester et al., 1991), we aimed to investigate whether ATRA 
would have a positive effect on ALDH activity. Overnight stimulation of MoDCs 
with 10 nM ATRA led to a significant increase in ALDH activity, increasing the 
mean to 37.75 ± 15.93. Stimulation of MoDCs in the presence of LPS alone (34.32 
± 11.50) (n = 7; p = 0.094) did not significantly increase the relative mean of ALDH 
activity, which was probably due to sample size and variation. Similarly, 
stimulation of MoDCs is the presence of CD40L alone led to a significant increase 
in ALDH activity (38.30 ± 13.83) when compared to unstimulated MoDCs. When 
co-cultured in the presence of LPS and CD40L, MoDCs experienced a significant 
increase in ALDH activity (50.64 ± 15.00). 
 
Unstimulated dDCs showed low basal levels of ALDH activity (2.32 ± 0.34) relative 
to the negative control. Although the relative ALDH activity of dDCs increased 
slightly in the presence of ATRA (5.51 ± 1.06), treatment of dDCs with ATRA did 
not lead to a significant change in ALDH activity. Overnight maturation of dDCs in 
the presence of LPS led to an increase in the relative mean ALDH activity (5.04 ± 
0.94) that was similar to that of ATRA-treated dDCs. Despite a strong increase in 
ALDH activity when overnight-matured with LPS (19.05 ± 9.82; p = 0.058), dDCs 
did not show a significant increase in ALDH activity in the presence of CD40L 
when compared to unstimulated dDCs. Finally, the combination of LPS and 
CD40L increased ALDH activity in dDCs (7.63 ± 2.30; 0.1250). However, due to 
sample size (n = 5), none of the treatment conditions showed a substantial change 
in ALDH activity of dDCs.  
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Finally, we tested in vitro-generated LCs for their capacity to express functional 
ALDH. As previously shown with dDCs, unstimulated LCs also showed low basal 
ALDH activity (3.74 ± 0.49). Upon treatment with ATRA, this level increased to 
4.15 ± 0.61 (p = 0.7500). Activation of LCs in the presence of LPS alone or CD40L 
alone did trigger an increase in ALDH activity to 6.10 ± 0.14 and 5.03 ± 0.46 
respectively (p = 0.2500). But combined treatment of LCs with these stimuli 
induced the highest level of activity, 23.06 ± 9.52 (p = 0.2500). Similarly to dDCs, 
statistical significance was not obtained for LCs, however, a trend towards an 
increase in ALDH activity in the presence of both, CD40L and LPS could be 
detected (p = 0.1250) . A549 cells served as a positive control (yellow bar). 
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Figure 5.9: Relative ALDH1 activity in human systemic DC subtypes. 
MoDCs (green; n = 7-8), dDCs (pink; n = 5), and LCs (blue; n = 3) were incubated overnight at 37 
C in the absence of any stimulus (control), in the presence of 10 nM ATRA, LPS only (Invivogen; 
50 μg/ 10
5
 cells), CD40L only (200 ng/ 10
5
 cells) or LPS and CD40L. Cells were subsequently 
harvested and stained for ALDH activity using the ALDEFLUOR Kit (Aldagen, USA). DEAB-treated 
cells were used as negative control, while A549 cells served as positive control (yellow). All data 
are represented as a ratio relative to the negative control. * p < 0.05 analysed by the Wilcoxon 
matched pair test. 
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5.3 Discussion 
The aptitude of intestinal DCs to control expression of gut homing receptors on 
lymphocytes is thought to be linked to their ability to metabolize vitamin A. This 
suggests that intestinal DCs express functional vitamin A metabolizing enzymes. 
Iwata et al. (2004) were first to report mucosal DCs to have the capacity to induce 
gut homing T cells through the de novo production of RA. Analysis of PPs-derived 
DCs for their expression of vitamin A metabolizing enzymes showed the presence 
of ADH isoenzymes 1 and 4 (Iwata et al., 2004), which both have been shown to 
oxidize all-trans retinol and 9-cis retinol (Yang et al., 1994; Duester et al., 2000).  
Although ALDH1 has been shown to catalyse the oxidation of all-trans, 9-
cis, and 13-cis retinal with equal efficiency, the affinity to all-trans retinal was 
shown to be 2-fold higher than to 9-cis and 13-cis retinal (Yoshida et al., 1992; 
Bhat and Samaha, 1999). Studies have shown that mucosal epithelial cells of the 
small intestine and many intestinal DCs express ALDH1 (Frota-Ruchon et al., 
2000; Iwata et al., 2004) and since RA is produced by RALDH+ DCs in PP, MLN, 
and small-intestinal LP, expression of ALDHs is thought to be crucial for the 
imprinting of lymphocytes with gut-homing specificity by DCs.  
 
 
5.3.1 Retinal increases α4β7 and decreases CLA Expressing CD4+ and CD8+ 
T Cells in the Presence of Systemic DCs 
Previous work by others has focused on the identification and characterisation of 
gut mucosal DCs and their role in the regulation of gut homing T cells, however 
little is known about the potential of systemic human DC subsets to induce T cells 
expressing a gut homing phenotype, in particular α4β7. Using models of human 
systemic DCs, as well as blood-isolated mDCs and skin-derived epidermal LCs, 
we were able to show a significant increase in α4β7 expressing T cells in the 
presence of retinal. In addition, we were able to show that the type of systemic DC 
present in the co-culture does influence the extent to which α4β7 expressing T cell 
stimulation occurs. As shown, all DC subtypes were proficient in supporting basal 
levels of α4β7 expressing T cells in the absence of retinal. However, addition of 
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retinal led to a dose-dependent increase in α4β7 expressing T cells (Figure 5.1 
and 5.2). The fold increase of α4β7 expressing T cells was influenced by the type 
of DC present in the culture. MoDCs seemed to be most proficient in modulating a 
fold increase in α4β7 expression. dDCs and mDCs were also able to induce 
moderate α4β7 expression levels, while in vitro-generated and epidermal LCs 
were least efficient in the modulation of a fold increase in α4β7 expressing cells. 
This is also reflected in the concentration of retinal required to mediate a 
significant up-regulation in α4β7 expressing T cells. While 0.01-0.1 µM of retinal 
were sufficient to mediate this effect, in vitro-generated dDCs, LCs, and mDCs all 
required 0.1 µM retinal. Epidermal LCs only significantly increased the 
percentages of α4β7 expressing CD8+ T cells in the presence of 10 µM retinal.  
 
Our results suggest that retinal is either metabolically oxidized to RA by systemic 
DCs, and that the conversion is influenced by the type of DC present in the co-
culture, or that retinal has the capability to influence α4β7 expressing T cells itself.  
In most cases, the concentration of retinal required to mediate a significant 
increase is 10 times higher than the concentration of ATRA. As the conversion of 
retinal to RA is a 1:1 relationship, our results suggest inefficient conversion of 
retinal to ATRA by DCs, possibly due to limited expression levels of retinal 
metabolizing enzymes. Alternatively, it may be due to the inability of synthesized 
RA to act on these cells because of low expression levels of other enzymes 
involved in retinoid-induced signalling pathways. As MoDC-stimulated T cells 
required the lowest retinal concentrations to significantly increase α4β7 expressing 
T cells, this may suggest that MoDCs efficiently metabolize retinal to RA. At the 
same time, it proposes epidermal LCs to be the least efficient in converting retinal 
to RA as concentrations of 0.1 and 1 μM retinal were required to mediate an 
increase in α4β7 expressing T cells.  
Another explanation could be the differential expression of RARs and RXRs 
across the various DC subsets.  
 
In the presence of low retinal concentrations, LCs, and to some extent dDCs, 
seemed slightly more efficient in the induction of α4β7 expressing T cells (Figure 
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5.1e and f), which may suggest higher expression levels of nuclear receptors. In 
the presence of 0.01 μM retinal, dDCs induced a sudden increase in α4β7 
expressing CD8+ T cells. As RA is thought to have a positive feedback on receptor 
expression (Elder et al., 1991; Ballow et al., 2003), this increase could be due to 
higher RARs/RXRs expression levels becoming available for signalling. Although 
RARs and RXRs are thought to be expressed in DCs as well as T cells (Chapter 
1.8), the fact that we did not see this rapid increase with any other DC subtype, 
this would suggest expression of RARs or RXRs by DCs to play a role in T cell 
regulation. The effect of RA on DCs is well documented. A stimulatory role of RA 
was previously shown by Park et al., (2004), who showed RA to up-regulate 
markers including HLA-DR, costimulatory molecules (CD80 and CD86), adhesion 
molecules (CD40), and chemokine receptors (CCR6).  
 
So far, retinal has been thought to only play an active role in light absorption for 
vision (chapter 1.6.1). However, here we have to consider the likelihood that 
retinol and retinal mediate the effect on α4β7 and CLA themselves. Because of 
their unsaturated nature and structural similarity to RA, retinal is believed to be 
very reactive and may hold the potential to bind to RARs and RXRs. Publications 
on the binding capacity of retinal to RARs have shown that retinal has the potential 
to bind RARs, although with a binding efficiency that is 500-fold lower of that of RA 
(Repa et al., 1993). However, there have been contradicting observations showing 
retinol and retinal to have little or no effect compared to RA in RAR competition 
assays (Crettaz et al., 1990). Furthermore, it has been shown (Ziouzenkova et al., 
2006) that retinal is able to bind CRBP1 and RBP4, and modulate RXR responses. 
Hence, the effect observed with retinal could simply be due to its binding to and 
activation of RARs and/or RXRs. 
A more recent publication (Amann et al., 2011) further supports the idea of retinol 
and retinal binding to retinoic acid receptors themselves and modulating gene 
expression. Amann et al. (2010) showed that cultivation of cells in the presence of 
retinol triggered a change in gene expression that was not the result of increased 
retinoic acid synthesis, suggesting that retinol itself is able to bind RARs and 
RXRs in order to module gene expression. Conversely, although they were able to 
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detect retinol, retinal and RA in the cytoplasm, they detected only retinol and 
retinal but no ATRA in nuclear fractions (Amann et al., 2010). Considering the 
nuclear function of ATRA as a regulator of gene expression one would assume 
ATRA to be present in the nucleus. The inability to detect nuclear levels of ATRA 
could be due to the limitations of the experimental method. 
Analysis of the numbers of CLA expressing T cells revealed a retinal-dose 
dependent decrease in CLA expressing β7+ T cells. These results further 
emphasize the potential of systemic DCs to metabolize retinal to RA and 
subsequently repress CLA expressing T cells. The variation observed between the 
different DC subsets could be due to differences in their ability to express retinal 
converting enzymes and to respond to stimulation with retinal-derived RA.  
 
Overall, these observations suggest that systemic DCs can modulate the extent to 
which retinoid-mediated stimulation influences α4β7 and CLA expressing T cells 
and that the amount of retinal present influences the efficiency with which DCs 
regulate the percentage of T cells expressing specific homing receptors. 
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5.3.2 Retinol increases α4β7 and decreases CLA Expressing CD4+ and CD8+ 
T Cells in the Presence of Systemic DCs 
The retinoids retinol and retinal are interconvertible, but once RA has been 
produced it cannot be converted back to retinal. To test whether systemic DCs 
could potentially support the full conversion of retinol to RA, we set up co-culture 
experiments in the presence of increasing retinol concentrations. Our results 
clearly showed a dose-dependent increase in α4β7 expressing T cells (Figure 5.5) 
and a dose-dependent decrease in CLA expressing T cells (Figure 5.6).  
 
Our data revealed MoDCs and dDCs to be good inducers of α4β7 expressing T 
cells in the presence of retinol (Figure 5.5a and b). However, in the presence of 
0.1 µM, MoDCs most efficiently up-regulated α4β7 expressing T cells (Figure 
5.5a). dDCs and mDCs both appeared slightly less efficient than MoDCs in 
promoting a fold increase in α4β7 expressing T cells. Although in vitro-generated 
and epidermal LCs were able to mediate a significant fold increase in the number 
of α4β7 expressing T cells, in the presence of 0.1 µM retinol they induced fold 
increases that were relatively low when compared to the MoDCs (MoDCs vs 
epidermal LCs; p = 0.0625).  
Our data further showed that, similar to retinal, retinol did not regulate α4β7 
expression with the same efficiency as ATRA. Even at concentrations that were up 
to 10-fold higher than those for ATRA the extent of α4β7 up-regulation mediated 
by retinol remained below the levels observed for ATRA. Also, the retinol 
concentrations required to mediate a significant decline in CLA+ T cell populations 
were between 10- and 100-fold higher that what was observed with ATRA. 
Overall, our data showed that higher concentrations of retinol were required for the 
regulation of homing receptors than retinal. This is in agreement with the notion 
that retinol has to be converted to retinal and subsequently to RA in order to 
mediate its effect. 
As with retinal, our observations suggest that retinol is converted at low 
concentrations to RA, which in turns functions to regulate gene expression and a 
decrease in CLA expressing T cells. However, it has previously been shown by 
Yamanaka et al. (2008), that precursor forms of vitamin A have little inhibitory 
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action on CLA surface expression. This publication is opposed to our findings of 
retinoids having a repressive effect on CLA expressing T cells when co-cultured 
with systemic DCs.  
 
As previously mentioned with retinal, these observations could be due to several 
factors, including inefficient oxidation of retinol to RA by the different DCs or a lack 
in alcohol dehydrogenases. Alternatively, it could be caused by the differential 
expression of RARs and RXRs by DCs, resulting in different responses. Like 
retinal, retinol has been proposed to directly bind to RARs (Repa et al., 1993). As 
the retinol binding kinetics to RAR have been shown to be much lower than ATRA 
(Repa et al., 1993) this may explain the requirement for greater retinol 
concentrations in order to induce similar effects. 
In addition, CRABP1 and CRABP2 are believed to play a role in regulating 
the metabolism of RA (Ong et al., 1994). Hence differences in the amounts of 
these proteins expressed by individual DC subtypes could constitute a contributing 
factor to the differences seen in the conversion of retinol and retinal to RA and 
subsequent regulation of β7 and CLA expression. On the other hand, it was shown 
by Lampron et al. (1995) that mice lacking these proteins did not show any 
abnormal tendencies, suggesting that these proteins are not essential for normal 
retinoid metabolism. 
Overall, this section has shown the ability of systemic DCs to support and increase 
in α4β7 expressing T cells and a decrease in CLA expressing β7+ T cells in the 
presence of retinol. 
 
 
5.3.3 Systemic DCs Express Dehydrogenases required for the Conversion of 
Vitamin A to RA 
Small intestinal CD103+ DCs have the selective ability to promote de novo 
generation of regulatory and gut homing T cells via the production of RA. However, 
de novo synthesis of RA requires the presence of vitamin A metabolizing enzymes 
such as cytosolic ADH and ALDH, which represent two of the four families 
responsible for oxidizing alcohols and aldehydes such as retinol and retinal. RA 
  Chapter 5 
   
244 
functions in the regulation of RAREs, which are implicated in many mammalian 
developmental and growth processes, such as the induction of β7 expression. To 
confirm the ability of systemic DCs to metabolize retinol and retinal to RA, we 
initially used RT-PCR to show MoDCs and LCs to be positive for the expression of 
ADH1 and ALDH1A2 (Figure 5.7).  
Distribution studies of alcohol dehydrogenases have shown that ADH1 is 
constitutively expressed in the skin and liver of the mouse, rat and guinea-pig 
(Cheung et al., 2003), as well as mouse intestine, liver, kidney, and uterus. Within 
the murine intestine, ADH1 localized exclusively to the villus epithelium of the 
small intestine and absorptive epithelium of the large intestine (Haselbeck and 
Duester, 1997). In the humans, ADH is widely distributed and has been detected 
in the cytoplasm of hepatocytes, human skin (abdomen, breast, and foreskin) and 
cultured lung fibroblasts (Petersen et al., 1980; Buehler et al., 1982).  
However, little is known about the specific expression pattern of ADH1 in 
human DC subtypes. Studies involving mice have shown murine ADH1 to be 
preferentially expressed by GALT-DCs compared to peripheral DCs (Iwata et al., 
2004). Unlike intestinal DCs, systemic DCs are not thought to express alcohol 
dehydrogenase enzymes that would allow oxidation of vitamin A to RA. The fact 
that we were able to detect alcohol dehydrogenase expression in systemic DCs 
suggests that they may in fact have the potential to metabolize retinol. Our findings 
are consistent with data by Manicassamy et al. (2009), who demonstrated in mice 
that splenic DCs constitutively express the RA metabolizing enzymes ADH1 and 
ADH5.  
 
Cytosolic ALDH is responsible for oxidizing intracellular aldehydes and high ALDH 
expression levels appear to be an important mechanism by which cells exert their 
functions. Despite the fact that liver cytosolic ALDH1 has been identified to be the 
specific isozyme involved in vitamin A metabolism (Yoshida et al., 1992; 
Labrecque et al., 1993), there is still a lack of knowledge about its regulation of 
expression in different human cell types of the immune system. ALDH1A2 
expression has been detected in basophil granulocytes (Spiegl et al., 2008), which 
have been suggested to comprise a major source of RA among human blood 
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cells. Nonetheless, the precise expression pattern of ALDH1, particularly in 
systemic DCs, needs to be clarified. As the ability of murine intestinal DCs to 
express ALDH1A2 is associated with their potential to metabolize vitamin A and 
induce gut homing T cells (Iwata et al., 2004), and since expression of ALDH1A2 
by human systemic DCs has not been previously shown, we investigated 
ALDH1A2 expression by in vitro-generated human DCs. Our RT-PCR data 
showed that purified systemic MoDCs and LCs do express ALDH1A2 (Figure 5.7).  
 
Opposing data on RALDH2 expression in murine DCs from peripheral lymh nodes 
(PLNs) has shown relatively low expression levels (Iwata et al., 2004). As 
expected, murine PP-DCs were shown to express ALDH1A1 (RALDH1) mRNA, 
and MLN-DC to be positive for ALDH1A2 (RALDH2) expression (Iwata et al., 
2004). Similarly, mucosal DCs in the LP of the small intestine were shown to 
express ALDH1A (Uematsu et al., 2008). In addition, recent studies indicate that 
DCs from mouse MLNs constitutively express RALDH2 mRNA and RA, which 
regulates the function and gut homing properties of lymphocytes. 
Notably, ALDH has been detected in erythrocytes, platelets, human blood, and 
leukocytes (Helander et al., 1987). More specifically, human lymphocytes have 
been shown to express ALDH isoenzymes 1 and 2 (Dyck et al., 1990), which 
suggests that lymphocytes themselves have the potential to metabolize retinal. 
However, it is believed that T cells do not express enough of the enzymes to 
metabolize retinoids. As previously shown by Kastan et al. (1990), ALDH can be 
detected at high levels in HPCs and intermediate levels in erythroid cells, while 
lymphocytes show the lowest level. 
 
However, detection of ALDH1 mRNA in systemic DCs does not imply expression 
of biologically functional enzymes that confer the ability to metabolize retinal. 
Identification and isolation of murine and human hematopoietic stem cells based 
on the functional expression of cytosolic ALDH activity was first reported by Jones 
et al. (1995) and Storms et al. (1999), when they discovered that dansyl 
aminoacetaldehyde (DAAA) could be used in flow cytometry experiments to isolate 
viable mouse and human cells based on their ALDH content and activity. To date, 
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high levels of ALDH expression have been described in stem cells other than 
those of hematopoietic origin (Cai et al., 2004; Visus et al., 2007).  
Using this approach, we were able to show that A549 cells are positive for ALDH1 
activity (Figure 5.9). This is in accordance with Moreb et al. (2004) and Muzio et al. 
(2006) who showed A549 cells to express aldehyde dehydrogenases. 
As unstimulated DCs showed moderate ALDH1 activity, this suggests their 
potential to actively metabolize retinal to RA. Although intestinal DCs are 
considered to be unique in their ability to express retinol converting enzymes and 
synthesize RA, our data are supported by recently published data, showing murine 
skin-draining lymph nodes to contain dermis-derived CD103– DCs that 
constitutively produce RA and even induce Foxp3+ regulatory T cells. Using the 
same flow cytometry–based assay to measure ALDH activity, Guilliams et al. 
(2010) recently showed that skin and lung-derived DCs as well as DCs from 
respective lymph nodes express ALDH. The ability of CD103- skin DCs to produce 
RA shows that CD103 expression does not constitute a universal marker for RA-
producing mouse DCs. Furthermore, they were able to show that the RA-
producing skin-derived DCs were able to induce regulatory T cells, a characteristic 
that previously had been assigned to intestinal DCs (Coombes et al., 2007).  
 
DC stimulation with various ligands showed the potential of systemic DCs to not 
only express but also up-regulate expression of functional ALDH1. It has been 
shown that RAR-α mediates ALDH1 gene expression in the absence of 
exogenous RA (Elizondo et al., 2009). In such cases, it is thought that RAR-α 
activation is the result of endogenous RA. As systemic DCs are not believed to 
naturally produce high amounts of RA, the low levels of ALDH1 activity detected 
by flow cytometry could be the result of RAR activation by serum-derived RA. The 
fact that unstimulated MoDCs expressed higher ALDH1 activity than dDCs (n = 5) 
and LCs (n = 3) could be the mere result of sample size. Alternatively, it has been 
shown that cytokines may in fact participate in RALDH production. Elgueta et al. 
(2004) showed that IL-4 enhanced ALDH1A2 expression in MLN-DCs and 
therefore can participate in the expression of gut homing receptors by enhancing 
RALDH2 expression. Similarly, using flow cytometry to estimate aldehyde 
  Chapter 5 
   
247 
dehydrogenase activity in individual DCs in MLN and PP, Yokota et al. (2009) 
were able to show the ability of GM-CSF and IL-4 to synergistically trigger DCs to 
acquire RA-producing capacity by inducing levels of aldehyde dehydrogenase 
expression and activity. With this in mind, we might be able to explain higher 
ALDH activity of MoDCs when compared to dDCs and LCs. Nonetheless, as dDCs 
are also cultured in the presence of IL-4 and GM-CSF, additional cell type specific 
factors must play a role in regulating ALDH1 activity in these cells. 
 
The ability of ATRA to induce a significant increase in ALDH1 activity in MoDCs 
and a slight increase in dDCs suggests that it may affect ALDH1 expression in 
DCs. The ability of RA to regulate ALDH1 expression has previously been 
reported (Niederreither et al., 1997). More refined studies revealed a pathway of 
negative feedback regulation of RA synthesis. RA was shown to inhibit its 
synthesis by decreasing expression of ALDH1 (Andreola et al., 1997). In 2000, 
Elizondo et al. more specifically showed that RA blocks ALDH1 and RAR-α 
expression by decreased levels of the nuclear factor C/EBP, which normally binds 
and activates the ALDH1 gene promoter. However, our data showed RA-treated 
DCs to increase ALDH1 activity. These observations are in concordance with data 
by Koenig et al. (2010) who showed that ALDH1A3 is transcriptionally activated by 
RA in human keratinocytes. However, they did not detect an up-regulation in 
ALDH1A1 and ALDH1A2. This shows that RA not only differently regulates 
expression levels of the different isoenzymes, but it also suggests that its effect 
may vary from cell to cell type. To understand the effect of RA on the different 
dehydrogenases further investigation is required. 
 
The fact that we were able to detect an increased ALDH1 activity with LPS-
stimulated dDCs (TLR4) suggests that Toll-like receptor-mediated signalling may 
be involved in the regulation of ALDH expression and activity. In accordance with 
our data, Manicassamy et al. (2009) showed that stimulation of DCs with zymosan 
(TLR6) led to an increase in their RALDH2 expression levels. At the same time 
this suggests that TLR signalling may play a role in inducing ALDH expression in 
DCs. Similarly, it was shown by Yokota et al. (2009) that expression of ALDH1A2 
  Chapter 5 
   
248 
could be enhanced by TLR ligands, specific for TLR 3, 4, 7, and 9. On the 
contrary, it has recently been shown that TLR activation or the presence of a 
commensal microflora is not essential for the induction of ALDH activity DC 
subsets (Guilliams et al., 2010). This stands in opposition to data published by 
Dudda et al. (2005) who showed that soluble factors produced during the 
interaction of DCs isolated from skin- or small intestine-associated tissues with T 
cells differentially modulate expression of homing receptors on murine CD8+ T 
cells and that DCs can reprogram the homing receptor phenotype of T cells 
previously induced in vitro for homing to skin or small intestine. In the light of these 
findings, we propose that the microenvironment of the gut may play an important 
factor by specifically inducing ALDH1A expression in DCs and that TLR signalling 
may play a role in ALDH1 regulation. 
 
We have shown that retinol and retinal exert an effect on the expression levels of 
α4β7 and CLA expressing T cells when co-cultured in the presence of systemic 
DCs. We further showed that these DCs express ADH1 and ALDH1A2 and have 
the potential to metabolize retinol and retinal to RA.  
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Chapter 6 
 
 
 
 
 
Modulatory Effects of the Active Form of Vitamin D on 
the Homing Receptors CCR4, CCR10, 47, and CLA in 
the Presence of in vitro-generated Systemic Human DC 
Subtypes 
 
 
 
6.1 Background and Aims 
Homing to the skin is a tightly regulated process dependent on the expression of 
specific homing molecules to guide the respective cells to their target tissue. 
Within the skin, specific chemokines and their corresponding receptors control the 
migration of immune cells. The CLA and the chemokine receptors 4 and 10, have 
each been proposed to play an important role in regulating skin-specific T cell 
homing. 
A difference in cell surface expression between cutaneous and 
noncutaneous T cells was first reported by Picker et al. (1990), who showed 
cutaneous T cells to express an epitope that is recognized by the monoclonal 
antibody HECA-452. This antibody was shown to react with the great majority of T 
cells in cutaneous inflammatory sites and the cells of most skin-based T-cell 
lymphomas. Eventually, this molecule was identified as CLA. CLA has been 
shown to function in the homing of memory T cells to the skin by interacting with 
vascular E-selectin (Berg et al., 1991), which is thought to allow the recruitment of 
CLA+ cells to the skin.  
In addition, it has been shown that CLA+ memory T cells express the chemokine 
receptor CCR4, suggesting that CCR4 may also play a role in lymphocyte 
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trafficking to or within the skin. Substantiating its involvement in skin homing, 
Campbell et al. (1999) showed that gut homing T cells are CCR4 negative. The 
ligand for CCR4 is the thymus and activation-regulated chemokine (TARC; 
CCL17), which is expressed by activated endothelial cells (Campbell et al., 1999) 
and by keratinocytes in the basal layer of the epidermis in atopic dermatitis 
(Vestergaard et al., 2000). More recently, it was shown that under normal 
physiological conditions, CCR4 is a nonredundant, necessary component of skin-
specific lymphocyte trafficking (Campbell et al., 2007). A third receptor that is 
thought to play a role in the regulation of skin homing lymphocytes is CCR10, 
which has been shown to direct memory T cells from the blood to the dermis 
(Reiss et al., 2001) by interacting with its ligand the cutaneous T cell-attracting 
chemokine (CTACK; CCL27). CCL27 was first identified by Morales et al. (1999) 
who showed that it preferentially attracts skin-homing memory T cells. It was not 
until 2000, when Homey et al. showed the interaction between CCL27 and 
CCR10. However, it has been suggested that CCR10 itself is not required for the 
recruitment of lymphocytes to the skin (Sigmundsdottir et al., 2007) but rather for 
the homing between epidermis and dermis. 
 
The microenvironment within the skin plays a significant role in regulating the 
expression of skin homing markers and recruiting immune cells. The active forms 
of vitamin A (chapter 4 and 5) and vitamin D have both been shown to play 
significant roles in modulating the immune system and their roles in the regulation 
of lymphocyte homing has been under thorough investigation. Vitamin D 
constitutes a group of prohormones, of which the active form vitamin D3 
(1,25(OH)2D3) is a secosteroid. Vitamin D3 is produced within the skin upon sun 
exposure. Although vitamin D deficiency has been implicated in diseases such as 
rickets, cancer, osteoporosis, and increased risk of viral infections, it has been 
suggested for treatment of diseases such as colitis (Pedersen et al., 2009).  
The VDR is present in numerous cell types, including those of the immune 
system. The VDR is expressed in T and B lymphocytes (Veldman et al., 2000) and 
on monocytes differentiating into DCs (Brennan et al., 1987). As shown by Goebel 
et al. (2009), the vitamin D3 receptor is induced by TGF-β and is involved in LC 
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differentiation. In addition, vitamin D has been implied in regulating homing of 
lymphocytes to the skin. Sigmundsdottir et al. (2007) showed that addition of 
vitamin D3 modulates surface expression of the skin homing marker CLA and that 
vitamin D increased expression of CCR10 on T cells. Although CCR4 is thought to 
play a role in directing lymphocytes to the skin, Sigmundsdottir et al. (2007) 
showed that 1,25(OH)2D3 failed to induce of CCR4 expression on T cells.  
In contrast, mucosal DCs are thought to play a crucial role in the induction of gut 
homing lymphocytes through their ability to metabolize vitamin A. However, at the 
same time, the role of systemic DCs in the regulation of systemic immune 
responses and induction of skin homing lymphocytes still needs to be investigated. 
Therefore, the role of systemic DCs in regulating skin homing lymphocytes in the 
absence or presence of vitamin D was investigated.  
 
The aim of this chapter was to investigate the effect of 1,25(OH)2D3 on the 
expression of the homing receptors α4β7, CLA, CCR4, and CCR10 in combination 
with in vitro-generated human DCs and DCs directly isolated from human 
peripheral blood or epidermal sheets. Overall, the data presented in this chapter 
show that vitamin D3 has a modulatory effect on the surface expression of the skin 
and gut homing receptors. Initially, Vitamin D3 was shown to have a modulatory 
effect on CCR4 and CCR10 expressing CD4+ and CD8+ T cells. In addition, co-
cultures of MoDCs and T cells in the presence of Vitamin D3 led to a decrease in 
the mean percentages of α4β7 and CLA expressing T cells. Finally, to examine 
whether ATRA and 1,25(OH)2D3 act in synergy, co-cultures with in vitro-generated 
DCs were established and expression of α4β7 and CLA expressing T cells was 
measured. 
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6.2 Results 
6.2.1 Vitamin D3 induces as Shift from CCR4
+CCR10- to CCR4-CCR10+ T Cells 
in the Presence of Systemic DCs 
The effect of 1,25(OH)2D3 and the various DC subsets on CCR4 and CCR10 
expressing CD4+ and CD8+ T cell populations was assessed by culturing different 
DC subtypes with increasing concentrations of 1,25(OH)2D3 for 24 hrs before 
adding total T cells. The cells were incubated for 7 days at 37 °C, and 
subsequently analysed for the expression of CCR4 and CCR10. To test whether 
there is a correlation between the expression of CCR4 and CCR10, we analysed 
single and double positive CD4+ and CD8+ T cell populations. Our data shows that 
the presence of 1,25(OH)2D3 in the culture does have an effect on the 
percentages of CCR4 and CCR10 expressing T cells. 
 
As shown in Figure 6.1 (red graphs), we were able to detect a significant decrease 
in the mean percentages of CCR4+CCR10- expressing CD4+ and CD8+ T cells 
with increasing concentrations of 1,25(OH)2D3. Although this decrease was 
independent of the type of DC used in the co-culture, different subtypes supported 
slightly different levels of CCR4 and CCR10 expressing T cells.  
In the absence of 1,25(OH)2D3 MoDCs supported a mean of 31.24 % ± 4.35 % of 
CCR4+CCR10-CD4+ T cells and a mean of 14.11 % ± 3.10 % CCR4+CCR10- CD8+ 
T cells (Figure 6.1a). For CD4+ T cells, a significant decrease in in the mean 
percentage of CCR4+CCR10- T cells was reached with only 1 nM 1,25(OH)2D3 
(17.48 % ± 3.96 %; p < 0.005), while 100 nM were required to markedly reduce 
the mean percentage of CCR4+CCR10-CD8+ T cells (8.84 % ± 2.68 %; p < 0.005).  
Similarly, dDCs induced 23.61 % ± 5.42 % of CCR4+CCR10-CD4+ T cells and 
17.12 % ± 5.71 % of CCR4+CCR10-CD8+ T cells in the absence of 1,25(OH)2D3 
(Figure 6.1d). In the presence of 100 nM 1,25(OH)2D3 a significant reduction in the 
mean percentages of CCR4+CCR10-CD4+ and CCR4+CCR10-CD8+ T cells was 
observed, reaching values of 5.62 % ± 1.14 % and 8.48 % ± 2.69 % respectively.  
When compared to dDCs, T cells co-cultured with in vitro-generated LCs showed 
similar mean levels of CCR4+CCR10- T cells in the presence as well as absence 
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of 1,25(OH)2D3 (Figure 6.1g). The initial levels of CCR4
+CCR10- T cell populations 
stimulated with LCs were 24.02 % ± 4.71 % for CD4+ T cells and 12.41 % ± 3.80 
% for CD8+ T cells. Comparable to MoDCs, a significant reduction in 
CD4+CCR4+CCR10- T cells was reached in the presence of 10 nM 1,25(OH)2D3 
(15.47 % ± 3.42 %), while a reduction in CD8+CCR4+CCR10- T cells (7.03 % ± 
2.18 %) required 100 nM 1,25(OH)2D3. 
In addition to testing in vitro-generated DCs we focused our investigations on the 
effect of 1,25(OH)2D3 on CCR4
+CCR10- T cells stimulated with blood-derived 
(Figure 6.1j-l) and epidermal DCs (Figure 6.1m-o). As expected, blood-derived 
mDCs were able to support CCR4+CCR10- T cell populations in the absence of 
1,25(OH)2D3. Interestingly, the mean percentages of CCR4
+CCR10-CD4+ T cells 
(22.74 % ± 6.36 %) and CD8+ T cells (12.43 % ± 3.84 %) were not much lower 
than those seen with in vitro-generated LCs. A significant reduction in 
CCR4+CCR10- T cells was seen with 1000 nM 1,25(OH)2D3 (Figure 6.1j). In 
contrast, epidermal LCs induced the lowest mean percentages of CCR4+CCR10- 
expressing T cells (CD4+: 17.23 % ± 3.02 %; CD8+: 6.60 % ± 0.86 %). Although 
there was a tendency of 1,25(OH)2D3 to reduce the mean percentage of 
CCR4+CCR10-CD4+ and CD8+ T cells, the lack of sample size did not allow us to 
achieve statistical significance (n = 3; p = 0.2500). 
 
Concurrent with a decrease in CCR4+CCR10- T cell populations, an increase in 
CCR4-CCR10+ expressing CD4+ and CD8+ T cells was detected (Figure 6.1; blue 
graphs). This rise was independent of the DC subtype used. However, overall the 
mean percentages of CCR4-CCR10+ T cell populations were much lower than 
those for CCR4+CCR10- T cells. In the absence of 1,25(OH)2D3 the mean 
percentages of CCR4-CCR10+ T cell populations were very low, maximally 
reaching mean values of 1.75 % ± 0.43 % for CD4+ T cells co-cultured with mDCs 
(Figure 6.1l). Although small, a significant increase in CCR4-CCR10+CD4+ and 
CCR4-CCR10+CD8+ T cell populations was reached with 10 nM (2.51 % ± 0.57 %) 
and 100 nM (2.05 5 ± 0.46 %) respectively (Figure 6.1l). Conversely, in the 
presence of 1,25(OH)2D3, dDCs most efficiently up-regulated CCR4
-CCR10+CD4+ 
and CD8+ T cells (Figure 6.1f). Addition of only 0.1 nM 1,25(OH)2D3 led to a 
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significant increase in CCR4-CCR10+ T cells. Rather than inducing a gradual 
increase, dDCs triggered a relatively abrupt surge in the mean percentage 
expression of CCR4-CCR10+ T cell populations. The mean percentage for CD4+ T 
cells rose from 1.22 % ± 0.35 % to 3.17 % ± 0.84 %, while the mean percentage 
for CD8+ T cells rose from 1.33 % ± 0.37 % to 2.66 % ± 0.89 %.  
T cell stimulation with MoDCs supported mean levels of 0.66 % ± 0.17 % 
(CD4) and 1.18 % ± 0.34 % (CD8) in the absence of the vitamin D metabolite. Yet, 
1,25(OH)2D3 significantly increased the means of CCR4
-CCR10+CD4+ T cells 
(1.95 % ± 0.45 %) and CD8+ T cells (2.94 % ± 0.95 %) when added to the culture 
(Figure 6.1c). 
Regardless of whether 1,25(OH)2D3 was present in the culture, T cells 
stimulated with LCs did not exceed a mean percentage of 2 for CCR4-CCR10+ 
populations (Figure 6.1i). Overall, the mean percentages were much lower than 
those for MoDCs and dDCs and the overall percentage increase was more 
gradual. In the absence of 1,25(OH)2D3, LCs triggered mean percentages of 1.21 
% ± 0.24 % for CD4+ and 1.08 % ± 0.29 % CD8+ T cells. In order to achieve a 
significant increase in CCR4-CCR10+ populations, concentrations of 100 nM and 
1000 nM were required. 
 Ex vivo testing of epidermal LCs showed that they were capable of 
supporting CCR4-CCR10+ populations in the absence and presence of 
1,25(OH)2D3. As anticipated, we were able to show a similar development as 
observed with the other DC subtypes (Figure 6.1o). Although no significance was 
obtained (n = 3), the mean percentages for CCR4-CCR10+ T cells stimulated with 
epidermal LCs was overall the lowest. Furthermore, it seemed that addition of 0.1 
nM 1,25(OH)2D3 led to change similar to that seen with dDCs, in that there was a 
sudden upsurge in CCR4-CCR10+ T cell populations. 
 
In addition to looking at single positive T cell populations, we also examined 
CCR4+CCR10+ T cells (Figure 6.1; green graphs). Depending on the DC subtype 
used in the co-culture, we were able to detect a significant decrease in 
CCR4+CCR10+ T cell populations. However, on the whole, the results seemed 
more variable. Stimulation of T cells with MoDCs and dDCs (Figure 6.1b and e) 
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led to a significant decrease in double positives in the presence of 1,25(OH)2D3. 
However, when culturing LCs and T cells in the presence of increasing 
concentrations of 1,25(OH)2D3, a significant reduction was only observed for CD8
+ 
T cells. In the absence of 1,25(OH)2D3, LCs supported a mean percentage of 4.22 
% ± 0.87 % for CD4+ T cells and 2.71 % ± 0.60 % for CD8+ T cells (Figure 6.1h). 
However, addition of 1,25(OH)2D3 reached statistical significance only with 
CCR4+CCR10+CD8+ T cells (1.79 % ± 0.28 %), while there was no significant 
reduction in CCR4+CCR10+CD4+ T cells, even when cultured in the presence of 
1000 nM 1,25(OH)2D3 (n = 11) (Figure 6.1h). 
Stimulation of T cells with mDCs in the presence of increasing concentrations of 
1,25(OH)2D3 led to a reduction in CCR4
+CCR10+ T cells (Figure 6.1k). Yet, in 
order to significantly reduce the mean percentages of CD4+ and CD8+ T cells, 
1000 nM 1,25(OH)2D3 were required.  
Lastly, we examined the effect of epidermal LCs on CCR4+CCR10+ T cells 
(Figure 6.1n). Although the sample size was large enough to detect a change of 
CCR4+CCR10- and CCR4-CCR10+ populations in the presence of 1,25(OH)2D3, 
there was no obvious trend with respect to an increase or decrease of 
CCR4+CCR10+ populations when treated with 1,25(OH)2D3. 
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Figure 6.1: 1,25(OH)2D3 mediates a shift in CCR4
+
CCR10
-
 CD4
+
 and CD8
+
 T cells. 
In vitro generated and tissue isolated DCs were co-cultured with total T cells in the presence or absence of increasing concentrations of 1,25(OH)2D3. MoDCs 
(a-c; n = 10-15), dDCs (d-f; n = 11-12), LCs (g-I; n= 14-15), blood-derived mDCs (h-j; n = 10 - 12) and epidermal LCs (k-m; n = 3). After 7 days, 
CCR4
+
CCR10
- 
(red), CCR4
+
CCR10
+
 (green), and CCR4
-
CCR10
+
 (blue) CD4
+
 and CD8
+
 T cells were identified by cell surface staining. * p < 0.05; ** p < 
0.005; statistical analysis was performed using the Wilcoxon matched pair test.  
 
mDCs 
Epidermal LCs 
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6.2.2 Vitamin D3 down-regulates the Percentage of α4β7 and CLA Expressing 
CD4+ and CD8+ T Cells in the Presence of Systemic DCs 
As the metabolically active form of vitamin D (1,25(OH)2D3) has been shown to 
have a modulatory effect on the percentage of CCR4 and CCR10 expressing T 
cells, further investigations were conducted to examine the effect of 1,25(OH)2D3 
on the percentage of α4β7 and CLA expressing T cell populations. For the 
purpose of our investigation, co-cultures of MoDCs with total T cells were 
established in the absence or presence of 1,25(OH)2D3. DC – T cell co-cultures 
were incubated for 7 days at 37 °C before being analysed for the expression of 
α4β7 and CLA. As represented in Figure 6.2, addition of 1,25(OH)2D3 was 
associated with a decrease in α4β7 expressing CD4+ (a-g) and CD8+ (h-n) T cells. 
 
 
a)             b)             c) 
   
d)             e)             f) 
   
g) 
 
18.5 % 14.4 % 12.3 % 
13.4 % 13.5 % 8.7 % 
7.7 % 
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h)             i)              j) 
   
k)             l)             m) 
   
n) 
 
 
Figure 6.2: Down-regulation of α4β7 expressing CD4
+
 and CD8
+
 T cells in the presence of 
1,25(OH)2D3. 
MoDCs were stimulated for 24 hrs in the presence of increasing concentrations of 1,25(OH)2D3 
before total T cells were added to the culture. Co-cultures were incubated for 7 days at 37 °C. 
CD4
+
 (a – f, m) and CD8
+
 (g – l, n) T cells were subsequently stained for the expression of α4β7. 
Respective isotypes can be found in Figure D.1 of the Appendix. 
 
 
Additional experiments showed that in the presence of 1 nM of 1,25(OH)2D3 there 
was a significant reduction in the mean percentages of α4β7 expressing CD4+ and 
CD8+ T cells (Figure 6.3). The mean percentage of CD4+ T cells was reduced from 
10.50 % ± 1.87 % in the absence of 1,25(OH)2D3 to 7.88 % ± 1.67 % in the 
presence of 1 nM 1,25(OH)2D3. Similarly, the mean percentage of CD8
+ T cells 
decreased from 15.57 % ± 3.04 % to 11.65 % ± 2.03 % in the presence of 
1,25(OH)2D3. 
 
19.9 % 11.8 % 17 % 
15.1 % 13.2 % 9.2 % 
20.2 % 
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a)         b) 
     
 
Figure 6.3: Down-regulation of α4β7 expressing CD4
+
 and CD8
+
 T cells in the presence of 
1,25(OH)2D3. 
MoDCs were co-cultured with total T cells in the presence of increasing concentrations of Vitamin 
D. The percentage of α4β7 and CLA positive CD4
+
 and CD8
+
 T cells was measured 7 days later by 
flow cytometric analysis. There was a significant decrease in the number of α4β7 positive CD4
+
 (a) 
and CD8
+
 (b) T cells (n = 11). * < 0.05; statistical analysis was performed using the Wilcoxon 
matched pair test.  
 
 
In addition to having an effect on α4β7 expressing T cells, we found 1,25(OH)2D3 
to down-regulate the percentages of CLA+α4+β7+CD4+ and CLA+ α4+β7+CD8+ T 
cells. As shown in Figure 6.4, the percentages of CLA+ β7+ T cells dropped in the 
presence of 1,25(OH)2D3 in a dose dependent manner. 
 
 
a)            b)             c) 
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d)            e)             f) 
   
g) 
 
h)             i)             j) 
   
k)            l)             m) 
   
n) 
 
Figure 6.4: Down-regulation of CLA on α4β7 expressing CD4
+
 
and CD8
+
 T cells in the presence of 1,25(OH)2D3. 
MoDCs were stimulated overnight in the presence of various 
concentrations of 1,25(OH)2D3 before total T cells were added to the 
culture. After 7 days, CD4
+
 (a-q) and CD8
+
 (h-n) T cells were stained 
for CLA expression on α4β7 positiveT cells. Respective isotypes can 
be found in Figure D.2 of the Appendix. 
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Further investigations showed that 10 nM 1,25(OH)2D3 was required to induce a 
significant decrease in the mean percentages of CD4+CLA+ (Figure 6.5a) and 
CD8+CLA+ (Figure 6.5b) expressing T cells. The presence of 1,25(OH)2D3 in the 
medium led to a significant reduction in CLA+α4+β7+CD4+ T cells from a mean of 
7.11 % ± 2.28 % to 2.68 % 0.60 %. At the same time, the mean for CLA+ 
α4+β7+CD8+ T cells was significantly reduced from 8.67 % ± 4.10 % to 2.38 % ± 
0.82 %. 
 
 
       a)         b) 
    
 
Figure 6.5: Down-regulation of CLA expressing T cells in the presence of 1,25(OH)2D3. 
MoDCs were co-cultured with total T cells in the presence of increasing concentrations of 
1,25(OH)2D3. The mean percentages CLA
+
α4
+
β7
+
CD4
+
 (a) and CLA
+
α4
+
β7
+
CD8
+
 (b) T cells was 
measured 7 days later by flow cytometric analysis. There was a significant decrease in the mean 
percentages of CLA expressing CD4
+
 (n = 9-10) and CD8
+
 (n = 10-11) T cells. * p < 0.05; statistical 
analysis was performed using the Wilcoxon matched pair test.  
 
 
Overall, these results show that 1,25(OH)2D3 has a negative effect on the mean 
percentage expressions of α4β7 and CLA expressing CD4+ and CD8+ T cells 
when co-cultured in the presence of MoDCs. 
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6.2.3 Combined Effect of 1,25(OH)2D3 and ATRA on α4β7 Expression 
Having investigated the individual effects of vitamin A (ATRA) and vitamin D 
(1,25(OH)2D3) on the expression of homing receptors on CD4
+ and CD8+ T cells, 
the combined effect of the active metabolites of these two vitamins was examined. 
Dendritic cells were incubated in the presence of either 1,25(OH)2D3 only, ATRA 
only, or a combination of both for 24 hrs before total T cells were added to the 
culture. The effect on α4β7 was determined 7 days into the co-culture by flow 
cytometry.  
As shown in Figure 6.6, in the absence of any of the vitamins tested, all DC 
subtypes were able to support intrinsic expression of α4+β7+ CD4+ and CD8+ T cell 
populations (white bars). However, LCs seemed to most efficiently support α4β7 
positive T cells in the absence of vitamins, reaching mean values of 24.05 % ± 
2.81 % for CD4+ T cells and 30.86 % ± 2.35 % for CD8+ T cells (Figure, 6.6e and f; 
white bars). Stimulation of T cells by MoDCs triggered mean percentages of 12.78 
% ± 3.22 % and 18.31 % ± 2.91 % for CD4+ and CD8+ T cells respectively (Figure 
6.6a and b). dDCs showed the lowest mean percentage values for CD4+ (9.39 % ± 
0.73 %) and CD8+ (15.21 % ± 3.04 %) T cells. 
In the presence of 100 nM 1,25(OH)2D3 a significant change in the mean 
percentages of α4β7 expressing CD4+ and CD8+ T cells could be observed for all 
DC subtypes (red bars). MoDCs and LCs mediated a marked down-regulation of 
α4β7 expressing CD4+ and CD8+ T cells in the presence of 100 nM 1,25(OH)2D3. 
The mean percentage values for MoDCs (CD4: 8.13 % ± 1.70 %; CD8: 12.04 % ± 
1.97 %) were lower than those obtained for LCs (CD4+: 19.42 % ± 2.58 %; CD8+: 
21.99 % ± 1.97 %). Interestingly however, dDCs showed a trend opposite to that 
of MoDCs and LCs. In the presence of 1,25(OH)2D3, dDCs supported a significant 
(p < 0.05) up-regulation in α4β7 expressing CD4+ and CD8+ T cells (Figure 6.3c 
and d). The mean percentages of α4β7 expressing CD4+ and CD8+ T cells rose to 
16.46 % ± 2.78 % and 18.47 % ± 3.98 % respectively. 
As expected, 10 nM and 100 nM ATRA triggered a significant increase in 
α4β7 T cell populations (blue bars). 
 
  Chapter 6 
   
264 
To test the combined effects of the two vitamins in culture and to determine 
whether they exert an additive, synergetic, or inhibitory effect, both vitamins were 
simultaneously added to the culture (Figure 6.6; purple bars). Under conditions 
where ATRA was kept constant (10 nM) and increasing concentrations of 
1,25(OH)2D3 were titrated into the culture, a gradual decrease in α4β7 expressing 
T cell populations was detected. This was the case for all co-cultures regardless of 
the DC subtypes tested. Nevertheless, the mean percentages for MoDCs-
stimulated T cells were generally lower than those obtained for dDCs and LCs. 
Overall, the data show that, in combination, ATRA has an up-regulatory effect on 
α4β7 expressing T cells, while 1,25(OH)2D3 decreases the mean percentages of 
α4β7 expressing T cells.  
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Figure 6.6: Combined effect of ATRA and 1,25(OH)2D3 on α4β7 expressing T cells. 
MoDCs (a and b; n = 10), dDCs (c and d; n = 8-9), and LCs (e and f; n = 8) were co-cultured with 
total T cells in the presence of either 1,25(OH)2D3 only, ATRA only, or a combination of both 
vitamins at different ratios for 7 days before being analysed for α4β7 surface expression. * p < 
0.05; ** p < 0.005; statistical analysis was performed using the Wilcoxon matched pair test.    
MoDCs 
dDCs 
LCs 
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6.2.4 Combined Effect of 1,25(OH)2D3 and ATRA on CLA Expression 
Having analysed the individual and combined effect of 1,25(OH)2D3, ATRA, and 
the different DC subtypes on α4β7 expression, we looked into the effect of these 
metabolites on the expression of the skin homing marker CLA on CD4+ and CD8+ 
T cells. Our analysis showed that ATRA and 1,25(OH)2D3 had an adverse effect 
on the expression of CLA+α4+β7+CD4+ and CLA+α4+β7+CD8+ T cells (Figure 6.7). 
DC-mediated stimulation in the absence of these vitamins triggered a significantly 
higher population of CLA expressing T cells (Figure 6.7; white bars). While MoDCs 
(11.48 % ± 4.24 %) and LCs (11.80 % ± 3.74 %) supported similar percentage 
means of CD4+ T cells, dDCs (14.19 % ± 3.66 %) showed slightly higher levels. 
For CD8+ T cells, MoDCs (22.04 % ± 7.43 %) and dDCs (21.00 % ± 5.58 %) were 
most efficient while LCs (13.36 % ± 2.72) supported the least amounts of CLA 
expressing T cells. 
However, upon addition of 1,25(OH)2D3 to the culture a significant reduction 
(p < 0.05) in the percentages of CLA+ T cells was observed. This down-regulation 
was independent of the type of DC used in the co-culture (red bars). The mean 
percentage values for CLA+CD4+ T cells stimulated with MoDCs (2.30 % ± 0.92 
%), dDCs (4.14 % ± 1.07 %), and LCs (4.25 % ± 1.12 %) were not only similar to 
one another but also to the values obtained for CLA+CD8+ T cells.  
As previously shown, the presence of 10 nM and 100 nM ATRA significantly 
reduced the mean percentages of CLA+ T cells (blue bars). 
 
When compared to the effect of ATRA or vitamin D3 alone, the combined addition 
of these vitamins to the culture did not have a significantly more efficient down-
modulatory effect on the percentages of CLA+ T cell populations (Figure 6.4; 
purple bars). Also, there was no significant difference between the percentages of 
CLA expressing T cells treated with 0.1 nM or 100 nM 1,25(OH)2D3 in the 
presence of 10 nM ATRA.  
Vitamin A and D both have a downregulatory effect of CLA expression. It has been 
suggested that both vitamins actively destroy the CLA epitope (Picker et al., 1993) 
and also reduce the mRNA level of fucosyltranserase VII, which is required for the 
generation of the CLA epitope (Ley and Kansas, 2004). However, based on these 
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results, we were not able to detect an additive or synergistic effect of 1,25(OH)2D3 
and ATRA on the percentages of CLA expressing T cells. A likely reason might 
have been the concentration used throughout the experiments. Even low levels 
(1nM) of each vitamin led to a prominent reduction in CLA expression, suggesting 
that the concentration of vitamin A and D used were too high to detect any synergy 
or additive effect. In order to test for an additive or synergistic effect of these two 
vitamins much lower concentrations should have been used. 
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Figure 6.7: Combined effect of ATRA and vitamin D on CLA expressing T cells. 
MoDCs (a and b; n = 7-8), dDCs (c and d; n = 7-8), or LCs (e and f; n = 8) were co-cultured with 
total T cells in the absence or presence of either 1,25(OH)2D3 only, ATRA only, or a combination of 
both for 7 days. DC-stimulated T cells were analysed for CLA
+
 expression on α4
+
β7
+
 cell by flow 
cytometry. * p < 0.05; ** p < 0.005; statistical analysis was performed using the Wilcoxon matched 
pair test.       
MoDCs 
dDCs 
LCs 
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6.3 Discussion 
In this chapter, we examined the influence of 1,25(OH)2D3 on the expression of 
the skin homing receptors CCR4 and CCR10 on CD4+ and CD8+ T cells 
stimulated by systemic DCs. Also, we looked into the modulatory effect of 
1,25(OH)2D3 on α4β7 and CLA expressing T cells. Lastly, we investigated the 
combined effect of ATRA and 1,25(OH)2D3 on the percentage expression of the 
lymphocyte homing receptors α4β7 and CLA. 
In section 6.2.1, we were able to show that 1,25(OH)2D3 can regulate CCR4 
and CCR10 expression on T cells by mediating a shift from CCR4+CCR10- 
populations to CCR4-CCR10+ populations. In parallel, we showed that 
1,25(OH)2D3 reduced the human T cell marker CLA and α4β7 (6.2.2). 
Furthermore, combined action of 1,25(OH)2D3 and ATRA was shown to down-
regulate the mean percentages of CLA and α4β7 expressing T cells when co-
cultured with different in vitro-generated DCs.  
 
CCR4 and CCR10 both play an important role in regulating skin homing 
lymphocytes. Interaction between CCR4 and CCL17 is required for T cell 
migration into the dermal layer of the skin (Santamaria Babi et al., 1995). Similarly, 
CCR10 interacts with the skin-specific ligand CCL27, which functions as a 
chemoattractant for cutaneous memory T cells (Sigmondsdottir et al., 2007).  
As previously shown (Morales et al., 1999), CCL27 is expressed by the 
keratinocytes of the epidermis, and is thought to mediate ‘epidermotropism’ of 
CCR10+ cells to the underlying dermis. Additionally, in vivo homing assays (Reiss 
et al., 2001) have shown that administration of an inhibitory anti-CTACK (CCL27) 
antibody abrogates skin recruitment of CCR4-deficient T cells, suggesting that 
CTACK and CCR4 can both support homing of T cells to skin. These data clearly 
suggest a role for these chemokine receptors in modulating lymphocyte homing to 
the skin. However, functionally specialized T and B cells may use specific subsets 
and combinations of different homing receptors in order to traffic to their effector 
site. Although small intestinal T cells are CCR10 negative (Sigmundsdottir et al., 
2007), IgA producing B cells express CCR10, which is involved in the recruitment 
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of B cells to the small and large intestine (Kunkel et al., 2008). This shows that 
CCR10 may be differentially involved in tissue homing of lymphocytes. In the 
present study, we examined the effect of 1,25(OH)2D3 on CCR4 and CCR10 
expression in the context of different systemic DC subtypes. As UVB radiation is a 
source of vitamin D3 synthesis in the skin (Webb et al., 1988) and since CCR4 and 
CCR10 play a role in lymphocyte homing to and within the skin (Santamaria Babi 
et al., 1995; Soler et al., 2003), understanding the complex relationship between 
those parameters is of immense importance when trying to modulate homing 
properties of T cells. In addition, the biological function and influence of different 
systemic DCs may be of importance in determining the strength and tissue-
specificity of the immune response. 
The presence of vitamin D3 within the skin might suggest a correlation 
between its synthesis and expression of CCR4 and CCR10 on skin homing T 
cells. Our results confirmed (Figure 6.1) a down-regulation of CCR4+CCR10- and 
CCR4+CCR10+ T cell populations and an increase in CCR10+CCR4- T cells when 
cultured in the presence of vitamin D3.  
In the absence of 1,25(OH)2D3, MoDCs supported the highest levels of CCR4
+ T 
cells. However, our data suggest MoDCs and dDCs to be most efficient in down-
regulating CCR4+CCR10- populations in the presence of 1,25(OH)2D3. In addition 
to testing the effect of MoDCs, we also investigated the impact of in vitro-
generated dDCs and LCs, mDCs, and skin-derived LCs on CCR4 and CCR10 
expressing T cells cultured in the presence of 1,25(OH)2D3. On the whole, all DC 
subtypes were able to support a significant down-regulation of CCR4+CCR10-.  
At the same time, this suggests a shift in the population dynamics and towards an 
increase in CCR10 expression. Based on the results presented in Figure 6.1, we 
conclude that 1,25(OH)2D3 does have an up-regulatory effect on CCR10 
expressing CD4+ and CD8+ T cell populations when co-cultured in the presence of 
systemic DCs. These findings are supported by an earlier publication 
(Sigmundsdottir et al., 2007) that showed vitamin D and 1,25(OH)2D3 to induce 
CCR10 expression on T cells in MoDC co-cultures. As previously shown by 
Shirakawa et al. (2008), 1,25(OH)2D3 directly induces CCR10 expression in 
terminally differentiating B cells by binding the VDR, which in turn is recruited to 
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the vitamin D response element upstream of the CCR10 gene. In addition, we 
were able to show differences in the up-regulation of CCR4-CCR10+ T cells by 
DCs. While MoDCs, dDCs, and epidermal LCs seemed to abruptly increase 
CCR4-CCR10+ populations in the presence of low levels of 1,25(OH)2D3, LCs and 
mDCs showed a slow and gradual increase in CCR4-CCR10+ T cells (Figure 6.1). 
The role of CCR10 in regulating T cell homing to the skin has been under 
intense investigation. As published by Soler et al. (2007), CLA+CCR4+ T cells that 
expressed CCR10 had no apparent advantage over their CCR10  counterparts in 
homing to inflamed cutaneous sites. In addition, controversial data has been 
published by Yamanaka et al. (2008) who showed that 1,25(OH)2D3 neither 
increased nor decreased the number of CCR10+ T cells in vitro. However, in their 
study T cells had been incubated in the absence of DCs. This fact may emphasize 
the role of APCs in modulating homing receptors on lymphocytes. 
 
The capacity of cells to respond to 1,25(OH)2D3 is related
 to their expression of the 
VDR, and the presence or absence of intracellular pathways that transfer VDR-
mediated responses. Hence, differences in the levels of VDR between the DC 
types or the ability of VDR ligand to recruit coactivators or partner receptors may 
explain this difference in their ability to regulate CCR4 and CCR10 expression on 
T cells. As shown by Wiese et al. (1992), treatment of mouse fibroblasts and 
intestinal epithelial cells with 1,25(OH)2D3 led to increased receptor half-life and 
elevated levels of VDR expression. This receptor accumulation resulted from the 
stabilization of the receptor by its ligand. Differences between the individual DC 
subtypes could therefore be attributed to variances in the initial levels of VDR 
expression as well as subsequent regulation of VDR stabilization in these cells. 
However, as shown by Hewison et al. (2003) addition of exogenous 1,25(OH)2D3 
to the culture did not induce any significant changes in VDR expression by 
MoDCs. Alternatively, DCs may differ in their ability to take up 1,25(OH)2D3. 
Although steroid hormones are generally taken up by passive diffusion, some 
active mechanism may be involved that differs between the various DC subtypes. 
Based on these data we conclude that in normal human skin, vitamin D may play 
an active role in recruiting T cells to the dermal and epidermal layers, as well as 
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orchestrating migration between the two layers by modulating expression of CCR4 
and CCR10. Furthermore, the various DC subtypes may play a modulatory role in 
order to support a skin-homing or mucosal-homing phenotype on T cells. 
 
To test whether 1,25(OH)2D3 also had an effect on α4β7 and CLA surface 
expression, we set up MoDC – T cell co-cultures in the presence of vitamin D3 
(Figure 6.2). The results clearly show a stimulatory effect of 1,25(OH)2D3 on α4β7 
expression and a down-regulatory effect on CLA expressing T cells. However, our 
findings contradict those by Yamanaka et al. (2008), who showed that 
1,25(OH)2D3 did not change the expression of the gut-homing receptor α4β7. 
Nonetheless, our results are supported by Sigmundsdottir et al. (2007) who 
showed that 1,25(OH)2D3 prevented up-regulation of α4β7 expression on T cells 
activated with anti-CD3 and anti-CD28 beads. This suggests a role for 
1,25(OH)2D3 in preventing the imprinting of a mucosal homing phenotype on T 
cells and inducing a mucosal immune response. However, it has been shown that 
subcutaneous vaccine delivery can induce systemic and mucosal immunity. 
Interestingly however, using 1,25(OH)2D3 in combination with the Hepatitis B 
surface antigen Daynes et al. (1996) were able to show induction of a mucosal 
immune response. These findings highlight the complexity of action of vitamin D 
and its modulatory effect on the immune system. 
Furthermore, considering the role of CLA in orchestrating lymphocyte 
homing to the skin, the down-regulation of CLA in the presence of 1,25(OH)2D3 
was not anticipated. However, these findings are supported by Yamanaka et al. 
(2008) who showed the mean percentage CLA expression levels to significantly 
decrease in the presence of 1 nM 1,25(OH)2D3. More specifically, they showed 
that 1,25(OH)2D3 disrupts expression of the CLA epitope on the PSGL-1 protein 
scaffold.  
 
Having investigated the individual effects of the active forms of vitamin A and D on 
skin and mucosal homing receptors, we were interested in the combined effect of 
these two reagents on α4β7 and CLA expression. As presented in section 6.2.3 
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and 6.2.4, the combined effects of these vitamins resulted in a decrease in the 
mean percentages of α4β7 and CLA expressing T cells.  
Overall, MoDCs induced slightly lower levels of β7 expression when cultured in the 
presence of ATRA alone, 1,25(OH)2D3 alone, or both vitamin metabolites (Figure 
6.6); however, this difference was not significant. One interesting observation 
made was the effect of 1,25(OH)2D3 on α4β7 expression in the presence of dDCs 
(Figure 6.6). Unexpectedly, we recorded an increase in α4β7 in the presence of 
1,25(OH)2D3 when co-cultured with dDCs. This observations stands in complete 
opposition to previous observations showing 1,25(OH)2D3 to repress α4β7 
expression. This clearly shows the different influence DCs may have on the 
homing regulation of T cells.  
Examining the combined effect of ATRA and 1,25(OH)2D3 on α4β7 surface 
expression in the context of different in vitro-generated DCs, we were able to show 
a gradual decrease in the mean percentages of α4β7 expressing T cells as 
1,25(OH)2D3 was titrated into the medium, suggesting a competitive relationship 
between 1,25(OH)2D3 and ATRA in the regulation of α4β7. Experiments using the 
active metabolites of both vitamins have previously shown an inhibitory effect of 
vitamin D on α4β7. As suggested by Sigmundsdottir et al. (2007) this may reflect 
competition between VDR and RAR for their common binding partner RXR. 
Retinoic acid signalling is mediated by its binding to the different RARs, 
which form heterodimers with RXRs. This complex in turn binds to RAREs in the 
regulatory regions of target genes (Figure 6.8a). However, it has also been shown 
that RXRs directly interact with VDRs and enhance binding on nuclear receptors 
conferring responsiveness to vitamin D (Kliewer et al., 1992). Hence, addition of 
vitamin D to the medium in the presence of ATRA may therefore competitively 
reduce β7 expression. 
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a) 
 
b) 
 
 
Figure 6.8: ATRA and 1,25(OH)2D3 compete for RXR binding. 
a) ATRA binds RAR and heterodimerizes with RXR to activate gene transcription. b) In the 
presence of 1,25(OH)2D3, ATRA and 1,25(OH)2D3 compete for the binding of RXR. 1,25(OH)2D3 
may bind RXR and divert it away from forming heterodimers activated by ATRA. Alternatively, 
1,25(OH)2D3 – activated receptors (VDR) may form heterodimers with RXR and mediate alternative 
gene regulation through binding of the VDRE (not shown).  
 
 
In addition to investigating the effect on α4β7 expression, we also looked at CLA 
expression. Our data showed that both, ATRA and 1,25(OH)2D3 mediated an 
inhibitory effect of CLA expression. Yamanaka et al. (2008) suggested that this 
down-regulation of CLA expression is a result of blocking CLA synthesis. 
Additionally, they also mentioned (data not shown) that ATRA and 1,25(OH)2D3 
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exert an additive effect on CLA expression levels when cells were cultured in the 
presence of both vitamins. However, in our experiments the combined influence of 
ATRA and 1,25(OH)2D3 did not more effectively down-modulate CLA expression 
on T cell populations. No significant difference between conditions containing 0.1 
nM or 100 nM 1,25(OH)2D3 in the presence of 10 nM ATRA were observed (Figure 
6.7). One explanation might be the low levels of CLA expression in the presence 
of just 10 nM ATRA. Henceforth, addition of increasing concentrations of 
1,25(OH)2D3 failed to induce significantly detectable changes in the mean 
percentages of CLA expressing T cells.  
 
Generally, 1,25(OH)2D3 is thought to promote expression of skin homing receptors 
on lymphocytes. Although we have been able to show that 1,25(OH)2D3 does 
decrease CLA expression on T cells, differences have been observed between 
DCs in the regulation of α4β7 in the presence of 1,25(OH)2D3. Further studies 
have established that the biologic effects of 1,25(OH)2D3 on T cells is more 
complex than previously thought. There have not only been conflicting publications 
on the function of 1,25(OH)2D3 in regulating CCR10 expression but 1,25(OH)2D3 
has also been proposed (Cantorna et al., 1998) to enhance TGF-β production. 
This raises the question of the regulatory effect of TGF-β on β7 expression, as one 
would expect β7 expression to increase in the presence of TGF-β. At the same 
time 1,25(OH)2D3 reduces CLA and CCR4 expression, two markers known to be 
expressed by skin homing cells. In addition, vitamin D may promote increased 
levels of CD4+CD25+ regulatory T cells (Gregori et al., 2001), a property also 
assigned to ATRA (Wang et al., 2009; Benson et al., 2007).  
 
In conclusion, we have shown the modulatory effect of 1,25(OH)2D3 on CCR4 and 
CCR10 expression on CD4+ and CD8+ T cells in the context of different systemic 
in vitro-generated, blood-derived, and tissue derived DC subtypes. In addition, we 
have confirmed the down-regulatory effect of 1,25(OH)2D3 on α4β7 and CLA 
expressing T cells. Overall, our findings may have implications in the development 
and delivery of vaccines and their compositions in order to direct systemic and 
mucosal immune responses.  
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Chapter 7 
 
 
 
 
 
The Effect of Retinoic Acid Receptor Neutralization and 
Dehydrogenase Inhibition on 47 and CLA Expressing T 
Cells stimulated by Systemic DCs in the Presence or 
Absence of Retinoids 
 
 
 
7.1 Background and Aims 
The purpose of this chapter was to investigate the role of RARs and 
dehydrogenases in the regulation of α4β7 and CLA expression on CD4+ and CD8+ 
T cells cultured with systemic DCs. First, an inhibitor of RAR-α was used to 
investigate the role of this receptor in the regulation of α4β7 and CLA expression 
on T cells cultured with MoDCs, dDCs, and LC. Secondly, we examined the 
combined effect of RAR-α and RAR-β/-γ inhibitors on the expression of homing 
receptors on T cells stimulated with MoDCs. Finally, we examined the effect of the 
retinoic acid synthesis inhibitor citral on the expression of α4β7 and CLA 
expressing CD4+ and CD8+ T cells stimulated with MoDCs in the presence and 
absence of retinol. 
 
With the discovery of the human nuclear receptors for RA (Petkovich et al., 1987; 
Giguere et al., 1987) a great advancement was made in understanding the 
molecular mechanism by which retinoids exert their regulatory effects. Retinoic 
acid signals through two families of retinoid receptors: the RAR (RAR-α, RAR-β, 
and RAR-γ) and RXR (RXR-α, RXR-β, and RXR-γ) families. Notably, each of the 
RAR and RXR subtypes can be found as multiple isoforms that only differ in the 5’-
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untranslated region and N-terminal region generated from differential promoter 
usage and alternative splicing (Leroy et al., 1991; Kojo et al., 2004). However, 
while RARs can be activated through all-trans RA and 9-cis RA, members of the 
RXR family can only be activated through 9-cis RA (Heyman et al., 1992; Levin et 
al. 1992; Allenby et al., 1993).  
Upon ligand binding, RARs and RXRs dimerize to form either homodimers 
or heterodimers. However, in most cases, the active receptor is an RAR/RXR 
heterodimer, which binds specific DNA regulatory sequences to regulate gene 
transcription (Chambon, 1996). Agonist binding to these receptors results in 
conformational changes and dissociation of corepressor molecules. Subsequently, 
recruitment and binding of coactivator proteins promotes transcription of 
downstream target gene(s). For a more detailed explanation on the regulation of 
transcription by RA please refer to chapter 1.8.3. 
 
Several studies investigated the effects of RAR antagonists on the regulation of 
gene expression. In particular, the role and necessity for RARs and RXRs in 
embryonic development has been widely studied. However, the immunological 
role of RARs in the regulation of gut or skin homing receptors on human systemic 
DCs and T cells has not been investigated. Antagonist (LE135) binding to RAR-β 
has been shown to significantly suppress the expression of α4β7 on naïve CD4+ T 
cells stimulated with DCs derived from the MLNs and PPs (Iwata et al., 2004). 
Similarly, Sauer et al. (2007) showed that in the presence of the RAR-α antagonist 
Ro41-5253, there was a significant decline in the expression of the β7 integrin and 
CCR9 mRNA by porcine lymphocytes stimulated with SEB-loaded MoDCs. Hence, 
to investigate the interplay in vitro between the three RAR subtypes (α, β, and γ) 
and systemic DCs in the presence of ATRA in the regulation of 47 and CLA on 
T cells, systemic DCs, T cells and ATRA were co-cultured in the absence or 
presence of RAR inhibitors. Here, we used Ro41-5253 as it was previously shown 
to specifically block the activity of RAR-α (Fitzgerald et al., 1997). Similarly, the 
role of RAR-β and -γ was investigated using the selective RARβ/γ antagonist 
CD2665 (Tocris Bioscience, UK).  
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However, as no retinol or retinal receptor has been identified so far, it is generally 
thought that vitamin A first needs to be metabolized from retinol to RA. As 
previously discussed (chapter 5), this requires the function of alcohol 
dehydrogenases and aldehyde dehydrogenases. Studies involving the blocking of 
ADHs and ALDHs have not only confirmed the role of RA in the regulation of gut 
homing receptors but also the requirement of dehydrogenases in the oxidation of 
retinol and retinal to RA. Citral is a well-known inhibitor of RA synthesis and acts 
by inhibiting the alcohol dehydrogenase that oxidizes retinol to retinaldehyde as 
well as the aldehyde dehydrogenase that oxidizes retinaldehyde to RA (Connor 
and Smit, 1987; Schuh et al., 1993; Tanaka et al., 1996). Also, citral has been 
previously shown (Chen et al., 1995) to inhibit the conversion of retinol to ATRA 
and that the capacity of MLN-DCs and PP-DCs to enhance α4β7 expression on T 
cells was repressed by citral (Iwata et al., 2004). 
Therefore, we decided to investigate the effect of citral on α4β7 and CLA 
expressing T cells in the absence or presence of retinol. 
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7.2 Results 
7.2.1 The Roles of RAR-α and RAR-β/γ in the Regulation of α4β7 Expressing 
T Cells 
7.2.1.1 Blocking of RAR-α down-regulates the Percentage of α4β7 Expressing T 
Cells  
Here, we investigated the effect of the RAR-α blocking reagent Ro41-5253, on 
ATRA-induced regulation of α4β7 and CLA expression on CD4+ and CD8+ T cells 
in the presence of systemic DCs. The different DC models were incubated in the 
presence of increasing concentrations of Ro41-5253 alone or Ro41-5253 in the 
presence of 10 nM ATRA for 24 hrs before total T cells were added. The DC-T cell 
co-cultures were incubated for 4 days before cells were harvested and analysed 
for α4β7 and CLA expression. 
 
As exemplified with LC-T cell co-cultures (Figure 7.1), in the absence of Ro41-
5253 moderate percentages of α4β7 expressing CD4+ (28.4 %) and CD8+ (15 %) 
T cells could be detected (Figure 7.1c and e). However, addition of 100 nM Ro41-
5253 reduced the percentages of α4β7 expressing CD4+ and CD8+ T cells to 10.5 
% and 8.7 % respectively (Figure 7.1d and f). Overall, we were able to observe an 
inverse correlation between the amount of Ro41-5253 in the co-culture and 
percentage of α4β7 expressing T cells.  
 
Testing different in vitro-generated DC subtypes, we were able to show that 
treatment of cells with increasing concentrations of Ro41-5253 alone led to a 
significant down-regulation of α4β7 expressing CD4+ and CD8+ T cells that was 
independent of the type of DCs used (Figure 7.2).  
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        c)     CD4+ T cells      d)     CD4+ T cells 
    
a)                  b) 
   
        e)      CD8+ T cells         f)      CD8+ T cells 
    
 
Figure 7.1: Ro41-5253 mediates a reduction in α4β7 expressing T cells. 
Langerhans cells were co-cultured in the presence of RO41-5253 for 24 hrs before total T cells were added to the culture. The DC - T cells cultures were 
incubated for 4 days before harvested and analysed for the expression of α4β7 on CD4
+
 and CD8
+
 T cells. Respective isotypes can be found in Figure E.1 of 
the Appendix. 
15 % 8.7 % 
α4β7 
28.4 % 10.5 % 
α4β7 
66.4 % 
45.2 % 
36.6 % 
  Chapter 7 
   
281 
In the absence of Ro41-5253, MoDCs supported 11.43 % ± 1.63 % and 14.43 % ± 
2.36 % of α4β7 expressing CD4+ and CD8+ T cells respectively (Figure 7.2a and 
b). Generaly, with increasing concentrations of the inhibitor the percentage 
expression of α4β7 T cells declined. A significant decrease in the mean 
percentages of α4β7 expressing CD4+ and CD8+ T cells was observed in the 
presence of 10 nM Ro41-5253 (p < 0.005). Concentrations higher than 10 nM did 
not induce a significantly higher level of α4β7 expressing CD4+ and CD8+ T cells 
when co-cultured with MoDCs (Figure 7.2a and b; red bars). To determine whether 
ATRA was directly involved in the signalling through RAR-α, experiments where 
established in which 10 nM ATRA were added to the culture in the presence of 
increasing concentrations of the RAR-α inhibitor (green bars). As expected, 
addition of 10 nM ATRA to the culture did mediate an increase in the mean 
percentages of α4β7 expressing CD4+ and CD8+ T cells (Figure 7.2a and b; blue 
bar). For CD4+ and CD8+ T cells stimulated with MoDCs, the mean average 
percentages were 16.98 % ± 1.56 % and 18.35 % ± 2.38 % respectively. A 
significant reduction in α4+β7+CD4+ and α4+β7+CD8+ T cells was observed with 
the addition of 1000 nM (11.86 % ± 1.52) and 10 nM (13.69 % ± 1.50 %) Ro41-
5253 respectively. 
For dDCs and LCs a comparable trend was observed. dDCs supported 
slightly lower percentages of α4+β7+CD4+ (10.08 % ± 1.99 %) and α4+β7+CD8+ 
(11.83 % ± 3.34 %) T cells in the absence of Ro41-5253 than MoDCs. In the 
presence of 10 nM Ro41-5253 a significant reduction in the percentages of α4β7 
expressing cells was observed (Figure 7.2c and d; red bars). Similar to MoDCs, 
high level α4+β7+ T cells were detected in the presence of 10 nM ATRA alone 
(blue bar). However, in the presence of constant ATRA, 10000 nM Ro41-5253 
were required to reach a significant reduction in the percentages of α4+β7+CD4+ 
and α4+β7+CD8+ T cells (9.2 % ± 2.17 % and 9.59 % ± 1.74 respectively).  
Stimulation of T cells in the presence of LCs gave similar results (Figure 
7.2e and f), though sample variation was much wider. Initial levels of α4+β7+CD4+ 
and α4+β7+CD8+ T cells were 12.47 % ± 1.58 % and 17.14 % ± 2.89 % in the 
absence of the inhibitor. A significant down-modulation in α4β7 expressing T cells 
was observed when 10 nM Ro41-5253 were added to the culture (p < 0.005). With 
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a mean percentage of 17.61 % ± 2.44 % for CD4+ T cells and 23.94 % ± 4.06 % 
for CD8+ T cells, LCs most efficiently supported α4β7 expressing T cells in the 
presence of 10 nM ATRA alone (blue bar). However, different concentrations of 
Ro41-5253 were required to reach a significant reduction in α4β7 expressing T 
cells. While CD4+ T cells required 10000 nM Ro41-5253 (9.34 % ± 1.02 %), the 
mean percentage of α4+β7+CD8+ T cells was significantly reduced in the presence 
of 100 nM Ro41-5253 (20.51 % ± 3.44 %). 
 
These data confirm that the regulation of α4β7 expressing T cell takes place 
through at least the RAR-α and that ATRA is closely involved in this process.  
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Figure 7.2: Ro41-5253-mediated blockage of RAR-α decreases α4β7 expressing CD4
+
 and 
CD8
+
 T cell populations. 
Dendritic-T cell co-cultures were established in the presence of increasing levels of the RAR-α 
inhibitor Ro41-5253 in the absence or presence of 10 nM ATRA. MoDCs (a and b; n = 10), dDCs (c 
and d; n = 7-8), and LCs (e and f; n = 14) were incubated in the presence of purified total T cells. 
After 4 days, CD4
+
 and CD8
+
 T cells were stained for 47 expression. * p < 0.05; ** p < 0.005; 
statistical analysis was performed using the Wilcoxon matched pair test.  
MoDCs 
dDCs 
LCs 
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7.2.1.2 Blockage of RAR-α increases the Percentage of CLA Expressing T Cells 
In addition to testing the effect of Ro41-5253 on the percentages of α4β7 
expressing T cells, its effect on CLA expressing CD4+ and CD8+ T cells was 
determined. As represented in Figure 7.3, increasing levels of the RAR-α inhibitor 
induced a significant up-regulation in the percentages of CLA+CD4+ and 
CLA+CD8+ T cells stimulated with LCs. Addition of Ro41-5253 triggered an 
increase in the percentages of CLA+CD4+ and CD8+ T cells to 48.8 % and 63.4 % 
respectively.  
This up-regulation was consistently observed for all three DC subtypes tested 
(Figure 7.4). In the absence of ATRA or Ro41-5253 moderate levels of CLA 
expression on β7+CD4+ and β7+CD8+ T cells were observed, while addition of the 
inhibitor led to an increase in CLA+ T cells in a dose dependent manner.  
For MoDCs a significant increase in CLA+ T cells was observed in the 
presence of 10 nM Ro41-5253, increasing from 3.73 % ± 0.68 % to 5.18 % 0.93 % 
for CD4+ T cells and from 4.37 % ± 1.24 % to 7.69 % ± 2.60 % for CD8+ T cells 
(Figure 7.4, a and b; red bars). As expected, addition of 10 nM ATRA resulted in a 
decline of CLA expressing populations to 2.58 % ± 0.55 % for CD4+ T cells and to 
3.17 % ± 1.32 % for CD8+ T cells (blue bars). In the presence of 10 nM ATRA and 
10 nM Ro41-5253, there was a significant increase in the mean percentages of 
CLA expressing CD4+ and CD8+ T cells (5.53 % ± 1.33 % and 5.13 % ± 1.33 %) 
(green bars). 
 
In the absence of ATRA, 10 nM of RAR-α blocking reagent were sufficient to 
significantly up-regulate CLA expression on CD4+ and CLA+CD8+ T cells from 
dDC-T cell co-cultures (Figure 7.4c and d). For CD4+ T cells the increase in CLA+ 
T cells was from 5.01 % ± 0.75 % to 10.27 % ± 2.75 %. At the same time, 
CLA+CD8+ T cells experienced an increase from 7.74 % ± 1.32 % to 11.81 % ± 
3.00 %. Again, a significant reduction in CLA+ expressing T cells was recorded in 
the presence of 10 nM ATRA alone (p < 0.05). While 10000 nM Ro41-5253 were 
required to significantly increase CLA+CD4+ populations (4.97 % ± 0.59 %) in the 
presence of 10 nM ATRA, only 10 nM Ro41-5253 were needed to elicit the same 
effect on CD8+ T cells (5.70 % ± 1.76 %). 
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a)                   b) 
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Figure 7.3: Ro41-5253 mediates an increase in CLA expressing T cells. 
DCs were co-cultured in the presence of Ro41-5253 for 24 hrs before T cells were added to the culture. The DC - T cells cultures were incubated for 4 days 
before harvested and analysed for CLA surface expression on β7
+
CD4
+
 and β7
+
CD8
+
 T cells. Respective isotypes can be found in Figure E.2 of the 
Appendix.   
9.4 % 48.8 % 
26.4 % 63.8 % 
CLA 
CLA 
66.4 % 
45.2 % 
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In the absence of ATRA and Ro41-5253, the percentages for CLA expressing 
CD4+ and CD8+ T cells stimulated with LCs was higher than those achieved with 
MoDCs or dDCs (Figure 7.4e and f). In addition, stimulation with LCs resulted in 
less variable data; however, the range was wider. Initially, LCs supported basal 
percentages of 9.39 % ± 1.99 % CD4+ T cells and 11.43 % ± 2.56 % CD8+ T cells. 
Both percentages were significantly raised in the presence of 100 nM and 10 nM 
Ro41-5253 to 15.07 % ± 4.06 % and 15.76 % ± 4.61 % respectively. This increase 
was overturned in the presence of 10 nM ATRA. In the presence of 10 nM ATRA, 
a significant increase in CLA+ T cells was only seen when 10000 nM Ro41-5253 
were added to the LC – T cell co-culture. 
Overall, the level of CLA expressing T cells that had been stimulated with DCs 
was higher than that of T cells alone (grey bars). 
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Figure 7.4: Ro41-5253-mediated blockage of RAR-α increases CLA expressing T cells. 
DC-T cell co-cultures were established in the presence of increasing Ro41-5253 concentrations in 
the absence or presence of 10 nM ATRA. MoDCs (a and b; n = 9-10), dDCs (c and d; n = 7-8), and 
LCs (e and f; n = 11-13) were incubated with isolated total T cells at 37 C for 4 days before 
stained for CLA expression. * p < 0.05; ** p < 0.005; statistical analysis was performed using the 
Wilcoxon matched pair test.  
MoDCs 
dDCs 
LCs 
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7.2.1.3 The Combined Effect of RAR-α and RAR-β/-γ Blockage on the Regulation 
of α4β7 Expressing T Cells 
After having determined the effect of RAR-α blockage on the percentage of α4β7 
and CLA expressing T cells further examination was conducted into the role of 
RAR-β and RAR-γ. To test whether RAR-β and RAR-γ play a role in the regulation 
of α4β7 and CLA expressing T cells, further receptor blocking experiments were 
conducted. MoDCs were cultured in the presence of total T cells with or without 
Ro41-5253 plus increasing concentrations of the selective RAR-β/-γ antagonist 
CD2665 (Tocris, Bioscience) (Figure 7.5).  
 
As shown in Figure 7.6, in the presence of 100 nM CD2665 a significant decrease 
in the mean percentage of α4β7 expressing T cells could be detected (blue bars). 
100 nM CD2665 triggered a reduction in the percentage mean from 7.92 % ± 1.16 
% to 5.32 % ± 0.93 % for CD4+ T cells and from 7.94 % ± 0.75 % to 6.26 % ± 1.10 
% for CD8+ T cells. These levels were similar to those detected for T cells alone 
(grey bars). As expected, RA significantly up-regulated the percentage of α4β7 
expressing CD4+ and CD8+ T cells (green bars).  
To examine whether Ro41-5253 and CD2665 exert a synergistic or additive 
effect on the down-regulation of α4β7 expressing T cells, MoDCs-T cells were 
treated with 10 nM ATRA and10 µM of the RAR-α inhibitor in the presence of 
increasing levels of the RAR-β/-γ antagonist (purple bars). In the presence of 1000 
nM CD2665, the mean percentage for CD4+ T cells was significantly reduced form 
7.58 % ± 1.38 % to 4.88 % ± 0.99 %, while CD8+ T cells experienced a reduction 
from 6.34 % ± 0.80 % to 4.79 % ± 0.55 %.  
 
As we observed a significant down-regulation of α4β7 expressing CD4+ and CD8+ 
T cells in the presence of 1000 nM CD2665, this suggests RA to signal through 
RAR-β and/or RAR-γ as well as RAR-α. 
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   a)          b)     c)         d) 
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Figure 7.5: Down-regulation of α4β7 expressing T 
cells in the presence of CD2665. 
MoDCs were co-cultured with total T cells in the 
presence of increasing concentrations of the selective 
RAR-β/γ inhibitor CD2665 for 4 days at 37°C. Cells were 
subsequently harvested and CD4
+
 and CD8
+
 T cells 
were analysed for α4β7 surface expression. Shown are 
representative data for CD4
+
 T cells. Respective 
isotypes can be found in Figure E.3 of the Appendix.  
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4.6% 25.9% 3.7% 
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Figure 7.6: Combined blockage of RAR-α and RAR-β/γ decreases α4β7 expressing T cells. 
MoDCs were incubated in the presence of increasing levels of CD2665 only (blue) or CD2665 in 
the presence of 10 nM ATRA and 10 µM Ro41-5253 (pink) for 24h before total T cells were added. 
The co-cultures were incubated for 4 days before being stained for α4β7 surface expression on a) 
CD4
+
 and b) CD8
+
 T cells. * p < 0.05; ** p < 0.005; statistical analysis was performed using the 
Wilcoxon matched pair test.  
 
 
 
7.2.1.4 The Combined Effect of RAR-α and RAR-β/-γ Blockage in the Regulation 
of CLA Expressing T Cells 
Once we had confirmed the negative effect of receptor blockage on the regulation 
of α4β7 expressing T cells, further research was conducted into the regulation of 
CLA by retinoic acid receptors. To examine the role of RAR-β and RAR-γ in the 
regulation of CLA, we set up co-culture experiments of total T cells with MoDCs in 
the absence or presence of CD2665 and Ro41-5253. As presented in Figure 7.7, 
there was a proportional correlation between the concentrations of CD2665 used 
in the experiments and the mean percentage of CLA expressing CD4+ and CD8+ T 
cells. MoDC - stimulated T cells showed an increase in CLA expressing T cells 
from 9.5 % in the absence of CD2665 up to 24 % in the presence of 100 nM 
CD2665. 
(nM) 
CD2665 CD2665 CD2665 CD2665 
(nM) 
(µM) 
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   i)          j)              k)         l) 
    
          m)         n)             o)         p) 
Figure 7.7: Up-regulation of CLA expressing T cells 
in the presence of CD2665. 
MoDCs were co-cultured with purified total T cells in the 
presence of increasing concentrations of the RAR-β/-γ 
inhibitor CD2665 for 4 days at 37°C. Cells were 
subsequently harvested and stained for the expression 
of CLA on β7
+
 CD4
+
 and CD8
+
 T cells. Respective 
isotypes can be found in Figure E.4 of the Appendix. 
5.3 % 4.9 % 9.2 % 
24 % 9.2 % 9.5 % 19.6 % 
6.3 % 
19.2 % 21.3 % 21.9 % 21.7 % 
23.7 % 18.1 % 8.9 % 10 % 
              Chapter 7 
  
292 
A significant increase in CLA expressing CD4+ T cells was achieved in the 
presence of 100 nM CD2665, increasing the levels from 8.23 % ± 1.36 % to 13.81 
% ± 2.95 % (Figure 7.8a; blue bars). Likewise, a the mean percentage for CD8+ T 
cell increased from 16.94 % ± 3.11 % to 28.07 % ± 3.10 % (Figure 7.8b; blue bars). 
As expected, 10 nM ATRA caused a reduction in CLA expressing CD4+ and CD8+ 
T cells (green bars).  
Concurrently, CD2665 was shown to have an effect on ATRA-induced down-
regulation of CLA when added to the co-culture. With increasing concentrations of 
CD2665, we were able to detect a rise in the mean percentages of CLA+CD4+ and 
CLA+CD8+ T cells (Figure 7.8; purple bars). This increase reached significance in 
the presence of 100 nM CD2665. For CD4+ T cells, we were able to detect an 
increase from 6.69 % ± 1.47 % to 11.44 % ± 2.45 %. In comparison, the level for 
CD8+ T cells increased from 11.76 % ± 1.94 % to 17.99 % ± 2.60 %. 
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Figure 7.8: Simultaneous blockage of RAR-α and RAR-β/-γ up-regulates CLA expressing T 
cells. 
MoDC-stimulated T cells were incubated with blocking reagents against RAR-α (Ro41-5253) and 
RAR-β and RAR-γ (CD2665) for 4 days before stained for the expression of CLA on β7
+
 CD4
+
 (n = 
9) and CD8
+
 (n = 7) T cells. * p < 0.05; statistical analysis was performed using the Wilcoxon 
matched pair test. 
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7.2.2 The Effect of Citral on α4β7 Expressing CD4+ and CD8+ T Cells 
To investigate the consequences of inhibiting the conversion of retinol to RA by 
targeting enzymes involved in the biosynthesis of RA, additional blocking 
experiments were set up. The conversion of of retinol to RA was blocked using 
citral, an inhibitor of RALDHs, which prevents de novo RA synthesis from vitamin A 
(Mora et al., 2004). We cultured MoDCs in the presence or absence of varying 
concentrations of retinol and citral (Figure 7.9). As shown in Figure 7.9a, there was 
a significant, dose-dependent increase in α4β7 expressing CD4+ T cells when co-
cultured in the presence of retinol. Addition of 100 nM retinol mediated an increase 
from 9.93 % ± 1.67 % to 25.81 % ± 4.97 %. When the MoDC - T cell co-culture 
was treated with 10 μM citral alone (8.35 % ± 1.49 %; red bar), there was no 
significant change in the mean percentage of α4β7 expressing CD4+ T cells when 
compared to MoDC – T cell alone. However, when MoDCs were cultured in the 
presence of 100 nM retinol and increasing doses of citral, a decrease in the mean 
percentage of α4β7 expressing CD4+ T cells was observed (green bars). Yet, this 
trend towards a lower percentage mean was not significant.  
Similarly, we were able to observe a change in the mean percentage levels for 
α4+β7+CD8+ T cells (Figure 7.9b). In the presence of 100 nM retinol, a significant 
increase in the mean percentage of α4+β7+CD8+ T cells was observed, increasing 
from 12.92 % ± 1.82 % to 19.71 % ± 2.09 % (blue bars). As previously seen with 
CD4+ T cells, addition of 10 μM citral to the culture alone, did not mediate a 
significant change (14.59 % ± 2.97 %; red bar). Subsequent analysis of MoDC-
stimulated CD8+ T cells grown in the presence of 100 nM retinol and increasing 
levels of citral did lead to a small reduction in α4β7 expression (p = 0.4065). 
Additionally, we investigated the effect of citral on CLA expressing T cells 
(Figure 7.9c and d). Our results clearly showed that in the presence of retinol, there 
was a significant decrease in CLA expressing CD4+ and CD8+ T cells, reaching 
levels of 1.68 % ± 0.52 % and 6.54 % ± 2.76 % respectively (blue bars). Addition of 
10 μM citral alone did not induce a significant change in the mean percentage of 
CLA expressing T cells. Likewise, we were unable to detect either a significant 
change nor trend when MoDC – T cells were grown in the presence of retinol and 
citral (green bars).  
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Figure 7.9: The effect of citral on α4β7 expressing CD4
+
 and CD8
+
 T cells. 
MoDCs were cultured in the presence of increasing concentrations of retinol (blue bars) or in the presence of increasing concentrations of citral (green bars) with 
100 nM retinol. Cells treated with 10 μM citral alone are shown in red. After 4 days, CD4
+
 (a and c) and CD8
+
 (b and d) T cells were analysed for the expression 
of α4β7 and CLA. * p < 0.05; ** p < 0.005; statistical analysis was performed using the Wilcoxon matched pair test.  
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7.3 Discussion 
With the discovery of the first retinoic acid receptors (RARs) in 1987, the notion of 
RA signalling via a nuclear receptor superfamily was established (Giguère et al., 
1987; Petkovich et al., 1987). Shortly after the first RAR had been identified, a 
second (RAR-β) (Brand et al., 1988) and third human retinoic acid receptor, RAR-
γ, were described (Krust et al., 1989). RARs function as ligand-inducible 
transcription factors (see chapter 1.8) and are expressed at various levels in 
different tissues throughout the human body.  
Although three subtypes of RARs have been identified, T cells usually only 
express RAR-α and RAR-γ (chapter 1.8.1). Differences in the regulation of RAR 
isoforms by ATRA and subsequent variation of expression in human lymphoid and 
myeloid cells may thus be an important factor in the modulation of T cell 
responses.  
 
The precise biological role of the differentially expressed RAR isoforms by 
activated human peripheral T cells is not fully understood. Throughout the 
previous chapters, systemic DCs were shown to up-regulate α4β7 expression on T 
cells in the presence of ATRA (chapter 4) as well as retinal and retinol (chapter 5). 
Here, we aimed to investigate the role of RARs in the modulation of α4β7 and CLA 
expressing T cells. More specifically, we aimed to investigate whether ATRA 
regulates α4β7 and CLA expression via RAR-α, RAR-β, and/or RAR-γ. 
In vitro experiments using DCs from PPs and MLNs, but not DCs from the 
spleen, have shown that intestinal DCs metabolize retinol to RA (Iwata et al., 
2004), and that the presence of ATRA or Am80 (Delescluse et al., 1991), which 
preferentially activates RAR-α, results in enhanced expression of α4β7 integrin 
and CCR9 in T cells. Consistent with these observations, we found that the RAR-α 
selective antagonist Ro41-5253 blocked the ability of systemic DCs to induce gut 
homing receptors on CD4+ and CD8+ T cells (Figure 7.2). The induction of a 
significant decrease in α4β7 expressing T cells in the absence of 10 nM Ro41-
5253 and ATRA was independent of the DC subtype (Figure 7.2; red bars). We 
also observed a significant decrease in α4β7 expressing T cells when co-cultured 
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with the inhibitor in the presence of ATRA (green bars). Our observations coincide 
with data published by Sauer et al. (2007) who showed that addition of 100 nM 
Ro41-5253 into the MoDC-lymphocyte co-culture impaired the up-regulation of β7 
induced by ATRA-pretreated MoDCs. Similarly, Amann et al. (2010) recently 
showed that retinoids can be blocked by Ro41-5253. However, the decrease in 
α4β7 expressing T cells in the absence of exogenously added ATRA, leads us to 
conclude that ATRA is either produced by DCs or that small concentrations of 
retinoids present in the culture medium contributed to higher levels of basal α4β7 
expression that were reduced in the presence of Ro41-5253.  
In the presence of constant ATRA levels, there were slight differences with 
respect to the amount of Ro41-5253 needed to induce a significant decrease in 
α4β7 expressing T cells depending on the DC subtype. As dDCs significantly 
down-regulated α4β7 T cells only in the presence of the highest Ro41-5253 
concentration tested, this proposes a greater tolerance for dDCs to Ro41-5253 
and may suggest higher expression levels of RAR-α. Although it was not the aim 
of this chapter to investigate mRNA or protein expression levels of various RARs, 
different DCs may express higher levels of RAR-α, explaining the greater Ro41-
5253 concentrations required to down-modulate α4β7 expression in the presence 
of ATRA. At the same time, the possibility of receptor redundancy cannot be 
excluded. Nevertheless, using systemic DCs, we were able to confirm results 
published by Iwata et al. (2004) who showed that blocking RAR significantly 
decreased the induction of α4β7 expression on T cells by GALT-resident DCs.  
 
In addition, we investigated the effect of Ro41-5253 on the percentage of CLA 
expressing T cells. Selective blockage of RAR-α led to an increase in the number 
of CLA expressing CD4+ and CD8+ T cells irrespective of the DC subtype. Our 
data showed MoDCs to significantly increase CLA expressing T cells in the 
presence of ATRA at Ro41-5253 concentrations of up to 1000-fold lower than 
dDCs and LCs (Figure 7.8). Again, this observation leads us to suggest higher 
RAR expression levels on dDCs and LCs, which – in the presence of ATRA – 
abrogate CLA expression. Upon receptor blockage, the level of CLA expressing T 
cells increased. However, whether this observation is dependent on the direct 
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action of ATRA on T cells and/or DCs, or whether it depends on the DC – T cell 
interaction needs further investigation.  
Interestingly, we showed an increase in CLA+β7+ T cells in the presence of Ro41-
5253. An increase in double positive T cells could however be a mere artefact of T 
cell activation. Alternatively, these double positive T cells could be undergoing 
transition from single to double positives and back to CLA+ single positive cells. 
 
Various studies have shown that RA can have varying effects on DCs, depending 
on the RA signalling pathway. Retinoic acid has been shown to not only affect DC 
activation and antigen presentation (Meunier et al., 1994; Bedford and Knight, 
1989), but also to exert a degenerative effect on epidermal LCs (Hachisuka and 
Uno, 1987) and induce DC apoptosis through RAR-α/ RXR heterodimers 
(Geismann et al., 2003). In conjunction with inflammatory cytokines, retinoids have 
also been shown to trigger expression of MHC class II and costimulatory 
molecules (Hengesbach and Hoag, 2004), induce the differentiation of immature 
DCs into mature DCs, and enhance antigen-specific T cell responses. Using DCs 
from the spleen, Svensson et al. (2008) showed that DCs are capable of 
generating RAR ligands, and that differences in the ability of MLN and splenic DCs 
to induce CCR9 and α4β7 on CD8+ T cells in vitro may lie in the levels of RAR 
ligands produced by the different DCs. Alternatively, DCs may experience 
differences in the kinetics of RAR ligand generation or in the production of 
additional factors. These findings could help explain differences seen between the 
various systemic DCs and further emphasize biological differences in their ability 
to induce gut homing receptors on T cells in the presence of ATRA. 
Furthermore, it has been shown that GM-CSF up-regulates RAR-α 
expression and receptor signalling (Mohty et al., 2003) on human monocytes 
cultured with GM-CSF and ATRA. Similar to cultures containing GM-CSF and IL-4 
for the generation of MoDCs, these cells develop into CD1a+ DCs. For our 
experiments, MoDCs were differentiated in vitro in the presence of IL-4 and GM-
CSF for 5 days, whereas dDCs and LCs were differentiated for 12-14 days in the 
presence of GM-CSF and other cytokines. Therefore, one might hypothesize all 
DCs generated in vitro experience slightly elevated levels of RAR-α expression 
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and receptor signalling. Since MoDCs were only cultured for 5 days in the 
presence of exogenously added GM-CSF one might expect MoDCs to express 
lower levels of RAR-α than dDCs or LCs. However, this is only hypothetical and 
further experiments are required to draw a conclusion. Furthermore, the half-life 
and turnover rate of RARs as well as temporal expression patterns need to be 
considered when making comparisons between the different DC populations. 
Hence, the effects of RA on the various DC subtypes, associated with 
differences in RA signalling pathways, could be a contributing factor to the 
differences seen in inhibitor concentration and α4β7 and CLA expression. Overall, 
ATRA may influence and change the responsiveness of DCs to RA, resulting in a 
change in cytokine production and subsequent T cell stimulation.  
As T cells do not normally express RAR-β, our data involving Ro41-5253 suggest 
that the regulation of α4β7 expression occurs at least through the RAR-α signaling 
pathway. However, as previously shown, RAR-β2 and RAR-α2 expression can be 
induced by ATRA (Ballow et al., 2003). Based on our data, we conclude that RAR-
α plays an important role in the regulation of α4β7 and CLA expression. However, 
we cannot eliminate the possible involvement of other receptors in this regulation. 
The fact that RAR signalling is involved in the regulation of gut homing T 
cells may also suggest a role in the regulation of Th17 and regulatory T cell 
differentiation. This hypothesis was supported by Elias et al. (2008) who found that 
inhibition of RAR-α function in isolated T cells inhibited Foxp3 expression and 
enhanced IL-17 production. This observation evidently argues for a role of 
retinoids and RAR-α in regulating the T reg and Th17 balance. As shown by 
Duraisingham et al. (2009) and as suggested by our data, different DC subtypes 
differentially influence T cell proliferation, receptor expression, and cytokine 
production. Hence the role of different DC subtypes in the regulation of Th17 and 
regulatory T cell responses in the presence of RA needs to be investigated. 
 
The function of RAR-γ in T cell gut tropism has previously been examined. 
Stimulation of RAR-γ-deficient CD4+ and CD8+ T cells in the presence of ATRA 
resulted in the up-regulation α4β7, suggesting that ATRA-dependent T cell gut 
tropism does not require RAR-γ (Dzhagalov et al., 2007). However, as mature T 
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cells express both RAR-α and RAR-γ, it is possible that RAR-α is able to 
compensate for the loss of RAR-γ.  
To investigate the possibility of receptor redundancy, we compared the capacity of 
T cells to express a gut homing phenotype in the presence or absence of RAR-α 
and RAR-β/-γ antagonists. The selective RAR-β/-γ antagonist CD2665 was used 
to test the effect of RAR-β/-γ receptor blockage on the regulation and percentage 
expression of α4β7 expressing T cells in the presence of MoDCs. As presented in 
Figure 7.6, addition of CD2665 to the culture alone in the absence of ATRA 
induced a significant decrease in α4β7 expressing T cells. This not only proposes 
a role for ATRA-induced RAR-γ/-β-mediated signalling in the regulation of α4β7 
expressing T cells but concurrently suggests that retinoids or other factors may be 
present in the culture medium potentially inducing low levels of α4β7 expression. 
However, whether RA is produced from retinol by MoDCs or whether retinoids are 
FCS-derived remains to be investigated. Alternatively, T cells may naturally 
express basal levels of α4β7 (Figure 7.6; grey bar) that are upregulated upon DC-
mediated T cell stimulation and become downregulated in the presence of 
CD2665. 
 
As T cells do not express RAR-β this further shows that RA-mediated signalling is 
involved in the regulation of α4β7 expression and that this regulation takes place 
in part via RAR-γ. In addition, we tested the simultaneous effect of Ro41-5253 and 
CD2665 on α4β7 expressing T cells, stimulated by MoDCs in the presence of 
ATRA. As shown in Figure 7.6, we were able to detect an additive effect of the 
RAR antagonists on α4β7 expressing T cells. As expected, in the presence of 
ATRA and 10 μM Ro41-5253 there was a decrease in α4β7 expressing T cells 
when compared to ATRA-stimulated T cells alone. Addition of CD2665 further 
decreased the percentage of α4β7 expressing T cells, confirming an additive effect 
of these antagonists on the regulation of α4β7 expressing T cells and the 
requirement for retinoic acid to modulate this regulation. Furthermore, it confirms 
the involvement of RAR-α and RAR-γ in the regulation of α4β7 expression. Also, it 
suggests RAR redundancy in that blockage of one receptor subtype does not 
completely abrogate α4β7 expression. 
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Overall, the expression patterns of RARs in skin and mucosal cell types may give 
an insight into the role of RA in the regulation of skin and gut homing T cells and 
will have to be considered when developing vaccines involving the use of 
retinoids. 
 
Citral and its isomers comprise a class of dehydrogenase inhibitors, which are 
substrates for dehydrogenases. Citral is an unsaturated aldehyde that consists of 
a mixture of the isomers geranial (trans-3,7-dimethyl-2,6-octadienal), which 
structurally resembles all-trans retinal, and neral (cis-3,7-dimethyl-2,6-octadienal) 
(Kikonyogo et al., 1999). According to several publications, citral can be used to 
inhibit oxidation of retinol and retinal. As shown by Kikonyogo et al. (1999), citral 
and its isomers are substrates for aldehyde dehydrogenases. Similarly, it has been 
shown (Connor and Smit, 1987) that retinol oxidation by epidermal extracts was 
inhibited by citral and that citral significantly inhibited RA formation from retinol in 
the epidermis in vivo. Likewise, the role of citral as an inhibitor of ADH but not 
microsomal retinol dehydrogenase was shown to eliminate in vitro oxidation of 
retinol in rat embryo homogenates (Chen et al., 1995). Interestingly, short-chain 
dehydrogenase/reductases are resistant to citral (Duester, 1996). 
Here we showed that pre-treatment of MoDCs with citral resulted in a reduction of 
α4β7 expressing T cells in the presence of retinol. This decline suggests that citral 
inhibited oxidation of retinol and/or retinal and thus reduced the amount of 
biologically active and available RA required for gene regulation. At the same time, 
this further strengthens the view that MoDCs do express functional 
dehydrogenases required for the metabolism of vitamin A.  
However, in previous experiments it has been shown that citral failed to suppress 
enhanced expression of β7 integrin on lymphocytes stimulated with RA-treated 
MoDCs (Sauer et al., 2007). Hence, they suggested that rather than generating de 
novo RA, MoDCs functioned as an efficient reservoir and carrier of bioactive RA. 
Although our results were not significant (p = 0.0625 and p = 0.4065), upon 
addition of citral, there was a tendency towards a reduction of retinol induced α4β7 
expressing T cells (Figure 7.9a and b). The fact that we and others failed to show 
a significant decrease could be due to either sample size or short half live of citral 
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(Djordjevic et al., 2007). Also, it has been proposed that citral is not a highly potent 
or strictly ALDH inhibitor (Connor and Smit, 1987). Although citral and the ALDH 
inhibitor DEAB have been widely used in developmental biology, only DEAB has 
been shown to inhibit de novo synthesis of RA (Russo et al., 1998).  
At the same time, addition of citral to the culture did not induce significant changes 
in CLA expressing T cells in the presence of constant retinol levels (Figure 7.9c 
and d). As expected, addition of retinol to the culture triggered a significant 
decrease in CLA expressing T cells. However, in the presence of increasing 
concentrations of citral, there was no significant change the levels of CLA 
expressing T cells. Our results suggest that citral prevents the conversion of retinol 
to RA and by targeting the dehydrogenases involved in retinol and retinal 
oxidation. 
Notably, as Ro41-5253-mediated blockage of RAR-α induced an increase 
in CLA expressing T cells but citral did not, we suggest that RAR-α has an 
inhibitory effect on CLA expression. As citral only modulates RA concentrations by 
inhibiting RA synthesis, RAR-α is still functional to regulate genes that prevent an 
increase in CLA expression. Previous competition experiments suggest that 
antagonists replace RA bound to RAR-α. As shown by Keidel et al. (1994), 
antagonist-bound RAR-α fails to activate gene transcription due to conformational 
changes in RAR-α that are different from those induced by agonists. In our case, 
this implies that Ro41-5253 is associated with gene repression that leads to a 
reduction in the synthesis of factors required to repress an increase in CLA 
expressing T cells (Figure 7.10a).  
In the case of citral however, RAR-α itself does not undergo an antagonist-induced 
conformational change that blocks its natural conformation and function. Citral only 
modulates the levels of RA produced from retinoid oxidation. Any RA present in 
the medium will have the potential to remain bound to RAR-α or any other retinoid 
receptor (Figure 7.10b). This leads us to conclude that CLA expressing cells are 
regulated on a molecular (receptor) level rather than ligand-dependent level.  
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Figure 7.10: Differential effects of Ro41-5253 and citral of CLA expressing T cells. 
a) Ro41-5253 binds to RAR-α and induces a conformational changes that results in receptor 
binding but failure in the transactivation of target genes. Expression of such genes allows an 
increase in CLA expressing T cells. b) RAR-α in still functional and able to bind agonists, even 
when the levels of RA synthesis are reduced by citral. Activation of down-stream genes results in 
prevention of an increase of CLA expressing T cells. 
 
 
Overall, we have shown that the blockage of RAR-α and RAR-β/-γ leads to a 
reduction in the percentage expression of α4β7 expressing T cells. At the same 
time, we observed an increase in CLA+ T cells. These findings highlight that the 
regulation of the gut homing receptor α4β7 and the skin homing receptor CLA 
occurs, in part, through the RAR-α and RAR-γ signalling pathways. Furthermore, 
we showed that this regulation is modulated by the type of DC present in the 
culture. In addition, we looked at the effect of citral on α4β7 expressing T cells and 
showed the tendency towards a decline in α4β7 expressing T cells when citral was 
added to the culture. Concurrently, we investigated the effect of RAR inhibition and 
citral on CLA expressing T cells and showed that RAR-α and RAR-γ are involved 
in CLA regulation. 
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Chapter 8 
 
 
 
 
 
Final Discussion, Concluding Remarks, and Future Work 
 
 
 
8.1 Summary 
The data presented in this thesis is concerned with the ability and capacity of 
systemic human DCs to induce a mucosal immune response reflective of the small 
intestine. The early work described in this thesis focuses on the phenotypic 
identification of different in vitro-generated DC subsets (chapter 3). In addition, we 
focused on the isolation and phenotypic characterisation of blood-derived and 
skin-derived DCs (chapter 3). In order to assess their potential to modulate 
expression of gut and skin homing receptors on T cells, these DC subsets were 
used in co-culture experiments with retinoic acid (chapter 4), retinol (chapter 5), 
retinal (chapter 5), or vitamin D (chapter 6). Furthermore, in vitro-generated DCs 
were analysed for their potential to metabolize vitamin A to its metabolically active 
form of RA by PCR and flow cytometry (chapter 5). Lastly, some research has 
been conducted into the role of RARs and the function of dehydrogenases in the 
regulation of α4β7 and CLA expression on T cells (chapter 7). 
 
 
8.2 Phenotypic Analysis of Systemic Human DC Subsets 
The results presented in chapter 3, focus on the differentiation and phenotypic 
analysis of in vitro-generated DCs, as well as isolation and phenotyping of 
systemic DCs from human peripheral blood and skin explants. In vitro-generation 
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of systemic DCs from CD14+ precursors (MoDCs) (Sallusto and Lanzavecchia, 
1994) and umbilical cord blood CD34+ precursors (dDCs and LCs) (Caux et al., 
1996) has previously been documented and was of outmost importance for the 
experiments described in this thesis. Although the method for the generation of 
dDCs has previously been optimized by our lab, the numbers of dDCs generated 
were relatively low throughout suggesting a bias towards LCs differentiation. In 
spite of this, phenotypic analysis confirmed that MoDCs and dDCs were 
representative of DCs naturally found in the dermis and interstitial tissue. Likewise, 
in vitro-generated LCs showed a phenotype that was descriptive of skin-derived 
epidermal LCs.  
In addition, an isolation protocol for immature dermal DCs and epidermal 
LCs from human skin was established. This part was proven challenging in that 
isolation of LCs from human epidermal sheets required the meticulous processing 
of human skin samples and separation of epidermis from dermis. In addition, 
isolation of dermal DCs was restricted by the consistency of the dermis and 
connective fibres after dispase and collagenase treatment. Isolation of LCs via the 
“walk out” method only allowed the isolation of mature LCs. These difficulties 
highlight the need for further improvement such that immature LCs and dermal 
DCs can readily be obtained.  
Future experiments will entail the continuation of current research, including the 
testing of in vitro-generated DCs for expression of surface markers associated with 
skin epidermal and dermal LCs, for their ability to present antigen, and for their 
sensitivity to radiation. Keeping in mind the diversity of skin DCs, additional 
research needs to be conducted into the characterisation of Langerin+ dermal 
DCs.  
We briefly looked into the effect of RA on receptor surface expression on 
MoDCs (Figure 3.9). The potential of RA to modulate the migratory properties of 
bone marrow-derived DCs has previously been reported (Taraboletti et al., 1997), 
showing enhanced expression and secretion of matrix metalloproteinases (MMPs), 
which are known to play a role in LC migration (Kobayashi et al., 1999). The ability 
of RA to induce migration of DCs from tumours to draining lymph nodes and 
antigen presentation to T cells proposes a role for RA in the initiation of immune 
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responses against tumours. This suggests that vaccination with RA in combination 
with antigens could hold the potential to modulate DC migration in order to induce 
specific mucosal immune responses. 
 
 
8.3 DCs differentially modulate α4β7 and CLA Expression on T 
Cells 
Overall, the aim of chapter 4 was to test the ability of systemic DCs to support 
induction of gut homing T cells in the presence of RA. The recent literature 
(Mucida et al., 2007; Benson et al., 2007; Sun et al., 2007; Iwata et al., 2004) 
supports the view that production of RA by murine gut epithelial cells and CD103+ 
DCs constitutes an imperative signal in promoting α4+β7+ gut homing T cells. 
However, the role of systemic human DCs in activating mucosal immune 
responses has yet to be determined. In view of these data, we investigated the 
ability of systemic DCs to regulate T cells with a mucosal homing phenotype. As 
shown in chapter 4, stimulation of T cells by systemic DCs in the presence of RA 
led to an up-regulation in the percentage and MFI of β7 and a decrease in CLA 
expression in a dose-dependent manner. These findings concur with data 
demonstrating RA-treated MoDCs to trigger up-regulation of β7 (Sauer et al., 
2007) and RA-treated DCs to undergo down-regulation of CLA expression 
(Yamanaka et al., 2008).  
In addition, the various DCs showed fundamental differences in their ability to 
induce T cells that expressed a mucosa homing phenotype. In vitro-generated LCs 
enhanced α4β7 expression most efficiently on naive T cells in the absence of RA 
(Figure 4.13 and 4.16), suggesting them to more efficiently activate naïve T cells 
than MoDCs or dDCs. Similarly, mDCs most efficiently induced α4β7 expressing 
memory T cells. At the same time, the various DC subsets showed inherent 
differences in their ability to induce CLA+ T cells in the absence of ATRA, with 
dDCs being the most efficient.  
Since FoxP3+ T cells can be induced by mucosal RA-producing CD103+ DCs 
(Coombes et al., 2007), it is likely that RA is a major signal that confers 
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immunological tolerance within the small intestine. Induction of FoxP3+ regulatory 
T cells has previously been shown in mice and humans (Kang et al., 2007). It 
would therefore be interesting to investigate the ability of systemic DCs to induce 
regulatory T cells in the presence of RA, and to see whether this correlates with 
the inhibition of Th17 cells. 
Although treatment of T cells with RA induces expression of gut homing receptors 
and T cells with the potential to migrate to the intestine, it has been shown (Arthos 
et al., 2008) that HIV-1 is able to bind α4β7 on T cells via the HIV-1 spike 
component gp120. These findings show that in the context of infection, as well as 
tolerance and autoimmunity, mucosal immune responses require tight regulatory 
mechanisms and additional factors that help regulate intestinal immune 
responses, in particular against HIV-1. In addition, further research needs to 
elucidate the mechanism underlying the specific induction of CD8+ T cells. 
 
 
8.4 Systemic DCs hold the potential to metabolize Vitamin A to RA 
The aim of chapter 5 was to examine the effect of retinol and retinal on the cell 
surface expression of α4β7 and CLA in the presence of the different systemic DC 
subsets and their ability to metabolize these retinoids. The ability of PP- and MLN-
derived DCs to express functional retinol and retinal dehydrogenases enables 
them to synthesize RA (Iwata et al., 2004). As RA modulates the expression of 
homing receptors on T cells, we aimed to determine the extent to which systemic 
DCs support vitamin A metabolism.  
We were not only able to show that retinol and retinal are able to regulate 
α4β7 and CLA expression, but also that in vitro-generated DCs express ADH1 and 
ALDH1A2 (chapter 5.2.5). The fact that MoDCs expressed higher levels of 
ALDH1A2 activity (Figure 5.9) could be associated with the nature of the DC 
subset and/or the culture condition, as IL-4 and GM-CSF have been shown to 
synergistically induce expression of ALDH1A2 in splenic DCs in vitro (Yokota et 
al., 2009). In addition, TLR2 signalling has been shown to induce RALDH2 and IL-
10 expression, and to promote vitamin A metabolism and Foxp3+ regulatory T cells 
(Manicassamy et al., 2008). At the same time, TLR2 stimulation led to the 
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suppression of Th17 cells. These observations show that the environment plays a 
role in the conditioning of DCs to produce vitamin A metabolizing enzymes. 
Hence, further investigation may entail examining the effect of TLR-mediated 
signalling on dehydrogenase expression and vitamin A metabolism by DCs. 
As the oxidation of retinal to RA is considered the rate-limiting step in the RA 
synthetic pathway, clarification of the role of ALDH and its isoforms in the context 
of each DC subset may help elucidate the significance and role of each DC 
subtype in RA synthesis and mucosal immunity. Using quantitative PCR (qPCR), 
Manicassamy et al. (2009) previously showed that splenic DCs constitutively 
express low levels of ADH and RALDH and that treatment with zymosan increased 
the levels of RALDH2.  
 
The ability of systemic DCs to synthesize vitamin A could have implications in 
vaccine development. Future experiments should entail transfection of DCs with 
expression plasmids coding for the retinol metabolizing enzymes ADH and ALDH. 
Data from such experiments may help elucidate the role of these enzymes in 
metabolizing vitamin A in the context of systemic DCs and may lead to the ex vivo 
modification of DCs to produce these enzymes followed by their reconstitution.  
In addition, DCs could be transfected with expression plasmids encoding CC-
chemokine ligands such as CCL25, CCL27, and CCL28. Subsequent usage of 
these DCs in migration assays would help clarify the role of these different ligands 
for DC subsets in initiating T cell migration to the mucosa. In addition, real time 
PCR could be used to quantify the amount of ALDH and ADH expressed by each 
DC subset. Knowing the amount of dehydrogenases expressed could lead to 
preferences in vaccine delivery through either the skin or systemically via the 
blood stream. 
 
In retrospect, one control that should have been included throughout the 
experiments consists of bead-stimulated T cells. The retinol and PCR data clearly 
support the hypothesis that systemic DCs express the enzymes necessary to 
produce RA and the various DCs show different abilities to induce α4β7 
expression. At the same time, there is some increase with bead-stimulated T cells 
  Chapter 8 
   
308 
(Figure 4.6), perhaps suggesting that α4β7 expression increases during 
proliferation. In order to exclude the possibility that an increase in α4β7 expression 
was merely due to T cell proliferation, α4β7 expression on DC-stimulated T cells 
should have been compared to T cells stimulated in the presence of activation 
beads. 
 
 
8.5 Vitamin D modulates CCR4, CCR10, CLA, and α4β7 Surface 
Expression on T Cells 
The results presented in chapter 6, show active vitamin D to modulate expression 
of skin and mucosal homing markers on T cells. The observation that 1,25(OH)2D3 
mediates an increase in CCR4-CCR10+ T cells strengthens the hypothesis that 
vitamin D regulates T cell homing to the skin. At the same time, vitamin D was 
seen to down regulate α4β7 and CLA expression. These findings coincide with 
data published by Sigmundsdottir et al. (2007), showing that 1,25(OH)2D3 causes 
up-regulation of CCR10 and down-regulation of α4β7 on T cells. However, the role 
of CCR10 in T cell homing to the skin needs further investigation as its 
requirement has been questioned (Soler et al., 2003). At the same time, 
1,25(OH)2D3 down-regulates CCR4
+CCR10- T cells. As CCR4 is required for T cell 
migration into the dermis (Santamaria Babi et al., 1995) this further suggests that 
1,25(OH)2D3 plays a role in the regulation of T cell migration into the epidermis. As 
expected, vitamin D was shown to concurrently down-regulate α4β7 expression.  
Within the skin, inactive vitamin D can be converted to its active from by residential 
DCs, keratinocytes, and macrophages, which requires the presence of functional 
CYP27A1 and CYP27B1 enzymes. Mature DCs express both CYP27A1 and 
CYP27B1 and therefore are capable of synthesizing 1,25(OH)2D3 (Prosser and 
Jones, 2004; Sigmundsdottir et al., 2007). This process is analogous to the 
conversion of vitamin A to RA by mucosal DCs that express ALDH1A1 and 
ALDH1A2. Hence future testing of in vitro-generated DCs, mDCs, and skin-derived 
DCs for their ability to convert inert vitamin D to its active metabolite could help 
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clarify the role of these DC subsets in the regulation of immune responses specific 
to the skin. 
Future experiments should also include investigating the role of vitamin D in 
regulating immune tolerance and autoimmune responses. Although vitamin A and 
vitamin D are implicated in promoting regulatory T cells, they differentially regulate 
expression of homing receptors. Furthermore, DCs and T cells need to be 
examined for their expression levels of VDRs, as differences in expression could 
lead to variations in responses to vitamin D. 
This shows the intricate and complex effects of vitamins on the immune system 
and calls for further investigation to clarify the different immunoregulatory roles of 
these vitamins. 
 
 
8.6 ATRA regulates α4β7 and CLA Surface Expression through 
RAR-α and RAR-β/γ Signalling 
Analysing the role of RARs in the regulation of gut homing T cells, we were able to 
show that RA-mediated up-regulation of α4β7 and down-regulation of CLA is, in 
part, dependent on the expression of functional RAR-α and RAR-β/γ (Chapter 
7.2). However, we are unable to draw any conclusions regarding the combined 
effect and interplay between RAR activation in DCs and RAR activation in T cells. 
Additional research needs to be conducted with regard to the types and levels of 
RAR expression by the various DC subsets and T cells. Variations in RAR 
expression by different DC subsets could have significant implications regarding 
their ability to respond to RA and thus regulate immune responses. Furthermore, 
potential differences in RXRs expression and signalling need to be considered, 
which were not investigated in this thesis. 
Given the essential role of retinoids in epidermal differentiation and their 
effectiveness in the treatment of various skin disorders, the cellular and tissue 
distribution of RARs and RXRs on dermal DCs and Langerhans cells needs further 
clarification.  
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8.7 Final Conclusion 
Overall, the data presented in this thesis show the modulatory ability of vitamin A 
and vitamin D to influence expression of gut and skin homing receptors on T cells 
in the presence of systemic DCs. At the same time, the type of DC was shown to 
determine the extent to which receptor expression was regulated. This thesis was 
the first study to show human systemic DCs to have the potential to metabolize 
vitamin A and induce gut homing T cells in vitro. In view of the fact that retinoids 
can exert immunosuppressive effects they have been considered as single or 
adjuvant agents to treat autoimmune diseases. Given the difficulty in administering 
mucosal vaccines, these findings could have major implications on the 
development of systemic vaccines against intestinal pathogens such as HIV-1.  
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Appendix A 
Chapter 3 
 
a)         b)               c)             d)          e) 
      
 
f)         g)               h)                     i)          j) 
      
 
k)         l) 
Figure A.1: Isotypes for MoDCs phenotyping. Isotypes for Figure 3.1. MoDCs were derived from 
CD14
+
 progenitor cells as described in Chapter 2.2.4.3. After 5 days, cells were harvested and 
phenotypes using cell surface staining.    
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a)               b)                 c)                    d)             e) 
      
 
f)               g)         h)                    i)              j) 
      
 
k) 
Figure A.2: Isotypes for MoDCs generated in serum free medium. Isotypes for Figure 3.2. MoDCs were generated as 
described in chapter 2.2.4.3. 
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a)              b) 
  
 
 
c)       d)              e)         f) 
    
 
Figure A.3: Isotypes for in vitro-generation of dDCs and LCs. Isotypes for Figure 3.3. dDCs 
and LCs were generated from CD34
+ 
progenitor cells as described in chapter 2.2.4.4.  
 
 
1.8 % 0.9 % 
0.1 % 
0.2 % 1.5 % 
0.7 % 
0.8 % 1.1 % 
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a)                 b)                     c)               d)           e) 
      
 
f)                g)                    h)               i)                    j) 
      
 
k)                l) 
 
Figure A.4: Isotypes for dDCs phenotyping. Isotypes for Figure 3.4. dDCs were derived 
from CD34
+
 progenitor cells as described in Chapter 2.2.4.4. Cells were harvested on day 12-
14 and phenotyped using cell surface staining. 
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a)              b)                c)                  d)            e) 
      
 
f)              g)                h)          i)            j) 
      
 
k)               l)        m) 
Figure A.5: Isotypes for LCs phenotyping. Isotypes for Figure 
3.5. LCs were differentiated from CD34
+
 progenitor cells as 
described in chapter 2.2.4.4. Cells were harvested after 12-14 
days and phenotyped using cell surface staining. 
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a)         b) 
  
 
 
c)         d)             e)          f) 
    
 
      g)      h)            i) 
   
 
Figure A.6: Isotypes for dermal DCs. Isotypes for Figure 3.6. Dermal DCs were isolated from the 
dermis of healthy individuals and phenotyped.  
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a)                b)          c)                     d)               e) 
     
  
f)                g)          h)                     i)                j) 
      
 
k) 
Figure A.7: Isotypes for epidermal LCs. Isotypes for Figure 3.7. Epidermal LCs were isolated from human epidermal skin 
samples as described in Chapter 3.2.4.2.  
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a)              b)                c)                 d)          e) 
      
 
f)              g)       h)                 i)          j) 
      
 
k) 
Figure A.8: Isotypes for blood-derived mDCs. Isotypes for Figure 3.8. mDCs were isolated from human peripheral blood as 
described in chapter 3.2.3.  
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  a)                 b)                    c)              d)       e)                   f)             g) 
       
 
  h)                  i)            j)              k)        l)          m)            n) 
       
 
  o)                 p)                   q)             r)       s)          t)                    u) 
       
Figure A.9: Isotypes for ATRA-treated MoDCs. These are the isotypes for Figure 3.8. MoDCs were overnight-cultured in the absence or presence of ATRA (10 nM 
– 1000 nM). The following day, MoDCs were analysed for cell surface expression of CD1a, HLA-DR, DC-SIGN, and CD86.  
 
 
10 nM 
1000 nM
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Appendix B 
Chapter 4 
 
 
a)           b) 
  
Figure B.1: Antigenic stimulation of isolated CFSE-labelled CD4
+
 memory T cells. Isotypes for 
Figure 4.1. 
 
 
a)           b)          c) 
   
Figure B.2: α4β7 expression on antigen-stimulated CD4
+
 memory T cells. Isotypes for Figure 
4.2. b) Isotypes for CD3 – PerCP and CD4 – Pe-Cy7. c) IgG2a – APC, isotype for β7 – APC. 
 
 
a)           b)       CD4+ T cells        c)       CD8+ T cells 
   
Figure B.3: α4β7 expression on CD4
+
 and CD8
+
 T cells from whole percoll pellets. Isotypes 
for Figure 4.7. Whole percoll pellet cells were co-cultured with dDCs in the absence or presence of 
10 nM ATRA for 7 days. In the absence of ATRA, low levels of α4
+
β7
+ 
T cells were supported. 10 
nM ATRA caused an increase in the number of α4
+
β7
+
 CD4
+
 and CD8
+
 T cells.  
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 CD4 T cells  CD4 T cells       CD8 T cells     CD8 T cells 
a)          b)       c)              d)            e)         f) 
      
 
e)          f)                g)                           h) 
                
 
i)          j)                 k)                 l) 
        
MoDCs 
dDCs 
LCs 
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m)          n)       o)               p)            q)         r) 
      
 
s)          t)       u)                   v)            w)         x) 
      
Figure B.4: α47 surface detection on CD4
+
 and CD8
+
 T cells. Isotypes for Figure 4.8. Pan T cells were co-cultured with systemic DCs in the absence or 
presence of RA and subsequently stained for 47 surface expression. In the absence of ATRA, CD4
+
 and CD8
+
 T cells stained positive for α4β7.  
mDCs 
Epidermal LCs 
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a)         b)      c) 
   
Figure B.5: Isotypes for purified naïve CD4
+
 T cells. Isotypes for Figure 4.11. 
 
a)         b)             c)           d)        e) 
     
Figure B.6: ATRA-enhanced expression of α4
+
β7
+
CD4
+
 naive T cells. Isotypes for Figure 4.12. 
 
a)                               b)                               c)                                d) 
    
Figure B.7: Isotypes for naive CD8
+
 T cell purification from umbilical cord blood. Isotypes for Figure 4.14. 
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a)         b)               c)            d) 
    
Figure B.8: ATRA-enhanced expression of 4
+
7
+
CD8
+
 naive T cells. Isotypes for Figure 4.15. 
 
a)         b)              c) 
   
Figure B.9: Purified memory CD4
+
 T cells. Isotypes for Figure 4.17. 
 
a)          b)       c)              d) 
    
Figure B.10: LCs co-cultured with CD4
+
 memory T cells. Isotypes for Figure 4.18. 
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a)          b)       c)              d) 
    
Figure B.11: Isolated CD8
+ 
memory T cells. Isotypes for Figure 4.20. 
 
a)          b)       c) 
   
Figure B.12: Isotypes for CD8
+
 memory T cells co-cultured with MoDCs. Isotypes for Figure 4.21. 
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a)       b) 
   
c)       d)          e)     f)         g)            h) 
      
i)        j) 
   
k)        l)             m)        n)             o)         p) 
      
MoDCs 
dDCs 
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q)       r) 
   
s)       t)           u)     v)          w)     x) 
      
y)       z) 
   
aa)       ab)          ac)      ad)                  ae)            af) 
      
LCs 
mDCs 
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ag)          ah) 
   
ai)         aj)      ak)             al)                  am)       an) 
      
Figure B.13: ATRA decreases the number of CLA expressing T cells and CLA surface expression on T cells. Isotypes for Figure 4.23. 
 
 
a)          b)       c)             d)          e) 
     
Figure B.14: Detection of CLA expressing naïve CD4
+
 T cells in the absence of ATRA. Isotypes for Figure 4.26. 
 
 
Epidermal LCs 
3 % 1.2 % 
   Appendix B 
    
330 
a)         b)       c)            d)        e) 
     
Figure B.15: CLA surface detection on α4
+
β7
+
CD8
+
 naïve T cells. Isotypes for Figure 4.28. Purified naïve CD8
+
 T cells were co-cultured with in vitro-
generated dDCs in the absence or presence of 10 nM ATRA. CLA expression on β7
+
 T cells was determined after 7 days using flow cytometry. 
 
a)          b)       c)              d)            e) 
     
Figure B.16: CLA expressing CD4
+
 memory T cells decrease in the presence of ATRA. Isotypes for Figure 4.30. LCs were co-cultured with CD4
+
 
memory T cells in the absence or presence of ATRA. a) Live gate. b) Isotypes for CD4 and CD3. Gated on CD4
+
CD3
+
 T cells. c) Isotype for β7. d) Isotype for 
Alpha4-PE.  
 
a)          b)        c)              d) 
    
Figure B.17: Co-culture of dDCs with CD8
+
 memory T cells. Isotypes for Figure 4.32. a) Live Gate. b) Isotype for CD4 and CD3. Gated on CD3
+
CD4
-
 T 
cells. c) Isotype for β7 – APC. Gated (P3) on β7
+
 cells. d) Isotype control for CLA – FITC.   
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Appendix C 
Chapter 5 
 
 
Low Molecular Weight Ladder   100bp Ladder 
       
LMW DNA Ladder     Promega 
 
Figure C.1: Molecular markers.  
 
 
 
 
 
 
Table C.1: Reference data for amplified genes. 
Gene 
Abbreviation 
NCBI Reference 
Number 
Gene 
ADH1A NM_000667.2 Alcohol Dehydrogenase 1 
ALDH1A2 NM_170696.1 Aldehyde Dehydrogenase 1A2 
GAPDH NM_002046 Glyceraldehyde 3-phosphate 
dehydrogenase 
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Appendix D 
Chapter 6 
 
 
a)               b)         c) 
   
 
 
d)              e)        f)                   g)  
    
Figure D.1: Isotypes for the down-regulation of α4β7 in the presence of 1,25(OH)2D3. Isotypes for Figure 6.2. 
 
 
   Appendix D 
    
333 
 
 
a)          b)        c)  
    
 
d)          e)        f)              g)            h)          i) 
      
Figure D.2: Isotypes for the down-regulation of CLA in the presence of 1,25(OH)2D3. Isotypes for Figure 6.4.  
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Appendix E 
Chapter 7 
 
c) CD4+ T cells        d) 
  
a)       b) 
   
           e)  CD8+ T cells       f) 
  
Figure E.1: Ro41-5253 mediates a reduction in α4β7 expressing T cells. Isotypes for Figure 7.1. 
α4β7 
α4β7 
0.4 % 
0.3 % 
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c) CD4+ T cells         d) 
  
a)    b) 
   
 
           e) CD8+ T cells         f) 
  
 
Figure E.2: Ro41-5253 mediates an increase in CLA expressing T cells. Isotypes for Figure 7.3. 
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a)        b)                   c)     d)               e) 
     
 
f)       g) 
  
Figure E.3: Down-regulation of α4β7 expressing T cells in the presence of CD2665. Isotypes for Figure 7.5. MoDCs were co-cultured with total T cells 
in the presence of increasing concentrations of the RAR-β/-γ inhibitor CD2665 for 4 days at 37 °C. Shown are CD4 T cells.  
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a)                b)                   c)    d)               e) 
     
 
f)      g)        h) 
   
Figure E.4: Up-regulation of CLA expressing T cells in the presence of CD2665. Isotypes for Figure 7.7. MoDCs were co-cultured with total T cells in 
the presence of increasing concentrations of the RAR-β/-γ inhibitor CD2665 for 4 days at 37 °C.  
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